8358726	142	Kaufmann SH	Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis.	Cancer research	1993	272
9271409	142	Mosser DD	Role of the human heat shock protein hsp70 in protection against stress-induced apoptosis.	Molecular and cellular biology	1997	137
10438458	142	Boulares AH	Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells.	The Journal of biological chemistry	1999	136
10508238	142	Lipton P	Ischemic cell death in brain neurons.	Physiological reviews	1999	439
10728709	142	Gamet-Payrastre L	Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells.	Cancer research	2000	103
12393461	142	Bharti AC	Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis.	Blood	2003	122
12716823	142	Ceriello A	New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy.	Diabetes care	2003	117
12821677	142	Ling YH	Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.	The Journal of biological chemistry	2003	97
14514658	142	Singh AV	Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo.	Carcinogenesis	2004	92
15659232	142	Tamagno E	Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways.	Journal of neurochemistry	2005	67
16306359	142	Obrosova IG	Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited.	Diabetes	2005	68
16728695	142	Catley L	Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.	Blood	2006	87
17016430	142	Chauhan D	A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.	Oncogene	2007	59
17339367	142	Pledgie-Tracy A	Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines.	Molecular cancer therapeutics	2007	70
18006697	142	Chauhan D	Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.	Blood	2008	60
18264087	142	Sakai W	Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.	Nature	2008	217
18264088	142	Edwards SL	Resistance to therapy caused by intragenic deletion in BRCA2.	Nature	2008	209
18483356	142	Sarkaria JN	Mechanisms of chemoresistance to alkylating agents in malignant glioma.	Clinical cancer research 	2008	69
18794155	142	Stan SD	Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo.	Cancer research	2008	63
18795165	142	Pacurari M	Raw single-wall carbon nanotubes induce oxidative stress and activate MAPKs, AP-1, NF-kappaB, and Akt in normal and malignant human mesothelial cells.	Environmental health perspectives	2008	52
19364967	142	Kummar S	Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.	Journal of clinical oncology 	2009	94
19509164	142	Ikeda H	The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.	Clinical cancer research 	2009	48
19762485	142	Kurtova AV	Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.	Blood	2009	87
19996272	142	Carboni JM	BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.	Molecular cancer therapeutics	2009	65
20072652	142	Lin L	A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.	Neoplasia	2010	52
20142589	142	Zarghooni M	Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets.	Journal of clinical oncology 	2010	90
20404278	142	Hoarau JJ	Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response.	Journal of immunology	2010	106
20406929	142	Fong PC	Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.	Journal of clinical oncology 	2010	202
20798217	142	Hastak K	Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin.	Cancer research	2010	45
21208101	142	O'Shaughnessy J	Iniparib plus chemotherapy in metastatic triple-negative breast cancer.	The New England journal of medicine	2011	180
21278435	142	Hudis CA	Triple-negative breast cancer: an unmet medical need.	The oncologist	2011	163
21487248	142	Dedes KJ	Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.	Cell cycle	2011	52
21709188	142	Norquist B	Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.	Journal of clinical oncology 	2011	85
21862407	142	Gelmon KA	Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.	The Lancet. Oncology	2011	225
21908496	142	Rojo F	Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer.	Annals of oncology 	2012	38
22330607	142	Kim A	Therapeutic strategies in epithelial ovarian cancer.	Journal of experimental and clinical cancer research 	2012	61
22416035	142	Williamson CT	Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.	EMBO molecular medicine	2012	40
22460902	142	Garnett MJ	Systematic identification of genomic markers of drug sensitivity in cancer cells.	Nature	2012	545
22641215	142	Tobin LA	Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.	Oncogene	2013	27
22682224	142	Cantó C	The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.	Cell metabolism	2012	167
22711857	142	Alsop K	BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.	Journal of clinical oncology 	2012	148
22902501	142	Doege CA	Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2.	Nature	2012	104
22912389	142	Wang ZC	Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome.	Clinical cancer research 	2012	37
22961666	142	Byers LA	Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.	Cancer discovery	2012	67
22993403	142	Schiewer MJ	Dual roles of PARP-1 promote cancer growth and progression.	Cancer discovery	2012	62
23097248	142	Ebrahimi KB	Decreased membrane complement regulators in the retinal pigmented epithelium contributes to age-related macular degeneration.	The Journal of pathology	2013	33
23370117	142	Curtin NJ	Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.	Molecular aspects of medicine	2013	64
23423489	142	Plummer R	A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.	Cancer chemotherapy and pharmacology	2013	30
23554447	142	Michels J	Cisplatin resistance associated with PARP hyperactivation.	Cancer research	2013	29
23656790	142	Bisso A	Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer.	Cell cycle	2013	30
23810467	142	Liu JF	A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.	European journal of cancer	2013	27
24063698	142	Dent RA	Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.	Breast cancer research 	2013	29
24270264	142	Meloche J	Role for DNA damage signaling in pulmonary arterial hypertension.	Circulation	2014	30
24435446	142	Fiskus W	Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.	Molecular cancer therapeutics	2014	39
24832602	142	Park EJ	β-Lapachone induces programmed necrosis through the RIP1-PARP-AIF-dependent pathway in human hepatocellular carcinoma SK-Hep1 cells.	Cell death and disease	2014	24
24912431	142	Cao Y	The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.	Leukemia	2015	15
24997452	142	Varga ZV	Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy.	Biochimica et biophysica acta	2015	31
25422887	142	Gong Z	LOC401317, a p53-regulated long non-coding RNA, inhibits cell proliferation and induces apoptosis in the nasopharyngeal carcinoma cell line HNE2.	PloS one	2014	22
25869442	142	Ferguson LR	Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition.	Seminars in cancer biology	2015	22
26004083	142	Severson TM	BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.	Molecular oncology	2015	18
26506418	142	Thorenoor N	Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer.	Oncotarget	2016	23
26779812	142	Du Y	Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.	Nature medicine	2016	13
27002934	142	Drew Y	Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.	British journal of cancer	2016	15
27376578	142	Adriaens C	p53 induces formation of NEAT1 lncRNA-containing paraspeckles that modulate replication stress response and chemosensitivity.	Nature medicine	2016	20
27908594	142	Swisher EM	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2017	18
9731568	174	-	A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators.	Hepatology	1998	231
10573521	174	Theise ND	The canals of Hering and hepatic stem cells in humans.	Hepatology	1999	113
11391528	174	Yao FY	Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.	Hepatology	2001	272
12547409	174	Imamura H	Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.	Journal of hepatology	2003	187
12851874	174	Capurro M	Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.	Gastroenterology	2003	134
15042359	174	Zhang BH	Randomized controlled trial of screening for hepatocellular carcinoma.	Journal of cancer research and clinical oncology	2004	201
15665226	174	Lencioni R	Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation.	Radiology	2005	112
16246200	174	Natsuizaka M	Clinical features of hepatocellular carcinoma with extrahepatic metastases.	Journal of gastroenterology and hepatology	2005	90
16542289	174	Farinati F	Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?	The American journal of gastroenterology	2006	68
16778155	174	Terai S	Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy.	Stem cells	2006	94
16890600	174	Takayasu K	Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.	Gastroenterology	2006	133
18069697	174	Forner A	Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.	Hepatology	2008	124
18350595	174	But DY	Natural history of hepatitis-related hepatocellular carcinoma.	World journal of gastroenterology	2008	66
18479363	174	Song W	Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.	International journal of clinical practice	2008	53
18580463	174	Zheng SS	Liver transplantation for hepatocellular carcinoma: Hangzhou experiences.	Transplantation	2008	89
18972441	174	Zhang L	The stem cell niche of human livers: symmetry between development and regeneration.	Hepatology	2008	65
19152426	174	Toso C	Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database.	Hepatology	2009	53
19362088	174	Marrero JA	Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.	Gastroenterology	2009	97
19454616	174	Wang M	Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma.	Cancer epidemiology, biomarkers and prevention 	2009	46
19731239	174	N'Kontchou G	Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis.	Hepatology	2009	55
19747749	174	Wu JC	Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma.	Journal of hepatology	2009	61
19801927	174	Cherqui D	Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation.	Annals of surgery	2009	48
19880964	174	Spee B	Characterisation of the liver progenitor cell niche in liver diseases: potential involvement of Wnt and Notch signalling.	Gut	2010	61
20066715	174	Carr BI	Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study.	Cancer	2010	44
20209641	174	Pomfret EA	Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States.	Liver transplantation 	2010	54
20351325	174	Glazer ES	Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma.	Journal of clinical oncology 	2010	44
20821352	174	Ghodsizadeh A	Generation of liver disease-specific induced pluripotent stem cells along with efficient differentiation to functional hepatocyte-like cells.	Stem cell reviews	2010	42
21278583	174	Qu KZ	Circulating microRNAs as biomarkers for hepatocellular carcinoma.	Journal of clinical gastroenterology	2011	62
21294289	174	DuBay D	Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion.	Annals of surgery	2011	45
21618574	174	Sangro B	Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.	Hepatology	2011	109
21621346	174	Yoon SM	Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes.	International journal of radiation oncology, biology, physics	2012	60
22750200	174	Duvoux C	Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.	Gastroenterology	2012	57
23041304	174	Cescon M	Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate.	Journal of hepatology	2013	26
23337478	174	Singal AG	Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?	The American journal of gastroenterology	2013	34
23874536	174	Zhong JH	Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization.	PloS one	2013	43
24002931	174	Flecken T	Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma.	Hepatology	2014	23
24096763	174	Zhong JH	Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma.	Annals of surgery	2014	69
24123097	174	Wong GL	On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir.	Hepatology	2014	23
25271081	174	Hu B	Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma.	Clinical cancer research 	2014	29
25714016	174	Tang J	Circulation long non-coding RNAs act as biomarkers for predicting tumorigenesis and metastasis in hepatocellular carcinoma.	Oncotarget	2015	27
25804634	174	Xu X	Liver transplantation for hepatocellular carcinoma beyond the Milan criteria.	Gut	2016	17
25845839	174	Wen Y	Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma.	International journal of cancer	2015	20
26628466	174	Wahl DR	Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.	Journal of clinical oncology 	2016	20
10200246	207	Cantley LC	New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway.	Proceedings of the National Academy of Sciences of the United States of America	1999	436
10749120	207	Zhong H	Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.	Cancer research	2000	300
10753955	207	Hsu AL	The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2.	The Journal of biological chemistry	2000	93
11357143	207	Blume-Jensen P	Oncogenic kinase signalling.	Nature	2001	728
11358816	207	Brognard J	Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.	Cancer research	2001	199
11673836	207	Tuder RM	Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis.	The Journal of pathology	2001	102
11948129	207	Malik SN	Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer.	Clinical cancer research 	2002	86
12062094	207	Humbert S	The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt.	Developmental cell	2002	112
12173037	207	Mitsiades CS	Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.	Oncogene	2002	104
12384559	207	Scotton CJ	Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer.	Cancer research	2002	115
12702506	207	Xu Q	Survival of acute myeloid leukemia cells requires PI3 kinase activation.	Blood	2003	109
12727836	207	Grille SJ	The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines.	Cancer research	2003	152
12897778	207	Matsunaga T	Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia.	Nature medicine	2003	133
14713953	207	Miyauchi H	Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21-dependent pathway.	The EMBO journal	2004	76
14737178	207	Steelman LS	JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.	Leukemia	2004	125
15059275	207	Hwang SY	IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Akt-dependent pathways.	Arthritis research and therapy	2004	81
15143086	207	Chakravarti A	The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.	Journal of clinical oncology 	2004	88
15156201	207	Majumder PK	mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.	Nature medicine	2004	274
15208673	207	Altomare DA	AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth.	Oncogene	2004	109
15505410	207	Osaki M	PI3K-Akt pathway: its functions and alterations in human cancer.	Apoptosis 	2004	203
15585641	207	deGraffenried LA	Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.	Clinical cancer research 	2004	77
15723049	207	Ohanna M	Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control.	Nature cell biology	2005	101
15735123	207	Dai DL	Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases.	Journal of clinical oncology 	2005	74
15765134	207	Dorn GW 2nd	Protein kinase cascades in the regulation of cardiac hypertrophy.	The Journal of clinical investigation	2005	178
15800227	207	Stallone G	Sirolimus for Kaposi's sarcoma in renal-transplant recipients.	The New England journal of medicine	2005	140
15833867	207	Takeuchi H	Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.	Cancer research	2005	155
16023083	207	Shishodia S	Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma.	Biochemical pharmacology	2005	78
16103100	207	Graff JR	The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.	Cancer research	2005	99
16324768	207	Tang JM	Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.	Lung cancer	2006	84
16428510	207	Qian DZ	Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.	Clinical cancer research 	2006	71
16532036	207	Mochizuki T	Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells.	Oncogene	2006	73
16537497	207	Liu H	Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2.	Proceedings of the National Academy of Sciences of the United States of America	2006	64
16543232	207	Misra UK	Activation and cross-talk between Akt, NF-kappaB, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78.	The Journal of biological chemistry	2006	69
16618740	207	Liu ZJ	Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression.	Cancer research	2006	82
16636132	207	Khakoo AY	Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma.	The Journal of experimental medicine	2006	181
16839745	207	Meng Q	Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.	Cellular signalling	2006	60
16885382	207	Xu Y	Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.	Cancer research	2006	97
16942488	207	Jia G	Insulin-like growth factor-1 and TNF-alpha regulate autophagy through c-jun N-terminal kinase and Akt pathways in human atherosclerotic vascular smooth cells.	Immunology and cell biology	2006	83
17043657	207	Baril P	Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway.	Oncogene	2007	77
17047067	207	Cao C	Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells.	Cancer research	2006	93
17182864	207	Shiojima I	Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway.	Genes and development	2006	112
17234779	207	Tabe Y	Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells.	Cancer research	2007	56
17311546	207	Maiese K	Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus.	Current neurovascular research	2007	62
17318262	207	Govindarajan B	Overexpression of Akt converts radial growth melanoma to vertical growth melanoma.	The Journal of clinical investigation	2007	86
17363567	207	Saxena NK	Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells.	Cancer research	2007	106
17395690	207	Aoki H	Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways.	Molecular pharmacology	2007	128
17404109	207	Puri N	c-Met is a potentially new therapeutic target for treatment of human melanoma.	Clinical cancer research 	2007	61
17483336	207	Ao M	Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium.	Cancer research	2007	77
17546049	207	Bauer S	KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.	Oncogene	2007	58
17551921	207	Shukla S	Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.	International journal of cancer	2007	73
17563753	207	Julien S	Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition.	Oncogene	2007	132
17611497	207	Carpten JD	A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.	Nature	2007	373
17627510	207	Maiese K	Mechanistic insights into diabetes mellitus and oxidative stress.	Current medicinal chemistry	2007	64
17873377	207	Dreesen O	Signaling pathways in cancer and embryonic stem cells.	Stem cell reviews	2007	84
17918180	207	Fraser M	Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.	International journal of cancer	2008	50
17998146	207	Schmitz KJ	Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection.	Journal of hepatology	2008	60
18240972	207	Léger B	Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation.	Rejuvenation research	2008	59
18245495	207	Hwang RF	Cancer-associated stromal fibroblasts promote pancreatic tumor progression.	Cancer research	2008	262
18281460	207	Hambardzumyan D	PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo.	Genes and development	2008	145
18324353	207	Hatcher H	Curcumin: from ancient medicine to current clinical trials.	Cellular and molecular life sciences 	2008	230
18339865	207	Yi T	Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling.	Cancer research	2008	51
18344980	207	Lim KH	Tumour maintenance is mediated by eNOS.	Nature	2008	97
18519702	207	Park CC	Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts.	Cancer research	2008	65
18649363	207	Li W	Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma.	International journal of cancer	2008	86
18676830	207	Stemke-Hale K	An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.	Cancer research	2008	299
18701483	207	Schnell CR	Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging.	Cancer research	2008	60
18838554	207	Degtyarev M	Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents.	The Journal of cell biology	2008	147
18843284	207	Podar K	Bone marrow microenvironment and the identification of new targets for myeloma therapy.	Leukemia	2009	87
18931688	207	Wang S	The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.	Oncogene	2008	50
18948577	207	Okawa Y	SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.	Blood	2009	47
19026743	207	Zhao WQ	Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease.	Biochimica et biophysica acta	2009	56
19110052	207	Chin YR	Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer.	Cellular signalling	2009	67
19195051	207	Fabregat I	Dysregulation of apoptosis in hepatocellular carcinoma cells.	World journal of gastroenterology	2009	60
19244107	207	Guo Z	A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.	Cancer research	2009	256
19265662	207	Bleau AM	PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.	Cell stem cell	2009	219
19270694	207	Lin HK	Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB.	Nature cell biology	2009	96
19270695	207	Gao D	Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction.	Nature cell biology	2009	96
19298854	207	Sarkar FH	Cellular signaling perturbation by natural products.	Cellular signalling	2009	53
19336660	207	Varma V	Muscle inflammatory response and insulin resistance: synergistic interaction between macrophages and fatty acids leads to impaired insulin action.	American journal of physiology. Endocrinology and metabolism	2009	58
19380449	207	Baselga J	Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.	Journal of clinical oncology 	2009	138
19425170	207	Salazar M	Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells.	The Journal of clinical investigation	2009	166
19483113	207	El Kebir D	15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury.	American journal of respiratory and critical care medicine	2009	60
19487299	207	Ricarte-Filho JC	Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.	Cancer research	2009	123
19556867	207	Di Vizio D	An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation.	Cell cycle	2009	60
19573808	207	Miao H	EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt.	Cancer cell	2009	110
19592505	207	Zong Y	ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.	Proceedings of the National Academy of Sciences of the United States of America	2009	85
19595306	207	Jiang BH	PI3K/PTEN signaling in angiogenesis and tumorigenesis.	Advances in cancer research	2009	109
19644473	207	Liu P	Targeting the phosphoinositide 3-kinase pathway in cancer.	Nature reviews. Drug discovery	2009	512
19796751	207	Rini BI	Resistance to targeted therapy in renal-cell carcinoma.	The Lancet. Oncology	2009	126
19808981	207	Golding SE	Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion.	Molecular cancer therapeutics	2009	83
19917848	207	Missiaglia E	Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway.	Journal of clinical oncology 	2010	84
19920197	207	Fu L	Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy.	Cancer research	2009	49
19996208	207	Davies MA	Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma.	Clinical cancer research 	2009	62
20049901	207	Morigi M	Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury.	Stem cells	2010	47
20051626	207	Ginestier C	CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts.	The Journal of clinical investigation	2010	205
20068177	207	Yu K	Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.	Cancer research	2010	56
20110532	207	Chimenti I	Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice.	Circulation research	2010	176
20133737	207	Ericson K	Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation.	Proceedings of the National Academy of Sciences of the United States of America	2010	43
20214616	207	Carnero A	The PKB/AKT pathway in cancer.	Current pharmaceutical design	2010	71
20360245	207	Meloni M	Nerve growth factor promotes cardiac repair following myocardial infarction.	Circulation research	2010	49
20388782	207	Ali S	Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.	Cancer research	2010	124
20460539	207	Giovannetti E	MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.	Cancer research	2010	109
20563248	207	Molina JR	Invasive glioblastoma cells acquire stemness and increased Akt activation.	Neoplasia	2010	59
20571069	207	Hirai H	MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.	Molecular cancer therapeutics	2010	271
20639898	207	Whittaker S	The role of signaling pathways in the development and treatment of hepatocellular carcinoma.	Oncogene	2010	190
20671189	207	Goldstein AS	Identification of a cell of origin for human prostate cancer.	Science	2010	201
20840586	207	Barash U	Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis.	The FEBS journal	2010	66
20876803	207	Chiarini F	Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.	Cancer research	2010	52
20972457	207	El Mjiyad N	Sugar-free approaches to cancer cell killing.	Oncogene	2011	54
21124782	207	Meng J	Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.	PloS one	2010	51
21205925	207	Chen KF	Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.	The Journal of pharmacology and experimental therapeutics	2011	61
21220598	207	Konopleva MY	Leukemia stem cells and microenvironment: biology and therapeutic targeting.	Journal of clinical oncology 	2011	107
21238503	207	Huang H	Regulation of FOXO protein stability via ubiquitination and proteasome degradation.	Biochimica et biophysica acta	2011	55
21325072	207	Song L	Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-κB pathway in human non-small cell lung cancer.	Clinical cancer research 	2011	49
21339740	207	Kim EK	Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis.	Oncogene	2011	37
21568903	207	Raimondi C	Targeting PDK1 in cancer.	Current medicinal chemistry	2011	39
21587219	207	Janku F	Autophagy as a target for anticancer therapy.	Nature reviews. Clinical oncology	2011	171
21618573	207	You H	c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma.	Hepatology	2011	56
21670080	207	Coloff JL	Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition.	Cancer research	2011	48
21752435	207	Behbakht K	Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.	Gynecologic oncology	2011	37
21757645	207	Dey-Guha I	Asymmetric cancer cell division regulated by AKT.	Proceedings of the National Academy of Sciences of the United States of America	2011	40
21878679	207	Chan JC	AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer.	Science signaling	2011	40
21884932	207	Sykes SM	AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias.	Cell	2011	76
21903249	207	Cho JA	Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts.	Gynecologic oncology	2011	45
21963805	207	Wang Z	Skp2: a novel potential therapeutic target for prostate cancer.	Biochimica et biophysica acta	2012	37
21975935	207	Yoo YA	Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer.	Cancer research	2011	80
22025163	207	Yap TA	First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.	Journal of clinical oncology 	2011	160
22057914	207	Cheng Y	MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis.	Molecular cancer therapeutics	2012	38
22067563	207	Wakimoto H	Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.	Neuro-oncology	2012	59
22116552	207	Rao E	The miRNA-17∼92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation.	Leukemia	2012	45
22234835	207	Fang Y	MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma.	Hepatology	2012	88
22248929	207	Garrett JT	Will PI3K pathway inhibitors be effective as single agents in patients with cancer?	Oncotarget	2011	35
22328975	207	Hanrahan AJ	Genomic complexity and AKT dependence in serous ovarian cancer.	Cancer discovery	2012	32
22355189	207	Sun Y	Inhibition of autophagy ameliorates acute lung injury caused by avian influenza A H5N1 infection.	Science signaling	2012	47
22402744	207	Weeraratne SD	Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma.	Acta neuropathologica	2012	53
22577490	207	Longato L	Insulin resistance, ceramide accumulation, and endoplasmic reticulum stress in human chronic alcohol-related liver disease.	Oxidative medicine and cellular longevity	2012	32
22579961	207	Bao B	The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness.	Biochimica et biophysica acta	2012	39
22585995	207	Xue G	Akt/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K/Akt and TGF-β signaling axes.	Cancer discovery	2012	32
22610073	207	Li XJ	As an independent unfavorable prognostic factor, IL-8 promotes metastasis of nasopharyngeal carcinoma through induction of epithelial-mesenchymal transition and activation of AKT signaling.	Carcinogenesis	2012	34
22846840	207	Salvesen HB	Markers for individualised therapy in endometrial carcinoma.	The Lancet. Oncology	2012	50
22875023	207	Ramaswamy B	Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.	Cancer research	2012	55
22898879	207	Wu K	Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development.	Hepatology	2012	43
23112296	207	Wang RC	Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation.	Science	2012	146
23135998	207	Xu L	MicroRNA-7-regulated TLR9 signaling-enhanced growth and metastatic potential of human lung cancer cells by altering the phosphoinositide-3-kinase, regulatory subunit 3/Akt pathway.	Molecular biology of the cell	2013	26
23251084	207	Naujokat C	Salinomycin as a drug for targeting human cancer stem cells.	Journal of biomedicine and biotechnology	2012	54
23255107	207	Würth R	Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt.	Cell cycle	2013	52
23263555	207	Strainic MG	Absence of signaling into CD4⁺ cells via C3aR and C5aR enables autoinductive TGF-β1 signaling and induction of Foxp3⁺ regulatory T cells.	Nature immunology	2013	69
23293329	207	Jankovic B	Clinical Review: Hashimoto's thyroiditis and papillary thyroid carcinoma: is there a correlation?	The Journal of clinical endocrinology and metabolism	2013	34
23355761	207	Xue G	PKB/Akt-dependent regulation of cell motility.	Journal of the National Cancer Institute	2013	44
23470275	207	O' Neill C	PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer's disease.	Experimental gerontology	2013	30
23515290	207	Vo BT	TGF-β effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway.	Endocrinology	2013	34
23579241	207	Azijli K	Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family.	Cell death and differentiation	2013	31
23589885	207	Kucharzewska P	Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development.	Proceedings of the National Academy of Sciences of the United States of America	2013	132
23593475	207	Wu S	Microvesicles derived from human umbilical cord Wharton's jelly mesenchymal stem cells attenuate bladder tumor cell growth in vitro and in vivo.	PloS one	2013	27
23778311	207	McCubrey JA	Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.	Leukemia	2014	34
23840064	207	Pfeifer M	PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma.	Proceedings of the National Academy of Sciences of the United States of America	2013	35
24065147	207	Niederst MJ	Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.	Science signaling	2013	53
24096870	207	Liu PP	Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway.	Cell death and differentiation	2014	38
24242861	207	Rosenberg JE	A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma.	Investigational new drugs	2014	32
24270740	207	Cheng S	BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.	Leukemia	2014	37
24280585	207	Li YC	Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells.	Cancer letters	2014	31
24333502	207	Polivka J Jr	Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.	Pharmacology and therapeutics	2014	71
24336570	207	Johnson BE	Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.	Science	2014	192
24393708	207	Francipane MG	mTOR pathway in colorectal cancer: an update.	Oncotarget	2014	30
24440717	207	Janku F	Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.	Cell reports	2014	50
24469833	207	Mathews Griner LA	High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.	Proceedings of the National Academy of Sciences of the United States of America	2014	60
24481312	207	Fruman DA	PI3K and cancer: lessons, challenges and opportunities.	Nature reviews. Drug discovery	2014	254
24606897	207	Yue S	Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness.	Cell metabolism	2014	66
24662831	207	Xiao L	Targeting Epstein-Barr virus oncoprotein LMP1-mediated glycolysis sensitizes nasopharyngeal carcinoma to radiation therapy.	Oncogene	2014	21
24705351	207	Zhai B	Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma.	Molecular cancer therapeutics	2014	36
24777052	207	Ocana A	Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis.	PloS one	2014	30
24838891	207	Chin YR	PTEN-deficient tumors depend on AKT2 for maintenance and survival.	Cancer discovery	2014	22
24861879	207	Shi Z	MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras.	Neuro-oncology	2014	27
24896186	207	Wang L	Novel somatic and germline mutations in intracranial germ cell tumours.	Nature	2014	26
24980823	207	Wang L	MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma.	Oncotarget	2014	36
24998913	207	Lee JV	Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation.	Cell metabolism	2014	64
25001183	207	Hu J	microRNA-128 plays a critical role in human non-small cell lung cancer tumourigenesis, angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C.	European journal of cancer	2014	23
25071141	207	Sabine VS	Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.	Journal of clinical oncology 	2014	21
25080109	207	Rodriguez J	Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways.	Cellular and molecular life sciences 	2014	23
25185240	207	Rothé F	Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.	Annals of oncology 	2014	35
25187230	207	Yu SH	miR-99a suppresses the metastasis of human non-small cell lung cancer cells by targeting AKT1 signaling pathway.	Journal of cellular biochemistry	2015	19
25202833	207	Hsueh AJ	Intraovarian control of early folliculogenesis.	Endocrine reviews	2015	21
25284585	207	Dillon LM	P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.	Oncogene	2015	17
25347742	207	Cai LM	EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN.	Oncogene	2015	33
25370471	207	Sarker D	First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.	Clinical cancer research 	2015	38
25590803	207	Choudhary GS	MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.	Cell death and disease	2015	49
25600436	207	Frigault MJ	Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells.	Cancer immunology research	2015	25
25704303	207	Zhang J	PI3K/Akt signaling in osteosarcoma.	Clinica chimica acta; international journal of clinical chemistry	2015	22
25749412	207	Warfel NA	PIM kinase (and Akt) biology and signaling in tumors.	Pharmacology and therapeutics	2015	22
25796440	207	Paw I	Mechanisms regulating glioma invasion.	Cancer letters	2015	31
25909227	207	Go H	MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.	Oncotarget	2015	16
25964336	207	Kuppusamy KT	Let-7 family of microRNA is required for maturation and adult-like metabolism in stem cell-derived cardiomyocytes.	Proceedings of the National Academy of Sciences of the United States of America	2015	28
26124089	207	Caino MC	PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion.	Proceedings of the National Academy of Sciences of the United States of America	2015	28
26299803	207	Cheng Z	A long noncoding RNA AB073614 promotes tumorigenesis and predicts poor prognosis in ovarian cancer.	Oncotarget	2015	26
26342236	207	Le Tourneau C	Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.	The Lancet. Oncology	2015	66
26364608	207	Coarfa C	Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.	Oncogene	2016	16
26451606	207	Sharma N	PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth.	Oncotarget	2015	33
26804739	207	Subramani R	Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition.	Scientific reports	2016	12
26826201	207	Abedalthagafi M	Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.	Neuro-oncology	2016	16
26832662	207	Lechman ER	miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells.	Cancer cell	2016	18
26947078	207	Chen F	Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma.	Cell reports	2016	24
27050099	207	Lee JK	N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.	Cancer cell	2016	18
27061150	207	Kim H	Mango polyphenolics reduce inflammation in intestinal colitis-involvement of the miR-126/PI3K/AKT/mTOR axis in vitro and in vivo.	Molecular carcinogenesis	2017	5
27524440	207	Liang Q	Zika Virus NS4A and NS4B Proteins Deregulate Akt-mTOR Signaling in Human Fetal Neural Stem Cells to Inhibit Neurogenesis and Induce Autophagy.	Cell stem cell	2016	19
27642729	207	Kaneda MM	PI3Kγ is a molecular switch that controls immune suppression.	Nature	2016	18
17920722	216	Patel M	ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors.	Lung cancer	2008	55
18371393	216	Ginestier C	ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.	Cell stem cell	2007	1089
18560594	216	Dylla SJ	Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy.	PloS one	2008	165
19276181	216	Jiang F	Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer.	Molecular cancer research 	2009	215
19329942	216	Chang B	ALDH1 expression correlates with favorable prognosis in ovarian cancers.	Modern pathology 	2009	46
19336570	216	Huang EH	Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis.	Cancer research	2009	319
19385968	216	Morimoto K	Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression.	Cancer science	2009	56
19911270	216	Resetkova E	Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment.	Breast cancer research and treatment	2010	57
20010854	216	Li T	ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome.	Laboratory investigation; a journal of technical methods and pathology	2010	103
20028757	216	Charafe-Jauffret E	Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer.	Clinical cancer research 	2010	213
20142235	216	Su Y	Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer.	Cancer epidemiology, biomarkers and prevention 	2010	65
20228222	216	Neumeister V	In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis.	The American journal of pathology	2010	45
20422001	216	Deng S	Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers.	PloS one	2010	141
20889728	216	Landen CN Jr	Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.	Molecular cancer therapeutics	2010	101
21118965	216	Sullivan JP	Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling.	Cancer research	2010	107
21552008	216	Marcato P	Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform.	Cell cycle	2011	123
22887839	216	Luo Y	ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets.	Stem cells	2012	67
23467088	216	Flesken-Nikitin A	Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche.	Nature	2013	84
23548270	216	Yu CC	miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer.	Cancer research	2013	35
24142344	216	Charafe-Jauffret E	ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program.	Cancer research	2013	30
24201124	216	Yang L	ALDH1A1 defines invasive cancer stem-like cells and predicts poor prognosis in patients with esophageal squamous cell carcinoma.	Modern pathology 	2014	23
24615157	216	Liu L	Triptolide reverses hypoxia-induced epithelial-mesenchymal transition and stem-like features in pancreatic cancer by NF-κB downregulation.	International journal of cancer	2014	22
24859412	216	Honjo S	Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer.	International journal of oncology	2014	21
25384215	216	Zhao D	NOTCH-induced aldehyde dehydrogenase 1A1 deacetylation promotes breast cancer stem cells.	The Journal of clinical investigation	2014	23
26020648	216	Grosse-Wilde A	Stemness of the hybrid Epithelial/Mesenchymal State in Breast Cancer and Its Association with Poor Survival.	PloS one	2015	28
26783961	216	Tomita H	Aldehyde dehydrogenase 1A1 in stem cells and cancer.	Oncotarget	2016	32
17414097	238	Coffin CM	Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases.	The American journal of surgical pathology	2007	113
17519389	238	Amin HM	Pathobiology of ALK+ anaplastic large-cell lymphoma.	Blood	2007	60
18089725	238	Christensen JG	Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.	Molecular cancer therapeutics	2007	157
18385450	238	Savage KJ	ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.	Blood	2008	118
18990089	238	Carén H	High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours.	The Biochemical journal	2008	61
19671850	238	Rodig SJ	Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.	Clinical cancer research 	2009	141
19737969	238	Lin E	Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.	Molecular cancer research 	2009	79
20660290	238	Schmitz N	Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.	Blood	2010	47
20979469	238	Kwak EL	Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.	The New England journal of medicine	2010	1033
21258247	238	Paik JH	Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.	Journal of thoracic oncology 	2011	68
21278610	238	Yi ES	Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH.	Journal of thoracic oncology 	2011	58
21288922	238	Shaw AT	Targeting anaplastic lymphoma kinase in lung cancer.	Clinical cancer research 	2011	48
21575866	238	Sakamoto H	CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.	Cancer cell	2011	114
21623265	238	Ou SH	Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.	Journal of thoracic oncology 	2011	96
21933749	238	Shaw AT	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.	The Lancet. Oncology	2011	199
22071784	238	McLeer-Florin A	Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study.	Journal of thoracic oncology 	2012	40
22129856	238	Paik JH	Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.	Lung cancer	2012	34
22184391	238	van Gaal JC	Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications.	Journal of clinical oncology 	2012	32
22589483	238	Matthay KK	Promising therapeutic targets in neuroblastoma.	Clinical cancer research 	2012	41
22735679	238	Ilie M	ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma.	Annals of oncology 	2012	37
22851556	238	d'Amore F	Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.	Journal of clinical oncology 	2012	43
23344087	238	Kim S	Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.	Journal of thoracic oncology 	2013	38
23533265	238	Sang J	Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.	Cancer discovery	2013	69
23598171	238	Mossé YP	Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.	The Lancet. Oncology	2013	100
23669222	238	Pailler E	Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.	Journal of clinical oncology 	2013	57
23724914	238	Awad MM	Acquired resistance to crizotinib from a mutation in CD74-ROS1.	The New England journal of medicine	2013	53
23904459	238	Ying J	Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma.	Annals of oncology 	2013	35
24478318	238	Ou SH	Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.	Annals of oncology 	2014	35
24629636	238	Pan Y	ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.	Lung cancer	2014	45
24675041	238	Friboulet L	The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.	Cancer discovery	2014	128
24736079	238	Ignatius Ou SH	Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.	Journal of thoracic oncology 	2014	33
24875859	238	Lovly CM	Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.	Cancer discovery	2014	30
24887559	238	Kodama T	Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.	Cancer letters	2014	28
24894770	238	Parrilla Castellar ER	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.	Blood	2014	25
25153538	238	Gadgeel SM	Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.	The Lancet. Oncology	2014	103
25173427	238	Lovly CM	Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.	Nature medicine	2014	51
25228534	238	Katayama R	Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.	Clinical cancer research 	2014	45
25526238	238	Gainor JF	Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.	Journal of thoracic oncology 	2015	23
25721120	238	Pekar-Zlotin M	Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.	The oncologist	2015	20
26544515	238	Nilsson RJ	Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.	Oncotarget	2016	14
26598747	238	Ou SH	Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.	Journal of clinical oncology 	2016	61
26698910	238	Shaw AT	Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.	The New England journal of medicine	2016	42
26916631	238	Marchetti A	ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.	Journal of thoracic oncology 	2016	13
26973324	238	Kim DW	Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.	The Lancet. Oncology	2016	45
27432917	238	Crinò L	Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.	Journal of clinical oncology 	2016	21
27863201	238	Gadgeel SM	Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2016	10
9663482	308	Herrmann M	Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus.	Arthritis and rheumatism	1998	152
10694520	308	Mallat Z	Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes.	Circulation	2000	124
10845625	308	Sparrow JR	The lipofuscin fluorophore A2E mediates blue light-induced damage to retinal pigmented epithelial cells.	Investigative ophthalmology and visual science	2000	125
12806611	308	Van den Brande JM	Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.	Gastroenterology	2003	80
16092118	308	Li L	Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis.	Cancer	2005	96
16192427	308	Amabile N	Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure.	Journal of the American Society of Nephrology 	2005	91
16357305	308	Teichert-Kuliszewska K	Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension.	Circulation research	2006	65
17431114	308	Liu TJ	Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.	Molecular cancer therapeutics	2007	59
17909050	308	Phillips PA	Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70.	Cancer research	2007	80
18523067	308	Blankenberg FG	In vivo detection of apoptosis.	Journal of nuclear medicine 	2008	62
18983485	308	Robert S	Standardization of platelet-derived microparticle counting using calibrated beads and a Cytomics FC500 routine flow cytometer: a first step towards multicenter studies?	Journal of thrombosis and haemostasis 	2009	63
24339880	308	Ren J	Signature of circulating microRNAs as potential biomarkers in vulnerable coronary artery disease.	PloS one	2013	36
25827830	308	Camus SM	Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease.	Blood	2015	22
8103819	348	Poirier J	Apolipoprotein E polymorphism and Alzheimer's disease.	Lancet	1993	159
8398148	348	Rebeck GW	Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions.	Neuron	1993	161
8415756	348	Schmechel DE	Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.	Proceedings of the National Academy of Sciences of the United States of America	1993	251
8446617	348	Strittmatter WJ	Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.	Proceedings of the National Academy of Sciences of the United States of America	1993	629
10227624	348	Jack CR Jr	Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment.	Neurology	1999	309
10487842	348	Lue LF	Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.	The American journal of pathology	1999	378
10762153	348	Killiany RJ	Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease.	Annals of neurology	2000	150
10783137	348	Mullins RF	Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease.	FASEB journal 	2000	249
11445259	348	Jernigan TL	Effects of age on tissues and regions of the cerebrum and cerebellum.	Neurobiology of aging	2001	186
11487050	348	Nunomura A	Oxidative damage is the earliest event in Alzheimer disease.	Journal of neuropathology and experimental neurology	2001	328
11916953	348	Peila R	Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study.	Diabetes	2002	246
12368303	348	Garnett CT	Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes.	Journal of virology	2002	82
12566949	348	Kuller LH	Risk factors for dementia in the cardiovascular health cognition study.	Neuroepidemiology	2003	86
14568809	348	Lopez OL	Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2.	Archives of neurology	2003	89
14729357	348	Anderson DH	Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration.	Experimental eye research	2004	85
14991811	348	Gorno-Tempini ML	Cognition and anatomy in three variants of primary progressive aphasia.	Annals of neurology	2004	291
15172743	348	Raber J	ApoE genotype accounts for the vast majority of AD risk and AD pathology.	Neurobiology of aging	2004	101
15473992	348	Ikonomovic MD	Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury.	Experimental neurology	2004	101
15477533	348	Tang-Wai DF	Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy.	Neurology	2004	110
15911795	348	Enzinger C	Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects.	Neurology	2005	71
15932949	348	Reiman EM	Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism.	Proceedings of the National Academy of Sciences of the United States of America	2005	120
15987548	348	Omalu BI	Chronic traumatic encephalopathy in a National Football League player.	Neurosurgery	2005	124
16289476	348	Scheff SW	Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment.	Neurobiology of aging	2006	162
16682537	348	Jicha GA	Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia.	Archives of neurology	2006	131
16782234	348	Zipser BD	Microvascular injury and blood-brain barrier leakage in Alzheimer's disease.	Neurobiology of aging	2007	84
16807921	348	Honig LS	Shorter telomeres are associated with mortality in those with APOE epsilon4 and dementia.	Annals of neurology	2006	60
17030756	348	Wishart HA	Regional brain atrophy in cognitively intact adults with a single APOE epsilon4 allele.	Neurology	2006	61
17470753	348	Scheff SW	Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment.	Neurology	2007	157
17515542	348	Bowman GL	Blood-brain barrier impairment in Alzheimer disease: stability and functional significance.	Neurology	2007	55
17698496	348	Lockhart A	PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis.	Brain 	2007	90
17879383	348	Sonnen JA	Pathological correlates of dementia in a longitudinal, population-based sample of aging.	Annals of neurology	2007	154
18054253	348	Vemuri P	Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies.	NeuroImage	2008	142
18349428	348	Calderón-Garcidueñas L	Long-term air pollution exposure is associated with neuroinflammation, an altered innate immune response, disruption of the blood-brain barrier, ultrafine particulate deposition, and accumulation of amyloid beta-42 and alpha-synuclein in children and young adults.	Toxicologic pathology	2008	103
18369648	348	Thal DR	Cerebral amyloid angiopathy and its relationship to Alzheimer's disease.	Acta neuropathologica	2008	57
18378884	348	Vernooij MW	Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study.	Neurology	2008	117
18401023	348	Cosentino S	APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease.	Neurology	2008	66
18412267	348	Mesulam M	Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia.	Annals of neurology	2008	135
18691658	348	Hua X	Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects.	NeuroImage	2008	135
18723162	348	Devanand DP	Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease.	Biological psychiatry	2008	68
18801597	348	Smith CD	White matter diffusion alterations in normal women at risk of Alzheimer's disease.	Neurobiology of aging	2010	42
19076441	348	Mosconi L	Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease.	Annals of the New York Academy of Sciences	2008	90
19251758	348	Schuff N	MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers.	Brain 	2009	166
19255410	348	Berlau DJ	APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old.	Neurology	2009	55
19319544	348	Bell RD	Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease.	Acta neuropathologica	2009	186
19339712	348	Drzezga A	Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease.	Neurology	2009	66
19587325	348	Okello A	Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.	Neurology	2009	106
19812458	348	Honea RA	Cardiorespiratory fitness and preserved medial temporal lobe volume in Alzheimer disease.	Alzheimer disease and associated disorders	2009	73
19901249	348	Migliaccio R	Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum.	Neurology	2009	57
19918254	348	Fotuhi M	Changing perspectives regarding late-life dementia.	Nature reviews. Neurology	2009	77
19923550	348	Salloway S	A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.	Neurology	2009	173
19966301	348	Finch CE	Evolution in health and medicine Sackler colloquium: Evolution of the human lifespan and diseases of aging: roles of infection, inflammation, and nutrition.	Proceedings of the National Academy of Sciences of the United States of America	2010	80
20031276	348	Rasgon NL	Insulin resistance and hippocampal volume in women at risk for Alzheimer's disease.	Neurobiology of aging	2011	41
20065246	348	Honea RA	Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease.	Neurology	2010	47
20155424	348	Grinberg LT	Vascular pathology in the aged human brain.	Acta neuropathologica	2010	61
20231448	348	Mosconi L	Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's.	Proceedings of the National Academy of Sciences of the United States of America	2010	59
20373342	348	Vemuri P	Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease.	Annals of neurology	2010	61
20428236	348	Wang L	Abundant lipid and protein components of drusen.	PloS one	2010	76
20537952	348	Huang Y	Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease.	Trends in molecular medicine	2010	44
20538373	348	Caroli A	The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort.	Neurobiology of aging	2010	46
20541837	348	Koch W	Diagnostic power of default mode network resting state fMRI in the detection of Alzheimer's disease.	Neurobiology of aging	2012	48
20620664	348	Risacher SL	Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort.	Neurobiology of aging	2010	82
20697045	348	De Meyer G	Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people.	Archives of neurology	2010	129
20739645	348	Ahtiluoto S	Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study.	Neurology	2010	90
20739649	348	Matsuzaki T	Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study.	Neurology	2010	79
20818789	348	Liang KY	Exercise and Alzheimer's disease biomarkers in cognitively normal older adults.	Annals of neurology	2010	59
20847408	348	Valla J	Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE ε4 allele, the major late-onset Alzheimer's susceptibility gene.	Journal of Alzheimer's disease 	2010	52
20862329	348	Cruchaga C	SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease.	PLoS genetics	2010	48
20864661	348	Zhu YC	Severity of dilated Virchow-Robin spaces is associated with age, blood pressure, and MRI markers of small vessel disease: a population-based study.	Stroke	2010	48
20876479	348	Poels MM	Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam scan study.	Stroke	2010	76
21045163	348	Bekris LM	Genetics of Alzheimer disease.	Journal of geriatric psychiatry and neurology	2010	61
21060014	348	Carmichael O	Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative.	Archives of neurology	2010	72
21158978	348	Morgan D	Immunotherapy for Alzheimer's disease.	Journal of internal medicine	2011	55
21283692	348	Twine NA	Whole transcriptome sequencing reveals gene expression and splicing differences in brain regions affected by Alzheimer's disease.	PloS one	2011	79
21422459	348	Gupta VB	Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging.	Neurology	2011	44
21529702	348	Pike KE	Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study.	Neuropsychologia	2011	45
21596774	348	Nelson PT	Hippocampal sclerosis in advanced age: clinical and pathological features.	Brain 	2011	69
21690377	348	Ding JD	Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration.	Proceedings of the National Academy of Sciences of the United States of America	2011	60
21706175	348	Schmidt R	Heterogeneity in age-related white matter changes.	Acta neuropathologica	2011	47
21802369	348	Murray ME	Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study.	The Lancet. Neurology	2011	118
21955814	348	Calderón-Garcidueñas L	Neuroinflammation, hyperphosphorylated tau, diffuse amyloid plaques, and down-regulation of the cellular prion protein in air pollution exposed children and young adults.	Journal of Alzheimer's disease 	2012	45
21969589	348	Johnson LV	Cell culture model that mimics drusen formation and triggers complement activation associated with age-related macular degeneration.	Proceedings of the National Academy of Sciences of the United States of America	2011	50
21971471	348	Reiman EM	Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments.	Journal of Alzheimer's disease 	2011	103
21975202	348	Jones DT	Age-related changes in the default mode network are more advanced in Alzheimer disease.	Neurology	2011	74
22095980	348	Averill MM	S100A8 and S100A9 in cardiovascular biology and disease.	Arteriosclerosis, thrombosis, and vascular biology	2012	34
22169231	348	Sabuncu MR	The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects.	Cerebral cortex	2012	32
22228589	348	Zhu Y	APOE genotype alters glial activation and loss of synaptic markers in mice.	Glia	2012	38
22305802	348	Sperling R	Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.	The Lancet. Neurology	2012	67
22409939	348	Jack CR Jr	Shapes of the trajectories of 5 major biomarkers of Alzheimer disease.	Archives of neurology	2012	42
22517093	348	Seppälä TT	CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings.	Neurology	2012	37
22613170	348	McDonald BC	Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study.	Brain, behavior, and immunity	2013	33
22633529	348	Fleisher AS	Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease.	Neurobiology of aging	2013	40
22637583	348	Koffie RM	Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β.	Brain 	2012	62
22825311	348	Honig LS	Association of shorter leukocyte telomere repeat length with dementia and mortality.	Archives of neurology	2012	37
22972646	348	Lo RY	Vascular burden and Alzheimer disease pathologic progression.	Neurology	2012	47
23018443	348	Soontornniyomkij V	Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers.	AIDS	2012	32
23037886	348	Irwin DJ	Neuropathologic substrates of Parkinson disease dementia.	Annals of neurology	2012	81
23100439	348	Hashimoto T	Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide.	The Journal of neuroscience 	2012	39
23142051	348	Pencheva N	Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis.	Cell	2012	70
23153970	348	Hua X	Unbiased tensor-based morphometry: improved robustness and sample size estimates for Alzheimer's disease clinical trials.	NeuroImage	2013	51
23240599	348	Jahanshad N	Disrupted brain networks in the aging HIV+ population.	Brain connectivity	2012	32
23280791	348	Vemuri P	Effect of lifestyle activities on Alzheimer disease biomarkers and cognition.	Annals of neurology	2012	35
23407718	348	Tsuang D	APOE ε4 increases risk for dementia in pure synucleinopathies.	JAMA neurology	2013	45
23424032	348	Knopman DS	Brain injury biomarkers are not dependent on β-amyloid in normal elderly.	Annals of neurology	2013	45
23424091	348	Gurol ME	Cerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomography/magnetic resonance imaging study.	Annals of neurology	2013	37
23599929	348	Protas HD	Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease.	JAMA neurology	2013	28
23883936	348	Rhinn H	Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease.	Nature	2013	51
24041970	348	Whiley L	Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease.	Neurobiology of aging	2014	31
24132374	348	Hughes TM	Pulse wave velocity is associated with β-amyloid deposition in the brains of very elderly adults.	Neurology	2013	31
24145819	348	Lim AS	Modification of the relationship of the apolipoprotein E ε4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep.	JAMA neurology	2013	34
24244562	348	Ridge PG	Alzheimer's disease: analyzing the missing heritability.	PloS one	2013	39
24269021	348	Johnson SC	Amyloid burden and neural function in people at risk for Alzheimer's Disease.	Neurobiology of aging	2014	29
24276092	348	Dean DC 3rd	Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study.	JAMA neurology	2014	46
24401693	348	Duan L	Stem cell derived basal forebrain cholinergic neurons from Alzheimer's disease patients are more susceptible to cell death.	Molecular neurodegeneration	2014	26
24450891	348	Salloway S	Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.	The New England journal of medicine	2014	245
24623176	348	Altmann A	Sex modifies the APOE-related risk of developing Alzheimer disease.	Annals of neurology	2014	61
24623839	348	Yates PA	Incidence of cerebral microbleeds in preclinical Alzheimer disease.	Neurology	2014	20
24713533	348	Romero JR	Risk factors, stroke prevention treatments, and prevalence of cerebral microbleeds in the Framingham Heart Study.	Stroke	2014	29
24748674	348	Mormino EC	Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease.	Neurology	2014	60
24818585	348	Kester MI	Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers.	JAMA neurology	2014	20
24886908	348	Donohue MC	The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.	JAMA neurology	2014	57
25178429	348	Mata IF	APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease.	JAMA neurology	2014	24
25217293	348	Michaelson DM	APOE ε4: the most prevalent yet understudied risk factor for Alzheimer's disease.	Alzheimer's and dementia 	2014	21
25253756	348	Kryscio RJ	Self-reported memory complaints: implications from a longitudinal cohort with autopsies.	Neurology	2014	31
25623662	348	Serrano-Pozo A	APOEε2 is associated with milder clinical and pathological Alzheimer disease.	Annals of neurology	2015	17
25672924	348	Wang R	Effects of vascular risk factors and APOE ε4 on white matter integrity and cognitive decline.	Neurology	2015	18
25805643	348	Murray ME	Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum.	Brain 	2015	39
25988462	348	Jansen WJ	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.	JAMA	2015	73
25988463	348	Ossenkoppele R	Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis.	JAMA	2015	36
26214150	348	Willette AA	Association of Insulin Resistance With Cerebral Glucose Uptake in Late Middle-Aged Adults at Risk for Alzheimer Disease.	JAMA neurology	2015	23
26354483	348	Jaunmuktane Z	Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy.	Nature	2015	41
26518018	348	Bieniek KF	Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank.	Acta neuropathologica	2015	26
26564908	348	Tambini MD	ApoE4 upregulates the activity of mitochondria-associated ER membranes.	EMBO reports	2016	13
27025652	348	Selkoe DJ	The amyloid hypothesis of Alzheimer's disease at 25 years.	EMBO molecular medicine	2016	126
27312738	348	Arvanitakis Z	Relation of cerebral vessel disease to Alzheimer's disease dementia and cognitive function in elderly people: a cross-sectional study.	The Lancet. Neurology	2016	16
27979356	348	Irwin DJ	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.	The Lancet. Neurology	2017	7
7857653	351	Saido TC	Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques.	Neuron	1995	118
8810256	351	Hsiao K	Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.	Science	1996	937
9126051	351	Ferguson B	Axonal damage in acute multiple sclerosis lesions.	Brain 	1997	190
10386999	351	Huang X	The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction.	Biochemistry	1999	136
10681545	351	Wang HY	beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology.	The Journal of biological chemistry	2000	144
10735393	351	Näslund J	Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline.	JAMA	2000	252
10833057	351	Roof RL	Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone.	Journal of neurotrauma	2000	105
11409420	351	Grabowski TJ	Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy.	Annals of neurology	2001	113
11910111	351	DeMattos RB	Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.	Science	2002	105
12084879	351	Thal DR	Phases of A beta-deposition in the human brain and its relevance for the development of AD.	Neurology	2002	398
12244078	351	Kuhlmann T	Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.	Brain 	2002	99
12702875	351	Kayed R	Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.	Science	2003	950
14643377	351	Oddo S	Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease.	Neurobiology of aging	2003	215
14676042	351	Ritchie CW	Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.	Archives of neurology	2003	146
14676043	351	Clark CM	Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?	Archives of neurology	2003	103
14970312	351	Cutler RG	Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease.	Proceedings of the National Academy of Sciences of the United States of America	2004	208
15123740	351	Hitomi J	Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Abeta-induced cell death.	The Journal of cell biology	2004	195
15148385	351	Craner MJ	Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger.	Proceedings of the National Academy of Sciences of the United States of America	2004	90
15474976	351	Tuppo EE	The role of inflammation in Alzheimer's disease.	The international journal of biochemistry and cell biology	2005	127
15731448	351	Stokin GB	Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease.	Science	2005	295
15864339	351	Gandy S	The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease.	The Journal of clinical investigation	2005	101
16401735	351	Markesbery WR	Neuropathologic substrate of mild cognitive impairment.	Archives of neurology	2006	155
16541076	351	Lesné S	A specific amyloid-beta protein assembly in the brain impairs memory.	Nature	2006	803
16738244	351	Deshpande A	Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons.	The Journal of neuroscience 	2006	115
16837572	351	Rajendran L	Alzheimer's disease beta-amyloid peptides are released in association with exosomes.	Proceedings of the National Academy of Sciences of the United States of America	2006	227
16959815	351	Cabrejo L	Phenotype associated with APP duplication in five families.	Brain 	2006	62
17086100	351	Nicoll JA	Abeta species removal after abeta42 immunization.	Journal of neuropathology and experimental neurology	2006	108
17187063	351	Fulga TA	Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo.	Nature cell biology	2007	110
17360908	351	Shankar GM	Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway.	The Journal of neuroscience 	2007	440
17430239	351	Craft S	Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment.	Current Alzheimer research	2007	126
17664130	351	Butterfield DA	Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment.	Free radical biology and medicine	2007	101
17950572	351	Lockstone HE	Gene expression profiling in the adult Down syndrome brain.	Genomics	2007	58
18359102	351	Selkoe DJ	Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior.	Behavioural brain research	2008	303
18458217	351	Bian H	CSF biomarkers in frontotemporal lobar degeneration with known pathology.	Neurology	2008	54
18667258	351	Guerreiro RJ	Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP.	Neurobiology of aging	2010	44
18953056	351	Boche D	Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.	Brain 	2008	80
19118806	351	Roher AE	Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease.	Alzheimer's and dementia 	2009	58
19228952	351	Meilandt WJ	Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice.	The Journal of neuroscience 	2009	54
19433662	351	Dong Y	The common inhalational anesthetic sevoflurane induces apoptosis and increases beta-amyloid protein levels.	Archives of neurology	2009	53
19581601	351	Britschgi M	Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease.	Proceedings of the National Academy of Sciences of the United States of America	2009	46
19828212	351	Vogt DL	Abnormal neuronal networks and seizure susceptibility in mice overexpressing the APP intracellular domain.	Neurobiology of aging	2011	35
19951690	351	Sun B	Imbalance between GABAergic and Glutamatergic Transmission Impairs Adult Neurogenesis in an Animal Model of Alzheimer's Disease.	Cell stem cell	2009	49
20008651	351	Storandt M	Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition.	Archives of neurology	2009	128
20101004	351	Hartz AM	Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease.	Molecular pharmacology	2010	63
20209079	351	Soscia SJ	The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide.	PloS one	2010	147
20237263	351	Kaneko M	Loss of HRD1-mediated protein degradation causes amyloid precursor protein accumulation and amyloid-beta generation.	The Journal of neuroscience 	2010	43
20552018	351	Schonrock N	Neuronal microRNA deregulation in response to Alzheimer's disease amyloid-beta.	PloS one	2010	56
21262831	351	Watts JC	Bioluminescence imaging of Abeta deposition in bigenic mouse models of Alzheimer's disease.	Proceedings of the National Academy of Sciences of the United States of America	2011	42
22017494	351	Rosen RF	Exogenous seeding of cerebral β-amyloid deposition in βAPP-transgenic rats.	Journal of neurochemistry	2012	36
22116809	351	Hartz AM	Amyloid-β contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy.	Stroke	2012	36
22635102	351	Bush AI	The metal theory of Alzheimer's disease.	Journal of Alzheimer's disease 	2013	28
22801501	351	Jonsson T	A mutation in APP protects against Alzheimer's disease and age-related cognitive decline.	Nature	2012	339
23575824	351	Cohen RM	A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss.	The Journal of neuroscience 	2013	40
24279329	351	Schedin-Weiss S	The role of protein glycosylation in Alzheimer disease.	The FEBS journal	2014	31
25620700	351	Matarin M	A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology.	Cell reports	2015	20
26651341	351	Head E	Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.	Current Alzheimer research	2016	13
26931567	351	Maeda S	Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice.	EMBO reports	2016	12
27114849	351	Plummer S	The Neuroprotective Properties of the Amyloid Precursor Protein Following Traumatic Brain Injury.	Aging and disease	2016	13
9605898	354	Catalona WJ	Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.	JAMA	1998	117
9749478	354	D'Amico AV	Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.	JAMA	1998	546
10984506	354	Mueller E	Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2000	94
11016644	354	Butler LM	Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.	Cancer research	2000	138
11238701	354	Hoffman RM	Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study.	Journal of the National Cancer Institute	2001	93
11294823	354	Yousef GM	The new human tissue kallikrein gene family: structure, function, and association to disease.	Endocrine reviews	2001	89
11317522	354	Korenchuk S	VCaP, a cell-based model system of human prostate cancer.	In vivo	2001	93
11744442	354	Partin AW	Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium.	Urology	2001	99
11792912	354	Hull GW	Cancer control with radical prostatectomy alone in 1,000 consecutive patients.	The Journal of urology	2002	98
12086878	354	Singh D	Gene expression correlates of clinical prostate cancer behavior.	Cancer cell	2002	388
12544300	354	Han M	Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.	The Journal of urology	2003	125
12837834	354	Cooperberg MR	National practice patterns and time trends in androgen ablation for localized prostate cancer.	Journal of the National Cancer Institute	2003	80
14581419	354	Hanks GE	Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.	Journal of clinical oncology 	2003	118
15020604	354	Small EJ	Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).	Journal of clinical oncology 	2004	109
15163773	354	Thompson IM	Prevalence of prostate cancer among men with a prostate-specific antigen level &amp;lt; or =4.0 ng per milliliter.	The New England journal of medicine	2004	383
15310996	354	Roehl KA	Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results.	The Journal of urology	2004	123
15988529	354	Seligson DB	Global histone modification patterns predict risk of prostate cancer recurrence.	Nature	2005	260
15998892	354	Thompson IM	Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.	JAMA	2005	123
16046649	354	Freedland SJ	Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.	JAMA	2005	217
16177248	354	Wang X	Autoantibody signatures in prostate cancer.	The New England journal of medicine	2005	150
16192588	354	Stephenson AJ	Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.	Journal of clinical oncology 	2005	108
16622122	354	Thompson IM	Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.	Journal of the National Cancer Institute	2006	193
16705126	354	Stephenson AJ	Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.	Journal of the National Cancer Institute	2006	93
16818701	354	Pantuck AJ	Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer.	Clinical cancer research 	2006	66
16921049	354	Stephenson AJ	Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition.	Journal of clinical oncology 	2006	84
16921051	354	Hussain M	Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).	Journal of clinical oncology 	2006	70
16952647	354	Zelefsky MJ	Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.	The Journal of urology	2006	71
17382159	354	Marks LS	PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.	Urology	2007	67
17404365	354	Loblaw DA	Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.	Journal of clinical oncology 	2007	98
17531401	354	Lawton CA	An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions.	International journal of radiation oncology, biology, physics	2007	67
17572194	354	Makarov DV	Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005.	Urology	2007	72
17644125	354	Cooperberg MR	Contemporary trends in low risk prostate cancer: risk assessment and treatment.	The Journal of urology	2007	91
17652279	354	Vickers AJ	The surgical learning curve for prostate cancer control after radical prostatectomy.	Journal of the National Cancer Institute	2007	72
17886253	354	Carducci MA	A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.	Cancer	2007	70
17971772	354	Nam RK	Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer.	British journal of cancer	2007	71
18056182	354	Danila DC	Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.	Clinical cancer research 	2007	153
18182665	354	Berthold DR	Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.	Journal of clinical oncology 	2008	184
18245462	354	Laxman B	A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.	Cancer research	2008	103
18295257	354	Deras IL	PCA3: a molecular urine assay for predicting prostate biopsy outcome.	The Journal of urology	2008	68
18309951	354	Scher HI	Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.	Journal of clinical oncology 	2008	394
18648226	354	Biki B	Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis.	Anesthesiology	2008	74
18755555	354	King CR	Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.	International journal of radiation oncology, biology, physics	2009	57
18785254	354	Nelson JB	Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer.	Cancer	2008	58
18824702	354	Tolcher AW	Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.	Journal of clinical oncology 	2008	59
18829513	354	de Bono JS	Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.	Clinical cancer research 	2008	409
19213602	354	Scher HI	Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.	The Lancet. Oncology	2009	138
19297566	354	Schröder FH	Screening and prostate-cancer mortality in a randomized European study.	The New England journal of medicine	2009	729
19359544	354	Tran C	Development of a second-generation antiandrogen for treatment of advanced prostate cancer.	Science	2009	438
19409690	354	Tomlins SA	ETS gene fusions in prostate cancer: from discovery to daily clinical practice.	European urology	2009	98
19509351	354	Cooperberg MR	Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.	Journal of the National Cancer Institute	2009	57
20006859	354	Hambrock T	Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen.	The Journal of urology	2010	56
20006878	354	Epstein JI	An update of the Gleason grading system.	The Journal of urology	2010	91
20047800	354	Arcangeli G	A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer.	International journal of radiation oncology, biology, physics	2010	44
20117878	354	Jentzmik F	Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours.	European urology	2010	44
20124169	354	Zietman AL	Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09.	Journal of clinical oncology 	2010	120
20159826	354	Zelefsky MJ	Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix.	Journal of clinical oncology 	2010	50
20233430	354	Sboner A	Molecular sampling of prostate cancer: a dilemma for predicting disease progression.	BMC medical genomics	2010	74
20424012	354	Stott SL	Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer.	Science translational medicine	2010	148
20807808	354	Zhu ML	Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.	Cancer research	2010	79
20843935	354	Vickers AJ	Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.	BMJ	2010	52
20934277	354	Yeoh EE	Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial.	International journal of radiation oncology, biology, physics	2011	42
21044246	354	Nonomura N	Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer.	BJU international	2011	39
21115873	354	Cooperberg MR	Outcomes of active surveillance for men with intermediate-risk prostate cancer.	Journal of clinical oncology 	2011	48
21195536	354	Dickinson L	Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting.	European urology	2011	93
21212412	354	Sun D	miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation.	Cancer research	2011	82
21300474	354	King CR	Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.	International journal of radiation oncology, biology, physics	2012	79
21353695	354	Fizazi K	Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.	Lancet	2011	288
21426475	354	Haffner J	Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection.	BJU international	2011	54
21432867	354	Tai S	PC3 is a cell line characteristic of prostatic small cell carcinoma.	The Prostate	2011	45
21537045	354	Hendrickson WK	Vitamin D receptor protein expression in tumor tissue and prostate cancer progression.	Journal of clinical oncology 	2011	37
21612468	354	de Bono JS	Abiraterone and increased survival in metastatic prostate cancer.	The New England journal of medicine	2011	760
21647869	354	Cooperberg MR	The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy.	Cancer	2011	49
21679984	354	Ahmed HU	Characterizing clinically significant prostate cancer using template prostate mapping biopsy.	The Journal of urology	2011	36
21849184	354	Pinto PA	Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging.	The Journal of urology	2011	86
21859988	354	Scher HI	End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice.	Journal of clinical oncology 	2011	41
21931019	354	Pili R	Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.	Journal of clinical oncology 	2011	45
22093187	354	Smith MR	Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.	Lancet	2012	149
22129890	354	Fizazi K	Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.	European journal of cancer	2012	36
22169079	354	Boorjian SA	A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes.	European urology	2012	31
22325447	354	Hoeks CM	Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.	European urology	2012	37
22330997	354	Zelefsky MJ	Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.	International journal of radiation oncology, biology, physics	2012	58
22336380	354	Epstein JI	Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades.	European urology	2012	70
22361632	354	Cuzick J	Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.	British journal of cancer	2012	62
22454414	354	Kelly WK	Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.	Journal of clinical oncology 	2012	134
22512844	354	Ahmed HU	Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study.	The Lancet. Oncology	2012	49
22537541	354	Arcangeli S	Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer.	International journal of radiation oncology, biology, physics	2012	34
22808955	354	Wilt TJ	Radical prostatectomy versus observation for localized prostate cancer.	The New England journal of medicine	2012	272
23017866	354	Vargas HA	Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer.	The Journal of urology	2012	35
23063807	354	Kasivisvanathan V	Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer.	The Journal of urology	2013	28
23083875	354	Vourganti S	Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies.	The Journal of urology	2012	50
23158413	354	Sonn GA	Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device.	The Journal of urology	2013	49
23375961	354	Lazzeri M	Serum isoform -2proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.	European urology	2013	35
23381039	354	Gulati R	Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.	Annals of internal medicine	2013	28
23440794	354	Ilic D	Screening for prostate cancer.	The Cochrane database of systematic reviews	2013	70
23523537	354	Sonn GA	Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen.	European urology	2014	52
23569308	354	Fizazi K	Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.	Journal of clinical oncology 	2013	41
23582482	354	Schellhammer PF	Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.	Urology	2013	34
23687298	354	Lin TH	Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.	The Journal of biological chemistry	2013	31
23727310	354	Rais-Bahrami S	Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer.	The Journal of urology	2013	37
23770138	354	Karnes RJ	Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.	The Journal of urology	2013	61
24002508	354	Rathkopf DE	Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.	Journal of clinical oncology 	2013	36
24166498	354	Formosa A	MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells.	Oncogene	2014	63
24321502	354	Heidenreich A	EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.	European urology	2014	165
24333515	354	Rastinehad AR	Improving detection of clinically significant prostate cancer: magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy.	The Journal of urology	2014	31
24382803	354	Badrising S	Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.	Cancer	2014	25
24449231	354	Halabi S	Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.	Journal of clinical oncology 	2014	42
24463248	354	Zu K	Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era.	Journal of the National Cancer Institute	2014	26
24478320	354	Sternberg CN	Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial.	Annals of oncology 	2014	28
24484606	354	Bancroft EK	Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.	European urology	2014	26
24518762	354	Thompson JE	Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study.	The Journal of urology	2014	27
24602293	354	Gacci M	Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis.	BJU international	2015	19
24666839	354	Pokorny MR	Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.	European urology	2014	56
24714754	354	Lin HM	Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.	British journal of cancer	2014	28
24727321	354	Beltran H	Aggressive variants of castration-resistant prostate cancer.	Clinical cancer research 	2014	47
24748218	354	Gurel B	Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.	Cancer epidemiology, biomarkers and prevention 	2014	40
24778277	354	Gulley JL	Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.	Cancer immunology research	2014	30
24836057	354	Klein EA	A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.	European urology	2014	68
24881730	354	Beer TM	Enzalutamide in metastatic prostate cancer before chemotherapy.	The New England journal of medicine	2014	244
25018038	354	Azad AA	Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.	European urology	2015	21
25024180	354	Hieronymus H	Copy number alteration burden predicts prostate cancer relapse.	Proceedings of the National Academy of Sciences of the United States of America	2014	44
25035207	354	Den RB	Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy.	International journal of radiation oncology, biology, physics	2014	32
25085000	354	Idorn M	Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer.	Cancer immunology, immunotherapy 	2014	23
25108889	354	Schröder FH	Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.	Lancet	2014	114
25159890	354	Womble PR	Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.	European urology	2015	29
25281467	354	Cuzick J	Prevention and early detection of prostate cancer.	The Lancet. Oncology	2014	44
25301760	354	James ND	Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).	European urology	2015	30
25385735	354	Wei JT	Can urinary PCA3 supplement PSA in the early detection of prostate cancer?	Journal of clinical oncology 	2014	36
25454615	354	Parekh DJ	A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.	European urology	2015	28
25457014	354	Loeb S	Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification.	European urology	2015	18
25463993	354	Loeb S	The prostate health index selectively identifies clinically significant prostate cancer.	The Journal of urology	2015	18
25466945	354	Klein EA	A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.	European urology	2015	28
25484141	354	van Soest RJ	Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.	European urology	2015	17
25512465	354	Klotz L	Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.	Journal of clinical oncology 	2015	69
25538172	354	Lorente D	Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use.	Annals of oncology 	2015	26
25613154	354	Gratzke C	EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.	European urology	2015	34
25624429	354	Fizazi K	Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.	Journal of clinical oncology 	2015	22
25626035	354	Siddiqui MM	Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.	JAMA	2015	86
25656808	354	Fütterer JJ	Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature.	European urology	2015	44
25667284	354	Den RB	Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.	Journal of clinical oncology 	2015	26
25682340	354	Stattin P	Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.	European urology	2015	19
25691677	354	Mason MD	Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer.	Journal of clinical oncology 	2015	21
25964175	354	Tomlins SA	Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.	European urology	2015	20
26181238	354	Antonarakis ES	Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.	JAMA oncology	2015	59
26188394	354	Onstenk W	Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.	European urology	2015	27
26244877	354	Sweeney CJ	Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.	The New England journal of medicine	2015	100
26324359	354	Tosoian JJ	Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer.	Journal of clinical oncology 	2015	20
26992225	354	Koppers-Lalic D	Non‑invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles.	Oncotarget	2016	11
27032035	354	McKiernan J	A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.	JAMA oncology	2016	16
27400947	354	Smith M	Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.	Journal of clinical oncology 	2016	10
28034081	354	Beer TM	Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.	Journal of clinical oncology 	2017	7
16831965	361	Pittock SJ	Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression.	Archives of neurology	2006	103
17449477	361	Takahashi T	Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.	Brain 	2007	109
18334978	361	Jarius S	Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica.	Nature clinical practice. Neurology	2008	66
19938104	361	Bennett JL	Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica.	Annals of neurology	2009	157
20047900	361	Saadoun S	Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.	Brain 	2010	140
20826711	361	Shimizu J	IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum.	Neurology	2010	48
21368286	361	Popescu BF	Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications.	Neurology	2011	57
21550068	361	Jarius S	Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures.	Journal of the neurological sciences	2011	41
22146605	361	Min JH	Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder.	Multiple sclerosis	2012	40
22260418	361	Jarius S	Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients.	Journal of neuroinflammation	2012	91
22387049	361	Wolburg H	The disturbed blood-brain barrier in human glioblastoma.	Molecular aspects of medicine	2012	35
22393049	361	Phuan PW	Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays.	The Journal of biological chemistry	2012	46
22577216	361	Kitley J	Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.	Brain 	2012	34
23142960	361	Jacob A	Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders.	Journal of neurology, neurosurgery, and psychiatry	2013	30
23486868	361	Matthews L	Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution.	Neurology	2013	25
23623397	361	Pittock SJ	Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.	The Lancet. Neurology	2013	53
23997151	361	Jiao Y	Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica.	Neurology	2013	28
24415568	361	Sato DK	Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.	Neurology	2014	73
24425068	361	Kitley J	Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.	JAMA neurology	2014	54
24700511	361	Titulaer MJ	Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis.	Annals of neurology	2014	43
25112508	361	Papadopoulos MC	Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.	Nature reviews. Neurology	2014	40
25695963	361	Kim HJ	MRI characteristics of neuromyelitis optica spectrum disorder: an international update.	Neurology	2015	32
25921037	361	Pandit L	Demographic and clinical features of neuromyelitis optica: A review.	Multiple sclerosis	2015	18
10318905	367	Yeh S	From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	1999	111
10363963	367	Taplin ME	Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.	Cancer research	1999	113
10835690	367	Zhao XY	Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor.	Nature medicine	2000	92
11032808	367	Migliaccio A	Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation.	The EMBO journal	2000	148
12888829	367	Edwards J	Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.	British journal of cancer	2003	78
14695335	367	Holzbeierlein J	Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance.	The American journal of pathology	2004	162
14760063	367	Mohler JL	The androgen axis in recurrent prostate cancer.	Clinical cancer research 	2004	203
15389811	367	Miyamoto H	Androgen deprivation therapy for prostate cancer: current status and future prospects.	The Prostate	2004	77
16000557	367	Titus MA	Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.	Clinical cancer research 	2005	134
16322242	367	Collins AT	Prospective identification of tumorigenic prostate cancer stem cells.	Cancer research	2005	698
17045208	367	Guo Z	Regulation of androgen receptor activity by tyrosine phosphorylation.	Cancer cell	2006	142
17409422	367	Miki J	Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens.	Cancer research	2007	101
17510410	367	Gu G	Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo.	Cancer research	2007	105
18539965	367	Maitland NJ	Prostate cancer stem cells: a new target for therapy.	Journal of clinical oncology 	2008	80
18676866	367	Locke JA	Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.	Cancer research	2008	215
18838208	367	Morgentaler A	Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.	European urology	2009	59
19117982	367	Hu R	Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.	Cancer research	2009	279
19118031	367	Snoek R	In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.	Clinical cancer research 	2009	52
19276271	367	Leversha MA	Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer.	Clinical cancer research 	2009	60
19289629	367	Mendiratta P	Genomic strategy for targeting therapy in castration-resistant prostate cancer.	Journal of clinical oncology 	2009	46
19366804	367	Steinkamp MP	Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.	Cancer research	2009	60
19668381	367	Lin B	Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor.	PloS one	2009	46
20440270	367	Niu Y	Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails.	Oncogene	2010	45
20644256	367	Sun S	Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.	The Journal of clinical investigation	2010	231
20859283	367	Seruga B	Drug resistance in metastatic castration-resistant prostate cancer.	Nature reviews. Clinical oncology	2011	61
21099110	367	Sharma A	The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression.	The Journal of clinical investigation	2010	103
21135112	367	Cai H	Invasive prostate carcinoma driven by c-Src and androgen receptor synergy.	Cancer research	2011	43
21248069	367	Li Y	Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression.	Cancer research	2011	72
21264529	367	He J	Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray.	Medical oncology	2012	37
21310761	367	Park S	Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers.	Annals of oncology 	2011	38
21552212	367	Collins LC	Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.	Modern pathology 	2011	39
21552559	367	Hörnberg E	Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.	PloS one	2011	122
21799031	367	Darshan MS	Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.	Cancer research	2011	109
21837479	367	Loibl S	Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.	Breast cancer research and treatment	2011	36
22064655	367	Huang WC	Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells.	Molecular cancer research 	2012	46
22083957	367	Tan PY	Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival.	Molecular and cellular biology	2012	50
22108827	367	Sun Y	Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.	Cancer research	2012	86
22114732	367	Zhang X	Androgen receptor variants occur frequently in castration resistant prostate cancer metastases.	PloS one	2011	95
22131877	367	Lonigro RJ	Detection of somatic copy number alterations in cancer using targeted exome capture sequencing.	Neoplasia	2011	42
22355276	367	Yamashita S	ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.	Neoplasia	2012	38
22831834	367	Lee SO	New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells.	Journal of molecular cell biology	2013	31
23069658	367	Shi XB	Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells.	Oncogene	2013	47
23093251	367	Miyamoto DT	Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.	Cancer discovery	2012	72
23260764	367	Sharma NL	The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man.	Cancer cell	2013	108
23576708	367	Loriot Y	Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).	Annals of oncology 	2013	62
23704919	367	Gao L	Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation.	PloS one	2013	31
23811619	367	Logothetis CJ	Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer.	Cancer discovery	2013	26
23982944	367	Izumi K	Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation.	EMBO molecular medicine	2013	35
24037531	367	Mishra S	Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer.	Oncogene	2014	26
24046116	367	McGhan LJ	Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype.	Annals of surgical oncology	2014	24
24101480	367	Nyquist MD	TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2013	33
24177177	367	Schroeder A	Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling.	Cancer research	2014	31
24200698	367	van Soest RJ	Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.	European journal of cancer	2013	36
24659820	367	Marín-Aguilera M	Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.	Molecular cancer therapeutics	2014	25
24740322	367	Liu C	Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.	Clinical cancer research 	2014	50
24742458	367	Cortes CJ	Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy.	Neuron	2014	36
24909511	367	Tan MH	Androgen receptor: structure, role in prostate cancer and drug discovery.	Acta pharmacologica Sinica	2015	30
25108912	367	Cortes CJ	Polyglutamine-expanded androgen receptor interferes with TFEB to elicit autophagy defects in SBMA.	Nature neuroscience	2014	26
25145503	367	Choi JE	Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.	Annals of surgical oncology	2015	21
25184630	367	Antonarakis ES	AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.	The New England journal of medicine	2014	256
25232177	367	Carreira S	Tumor clone dynamics in lethal prostate cancer.	Science translational medicine	2014	68
25307492	367	Kong D	Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes.	The Prostate	2015	21
25712683	367	Azad AA	Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.	Clinical cancer research 	2015	51
25830880	367	Gundem G	The evolutionary history of lethal metastatic prostate cancer.	Nature	2015	108
26117829	367	Nakazawa M	Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.	Annals of oncology 	2015	30
26160840	367	Zhang G	Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents.	Oncotarget	2015	18
26196735	367	Crawford ED	Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.	The Journal of urology	2015	19
26855148	367	Beltran H	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.	Nature medicine	2016	57
27184417	367	Bianchini G	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.	Nature reviews. Clinical oncology	2016	42
28059768	367	Mu P	SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.	Science	2017	14
9701363	672	Lakhani SR	Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.	Journal of the National Cancer Institute	1998	119
10359546	672	Peto J	Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.	Journal of the National Cancer Institute	1999	148
11207349	672	Hedenfalk I	Gene-expression profiles in hereditary breast cancer.	The New England journal of medicine	2001	260
11320250	672	Ruffner H	Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity.	Proceedings of the National Academy of Sciences of the United States of America	2001	96
12162889	672	Radmacher MD	A paradigm for class prediction using gene expression profiles.	Journal of computational biology 	2002	82
15041722	672	Foulkes WD	Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.	Clinical cancer research 	2004	76
15197194	672	Metcalfe K	Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.	Journal of clinical oncology 	2004	111
15784178	672	Dumitrescu RG	Understanding breast cancer risk -- where do we stand in 2005?	Journal of cellular and molecular medicine	2005	81
16137750	672	Finch A	Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.	Gynecologic oncology	2006	73
16284991	672	Pal T	BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.	Cancer	2005	156
16293877	672	Kuhl CK	Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer.	Journal of clinical oncology 	2005	116
16434898	672	Medeiros F	The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.	The American journal of surgical pathology	2006	135
16488803	672	Fentiman IS	Male breast cancer.	Lancet	2006	77
17117391	672	Lee Y	A candidate precursor to serous carcinoma that originates in the distal fallopian tube.	The Journal of pathology	2007	198
17218844	672	Crum CP	The distal fallopian tube: a new model for pelvic serous carcinogenesis.	Current opinion in obstetrics and gynecology	2007	114
17456833	672	Crum CP	Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.	Clinical medicine and research	2007	64
17761984	672	Callahan MJ	Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.	Journal of clinical oncology 	2007	100
18342932	672	Folkins AK	A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.	Gynecologic oncology	2008	62
18649131	672	Byrski T	Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.	Breast cancer research and treatment	2009	72
18779615	672	Atchley DP	Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.	Journal of clinical oncology 	2008	107
19060844	672	Clarke B	Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.	Modern pathology 	2009	60
19460581	672	Anders CK	Breast cancer before age 40 years.	Seminars in oncology	2009	85
19479960	672	Wittwer CT	High-resolution DNA melting analysis: advancements and limitations.	Human mutation	2009	78
19491823	672	Poley JW	The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer.	The American journal of gastroenterology	2009	64
19636370	672	Brown PO	The preclinical natural history of serous ovarian cancer: defining the target for early detection.	PLoS medicine	2009	57
19648928	672	Lim E	Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.	Nature medicine	2009	454
19858402	672	Graeser MK	Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.	Journal of clinical oncology 	2009	52
20177395	672	Moynahan ME	Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis.	Nature reviews. Molecular cell biology	2010	267
20368571	672	Malone KE	Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.	Journal of clinical oncology 	2010	46
20427433	672	Amir E	Assessing women at high risk of breast cancer: a review of risk assessment models.	Journal of the National Cancer Institute	2010	89
20516115	672	Lee MS	Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.	Cancer research	2010	40
20609467	672	Tutt A	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.	Lancet	2010	389
20609468	672	Audeh MW	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.	Lancet	2010	309
21135251	672	Villarroel MC	Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.	Molecular cancer therapeutics	2011	65
21233401	672	Gonzalez-Angulo AM	Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.	Clinical cancer research 	2011	109
21324516	672	Zhang S	Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.	Gynecologic oncology	2011	52
21464413	672	King TA	Clinical management factors contribute to the decision for contralateral prophylactic mastectomy.	Journal of clinical oncology 	2011	48
21727289	672	Schousboe JT	Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness.	Annals of internal medicine	2011	62
21990299	672	Yang D	Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.	JAMA	2011	104
22203755	672	Kaye SB	Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.	Journal of clinical oncology 	2012	94
22452356	672	Ledermann J	Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.	The New England journal of medicine	2012	200
22505045	672	Houdayer C	Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants.	Human mutation	2012	36
22614657	672	Hartman AR	Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer.	Cancer	2012	37
22933060	672	Popova T	Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.	Cancer research	2012	57
23257159	672	McLaughlin JR	Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2.	Journal of the National Cancer Institute	2013	26
23558900	672	Lips EH	Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers.	British journal of cancer	2013	33
23569316	672	Castro E	Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.	Journal of clinical oncology 	2013	59
23810788	672	Sandhu SK	The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.	The Lancet. Oncology	2013	84
24346285	672	Lee AJ	BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.	British journal of cancer	2014	21
24478461	672	Laddha SV	Mutational landscape of the essential autophagy gene BECN1 in human cancers.	Molecular cancer research 	2014	37
24567435	672	Finch AP	Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.	Journal of clinical oncology 	2014	57
24618965	672	Dewey FE	Clinical interpretation and implications of whole-genome sequencing.	JAMA	2014	118
24675953	672	Couch FJ	Two decades after BRCA: setting paradigms in personalized cancer care and prevention.	Science	2014	57
24675954	672	Venkitaraman AR	Cancer suppression by the chromosome custodians, BRCA1 and BRCA2.	Science	2014	31
25072261	672	Golan T	Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.	British journal of cancer	2014	24
25348513	672	Zhong Q	Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.	Clinical cancer research 	2015	19
25366685	672	Kaufman B	Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.	Journal of clinical oncology 	2015	144
25398451	672	Candido-dos-Reis FJ	Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.	Clinical cancer research 	2015	16
25454609	672	Castro E	Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.	European urology	2015	16
25481791	672	Oza AM	Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.	The Lancet. Oncology	2015	70
25800746	672	Wang P	Identification of lncRNA-associated competing triplets reveals global patterns and prognostic markers for cancer.	Nucleic acids research	2015	28
26187614	672	Kim G	FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.	Clinical cancer research 	2015	35
12970315	673	Namba H	Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers.	The Journal of clinical endocrinology and metabolism	2003	78
14500344	673	Hingorani SR	Suppression of BRAF(V599E) in human melanoma abrogates transformation.	Cancer research	2003	105
15488754	673	Garnett MJ	Guilty as charged: B-RAF is a human oncogene.	Cancer cell	2004	156
16079850	673	Michaloglou C	BRAFE600-associated senescence-like cell cycle arrest of human naevi.	Nature	2005	551
16174717	673	Xing M	BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.	The Journal of clinical endocrinology and metabolism	2005	147
17148775	673	Samowitz WS	Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer.	Journal of the National Cancer Institute	2006	105
17785355	673	Lupi C	Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.	The Journal of clinical endocrinology and metabolism	2007	60
17940185	673	Xing M	BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.	Endocrine reviews	2007	186
18398503	673	Pfister S	BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas.	The Journal of clinical investigation	2008	112
18519771	673	French AJ	Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer.	Clinical cancer research 	2008	71
18532874	673	Viros A	Improving melanoma classification by integrating genetic and morphologic features.	PLoS medicine	2008	59
18682506	673	Elisei R	BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.	The Journal of clinical endocrinology and metabolism	2008	92
18832519	673	Ogino S	CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.	Gut	2009	259
19255327	673	Kloos RT	Phase II trial of sorafenib in metastatic thyroid cancer.	Journal of clinical oncology 	2009	123
19861538	673	Riesco-Eizaguirre G	The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.	Cancer research	2009	48
19883729	673	Xing M	Prognostic utility of BRAF mutation in papillary thyroid cancer.	Molecular and cellular endocrinology	2010	41
20450891	673	Inamdar GS	Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.	Biochemical pharmacology	2010	41
20519626	673	Badalian-Very G	Recurrent BRAF mutations in Langerhans cell histiocytosis.	Blood	2010	108
20551065	673	Yang H	RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.	Cancer research	2010	102
20818844	673	Flaherty KT	Inhibition of mutated, activated BRAF in metastatic melanoma.	The New England journal of medicine	2010	938
20823850	673	Bollag G	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.	Nature	2010	428
20959481	673	Gopal YN	Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.	Cancer research	2010	96
21139585	673	Arkenau HT	Targeting BRAF for patients with melanoma.	British journal of cancer	2011	36
21169256	673	Comin-Anduix B	The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations.	Clinical cancer research 	2010	50
21274720	673	Schindler G	Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.	Acta neuropathologica	2011	134
21285991	673	Yokota T	BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer.	British journal of cancer	2011	79
21343559	673	Long GV	Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.	Journal of clinical oncology 	2011	163
21456008	673	Tran B	Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer.	Cancer	2011	92
21479234	673	Dias-Santagata D	BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.	PloS one	2011	57
21663470	673	Tiacci E	BRAF mutations in hairy-cell leukemia.	The New England journal of medicine	2011	157
21825258	673	Marchetti A	Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.	Journal of clinical oncology 	2011	84
22012135	673	Capper D	Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases.	Acta neuropathologica	2012	40
22038996	673	Nicolaides TP	Targeted therapy for BRAFV600E malignant astrocytoma.	Clinical cancer research 	2011	51
22105174	673	Chakravarty D	Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.	The Journal of clinical investigation	2011	59
22147942	673	Ogino S	Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.	Clinical cancer research 	2012	80
22180495	673	Yang H	Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.	Cancer research	2012	54
22217739	673	Nikolaou VA	Melanoma: new insights and new therapies.	The Journal of investigative dermatology	2012	44
22235286	673	Yancovitz M	Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.	PloS one	2012	59
22239440	673	Santarpia L	Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy.	Expert opinion on therapeutic targets	2012	108
22306669	673	Halait H	Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.	Diagnostic molecular pathology 	2012	35
22332713	673	Anderson S	Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma.	Archives of pathology and laboratory medicine	2012	37
22385436	673	Finn L	Therapy for metastatic melanoma: the past, present, and future.	BMC medicine	2012	44
22393095	673	Popovici V	Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer.	Journal of clinical oncology 	2012	47
22454415	673	McArthur GA	Marked, homogeneous, and early 18Ffluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.	Journal of clinical oncology 	2012	33
22535154	673	Menzies AM	Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.	Clinical cancer research 	2012	64
22549727	673	Vredeveld LC	Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.	Genes and development	2012	80
22640478	673	Ascierto PA	Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.	Journal of translational medicine	2012	30
22743296	673	Gautschi O	A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.	Journal of thoracic oncology 	2012	37
22798288	673	Dahlman KB	BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.	Cancer discovery	2012	49
22850568	673	Khalili JS	Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma.	Clinical cancer research 	2012	59
22859608	673	Sahm F	BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis.	Blood	2012	34
22930283	673	Grisham RN	BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.	Cancer	2013	27
22941165	673	Howell GM	BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer.	Annals of surgical oncology	2013	27
22972589	673	Patel SP	Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.	Cancer	2013	28
23026937	673	Long GV	Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.	The American journal of surgical pathology	2013	46
23055546	673	Li C	BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis.	The Journal of clinical endocrinology and metabolism	2012	36
23066120	673	Elisei R	The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.	The Journal of clinical endocrinology and metabolism	2012	34
23258922	673	Haroche J	Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.	Blood	2013	74
23569304	673	Trunzer K	Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.	Journal of clinical oncology 	2013	83
23571588	673	Xing M	Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.	JAMA	2013	123
23612012	673	Andrulis M	Targeting the BRAF V600E mutation in multiple myeloma.	Cancer discovery	2013	35
23735514	673	Robert C	Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.	The Lancet. Oncology	2013	36
23833299	673	Nathanson KL	Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).	Clinical cancer research 	2013	36
23852808	673	Roepman P	Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition.	International journal of cancer	2014	47
23890088	673	Botton T	Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.	Pigment cell and melanoma research	2013	28
23903755	673	Corcoran RB	TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.	Science translational medicine	2013	49
23918947	673	Ascierto PA	Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.	Journal of clinical oncology 	2013	60
24295639	673	Dummer R	Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.	European journal of cancer	2014	36
24345920	673	Hutchinson KE	BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.	Clinical cancer research 	2013	33
24410877	673	Ihle MA	Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.	BMC cancer	2014	46
24463458	673	Rizos H	BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.	Clinical cancer research 	2014	63
24582505	673	Larkin J	Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.	The Lancet. Oncology	2014	28
24617711	673	Liu X	TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.	The Journal of clinical endocrinology and metabolism	2014	41
24638167	673	Berres ML	BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.	The Journal of experimental medicine	2014	42
24671772	673	Cangi MG	BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease.	Annals of the rheumatic diseases	2015	17
24725538	673	Robinson GW	Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy.	BMC cancer	2014	24
24737664	673	Yaeger R	BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer.	Cancer	2014	29
24991839	673	Rangwala R	Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.	Autophagy	2014	63
25024077	673	Xing M	BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.	Journal of clinical oncology 	2014	57
25139339	673	Venderbosch S	Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.	Clinical cancer research 	2014	23
25332244	673	Xing M	Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.	Journal of clinical oncology 	2015	48
25353071	673	Dadu R	Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.	The Journal of clinical endocrinology and metabolism	2015	17
25411185	673	Sanmamed MF	Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors.	Clinical chemistry	2015	23
25617424	673	Wang T	BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth.	Clinical cancer research 	2015	15
25713148	673	Loupakis F	Primary tumor location as a prognostic factor in metastatic colorectal cancer.	Journal of the National Cancer Institute	2015	27
25918280	673	Fakih MG	Metastatic colorectal cancer: current state and future directions.	Journal of clinical oncology 	2015	33
26038390	673	Campbell PT	Association between body mass index and mortality for colorectal cancer survivors: overall and by tumor molecular phenotype.	Cancer epidemiology, biomarkers and prevention 	2015	16
26338525	673	Cremolini C	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.	The Lancet. Oncology	2015	39
26527776	673	André T	Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.	Journal of clinical oncology 	2015	20
26811525	673	Long GV	Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.	Journal of clinical oncology 	2016	21
27070934	673	Chan JC	The Lymphocyte-to-Monocyte Ratio is a Superior Predictor of Overall Survival in Comparison to Established Biomarkers of Resectable Colorectal Cancer.	Annals of surgery	2017	13
27080216	673	Planchard D	Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2016	18
7540117	920	Fisher GH	Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome.	Cell	1995	207
8095306	920	Connor RI	Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals.	Journal of virology	1993	135
8096068	920	Embretson J	Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS.	Nature	1993	306
8187174	920	York IA	A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes.	Cell	1994	164
9188531	920	Orenstein JM	Macrophages as a source of HIV during opportunistic infections.	Science	1997	152
10500077	920	Gerlach JT	Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C.	Gastroenterology	1999	163
11009139	920	Whitworth J	Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study.	Lancet	2000	106
11076879	920	Spiller RC	Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome.	Gut	2000	188
11348697	920	Siegrist CA	Neonatal and early life vaccinology.	Vaccine	2001	132
11431351	920	Nakano O	Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity.	Cancer research	2001	107
11748275	920	Kovacs JA	Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV.	The Journal of experimental medicine	2001	85
12218162	920	Sousa AE	CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load.	Journal of immunology	2002	154
12648460	920	Silvestri G	Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia.	Immunity	2003	257
14557656	920	Guadalupe M	Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy.	Journal of virology	2003	336
14614606	920	Kamisawa T	A new clinicopathological entity of IgG4-related autoimmune disease.	Journal of gastroenterology	2003	132
14966528	920	Papagno L	Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection.	PLoS biology	2004	124
15023877	920	Hsue PY	Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection.	Circulation	2004	148
15327410	920	Szczech LA	The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection.	Kidney international	2004	80
15376257	920	Ulrichs T	Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung.	The Journal of pathology	2004	82
15753209	920	Song Z	Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis.	The Journal of experimental medicine	2005	74
15771578	920	Anderson MS	The NOD mouse: a model of immune dysregulation.	Annual review of immunology	2005	301
15793563	920	Mattapallil JJ	Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection.	Nature	2005	557
16081852	920	Sutherland JS	Activation of thymic regeneration in mice and humans following androgen blockade.	Journal of immunology	2005	103
16147978	920	Sylwester AW	Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects.	The Journal of experimental medicine	2005	363
16182404	920	Bräu N	Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy.	Journal of hepatology	2006	89
16227428	920	Thompson PM	Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline.	Proceedings of the National Academy of Sciences of the United States of America	2005	117
16319344	920	Nicolls MR	Autoimmunity and pulmonary hypertension: a perspective.	The European respiratory journal	2005	79
16339561	920	Fletcher JM	Cytomegalovirus-specific CD4+ T cells in healthy carriers are continuously driven to replicative exhaustion.	Journal of immunology	2005	66
17035049	920	Chiang MC	3D pattern of brain atrophy in HIV/AIDS visualized using tensor-based morphometry.	NeuroImage	2007	73
17090675	920	Levine BL	Gene transfer in humans using a conditionally replicating lentiviral vector.	Proceedings of the National Academy of Sciences of the United States of America	2006	159
17210718	920	Piersma SJ	High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer.	Cancer research	2007	70
17570691	920	He B	Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL.	Immunity	2007	180
17717638	920	Talmadge JE	Inflammatory cell infiltration of tumors: Jekyll or Hyde.	Cancer metastasis reviews	2007	75
17916442	920	Boasso A	Chronic innate immune activation as a cause of HIV-1 immunopathogenesis.	Clinical immunology	2008	78
17986574	920	Koch S	Cytomegalovirus infection: a driving force in human T cell immunosenescence.	Annals of the New York Academy of Sciences	2007	62
18664624	920	Brenchley JM	Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections.	Blood	2008	245
18802153	920	Dieu-Nosjean MC	Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.	Journal of clinical oncology 	2008	160
19079157	920	Brenchley JM	HIV infection and the gastrointestinal immune system.	Mucosal immunology	2008	132
19174797	920	Cremon C	Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms.	The American journal of gastroenterology	2009	69
19383966	920	Hasegawa A	The level of monocyte turnover predicts disease progression in the macaque model of AIDS.	Blood	2009	61
19647202	920	Carson KR	Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project.	The Lancet. Oncology	2009	110
19728788	920	French MA	Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells.	The Journal of infectious diseases	2009	67
20086230	920	Vendrame F	Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells.	Diabetes	2010	62
20113183	920	Cohen RA	Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era.	Journal of neurovirology	2010	72
20139992	920	Flatz L	Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity.	Nature medicine	2010	43
20208541	920	Carter CC	HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs.	Nature medicine	2010	112
20399961	920	Mougiakakos D	Regulatory T cells in cancer.	Advances in cancer research	2010	88
20559035	920	Wallet MA	Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy.	AIDS	2010	55
20889546	920	Gordon SN	Disruption of intestinal CD4+ T cell homeostasis is a key marker of systemic CD4+ T cell activation in HIV-infected individuals.	Journal of immunology	2010	48
21220772	920	Kaplan RC	T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women.	The Journal of infectious diseases	2011	106
21378536	920	Chege D	Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy.	AIDS	2011	44
21398051	920	Finkelstein SE	Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients.	International journal of radiation oncology, biology, physics	2012	35
21471231	920	Ciccone EJ	CD4+ T cells, including Th17 and cycling subsets, are intact in the gut mucosa of HIV-1-infected long-term nonprogressors.	Journal of virology	2011	35
21502920	920	Okulicz JF	Epidemiology and clinical characteristics of elite controllers.	Current opinion in HIV and AIDS	2011	37
21690475	920	Slingluff CL Jr	Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.	Journal of clinical oncology 	2011	37
21725250	920	Byrd DA	Neurocognitive impact of substance use in HIV infection.	Journal of acquired immune deficiency syndromes	2011	46
21737504	920	Grossman SA	Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide.	Clinical cancer research 	2011	75
22101430	920	Waggoner SN	Natural killer cells act as rheostats modulating antiviral T cells.	Nature	2011	142
22174559	920	Marshall NB	Cytotoxic CD4 T cells in antiviral immunity.	Journal of biomedicine and biotechnology	2011	52
22219223	920	Mahnke YD	Selective expansion of polyfunctional pathogen-specific CD4(+) T cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome.	Blood	2012	36
22291913	920	Lassen KG	A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs.	PloS one	2012	42
22553251	920	Scholler J	Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells.	Science translational medicine	2012	143
22673491	920	Damjanovic D	Immunopathology in influenza virus infection: uncoupling the friend from foe.	Clinical immunology	2012	37
22745608	920	Cohen CR	Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples.	PLoS medicine	2012	81
22990012	920	Brenchley JM	Differential infection patterns of CD4+ T cells and lymphoid tissue viral burden distinguish progressive and nonprogressive lentiviral infections.	Blood	2012	56
23254153	920	Abraham AG	Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study.	Journal of acquired immune deficiency syndromes	2013	36
23292280	920	Yang M	Regulatory B cells in autoimmune diseases.	Cellular and molecular immunology	2013	38
23324657	920	Zanni MV	Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men.	AIDS	2013	27
23395677	920	Su LF	Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults.	Immunity	2013	113
23525034	920	Chang CC	Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome.	AIDS	2013	27
23772616	920	Paiardini M	HIV-associated chronic immune activation.	Immunological reviews	2013	47
23794702	920	Nagaraj S	Reciprocal relationship between myeloid-derived suppressor cells and T cells.	Journal of immunology	2013	38
23943825	920	Grant PM	Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation.	Clinical infectious diseases 	2013	29
23950730	920	Absher DM	Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations.	PLoS genetics	2013	70
24041796	920	Naranbhai V	Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy.	The Journal of infectious diseases	2014	21
24045046	920	Jane-Wit D	Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-κB signaling in endothelial cells.	Circulation	2013	28
24198226	920	Lahuerta M	Advanced HIV disease at entry into HIV care and initiation of antiretroviral therapy during 2006-2011: findings from four sub-saharan African countries.	Clinical infectious diseases 	2014	38
24226057	920	Luetkemeyer AF	Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs.	Journal of acquired immune deficiency syndromes	2014	21
24384692	920	Ananworanich J	Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children.	AIDS	2014	23
24417396	920	Cribbs SK	Metabolomics of bronchoalveolar lavage differentiate healthy HIV-1-infected subjects from controls.	AIDS research and human retroviruses	2014	20
24508219	920	Pfefferbaum A	Accelerated aging of selective brain structures in human immunodeficiency virus infection: a controlled, longitudinal magnetic resonance imaging study.	Neurobiology of aging	2014	28
25187662	920	Derhovanessian E	Latent infection with cytomegalovirus is associated with poor memory CD4 responses to influenza A core proteins in the elderly.	Journal of immunology	2014	23
25277040	920	Lueg G	Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease.	Neurobiology of aging	2015	20
25363779	920	Farh KK	Genetic and epigenetic fine mapping of causal autoimmune disease variants.	Nature	2015	216
25378643	920	Adusumilli PS	Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.	Science translational medicine	2014	62
25382623	920	Jaafoura S	Progressive contraction of the latent HIV reservoir around a core of less-differentiated CD4⁺ memory T Cells.	Nature communications	2014	27
25593279	920	Hofmann U	Role of lymphocytes in myocardial injury, healing, and remodeling after myocardial infarction.	Circulation research	2015	20
25594465	920	Ueno H	Pathophysiology of T follicular helper cells in humans and mice.	Nature immunology	2015	60
25681373	920	Fouts TR	Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.	Proceedings of the National Academy of Sciences of the United States of America	2015	26
25706232	920	Osinusi A	Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.	JAMA	2015	41
25775592	920	McElroy AK	Human Ebola virus infection results in substantial immune activation.	Proceedings of the National Academy of Sciences of the United States of America	2015	39
25908663	920	Hepworth MR	Immune tolerance. Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4⁺ T cells.	Science	2015	46
25967273	920	Wang Z	Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8⁺ T cells.	Nature communications	2015	19
26169416	920	Spivak AM	Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.	Antimicrobial agents and chemotherapy	2015	20
26349551	920	Cao W	Early Initiation Rather Than Prolonged Duration of Antiretroviral Therapy in HIV Infection Contributes to the Normalization of CD8 T-Cell Counts.	Clinical infectious diseases 	2016	13
26842680	920	Muller L	Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets.	Scientific reports	2016	14
26858442	920	Simonetti FR	Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2016	40
26934227	920	Ma C	NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.	Nature	2016	23
26962942	920	Monaco CL	Altered Virome and Bacterial Microbiome in Human Immunodeficiency Virus-Associated Acquired Immunodeficiency Syndrome.	Cell host and microbe	2016	24
27738167	920	Byrareddy SN	Sustained virologic control in SIV+ macaques after antiretroviral and α4β7 antibody therapy.	Science	2016	20
10545506	1000	Nieman MT	N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression.	The Journal of cell biology	1999	175
12062341	1000	Kostin S	Structural correlate of atrial fibrillation in human patients.	Cardiovascular research	2002	88
15851108	1000	Kaplan SR	Remodeling of myocyte gap junctions in arrhythmogenic right ventricular cardiomyopathy due to a deletion in plakoglobin (Naxos disease).	Heart rhythm	2004	78
15970553	1000	Meier F	The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma.	Frontiers in bioscience 	2005	76
16397214	1000	Yang AD	Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells.	Cancer research	2006	70
17409456	1000	Alonso SR	A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis.	Cancer research	2007	79
17458507	1000	Sullivan R	Hypoxia-driven selection of the metastatic phenotype.	Cancer metastasis reviews	2007	106
17987116	1000	Rosell R	BRCA1: a novel prognostic factor in resected non-small-cell lung cancer.	PloS one	2007	65
18056176	1000	Gravdal K	A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer.	Clinical cancer research 	2007	115
18056451	1000	Eastham AM	Epithelial-mesenchymal transition events during human embryonic stem cell differentiation.	Cancer research	2007	75
18281472	1000	Sarrió D	Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype.	Cancer research	2008	307
18362184	1000	Shintani Y	Collagen I-mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1.	The Journal of cell biology	2008	64
18381457	1000	Graham TR	Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells.	Cancer research	2008	119
18698038	1000	Tothill RW	Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.	Clinical cancer research 	2008	325
19279339	1000	Asimaki A	A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy.	The New England journal of medicine	2009	93
20149220	1000	Minogue BM	Transcriptional profiling of bovine intervertebral disc cells: implications for identification of normal and degenerate human intervertebral disc cell phenotypes.	Arthritis research and therapy	2010	55
20368523	1000	Campagnolo P	Human adult vena saphena contains perivascular progenitor cells endowed with clonogenic and proangiogenic potential.	Circulation	2010	67
20808935	1000	Klopp AH	Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells.	PloS one	2010	50
21125666	1000	Castilla MÁ	Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma.	The Journal of pathology	2011	53
21356352	1000	Hou JM	Circulating tumor cells as a window on metastasis biology in lung cancer.	The American journal of pathology	2011	96
21618587	1000	Latifi A	Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile.	Journal of cellular biochemistry	2011	63
21665936	1000	Armstrong AJ	Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.	Molecular cancer research 	2011	158
22402125	1000	Ru P	miRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling.	Molecular cancer therapeutics	2012	59
22798562	1000	Ma D	Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy.	European heart journal	2013	45
22844540	1000	Balasubramanian P	Multiparameter analysis, including EMT markers, on negatively enriched blood samples from patients with squamous cell carcinoma of the head and neck.	PloS one	2012	32
23002959	1000	Li T	Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis.	Stem cells and development	2013	80
23299311	1000	Zhang B	Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.	Blood	2013	59
23469181	1000	Wang P	Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines.	PloS one	2013	32
23686305	1000	Davis FM	Induction of epithelial-mesenchymal transition (EMT) in breast cancer cells is calcium signal dependent.	Oncogene	2014	42
23947765	1000	Gomez-Casal R	Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes.	Molecular cancer	2013	41
24085799	1000	Li LZ	miR-720 inhibits tumor invasion and migration in breast cancer by targeting TWIST1.	Carcinogenesis	2014	25
24704494	1000	Medyouf H	Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit.	Cell stem cell	2014	51
25056574	1000	Zhao Z	Nestin positively regulates the Wnt/β-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells.	Breast cancer research 	2014	26
25301732	1000	Wang D	Oct-4 and Nanog promote the epithelial-mesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients.	Oncotarget	2014	35
25600338	1000	Wang H	The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells.	Cancer cell	2015	37
25728352	1000	Islam SS	Sonic hedgehog (Shh) signaling promotes tumorigenicity and stemness via activation of epithelial-to-mesenchymal transition (EMT) in bladder cancer.	Molecular carcinogenesis	2016	13
25797269	1000	Kim HS	MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer.	Oncotarget	2015	24
25945841	1000	Huang N	MiR-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling.	Oncotarget	2015	22
26487301	1000	Yue B	LncRNA-ATB mediated E-cadherin repression promotes the progression of colon cancer and predicts poor prognosis.	Journal of gastroenterology and hepatology	2016	12
27629879	1000	Lu M	The high expression of long non-coding RNA PANDAR indicates a poor prognosis for colorectal cancer and promotes metastasis by EMT pathway.	Journal of cancer research and clinical oncology	2017	7
11401930	1003	Shintani S	Mobilization of endothelial progenitor cells in patients with acute myocardial infarction.	Circulation	2001	156
11416160	1003	Hendrix MJ	Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry.	Proceedings of the National Academy of Sciences of the United States of America	2001	97
11490021	1003	Shaw SK	Real-time imaging of vascular endothelial-cadherin during leukocyte transmigration across endothelium.	Journal of immunology	2001	88
16141364	1003	Weksler BB	Blood-brain barrier-specific properties of a human adult brain endothelial cell line.	FASEB journal 	2005	269
17767154	1003	Zheng B	Prospective identification of myogenic endothelial cells in human skeletal muscle.	Nature biotechnology	2007	107
19118716	1003	Wojakowski W	Mobilization of bone marrow-derived Oct-4+ SSEA-4+ very small embryonic-like stem cells in patients with acute myocardial infarction.	Journal of the American College of Cardiology	2009	66
19875721	1003	Nourse MB	VEGF induces differentiation of functional endothelium from human embryonic stem cells: implications for tissue engineering.	Arteriosclerosis, thrombosis, and vascular biology	2010	43
19957372	1003	Sun T	Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry.	Hepatology	2010	72
20332120	1003	Lampugnani MG	CCM1 regulates vascular-lumen organization by inducing endothelial polarity.	Journal of cell science	2010	70
21102433	1003	Wang R	Glioblastoma stem-like cells give rise to tumour endothelium.	Nature	2010	312
21123455	1003	Lo CW	IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer.	Cancer research	2011	39
21630268	1003	Taverna S	Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis.	International journal of cancer	2012	40
22765916	1003	Redies C	Cadherins and neuropsychiatric disorders.	Brain research	2012	57
23171949	1003	Craig DW	Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.	Molecular cancer therapeutics	2013	50
24589413	1003	Du J	Hypoxia promotes vasculogenic mimicry formation by inducing epithelial-mesenchymal transition in ovarian carcinoma.	Gynecologic oncology	2014	31
25956031	1003	Good RB	Endothelial to Mesenchymal Transition Contributes to Endothelial Dysfunction in Pulmonary Arterial Hypertension.	The American journal of pathology	2015	21
26360820	1003	Mendoza FA	Endothelial Cells Expressing Endothelial and Mesenchymal Cell Gene Products in Lung Tissue From Patients With Systemic Sclerosis-Associated Interstitial Lung Disease.	Arthritis and rheumatology	2016	10
27224670	1003	Mikus M	Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury.	Liver international 	2017	6
9284049	1017	Jones DL	The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2.	Genes and development	1997	115
10323868	1017	Montagnoli A	Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation.	Genes and development	1999	151
10919634	1017	Sherr CJ	The Pezcoller lecture: cancer cell cycles revisited.	Cancer research	2000	213
15126355	1017	Stephen RL	Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines.	Cancer research	2004	70
16546962	1017	Wang Z	Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells.	Molecular cancer therapeutics	2006	100
19234140	1017	Chen R	Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.	Blood	2009	46
19915147	1017	Bogunovic D	Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival.	Proceedings of the National Academy of Sciences of the United States of America	2009	87
20479412	1017	Tong WG	Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.	Journal of clinical oncology 	2010	43
20630104	1017	Sasaki K	Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells.	BMC cancer	2010	68
21062975	1017	Lin SL	MicroRNA miR-302 inhibits the tumorigenecity of human pluripotent stem cells by coordinate suppression of the CDK2 and CDK4/6 cell cycle pathways.	Cancer research	2010	50
21321214	1017	Scaltriti M	Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.	Proceedings of the National Academy of Sciences of the United States of America	2011	79
22231403	1017	Buis J	Mre11 regulates CtIP-dependent double-strand break repair by interaction with CDK2.	Nature structural and molecular biology	2012	32
24444383	1017	Kang J	Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.	BMC cancer	2014	26
25395429	1017	Kumar SK	Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.	Blood	2015	30
25633797	1017	Asghar U	The history and future of targeting cyclin-dependent kinases in cancer therapy.	Nature reviews. Drug discovery	2015	110
26824338	1017	Zakraoui O	Lebein, a snake venom disintegrin, suppresses human colon cancer cells proliferation and tumor-induced angiogenesis through cell cycle arrest, apoptosis induction and inhibition of VEGF expression.	Molecular carcinogenesis	2017	5
16413469	1019	Yu Q	Requirement for CDK4 kinase function in breast cancer.	Cancer cell	2006	84
17023580	1019	Rodriguez PC	L-arginine availability regulates T-lymphocyte cell-cycle progression.	Blood	2007	144
17360326	1019	Dechat T	Alterations in mitosis and cell cycle progression caused by a mutant lamin A known to accelerate human aging.	Proceedings of the National Academy of Sciences of the United States of America	2007	92
19001083	1019	Joshi I	Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases.	Blood	2009	53
19091943	1019	Luo B	Highly parallel identification of essential genes in cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	2008	202
19874578	1019	Finn RS	PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.	Breast cancer research 	2009	194
20179208	1019	Zhong Z	Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells.	Cancer research	2010	45
20440268	1019	Liu F	Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate.	Oncogene	2010	83
20951943	1019	Aggarwal P	Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase.	Cancer cell	2010	66
21200143	1019	Wang C	Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology.	Cell cycle	2011	41
21412932	1019	Birnbaum DJ	Genome profiling of pancreatic adenocarcinoma.	Genes, chromosomes and cancer	2011	43
21552124	1019	Crago AM	Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma.	Current opinion in oncology	2011	56
22711607	1019	Cen L	p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.	Neuro-oncology	2012	34
22767154	1019	Dean JL	Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.	Cell cycle	2012	44
23079656	1019	Sawai CM	Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.	Cancer cell	2012	38
23449933	1019	Sato M	Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations.	Molecular cancer research 	2013	52
23569312	1019	Dickson MA	Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.	Journal of clinical oncology 	2013	75
24045179	1019	Rader J	Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.	Clinical cancer research 	2013	51
24495407	1019	Young RJ	Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.	Pigment cell and melanoma research	2014	25
24604117	1019	Liu G	MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer.	The Journal of pathology	2014	25
24919854	1019	Gelbert LM	Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.	Investigational new drugs	2014	40
25082755	1019	Chiron D	Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.	Cancer discovery	2014	33
25498841	1019	Carneiro BA	Emerging therapeutic targets in bladder cancer.	Cancer treatment reviews	2015	16
25501126	1019	DeMichele A	CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.	Clinical cancer research 	2015	42
25524798	1019	Finn RS	The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.	The Lancet. Oncology	2015	183
25609060	1019	Di Stefano AL	Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.	Clinical cancer research 	2015	19
25803170	1019	Kovatcheva M	MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition.	Oncotarget	2015	16
26324739	1019	Beaver JA	FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.	Clinical cancer research 	2015	24
26923330	1019	Johnson J	Targeting the RB-E2F pathway in breast cancer.	Oncogene	2016	13
26947331	1019	Cristofanilli M	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.	The Lancet. Oncology	2016	40
26977878	1019	Goel S	Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.	Cancer cell	2016	18
27717303	1019	Hortobagyi GN	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.	The New England journal of medicine	2016	25
27849562	1019	Bollard J	Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.	Gut	2017	6
7585571	1026	Waldman T	p21 is necessary for the p53-mediated G1 arrest in human cancer cells.	Cancer research	1995	282
7885482	1026	Chen J	Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA.	Nature	1995	117
8118801	1026	el-Deiry WS	WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.	Cancer research	1994	376
10200307	1026	Saito A	A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.	Proceedings of the National Academy of Sciences of the United States of America	1999	107
10430607	1026	Bunz F	Disruption of p53 in human cancer cells alters the responses to therapeutic agents.	The Journal of clinical investigation	1999	247
11309634	1026	Watanabe T	Molecular predictors of survival after adjuvant chemotherapy for colon cancer.	The New England journal of medicine	2001	174
11517191	1026	Lazennec G	ER beta inhibits proliferation and invasion of breast cancer cells.	Endocrinology	2001	94
11745677	1026	Piek JM	Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.	The Journal of pathology	2001	132
12773551	1026	Zhu WG	Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter.	Molecular and cellular biology	2003	77
14617782	1026	Kondapaka SB	Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.	Molecular cancer therapeutics	2003	100
15031206	1026	Jison ML	Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease.	Blood	2004	75
15173093	1026	Pei XY	Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.	Clinical cancer research 	2004	92
16794190	1026	Matthews C	Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress.	Circulation research	2006	93
16854453	1026	McCubrey JA	Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.	Advances in enzyme regulation	2006	155
17172425	1026	Kuo PL	Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells.	Molecular cancer therapeutics	2006	64
18413741	1026	Majid S	Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification.	Cancer research	2008	54
18590585	1026	Abukhdeir AM	P21 and p27: roles in carcinogenesis and drug resistance.	Expert reviews in molecular medicine	2008	92
19010882	1026	Godlewski J	Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal.	Cancer research	2008	229
19440038	1026	Liu B	Metformin induces unique biological and molecular responses in triple negative breast cancer cells.	Cell cycle	2009	116
19671864	1026	Badros A	Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.	Clinical cancer research 	2009	67
19858489	1026	Liu M	p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2009	65
20020197	1026	Györffy B	An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.	Breast cancer research and treatment	2010	435
20571512	1026	Wilting RH	Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis.	The EMBO journal	2010	60
20851997	1026	Hong L	The miR-17-92 cluster of microRNAs confers tumorigenicity by inhibiting oncogene-induced senescence.	Cancer research	2010	55
20858478	1026	Vidya Priyadarsini R	The flavonoid quercetin induces cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells through p53 induction and NF-κB inhibition.	European journal of pharmacology	2010	46
21209038	1026	Nandakumar V	(-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells.	Carcinogenesis	2011	64
21331045	1026	Elyada E	CKIα ablation highlights a critical role for p53 in invasiveness control.	Nature	2011	56
21383005	1026	Fan T	EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression.	Molecular cancer research 	2011	46
21703415	1026	Cesselli D	Effects of age and heart failure on human cardiac stem cell function.	The American journal of pathology	2011	54
21747117	1026	Mazumdar T	Blocking Hedgehog survival signaling at the level of the GLI genes induces DNA damage and extensive cell death in human colon carcinoma cells.	Cancer research	2011	43
22249270	1026	Yi C	MiR-663, a microRNA targeting p21(WAF1/CIP1), promotes the proliferation and tumorigenesis of nasopharyngeal carcinoma.	Oncogene	2012	50
22287560	1026	Baraniskin A	MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL.	Carcinogenesis	2012	46
22580610	1026	Yin D	miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme.	Oncogene	2013	27
22683204	1026	Ceccaldi R	Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells.	Cell stem cell	2012	77
22684298	1026	Capparelli C	Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis via glycolysis and ketone production.	Cell cycle	2012	54
22935696	1026	Capparelli C	CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis.	Cell cycle	2012	41
23074173	1026	Lui GY	The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.	Molecular pharmacology	2013	26
23632475	1026	Storozhuk Y	Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK.	British journal of cancer	2013	49
23723074	1026	Dong Y	Tumor suppressor functions of miR-133a in colorectal cancer.	Molecular cancer research 	2013	27
23950209	1026	Segura MF	BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy.	Cancer research	2013	41
24027026	1026	Irshad S	A molecular signature predictive of indolent prostate cancer.	Science translational medicine	2013	32
24100703	1026	Sanli T	AMP-activated protein kinase (AMPK) beyond metabolism: a novel genomic stress sensor participating in the DNA damage response pathway.	Cancer biology and therapy	2014	37
24122720	1026	Wang D	MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts.	Circulation research	2014	37
24603685	1026	Dayeh T	Genome-wide DNA methylation analysis of human pancreatic islets from type 2 diabetic and non-diabetic donors identifies candidate genes that influence insulin secretion.	PLoS genetics	2014	88
24991835	1026	Mahalingam D	Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.	Autophagy	2014	63
25633810	1026	Ohta K	MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A.	Oncotarget	2015	26
25728677	1026	Xu TP	SP1-induced upregulation of the long noncoding RNA TINCR regulates cell proliferation and apoptosis by affecting KLF2 mRNA stability in gastric cancer.	Oncogene	2015	43
26913601	1026	Zhang E	Increased expression of long noncoding RNA TUG1 predicts a poor prognosis of gastric cancer and regulates cell proliferation by epigenetically silencing of p57.	Cell death and disease	2016	17
9018243	1027	Porter PL	Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients.	Nature medicine	1997	135
9018244	1027	Catzavelos C	Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer.	Nature medicine	1997	114
10213503	1027	Huang SM	Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.	Cancer research	1999	109
11073822	1027	Ouyang H	Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype.	The American journal of pathology	2000	102
11593406	1027	Hideshima T	Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma.	Oncogene	2001	90
11784790	1027	Back SA	Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia.	The Journal of neuroscience 	2002	171
12244301	1027	Shin I	PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.	Nature medicine	2002	195
12244303	1027	Viglietto G	Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer.	Nature medicine	2002	153
12773099	1027	Sharpe RM	Proliferation and functional maturation of Sertoli cells, and their relevance to disorders of testis function in adulthood.	Reproduction	2003	154
15096506	1027	Mammoto A	Role of RhoA, mDia, and ROCK in cell shape-dependent control of the Skp2-p27kip1 pathway and the G1/S transition.	The Journal of biological chemistry	2004	72
15652749	1027	Baldassarre G	p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion.	Cancer cell	2005	84
17030811	1027	Pellegata NS	Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans.	Proceedings of the National Academy of Sciences of the United States of America	2006	91
17721077	1027	Gillies JK	Regulation of p27Kip1 by miRNA 221/222 in glioblastoma.	Cell cycle	2007	64
18246122	1027	Garofalo M	MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer.	Oncogene	2008	95
18521080	1027	Fornari F	MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma.	Oncogene	2008	176
18691549	1027	Majumder PK	A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression.	Cancer cell	2008	67
19221487	1027	Wang X	MicroRNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D3.	Cell cycle	2009	52
19221498	1027	Alimova IN	Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro.	Cell cycle	2009	126
21245089	1027	Gilmartin AG	GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.	Clinical cancer research 	2011	130
21523318	1027	Yamaguchi T	Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo.	International journal of oncology	2011	43
23479461	1027	Di Martino MT	In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma.	Oncotarget	2013	43
23933118	1027	Thakker RV	Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4).	Molecular and cellular endocrinology	2014	37
24423924	1027	Hou T	MicroRNA-196a promotes cervical cancer proliferation through the regulation of FOXO1 and p27Kip1.	British journal of cancer	2014	23
25151966	1027	Fernandez S	miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer.	Oncogene	2015	29
26551667	1027	da Silva Almeida AC	The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.	Nature genetics	2015	27
27591936	1027	Pan J	Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.	Cancer letters	2016	13
7585152	1029	Merlo A	5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.	Nature medicine	1995	274
8622687	1029	Hara E	Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence.	Molecular and cellular biology	1996	126
8939849	1029	Sherr CJ	Cancer cell cycles.	Science	1996	911
9135016	1029	Rozenblum E	Tumor-suppressive pathways in pancreatic carcinoma.	Cancer research	1997	154
10416987	1029	Ishii N	Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines.	Brain pathology	1999	155
11016622	1029	Eads CA	Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma.	Cancer research	2000	100
11291057	1029	Klaes R	Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri.	International journal of cancer	2001	132
11309301	1029	Eads CA	Epigenetic patterns in the progression of esophageal adenocarcinoma.	Cancer research	2001	136
11325821	1029	Issa JP	Accelerated age-related CpG island methylation in ulcerative colitis.	Cancer research	2001	129
11355949	1029	Vonlanthen S	The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression.	British journal of cancer	2001	90
11544531	1029	Sharpless NE	Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis.	Nature	2001	231
12692724	1029	Sipos B	A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform.	Virchows Archiv 	2003	84
12810640	1029	van Engeland M	Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer.	Cancer research	2003	76
12937151	1029	Yang B	Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma.	The American journal of pathology	2003	87
14507645	1029	Lee S	Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis.	The American journal of pathology	2003	79
14722605	1029	Sharpless NE	Telomeres, stem cells, senescence, and cancer.	The Journal of clinical investigation	2004	112
14729608	1029	Ginos MA	Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck.	Cancer research	2004	99
15026333	1029	Yegnasubramanian S	Hypermethylation of CpG islands in primary and metastatic human prostate cancer.	Cancer research	2004	128
15082532	1029	Kalinichenko VV	Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor.	Genes and development	2004	137
15520862	1029	Krishnamurthy J	Ink4a/Arf expression is a biomarker of aging.	The Journal of clinical investigation	2004	364
15930332	1029	Singhal S	Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review.	Clinical cancer research 	2005	66
15977639	1029	Ohgaki H	Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.	Journal of neuropathology and experimental neurology	2005	237
16054941	1029	Robinson BW	Malignant mesothelioma.	Lancet	2005	126
16115905	1029	Begum S	Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma.	Clinical cancer research 	2005	66
16401683	1029	Weinberger PM	Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis.	Journal of clinical oncology 	2006	171
16424060	1029	Matsubayashi H	DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease.	Cancer research	2006	62
16778197	1029	Song LB	Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells.	Cancer research	2006	121
16840774	1029	Nyunoya T	Cigarette smoke induces cellular senescence.	American journal of respiratory cell and molecular biology	2006	63
16880792	1029	Gray-Schopfer VC	Cellular senescence in naevi and immortalisation in melanoma: a role for p16?	British journal of cancer	2006	101
16888288	1029	Tsuji T	Alveolar cell senescence in patients with pulmonary emphysema.	American journal of respiratory and critical care medicine	2006	96
16964246	1029	Denoyelle C	Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway.	Nature cell biology	2006	97
17065427	1029	Ogino S	CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations.	The Journal of molecular diagnostics 	2006	134
17326708	1029	Galipeau PC	NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.	PLoS medicine	2007	87
17456751	1029	Ohgaki H	Genetic pathways to primary and secondary glioblastoma.	The American journal of pathology	2007	299
17498290	1029	Le Maitre CL	Accelerated cellular senescence in degenerate intervertebral discs: a possible role in the pathogenesis of intervertebral disc degeneration.	Arthritis research and therapy	2007	66
17654117	1029	Cánepa ET	INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions.	IUBMB life	2007	64
18305067	1029	Leedham SJ	Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus.	Gut	2008	56
18324472	1029	Lund MJ	Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.	Breast cancer research and treatment	2009	108
18353141	1029	Bennett DC	How to make a melanoma: what do we know of the primary clonal events?	Pigment cell and melanoma research	2008	54
18360824	1029	Hafkamp HC	Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas.	International journal of cancer	2008	70
18394558	1029	Wiedemeyer R	Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development.	Cancer cell	2008	59
18806226	1029	Dumont N	Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers.	Proceedings of the National Academy of Sciences of the United States of America	2008	80
18843198	1029	Bueno MJ	Control of cell proliferation pathways by microRNAs.	Cell cycle	2008	93
18922929	1029	Barault L	Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.	Cancer research	2008	106
19427557	1029	Kong CS	The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas.	International journal of radiation oncology, biology, physics	2009	61
19470766	1029	Beroukhim R	Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney.	Cancer research	2009	119
19509227	1029	Novak P	Stepwise DNA methylation changes are linked to escape from defined proliferation barriers and mammary epithelial cell immortalization.	Cancer research	2009	56
19593635	1029	Hollestelle A	Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.	Breast cancer research and treatment	2010	83
19718709	1029	Mohseny AB	Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2.	The Journal of pathology	2009	71
19787792	1029	Ottaviano L	Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort.	Genes, chromosomes and cancer	2010	48
19825961	1029	Ogino S	Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype.	Clinical cancer research 	2009	92
19853898	1029	D'Angelo E	Uterine sarcomas: a review.	Gynecologic oncology	2010	101
19966864	1029	Worthley DL	DNA methylation within the normal colorectal mucosa is associated with pathway-specific predisposition to cancer.	Oncogene	2010	42
20146264	1029	Braconi C	MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes.	Hepatology	2010	106
20186832	1029	Singhi AD	Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience.	Cancer	2010	84
20427430	1029	Kerlikowske K	Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.	Journal of the National Cancer Institute	2010	81
20451455	1029	Marur S	HPV-associated head and neck cancer: a virus-related cancer epidemic.	The Lancet. Oncology	2010	283
20460471	1029	Jönsson G	Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.	Clinical cancer research 	2010	58
20522802	1029	Kajstura J	Cardiomyogenesis in the adult human heart.	Circulation research	2010	101
20549699	1029	Ozenne P	The ARF tumor suppressor: structure, functions and status in cancer.	International journal of cancer	2010	44
20587061	1029	Dayyani F	Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC).	Head and neck oncology	2010	74
20596971	1029	Chernock RD	HPV-related nonkeratinizing squamous cell carcinoma of the oropharynx: utility of microscopic features in predicting patient outcome.	Head and neck pathology	2009	47
20697079	1029	Rischin D	Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.	Journal of clinical oncology 	2010	121
20876795	1029	Verna EC	Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics.	Clinical cancer research 	2010	60
21129377	1029	Vasen HF	Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation.	Gastroenterology	2011	39
21145824	1029	Um TH	Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis.	Journal of hepatology	2011	41
21248843	1029	Notta F	Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells.	Nature	2011	154
21294121	1029	Marsh D	Stromal features are predictive of disease mortality in oral cancer patients.	The Journal of pathology	2011	47
21509761	1029	Ahn JB	DNA methylation predicts recurrence from resected stage III proximal colon cancer.	Cancer	2011	47
21636552	1029	Raabe EH	BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model.	Clinical cancer research 	2011	42
21836494	1029	Ukpo OC	High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma.	The American journal of surgical pathology	2011	50
21837480	1029	Cho YH	Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients.	Breast cancer research and treatment	2012	33
21952072	1029	Beltran AS	Generation of tumor-initiating cells by exogenous delivery of OCT4 transcription factor.	Breast cancer research 	2011	37
22065079	1029	Carbone M	Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma.	Clinical cancer research 	2012	46
22067401	1029	Oberholzer PA	RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.	Journal of clinical oncology 	2012	79
22084097	1029	Nagai H	Diameter and rigidity of multiwalled carbon nanotubes are critical factors in mesothelial injury and carcinogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2011	89
22180304	1029	El-Naggar AK	p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guide for interpretative relevance and consistency.	Head and neck	2012	38
22251937	1029	Yachida S	Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.	The American journal of surgical pathology	2012	39
22256804	1029	Su F	RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.	The New England journal of medicine	2012	200
22422852	1029	Szarewski A	Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study.	Journal of clinical microbiology	2012	31
22565003	1029	Gillison ML	Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer.	Journal of clinical oncology 	2012	73
22612594	1029	Waaijer ME	The number of p16INK4a positive cells in human skin reflects biological age.	Aging cell	2012	33
22782226	1029	Lewis JS Jr	p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma.	Head and neck pathology	2012	35
22782230	1029	Isayeva T	Human papillomavirus in non-oropharyngeal head and neck cancers: a systematic literature review.	Head and neck pathology	2012	31
22888763	1029	Jeck WR	Review: a meta-analysis of GWAS and age-associated diseases.	Aging cell	2012	37
22949073	1029	Rietbergen MM	Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm.	International journal of cancer	2013	25
22975375	1029	Navas C	EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma.	Cancer cell	2012	91
22984612	1029	Bhat R	Astrocyte senescence as a component of Alzheimer's disease.	PloS one	2012	43
22991414	1029	Yachida S	Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors.	Clinical cancer research 	2012	35
23095507	1029	Bishop JA	Human papillomavirus-related carcinomas of the sinonasal tract.	The American journal of surgical pathology	2013	28
23373539	1029	Etchin J	KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.	British journal of haematology	2013	63
23460709	1029	Martins RG	Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.	Journal of clinical oncology 	2013	26
23585871	1029	Amir S	Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer.	PloS one	2013	29
23663786	1029	Yang L	Diverse mechanisms of somatic structural variations in human cancer genomes.	Cell	2013	74
23677068	1029	Sekido Y	Molecular pathogenesis of malignant mesothelioma.	Carcinogenesis	2013	32
23746666	1029	Vermorken JB	Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.	The Lancet. Oncology	2013	56
23887298	1029	Ross JS	Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy.	Modern pathology 	2014	36
24127483	1029	Fabbri G	Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome.	The Journal of experimental medicine	2013	26
24177760	1029	Walline HM	High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods.	JAMA otolaryngology-- head and neck surgery	2013	29
24522534	1029	Sousa-Victor P	Geriatric muscle stem cells switch reversible quiescence into senescence.	Nature	2014	126
24681605	1029	Sanoff HK	Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer.	Journal of the National Cancer Institute	2014	31
24910096	1029	Johmura Y	Necessary and sufficient role for a mitosis skip in senescence induction.	Molecular cell	2014	32
25009010	1029	De Mattos-Arruda L	Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.	Annals of oncology 	2014	47
25010205	1029	Brohl AS	The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation.	PLoS genetics	2014	53
25092538	1029	Kim PH	Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.	European urology	2015	19
25154822	1029	Ang KK	Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.	Journal of clinical oncology 	2014	101
25223734	1029	Tirode F	Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations.	Cancer discovery	2014	57
25366680	1029	Nguyen-Tan PF	Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.	Journal of clinical oncology 	2014	25
25479140	1029	Grant RC	Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer.	Gastroenterology	2015	23
25503501	1029	Maxwell KN	Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer.	Genetics in medicine 	2015	24
25536104	1029	Churi CR	Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.	PloS one	2014	40
25584893	1029	Damsky W	mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.	Cancer cell	2015	15
25712460	1029	Chung CH	Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing.	Annals of oncology 	2015	17
25754026	1029	Huang T	Meta-analyses of gene methylation and smoking behavior in non-small cell lung cancer patients.	Scientific reports	2015	18
25822088	1029	Schulze K	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.	Nature genetics	2015	104
25890171	1029	Kong R	Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16.	Molecular cancer	2015	26
26024833	1029	Fu WM	Hotair mediates hepatocarcinogenesis through suppressing miRNA-218 expression and activating P14 and P16 signaling.	Journal of hepatology	2015	24
26192918	1029	Stachler MD	Paired exome analysis of Barrett's esophagus and adenocarcinoma.	Nature genetics	2015	30
26551670	1029	Wang L	Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes.	Nature genetics	2015	24
26658419	1029	Roberts NJ	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer.	Cancer discovery	2016	14
26762611	1029	Alemany L	Role of Human Papillomavirus in Penile Carcinomas Worldwide.	European urology	2016	16
26823521	1029	Castellsagué X	HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients.	Journal of the National Cancer Institute	2016	27
26830752	1029	Kamisawa T	Pancreatic cancer.	Lancet	2016	47
26873401	1029	Sawada G	Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population.	Gastroenterology	2016	17
26950362	1029	Helman A	p16(Ink4a)-induced senescence of pancreatic beta cells enhances insulin secretion.	Nature medicine	2016	19
27007578	1029	Mehanna H	PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer.	The New England journal of medicine	2016	15
27114589	1029	Vasen H	Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.	Journal of clinical oncology 	2016	16
27213815	1029	Dauch D	A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.	Nature medicine	2016	15
20664940	1045	Minoo P	Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles.	International journal of oncology	2010	51
21949732	1045	Williams BL	Impaired carbohydrate digestion and transport and mucosal dysbiosis in the intestines of children with autism and gastrointestinal disturbances.	PloS one	2011	70
22104201	1045	Jang BG	Molecular pathology of gastric carcinoma.	Pathobiology 	2011	41
24764661	1045	Kim JH	Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.	World journal of gastroenterology	2014	21
26789870	1045	Dalerba P	CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.	The New England journal of medicine	2016	28
9922383	1080	Pilewski JM	Role of CFTR in airway disease.	Physiological reviews	1999	108
16888286	1080	Guilbault C	Cystic fibrosis mouse models.	American journal of respiratory cell and molecular biology	2007	61
18063840	1080	Sueblinvong V	Derivation of lung epithelium from human cord blood-derived mesenchymal stem cells.	American journal of respiratory and critical care medicine	2008	63
18083779	1080	De La Fuente R	Small-molecule screen identifies inhibitors of a human intestinal calcium-activated chloride channel.	Molecular pharmacology	2008	61
18639722	1080	Farrell PM	Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report.	The Journal of pediatrics	2008	150
19621064	1080	Zhang L	CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium.	PLoS biology	2009	53
19846789	1080	Van Goor F	Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770.	Proceedings of the National Academy of Sciences of the United States of America	2009	219
20059346	1080	Whitcomb DC	Genetic aspects of pancreatitis.	Annual review of medicine	2010	42
20110417	1080	Meyerholz DK	Pathology of gastrointestinal organs in a porcine model of cystic fibrosis.	The American journal of pathology	2010	56
20622026	1080	Meyerholz DK	Loss of cystic fibrosis transmembrane conductance regulator function produces abnormalities in tracheal development in neonatal pigs and young children.	American journal of respiratory and critical care medicine	2010	59
21262823	1080	Takiar V	Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2011	47
21397320	1080	Braganza JM	Chronic pancreatitis.	Lancet	2011	84
21976485	1080	Van Goor F	Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809.	Proceedings of the National Academy of Sciences of the United States of America	2011	180
22265409	1080	Mendoza JL	Requirements for efficient correction of ΔF508 CFTR revealed by analyses of evolved sequences.	Cell	2012	76
22768130	1080	Sloane PA	A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease.	PloS one	2012	58
22980976	1080	Govindan R	Genomic landscape of non-small cell lung cancer in smokers and never-smokers.	Cell	2012	233
23704228	1080	Cohen-Cymberknoh M	Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications.	Thorax	2013	29
23727931	1080	Dekkers JF	A functional CFTR assay using primary cystic fibrosis intestinal organoids.	Nature medicine	2013	86
23924900	1080	Ren HY	VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1.	Molecular biology of the cell	2013	39
24251786	1080	Xue X	Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor.	American journal of respiratory cell and molecular biology	2014	27
24315439	1080	Schwank G	Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients.	Cell stem cell	2013	167
24608905	1080	Tuggle KL	Characterization of defects in ion transport and tissue development in cystic fibrosis transmembrane conductance regulator (CFTR)-knockout rats.	PloS one	2014	26
25033378	1080	LaRusch J	Mechanisms of CFTR functional variants that impair regulated bicarbonate permeation and increase risk for pancreatitis but not for cystic fibrosis.	PLoS genetics	2014	27
25101886	1080	Cholon DM	Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis.	Science translational medicine	2014	54
25101887	1080	Veit G	Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression.	Science translational medicine	2014	57
25814049	1080	Cantin AM	Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy.	Journal of cystic fibrosis 	2015	31
26149841	1080	Alton EWFW	Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial.	The Lancet. Respiratory medicine	2015	27
26417704	1080	Corvol H	Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis.	Nature communications	2015	24
26677983	1080	Foulke-Abel J	Human Enteroids as a Model of Upper Small Intestinal Ion Transport Physiology and Pathophysiology.	Gastroenterology	2016	16
26761715	1080	Soukarieh O	Exonic Splicing Mutations Are More Prevalent than Currently Estimated and Can Be Predicted by Using In Silico Tools.	PLoS genetics	2016	17
7740812	1084	Scheele J	Resection of colorectal liver metastases.	World journal of surgery	1995	197
8608500	1084	Nordlinger B	Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie.	Cancer	1996	222
10202129	1084	Hammarström S	The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues.	Seminars in cancer biology	1999	215
11274010	1084	Duffy MJ	Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?	Clinical chemistry	2001	94
12685552	1084	Terada T	Minute mixed ductal-endocrine carcinoma of the pancreas with predominant intraductal growth.	Pathology international	2002	96
15131794	1084	Brugge WR	Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study.	Gastroenterology	2004	170
15849507	1084	Pawlik TM	Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases.	Annals of surgery	2005	169
18818422	1084	Abd Hamid UM	A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression.	Glycobiology	2008	59
19152896	1084	Khalid A	Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study.	Gastrointestinal endoscopy	2009	78
20103634	1084	Galanis E	Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.	Cancer research	2010	98
21422427	1084	Iinuma H	Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.	Journal of clinical oncology 	2011	78
21606835	1084	Hartwig W	Pancreatic cancer surgery in the new millennium: better prediction of outcome.	Annals of surgery	2011	63
21775920	1084	Cizginer S	Cyst fluid carcinoembryonic antigen is an accurate diagnostic marker of pancreatic mucinous cysts.	Pancreas	2011	42
23307251	1084	He W	Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer.	Medical oncology	2013	40
23315099	1084	Haas M	Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.	Journal of cancer research and clinical oncology	2013	29
23572188	1084	Shimada H	Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association.	Gastric cancer 	2014	32
23657083	1084	Morse MA	A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer.	Annals of surgery	2013	30
24373959	1084	Hiroshima Y	Hand-held high-resolution fluorescence imaging system for fluorescence-guided surgery of patient and cell-line pancreatic tumors growing orthotopically in nude mice.	The Journal of surgical research	2014	33
24494971	1084	Hiroshima Y	Successful fluorescence-guided surgery on human colon cancer patient-derived orthotopic xenograft mouse models using a fluorophore-conjugated anti-CEA antibody and a portable imaging system.	Journal of laparoendoscopic and advanced surgical techniques. Part A	2014	37
25087904	1084	Isik A	Importance of metastatic lymph node ratio in non-metastatic, lymph node-invaded colon cancer: a clinical trial.	Medical science monitor 	2014	44
25273947	1084	Liu L	A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer.	International journal of cancer	2015	19
25851626	1084	Tie J	Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.	Annals of oncology 	2015	38
12446774	1111	Heffernan TP	An ATR- and Chk1-dependent S checkpoint inhibits replicon initiation following UVC-induced DNA damage.	Molecular and cellular biology	2002	90
14608368	1111	d'Adda di Fagagna F	A DNA damage checkpoint response in telomere-initiated senescence.	Nature	2003	634
17051156	1111	Bao S	Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.	Nature	2006	1463
17991895	1111	Palii SS	DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.	Molecular and cellular biology	2008	92
19716789	1111	Zhang YW	The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress.	Molecular cell	2009	61
20501833	1111	Morgan MA	Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.	Cancer research	2010	95
20581868	1111	Bartkova J	Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas.	Oncogene	2010	53
21458083	1111	Garrett MD	Anticancer therapy with checkpoint inhibitors: what, where and when?	Trends in pharmacological sciences	2011	58
22825331	1111	Prevo R	The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.	Cancer biology and therapy	2012	53
23242585	1111	Ma CX	A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.	Breast cancer research and treatment	2013	27
23593991	1111	Thompson R	The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design.	British journal of clinical pharmacology	2013	31
24448638	1111	Sausville E	Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.	Cancer chemotherapy and pharmacology	2014	28
25132270	1111	Sarmento LM	CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress.	Oncogene	2015	17
25931285	1111	Khanna A	DNA damage in cancer therapeutics: a boon or a curse?	Cancer research	2015	17
12874759	1113	Roudier MP	Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone.	Human pathology	2003	88
16007257	1113	Mahapatra NR	Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog.	The Journal of clinical investigation	2005	88
16253899	1113	Oberg K	Endocrine tumours of the pancreas.	Best practice and research. Clinical gastroenterology	2005	69
16728727	1113	Rozengurt N	Colocalization of the alpha-subunit of gustducin with PYY and GLP-1 in L cells of human colon.	American journal of physiology. Gastrointestinal and liver physiology	2006	72
17505000	1113	Ekeblad S	Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.	Clinical cancer research 	2007	62
18261235	1113	Immervoll H	Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas.	BMC cancer	2008	59
18603570	1113	Pape UF	Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.	Endocrine-related cancer	2008	53
18703061	1113	Metz DC	Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.	Gastroenterology	2008	103
23845449	1113	Vélayoudom-Céphise FL	Are G3 ENETS neuroendocrine neoplasms heterogeneous?	Endocrine-related cancer	2013	26
24316398	1113	El-Salhy M	Abnormal rectal endocrine cells in patients with irritable bowel syndrome.	Regulatory peptides	2014	21
25646366	1113	Caplin ME	Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.	Annals of oncology 	2015	21
20007781	1302	Brachmann SM	Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	2009	105
20060649	1302	Bosch A	Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.	Cancer treatment reviews	2010	55
20802015	1302	Graeser M	A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer.	Clinical cancer research 	2010	55
21859835	1302	Munagala R	Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells.	Carcinogenesis	2011	45
24270682	1302	Bouwman P	Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?	Clinical cancer research 	2014	40
24980887	1302	Jeffries MA	Genome-wide DNA methylation study identifies significant epigenomic changes in osteoarthritic cartilage.	Arthritis and rheumatology	2014	35
26196320	1302	Kwegyir-Afful AK	Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo.	Oncotarget	2015	23
26774285	1302	Tkáč J	HELB Is a Feedback Inhibitor of DNA End Resection.	Molecular cell	2016	13
27056384	1302	Shang C	Silence of long noncoding RNA UCA1 inhibits malignant proliferation and chemotherapy resistance to adriamycin in gastric cancer.	Cancer chemotherapy and pharmacology	2016	15
7977430	1351	Mazzaferri EL	Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.	The American journal of medicine	1994	236
12782577	1351	Choe G	Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.	Cancer research	2003	105
12885809	1351	Le Voyer TE	Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089.	Journal of clinical oncology 	2003	153
15317891	1351	Cristofanilli M	Circulating tumor cells, disease progression, and survival in metastatic breast cancer.	The New England journal of medicine	2004	839
15547162	1351	Devereux RB	Prognostic significance of left ventricular mass change during treatment of hypertension.	JAMA	2004	104
17179478	1351	Chlebowski RT	Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study.	Journal of the National Cancer Institute	2006	163
18315614	1351	Nichols WL	von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).	Haemophilia 	2008	83
18329481	1351	Flores RM	Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.	The Journal of thoracic and cardiovascular surgery	2008	72
18936567	1351	Peyre CG	The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection.	Annals of surgery	2008	62
19012918	1351	Huang WC	Partial nephrectomy versus radical nephrectomy in patients with small renal tumors--is there a difference in mortality and cardiovascular outcomes?	The Journal of urology	2009	108
19033573	1351	Benedetti Panici P	Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.	Journal of the National Cancer Institute	2008	134
20152963	1351	Stoodley CJ	Evidence for topographic organization in the cerebellum of motor control versus cognitive and affective processing.	Cortex; a journal devoted to the study of the nervous system and behavior	2010	187
20670867	1351	Englesbe MJ	Sarcopenia and mortality after liver transplantation.	Journal of the American College of Surgeons	2010	74
23382293	1351	Idilman IS	Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy.	Radiology	2013	29
23555212	1351	Zhang W	Network-based survival analysis reveals subnetwork signatures for predicting outcomes of ovarian cancer treatment.	PLoS computational biology	2013	33
23897954	1351	Metzger-Filho O	Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.	Journal of clinical oncology 	2013	40
24192549	1351	Maegele M	An update on the coagulopathy of trauma.	Shock	2014	20
24693890	1351	Corley DA	Adenoma detection rate and risk of colorectal cancer and death.	The New England journal of medicine	2014	107
24927536	1351	Park CY	Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs.	Proceedings of the National Academy of Sciences of the United States of America	2014	23
25485684	1351	Johansson JU	Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models.	The Journal of clinical investigation	2015	29
25609685	1351	Marko MK	Behavioural and neural basis of anomalous motor learning in children with autism.	Brain 	2015	15
25663689	1351	Hur K	Identification of a metastasis-specific MicroRNA signature in human colorectal cancer.	Journal of the National Cancer Institute	2015	34
7934491	1401	Elliott MJ	Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.	Lancet	1994	216
9655393	1401	Staels B	Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.	Nature	1998	144
9870876	1401	Bresnihan B	Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.	Arthritis and rheumatism	1998	137
10231453	1401	Stenvinkel P	Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure.	Kidney international	1999	158
10903648	1401	Danesh J	Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses.	BMJ	2000	214
11157411	1401	Geffken DF	Association between physical activity and markers of inflammation in a healthy elderly population.	American journal of epidemiology	2001	99
11282915	1401	Ridker PM	High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.	Circulation	2001	143
11440492	1401	Peters A	Particulate air pollution is associated with an acute phase response in men; results from the MONICA-Augsburg Study.	European heart journal	2001	103
11673759	1401	Festa A	The relation of body fat mass and distribution to markers of chronic inflammation.	International journal of obesity and related metabolic disorders 	2001	107
12234944	1401	Venugopal SK	Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells.	Circulation	2002	99
14530185	1401	Naghavi M	From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I.	Circulation	2003	322
14557340	1401	Naghavi M	From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II.	Circulation	2003	153
14996776	1401	Nissen SE	Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.	JAMA	2004	214
15197140	1401	Esposito K	Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.	Circulation	2004	73
15337754	1401	Black S	C-reactive Protein.	The Journal of biological chemistry	2004	186
15472670	1401	Daperno M	Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD.	Gastrointestinal endoscopy	2004	108
15699278	1401	Desvarieux M	Periodontal microbiota and carotid intima-media thickness: the Oral Infections and Vascular Disease Epidemiology Study (INVEST).	Circulation	2005	111
15818697	1401	Smolen JS	Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.	Arthritis and rheumatism	2005	79
16043984	1401	Solem CA	Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease.	Inflammatory bowel diseases	2005	73
16135490	1401	Maltoni M	Prognostic factors in advanced cancer patients: evidence-based clinical recommendations--a study by the Steering Committee of the European Association for Palliative Care.	Journal of clinical oncology 	2005	75
16207336	1401	van der Helm-van Mil AH	Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis.	Arthritis research and therapy	2005	78
16505242	1401	Devaraj S	Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes.	Diabetes	2006	84
16595481	1401	Bauer TW	Diagnosis of periprosthetic infection.	The Journal of bone and joint surgery. American volume	2006	64
16618517	1401	Haukeland JW	Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2.	Journal of hepatology	2006	89
16631001	1401	Klem I	Improved detection of coronary artery disease by stress perfusion cardiovascular magnetic resonance with the use of delayed enhancement infarction imaging.	Journal of the American College of Cardiology	2006	77
16631505	1401	Virmani R	Pathology of the vulnerable plaque.	Journal of the American College of Cardiology	2006	310
16642000	1401	Pepys MB	Targeting C-reactive protein for the treatment of cardiovascular disease.	Nature	2006	121
16952548	1401	Bekri S	Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH.	Gastroenterology	2006	88
17164456	1401	Lange LA	Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events.	JAMA	2006	65
17192290	1401	Stewart FM	Longitudinal assessment of maternal endothelial function and markers of inflammation and placental function throughout pregnancy in lean and obese mothers.	The Journal of clinical endocrinology and metabolism	2007	59
17341558	1401	Balagopal P	Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation.	The Journal of clinical endocrinology and metabolism	2007	61
17389308	1401	Jefferson AL	Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study.	Neurology	2007	64
17540785	1401	Celli BR	Exacerbations of chronic obstructive pulmonary disease.	The European respiratory journal	2007	60
17556718	1401	Drager LF	Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea.	American journal of respiratory and critical care medicine	2007	93
17709633	1401	Pou KM	Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study.	Circulation	2007	196
17916108	1401	Langhorst J	Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.	The American journal of gastroenterology	2008	96
18022866	1401	Sipponen T	Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings.	Inflammatory bowel diseases	2008	65
18166598	1401	Fabbri LM	Complex chronic comorbidities of COPD.	The European respiratory journal	2008	97
18376000	1401	Kastelein JJ	Simvastatin with or without ezetimibe in familial hypercholesterolemia.	The New England journal of medicine	2008	172
18452641	1401	McMillan DC	An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer.	The Proceedings of the Nutrition Society	2008	66
18480203	1401	Zethelius B	Use of multiple biomarkers to improve the prediction of death from cardiovascular causes.	The New England journal of medicine	2008	179
18566104	1401	Henriksen M	C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.	Gut	2008	52
18571548	1401	Tremoulet AH	Resistance to intravenous immunoglobulin in children with Kawasaki disease.	The Journal of pediatrics	2008	56
18765397	1401	Serruys PW	Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque.	Circulation	2008	89
19470939	1401	Pierce BL	Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients.	Journal of clinical oncology 	2009	147
19520972	1401	Eisenhardt SU	Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques.	Circulation research	2009	46
19622801	1401	Schaap LA	Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength.	The journals of gerontology. Series A, Biological sciences and medical sciences	2009	89
19630828	1401	Ridker PM	Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT).	Journal of thrombosis and haemostasis 	2009	71
19712036	1401	Ross AC	Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy.	Clinical infectious diseases 	2009	75
19755969	1401	Schoepfer AM	Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.	The American journal of gastroenterology	2010	55
19805772	1401	Helfand M	Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force.	Annals of internal medicine	2009	62
20194272	1401	Skinner AC	Multiple markers of inflammation and weight status: cross-sectional analyses throughout childhood.	Pediatrics	2010	50
20421535	1401	Chaturvedi AK	C-reactive protein and risk of lung cancer.	Journal of clinical oncology 	2010	54
21106722	1401	Sarnaik AA	Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma.	Clinical cancer research 	2011	37
21266974	1401	Proctor MJ	An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study.	British journal of cancer	2011	66
21364762	1401	Erdman LK	Combinations of host biomarkers predict mortality among Ugandan children with severe malaria: a retrospective case-control study.	PloS one	2011	48
21560033	1401	Shozushima T	Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome.	Journal of infection and chemotherapy 	2011	39
21680719	1401	Tan ZS	Association of metabolic dysregulation with volumetric brain magnetic resonance imaging and cognitive markers of subclinical brain aging in middle-aged adults: the Framingham Offspring Study.	Diabetes care	2011	42
21688163	1401	Oh B	Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial.	Supportive care in cancer 	2012	32
21718915	1401	Al Mheid I	Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans.	Journal of the American College of Cardiology	2011	62
21724383	1401	Proctor MJ	A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study.	European journal of cancer	2011	122
21792295	1401	Kones R	Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.	Drug design, development and therapy	2011	39
21835901	1401	Colish J	Obstructive sleep apnea: effects of continuous positive airway pressure on cardiac remodeling as assessed by cardiac biomarkers, echocardiography, and cardiac MRI.	Chest	2012	32
22055018	1401	Wikgren M	Short telomeres in depression and the general population are associated with a hypocortisolemic state.	Biological psychiatry	2012	41
22184371	1401	Tarhini AA	Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.	Journal of clinical oncology 	2012	33
22294344	1401	Sibley CH	Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes.	Arthritis and rheumatism	2012	44
22307011	1401	Pinato DJ	Inflammation-based prognostic indices in malignant pleural mesothelioma.	Journal of thoracic oncology 	2012	36
22345378	1401	Wood LG	The neutrophilic inflammatory phenotype is associated with systemic inflammation in asthma.	Chest	2012	46
22357713	1401	Satizabal CL	Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-Dijon Study.	Neurology	2012	39
22367431	1401	Jenny NS	Long-term assessment of inflammation and healthy aging in late life: the Cardiovascular Health Study All Stars.	The journals of gerontology. Series A, Biological sciences and medical sciences	2012	38
22406004	1401	Liu L	Fatigue and sleep quality are associated with changes in inflammatory markers in breast cancer patients undergoing chemotherapy.	Brain, behavior, and immunity	2012	38
22446338	1401	Gondo T	Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy.	Urology	2012	39
22476808	1401	Wang DS	Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer.	Medical oncology	2012	41
22492856	1401	Parrinello CM	Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women.	The Journal of infectious diseases	2012	41
22562973	1401	Kavanaugh A	Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study.	Annals of the rheumatic diseases	2013	36
22564993	1401	Bonanni B	Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.	Journal of clinical oncology 	2012	60
22606276	1401	Sutherland ER	Cluster analysis of obesity and asthma phenotypes.	PloS one	2012	36
22624038	1401	Agustí A	Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype.	PloS one	2012	123
22708923	1401	Bartlett DB	The age-related increase in low-grade systemic inflammation (Inflammaging) is not driven by cytomegalovirus infection.	Aging cell	2012	31
22772328	1401	Sieper J	Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).	Annals of the rheumatic diseases	2013	49
22809118	1401	Su L	Value of soluble TREM-1, procalcitonin, and C-reactive protein serum levels as biomarkers for detecting bacteremia among sepsis patients with new fever in intensive care units: a prospective cohort study.	BMC infectious diseases	2012	41
22820791	1401	Subramanian S	Arterial inflammation in patients with HIV.	JAMA	2012	122
22933030	1401	Niraula S	Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study.	Breast cancer research and treatment	2012	62
22995477	1401	McMillan DC	The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.	Cancer treatment reviews	2013	124
23089630	1401	Lamers F	Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression.	Molecular psychiatry	2013	65
23659971	1401	Kurzrock R	A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.	Clinical cancer research 	2013	36
23687099	1401	Neeland IJ	Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults.	Obesity	2013	48
23820256	1401	Ishizuka M	Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer.	British journal of cancer	2013	29
23844064	1401	Gary T	Platelet-to-lymphocyte ratio: a novel marker for critical limb ischemia in peripheral arterial occlusive disease patients.	PloS one	2013	26
23872668	1401	Forbes GM	A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy.	Clinical gastroenterology and hepatology 	2014	42
23897768	1401	Filková M	Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis.	Annals of the rheumatic diseases	2014	21
23974954	1401	Peyrin-Biroulet L	Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.	Gut	2014	35
24201751	1401	Szkandera J	Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients.	British journal of cancer	2014	25
24389297	1401	Poddubnyy D	Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).	Annals of the rheumatic diseases	2014	28
24396135	1401	Simonsen KA	Early-onset neonatal sepsis.	Clinical microbiology reviews	2014	49
24429405	1401	Sinha A	Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.	Kidney international	2014	21
24443059	1401	Aleksandrova K	Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer.	Hepatology	2014	29
24481424	1401	Klein R	Markers of inflammation, oxidative stress, and endothelial dysfunction and the 20-year cumulative incidence of early age-related macular degeneration: the Beaver Dam Eye Study.	JAMA ophthalmology	2014	31
24695951	1401	Simeone E	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma.	Cancer immunology, immunotherapy 	2014	28
24819981	1401	Semba RD	Resveratrol levels and all-cause mortality in older community-dwelling adults.	JAMA internal medicine	2014	22
25054777	1401	Freedman BI	APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes.	Kidney international	2015	26
25190127	1401	Kinoshita A	The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma.	Annals of surgical oncology	2015	36
25390655	1401	Willeit P	Leucocyte telomere length and risk of type 2 diabetes mellitus: new prospective cohort study and literature-based meta-analysis.	PloS one	2014	25
25527668	1401	Karakochuk CD	Genetic hemoglobin disorders rather than iron deficiency are a major predictor of hemoglobin concentration in women of reproductive age in rural prey Veng, Cambodia.	The Journal of nutrition	2015	16
25710246	1401	Hajat A	Long-term exposure to air pollution and markers of inflammation, coagulation, and endothelial activation: a repeat-measures analysis in the Multi-Ethnic Study of Atherosclerosis (MESA).	Epidemiology	2015	21
25835438	1401	Puri R	Impact of statins on serial coronary calcification during atheroma progression and regression.	Journal of the American College of Cardiology	2015	25
25934640	1401	Wei XL	A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio.	BMC cancer	2015	20
26063409	1401	Zhang WW	Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients.	Tumour biology 	2015	19
26271406	1401	Hunt L	Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study.	The Lancet. Infectious diseases	2015	32
26351344	1401	Hurwitz HI	Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.	Journal of clinical oncology 	2015	26
26467665	1401	Tang LQ	Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma.	Journal of the National Cancer Institute	2016	16
26530445	1401	Ishizuka M	Clinical Significance of the C-Reactive Protein to Albumin Ratio for Survival After Surgery for Colorectal Cancer.	Annals of surgical oncology	2016	13
27013319	1401	Odegaard AO	Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes.	Cardiovascular diabetology	2016	16
12853196	1432	Maiuri L	Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease.	Lancet	2003	97
14997933	1432	Ferrer I	Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease.	Brain pathology	2004	152
15184882	1432	Xiao D	Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2.	Oncogene	2004	73
15746443	1432	Pathak A	Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1.	Circulation research	2005	73
15753463	1432	Gutierrez MC	Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.	Journal of clinical oncology 	2005	122
15855434	1432	Zink MC	Neuroprotective and anti-human immunodeficiency virus activity of minocycline.	JAMA	2005	65
16402404	1432	Sadeghi K	Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns.	European journal of immunology	2006	100
16452201	1432	Zetser A	Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation.	Cancer research	2006	80
16799564	1432	Androutsellis-Theotokis A	Notch signalling regulates stem cell numbers in vitro and in vivo.	Nature	2006	260
17634369	1432	Yune TY	Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury.	The Journal of neuroscience 	2007	63
17720811	1432	Chang J	Noncanonical Wnt-4 signaling enhances bone regeneration of mesenchymal stem cells in craniofacial defects through activation of p38 MAPK.	The Journal of biological chemistry	2007	55
17906618	1432	Plun-Favreau H	The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1.	Nature cell biology	2007	145
18276609	1432	Tang G	Autophagy induced by Alexander disease-mutant GFAP accumulation is regulated by p38/MAPK and mTOR signaling pathways.	Human molecular genetics	2008	52
18285558	1432	Ali TK	Peroxynitrite mediates retinal neurodegeneration by inhibiting nerve growth factor survival signaling in experimental and human diabetes.	Diabetes	2008	61
18339885	1432	Lakshman M	Dietary genistein inhibits metastasis of human prostate cancer in mice.	Cancer research	2008	57
18492738	1432	Bhavsar P	Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma.	Thorax	2008	63
19236889	1432	Siu ER	Cadmium-induced testicular injury.	Toxicology and applied pharmacology	2009	54
19617536	1432	Markovic DS	Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion.	Proceedings of the National Academy of Sciences of the United States of America	2009	68
19654295	1432	Yodkeeree S	Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: Evidence for an essential role of reactive oxygen species.	Cancer research	2009	45
19843704	1432	Wong CK	Thymic stromal lymphopoietin induces chemotactic and prosurvival effects in eosinophils: implications in allergic inflammation.	American journal of respiratory cell and molecular biology	2010	41
19951717	1432	Munoz L	Targeting p38 MAPK pathway for the treatment of Alzheimer's disease.	Neuropharmacology	2010	57
20802523	1432	Wendt MK	Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression.	Oncogene	2010	75
20957344	1432	Ali TK	Diabetes-induced peroxynitrite impairs the balance of pro-nerve growth factor and nerve growth factor, and causes neurovascular injury.	Diabetologia	2011	44
21047517	1432	Földes G	Modulation of human embryonic stem cell-derived cardiomyocyte growth: a testbed for studying human cardiac hypertrophy?	Journal of molecular and cellular cardiology	2011	36
21144973	1432	Rajesh M	Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy.	Journal of the American College of Cardiology	2010	56
21163347	1432	Henriksen EJ	Oxidative stress and the etiology of insulin resistance and type 2 diabetes.	Free radical biology and medicine	2011	80
24149188	1432	Felipo V	Hepatic encephalopathy: effects of liver failure on brain function.	Nature reviews. Neuroscience	2013	33
24185179	1432	Sato A	Pivotal role for ROS activation of p38 MAPK in the control of differentiation and tumor-initiating capacity of glioma-initiating cells.	Stem cell research	2014	21
24362529	1432	Xiang T	Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer.	Oncogene	2015	21
24465942	1432	Ahn HJ	Targeting cancer cells with reactive oxygen and nitrogen species generated by atmospheric-pressure air plasma.	PloS one	2014	36
24759787	1432	Aye IL	Increasing maternal body mass index is associated with systemic inflammation in the mother and the activation of distinct placental inflammatory pathways.	Biology of reproduction	2014	35
24928860	1432	Wang J	Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells.	Blood	2014	35
25110412	1432	Grossi V	p38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance.	World journal of gastroenterology	2014	21
25374165	1432	Lei YY	Mitogen-activated protein kinase signal transduction in solid tumors.	Asian Pacific journal of cancer prevention 	2014	20
25595279	1432	Gonzalez-Villasana V	Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer.	Clinical cancer research 	2015	16
26601950	1432	Purushothaman A	Fibronectin on the Surface of Myeloma Cell-derived Exosomes Mediates Exosome-Cell Interactions.	The Journal of biological chemistry	2016	17
27563484	1432	Wu M	TGF-β and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease.	Bone research	2016	16
3258626	1435	Gendelman HE	Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes.	The Journal of experimental medicine	1988	307
14755726	1435	Henkel JS	Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue.	Annals of neurology	2004	105
16904609	1435	Budhu A	Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment.	Cancer cell	2006	181
17374712	1435	Harman-Boehm I	Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity.	The Journal of clinical endocrinology and metabolism	2007	106
18553315	1435	Komohara Y	Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas.	The Journal of pathology	2008	120
19188147	1435	Beck AH	The macrophage colony-stimulating factor 1 response signature in breast carcinoma.	Clinical cancer research 	2009	58
19432671	1435	Kawamura K	Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors.	Pathology international	2009	55
19934330	1435	Patsialou A	Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor.	Cancer research	2009	94
20335529	1435	Gleissner CA	CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages.	Journal of immunology	2010	47
20580464	1435	Sierra-Filardi E	Heme Oxygenase-1 expression in M-CSF-polarized M2 macrophages contributes to LPS-induced IL-10 release.	Immunobiology	2010	50
20957152	1435	Wauquier N	Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis.	PLoS neglected tropical diseases	2010	96
21911939	1435	Vogt G	In vitro differentiation of human macrophages with enhanced antimycobacterial activity.	The Journal of clinical investigation	2011	38
22161841	1435	Laoui D	Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions.	The International journal of developmental biology	2011	57
22880072	1435	Rey-Giraud F	In vitro generation of monocyte-derived macrophages under serum-free conditions improves their tumor promoting functions.	PloS one	2012	43
24898549	1435	Ries CH	Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.	Cancer cell	2014	126
25429076	1435	Pignatelli J	Invasive breast carcinoma cells from patients exhibit MenaINV- and macrophage-dependent transendothelial migration.	Science signaling	2014	23
26179200	1435	Cassier PA	CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.	The Lancet. Oncology	2015	20
26222558	1435	Tap WD	Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.	The New England journal of medicine	2015	29
26449250	1435	Butowski N	Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.	Neuro-oncology	2016	22
26538619	1435	Stafford JH	Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization.	Neuro-oncology	2016	15
11238037	1437	Sugiyama S	Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes.	The American journal of pathology	2001	100
15871677	1437	Hughes MS	Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions.	Human gene therapy	2005	77
16204061	1437	Queen MM	Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression.	Cancer research	2005	73
16774798	1437	Smith CD	Age and gender effects on human brain anatomy: a voxel-based morphometric study in healthy elderly.	Neurobiology of aging	2007	76
17121894	1437	Hu JC	A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.	Clinical cancer research 	2006	109
17261184	1437	Chavey C	Oestrogen receptor negative breast cancers exhibit high cytokine content.	Breast cancer research 	2007	80
17284714	1437	Hershman D	Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.	Journal of the National Cancer Institute	2007	70
17577033	1437	Filipazzi P	Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.	Journal of clinical oncology 	2007	230
17786229	1437	Cao Y	Angiogenesis modulates adipogenesis and obesity.	The Journal of clinical investigation	2007	146
17827035	1437	Teipel SJ	Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment.	NeuroImage	2007	59
18287062	1437	Hodi FS	Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.	Proceedings of the National Academy of Sciences of the United States of America	2008	171
18292469	1437	O'Reilly MA	Neonatal hyperoxia enhances the inflammatory response in adult mice infected with influenza A virus.	American journal of respiratory and critical care medicine	2008	53
18316569	1437	Laheru D	Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.	Clinical cancer research 	2008	95
18495536	1437	Park BH	Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.	The Lancet. Oncology	2008	135
18535155	1437	Banas A	IFATS collection: in vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury.	Stem cells	2008	58
18628758	1437	Liu TC	The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma.	Molecular therapy 	2008	62
19157572	1437	Li X	Elevated immune response in the brain of autistic patients.	Journal of neuroimmunology	2009	132
19308771	1437	Berg M	Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.	Cytotherapy	2009	72
19487648	1437	Driscoll I	Longitudinal pattern of regional brain volume change differentiates normal aging from MCI.	Neurology	2009	118
19609242	1437	Weide B	Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients.	Journal of immunotherapy	2009	45
19636017	1437	McNeel DG	Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.	Journal of clinical oncology 	2009	74
19726877	1437	Choi KD	Generation of mature human myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34+CD43+CD45+ progenitors.	The Journal of clinical investigation	2009	55
19890632	1437	Gulley JL	Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.	Cancer immunology, immunotherapy 	2010	109
19915919	1437	Kaufman HL	Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.	Annals of surgical oncology	2010	118
20075088	1437	Walhovd KB	Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease.	AJNR. American journal of neuroradiology	2010	90
20145120	1437	Holland SJ	R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.	Cancer research	2010	111
20179677	1437	Morgan RA	Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.	Molecular therapy 	2010	397
20386463	1437	Correale P	Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.	Journal of immunotherapy	2010	60
20484626	1437	Emmanouilidou E	Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival.	The Journal of neuroscience 	2010	237
20817712	1437	Tadokera R	Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome.	The European respiratory journal	2011	47
21315783	1437	Finke J	MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.	International immunopharmacology	2011	64
21632504	1437	Schuster SJ	Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.	Journal of clinical oncology 	2011	78
21734236	1437	Solito S	A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells.	Blood	2011	77
21772252	1437	Hwang TH	A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma.	Molecular therapy 	2011	42
22302554	1437	Mattsson N	Age and diagnostic performance of Alzheimer disease CSF biomarkers.	Neurology	2012	34
23088985	1437	Burke JM	A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer.	The Journal of urology	2012	38
23365250	1437	Douaud G	Brain microstructure reveals early abnormalities more than two years prior to clinical progression from mild cognitive impairment to Alzheimer's disease.	The Journal of neuroscience 	2013	35
23493351	1437	Kanerva A	Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.	Clinical cancer research 	2013	42
23677592	1437	Kim MK	Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.	Science translational medicine	2013	36
24217582	1437	Burmester GR	Emerging cell and cytokine targets in rheumatoid arthritis.	Nature reviews. Rheumatology	2014	32
24458546	1437	Helm O	Tumor-associated macrophages exhibit pro- and anti-inflammatory properties by which they impact on pancreatic tumorigenesis.	International journal of cancer	2014	25
24520093	1437	Rapoport AP	Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.	Clinical cancer research 	2014	27
24816404	1437	Wu P	γδT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer.	Immunity	2014	60
24823638	1437	Su S	A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis.	Cancer cell	2014	85
24907636	1437	Mittendorf EA	Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients.	Annals of oncology 	2014	28
24942756	1437	Lutz ER	Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation.	Cancer immunology research	2014	63
24954781	1437	Middleton G	Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.	The Lancet. Oncology	2014	45
25215458	1437	Singh VK	Colony-stimulating factors for the treatment of the hematopoietic component of the acute radiation syndrome (H-ARS): a review.	Cytokine	2015	20
25236348	1437	Thrane AS	Drowning stars: reassessing the role of astrocytes in brain edema.	Trends in neurosciences	2014	33
25369488	1437	Hodi FS	Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.	JAMA	2014	51
25714011	1437	Hemminki O	Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy.	Oncotarget	2015	21
26014293	1437	Andtbacka RH	Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.	Journal of clinical oncology 	2015	197
26095785	1437	Golden EB	Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.	The Lancet. Oncology	2015	50
26491076	1437	Li R	Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy.	Science translational medicine	2015	28
26554728	1437	De Mattos-Arruda L	Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.	Nature communications	2015	20
26783184	1437	Scheibe K	IL-36R signalling activates intestinal epithelial cells and fibroblasts and promotes mucosal healing in vivo.	Gut	2017	7
27374224	1437	Singhal S	Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer.	Cancer cell	2016	13
10477735	1440	Holyoake T	Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia.	Blood	1999	100
11756187	1440	Graham SM	Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.	Blood	2002	262
15743872	1440	Ishizu T	Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis.	Brain 	2005	70
15824174	1440	Gorelik E	Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer.	Cancer epidemiology, biomarkers and prevention 	2005	82
16046292	1440	Cancello R	Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss.	Diabetes	2005	222
16507801	1440	Zohlnhöfer D	Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial.	JAMA	2006	77
16534028	1440	Iwasaki H	Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery after myocardial infarction.	Circulation	2006	62
17227995	1440	Lewis IJ	Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.	Journal of the National Cancer Institute	2007	57
17330101	1440	Jiang X	Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies.	Leukemia	2007	80
17942672	1440	Ebos JM	Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.	Proceedings of the National Academy of Sciences of the United States of America	2007	112
18728788	1440	Levina V	Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties.	PloS one	2008	127
19711453	1440	Kawamoto A	Intramuscular transplantation of G-CSF-mobilized CD34(+) cells in patients with critical limb ischemia: a phase I/IIa, multicenter, single-blinded, dose-escalation clinical trial.	Stem cells	2009	49
20160717	1440	Saito Y	Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML.	Nature biotechnology	2010	85
20599449	1440	Essers MA	Targeting leukemic stem cells by breaking their dormancy.	Molecular oncology	2010	46
20717122	1440	Helmy A	The cytokine response to human traumatic brain injury: temporal profiles and evidence for cerebral parenchymal production.	Journal of cerebral blood flow and metabolism 	2011	73
21636707	1440	Raychaudhuri B	Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma.	Neuro-oncology	2011	85
21907922	1440	Granot Z	Tumor entrained neutrophils inhibit seeding in the premetastatic lung.	Cancer cell	2011	105
22119930	1440	Garg V	Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure.	Gastroenterology	2012	41
22516264	1440	Zhang B	Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia.	Cancer cell	2012	76
22828446	1440	Mougiakakos D	Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation.	Leukemia	2013	27
22841419	1440	Elliott MJ	Stem-cell-based, tissue engineered tracheal replacement in a child: a 2-year follow-up study.	Lancet	2012	55
24621603	1440	Acosta SA	Combination therapy of human umbilical cord blood cells and granulocyte colony stimulating factor reduces histopathological and motor impairments in an experimental model of chronic traumatic brain injury.	PloS one	2014	29
25303306	1440	Fischer JA	Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody.	Arthritis and rheumatology	2015	26
11152469	1490	Holmes A	CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling.	The Journal of biological chemistry	2001	113
12842083	1490	Kang Y	A multigenic program mediating breast cancer metastasis to bone.	Cancer cell	2003	660
16878133	1490	Dews M	Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster.	Nature genetics	2006	334
17376414	1490	Ruiz-Ortega M	TGF-beta signaling in vascular fibrosis.	Cardiovascular research	2007	125
19096030	1490	Duisters RF	miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling.	Circulation research	2009	227
19132753	1490	Sodek KL	Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype.	International journal of cancer	2009	58
19153601	1490	Pandey DP	Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF.	The EMBO journal	2009	80
20051102	1490	Câmara J	Epithelial-mesenchymal transition in primary human bronchial epithelial cells is Smad-dependent and enhanced by fibronectin and TNF-alpha.	Fibrogenesis and tissue repair	2010	51
20305691	1490	Ernst A	De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures.	Oncogene	2010	57
21349946	1490	Lai D	Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF.	Cancer research	2011	93
22101332	1490	Fuchshofer R	The role of TGF-β in the pathogenesis of primary open-angle glaucoma.	Cell and tissue research	2012	58
22552965	1490	Pupo M	Bisphenol A induces gene expression changes and proliferative effects through GPER in breast cancer cells and cancer-associated fibroblasts.	Environmental health perspectives	2012	50
22684333	1490	Capparelli C	CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth.	Cell cycle	2012	37
23390502	1490	Lee HK	MicroRNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor.	PloS one	2013	35
24837142	1490	Brodowska K	The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation.	Experimental eye research	2014	24
25003330	1490	Tsai HC	CTGF increases matrix metalloproteinases expression and subsequently promotes tumor metastasis in human osteosarcoma through down-regulating miR-519d.	Oncotarget	2014	29
25738362	1490	Chuang JY	WISP-1 a novel angiogenic regulator of the CCN family promotes oral squamous cell carcinoma angiogenesis through VEGF-A expression.	Oncotarget	2015	16
26098215	1490	Rice LM	Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients.	The Journal of clinical investigation	2015	20
10225967	1493	Abrams JR	CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.	The Journal of clinical investigation	1999	98
12193750	1493	Liyanage UK	Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.	Journal of immunology	2002	314
12576425	1493	Wolf AM	Increase of regulatory T cells in the peripheral blood of cancer patients.	Clinical cancer research 	2003	159
12826605	1493	Phan GQ	Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.	Proceedings of the National Academy of Sciences of the United States of America	2003	320
15128835	1493	de Kleer IM	CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis.	Journal of immunology	2004	78
15611238	1493	Sugiyama H	Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation.	Journal of immunology	2005	76
15613700	1493	Sanderson K	Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.	Journal of clinical oncology 	2005	85
15914560	1493	Beyer M	Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.	Blood	2005	103
16204013	1493	Ribas A	Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.	Journal of clinical oncology 	2005	101
16224277	1493	Blansfield JA	Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.	Journal of immunotherapy	2005	71
16505437	1493	Cesana GC	Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma.	Journal of clinical oncology 	2006	66
16903919	1493	Izcue A	Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation.	Immunological reviews	2006	150
17606437	1493	Prevosto C	Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction.	Haematologica	2007	83
17673617	1493	Weber J	Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.	The oncologist	2007	65
17982122	1493	Downey SG	Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.	Clinical cancer research 	2007	99
18523152	1493	Kavanagh B	CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.	Blood	2008	59
19074257	1493	Yuan J	CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.	Proceedings of the National Academy of Sciences of the United States of America	2008	111
19130927	1493	Shreffler WG	Association of allergen-specific regulatory T cells with the onset of clinical tolerance to milk protein.	The Journal of allergy and clinical immunology	2009	45
19247441	1493	Nakamoto N	Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade.	PLoS pathogens	2009	113
19338264	1493	Oble DA	Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.	Cancer immunity	2009	53
19789309	1493	Ribas A	Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.	Clinical cancer research 	2009	53
20220088	1493	Allen CE	Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells.	Journal of immunology	2010	43
20437560	1493	Correale J	Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple sclerosis.	Annals of neurology	2010	41
21723783	1493	Wing K	Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation.	Trends in immunology	2011	50
21900389	1493	Lipson EJ	Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.	Clinical cancer research 	2011	79
22146893	1493	Ji RR	An immune-active tumor microenvironment favors clinical response to ipilimumab.	Cancer immunology, immunotherapy 	2012	127
22271879	1493	Prieto PA	CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.	Clinical cancer research 	2012	140
22397654	1493	Postow MA	Immunologic correlates of the abscopal effect in a patient with melanoma.	The New England journal of medicine	2012	313
22585562	1493	Schuler PJ	Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients.	European journal of immunology	2012	33
23028051	1493	Corrales L	Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.	Journal of immunology	2012	36
23341990	1493	Voskens CJ	The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.	PloS one	2013	45
23356291	1493	Whiteside TL	Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes).	Biochemical Society transactions	2013	55
23690483	1493	Besser MJ	Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.	Clinical cancer research 	2013	42
23724867	1493	Wolchok JD	Nivolumab plus ipilimumab in advanced melanoma.	The New England journal of medicine	2013	793
23913718	1493	Luke JJ	Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.	Cancer	2013	33
23960017	1493	Han Y	Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.	Hepatology	2014	26
24035405	1493	Calabrò L	Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.	The Lancet. Oncology	2013	42
24054424	1493	Eggermont AM	Cutaneous melanoma.	Lancet	2014	64
24089443	1493	Ott PA	CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.	Clinical cancer research 	2013	106
24388175	1493	Rong Z	An effective approach to prevent immune rejection of human ESC-derived allografts.	Cell stem cell	2014	25
24563870	1493	Golden EB	An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.	Cancer immunology research	2013	85
24583799	1493	Robert L	CTLA4 blockade broadens the peripheral T-cell receptor repertoire.	Clinical cancer research 	2014	44
24860567	1493	Corthay A	Does the immune system naturally protect against cancer?	Frontiers in immunology	2014	29
25213377	1493	Kuehn HS	Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.	Science	2014	83
25409260	1493	Snyder A	Genetic basis for clinical response to CTLA-4 blockade in melanoma.	The New England journal of medicine	2014	455
25415283	1493	Soares KC	PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.	Journal of immunotherapy	2015	49
25583297	1493	Zamarin D	Immune checkpoint modulation: rational design of combination strategies.	Pharmacology and therapeutics	2015	24
25672397	1493	Beavis PA	Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses.	Cancer immunology research	2015	16
25682878	1493	Luke JJ	PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma.	Oncotarget	2015	22
25795410	1493	Weber JS	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.	The Lancet. Oncology	2015	227
25824720	1493	Carosella ED	A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.	European urology	2015	24
25918390	1493	Romano E	Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.	Proceedings of the National Academy of Sciences of the United States of America	2015	38
26027431	1493	Larkin J	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.	The New England journal of medicine	2015	521
26206937	1493	Lo B	AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy.	Science	2015	32
26258847	1493	Ungewickell A	Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2.	Nature genetics	2015	27
26323609	1493	Nduom EK	PD-L1 expression and prognostic impact in glioblastoma.	Neuro-oncology	2016	30
26325034	1493	Buchbinder E	Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.	The Journal of clinical investigation	2015	20
26359337	1493	Van Allen EM	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.	Science	2015	151
26420858	1493	Mak MP	A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.	Clinical cancer research 	2016	24
26707829	1493	Ugurel S	Survival of patients with advanced metastatic melanoma: The impact of novel therapies.	European journal of cancer	2016	11
26715621	1493	Champiat S	Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.	Annals of oncology 	2016	19
26765102	1493	Michot JM	Immune-related adverse events with immune checkpoint blockade: a comprehensive review.	European journal of cancer	2016	41
26837003	1493	Dubin K	Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis.	Nature communications	2016	12
26850630	1493	Redman JM	Advances in immunotherapy for melanoma.	BMC medicine	2016	11
26858122	1493	Antonia S	Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.	The Lancet. Oncology	2016	41
26940869	1493	McGranahan N	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.	Science	2016	126
26972336	1493	Webb JR	PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.	Gynecologic oncology	2016	17
27084739	1493	Zarour HM	Reversing T-cell Dysfunction and Exhaustion in Cancer.	Clinical cancer research 	2016	15
27410923	1493	Davids MS	Ipilimumab for Patients with Relapse after Allogeneic Transplantation.	The New England journal of medicine	2016	23
27828943	1493	De Henau O	Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.	Nature	2016	12
7568023	1499	Rimm DL	Alpha 1(E)-catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to the membrane adhesion complex.	Proceedings of the National Academy of Sciences of the United States of America	1995	194
9708792	1499	Hirohashi S	Inactivation of the E-cadherin-mediated cell adhesion system in human cancers.	The American journal of pathology	1998	161
9990071	1499	Mann B	Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas.	Proceedings of the National Academy of Sciences of the United States of America	1999	180
10023660	1499	Latres E	The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin.	Oncogene	1999	124
10192393	1499	Chan EF	A common human skin tumour is caused by activating mutations in beta-catenin.	Nature genetics	1999	126
10514384	1499	Brabletz T	beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer.	The American journal of pathology	1999	138
10759547	1499	Lin SY	Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression.	Proceedings of the National Academy of Sciences of the United States of America	2000	203
11381089	1499	Gottardi CJ	E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner.	The Journal of cell biology	2001	150
11533658	1499	Ryo A	Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC.	Nature cell biology	2001	131
11752446	1499	Yan D	Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/beta -catenin signaling is activated in human colon tumors.	Proceedings of the National Academy of Sciences of the United States of America	2001	116
12086864	1499	Weeraratna AT	Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma.	Cancer cell	2002	231
12398896	1499	Deng J	beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer.	Cancer cell	2002	91
12841864	1499	Hirohashi S	Cell adhesion system and human cancer morphogenesis.	Cancer science	2003	82
15208662	1499	You L	Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells.	Oncogene	2004	73
15316903	1499	Chen G	Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications.	Cancer	2004	73
15480989	1499	Merle P	Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma.	Gastroenterology	2004	72
15690474	1499	Sirica AE	Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy.	Hepatology	2005	97
15761464	1499	Bell DA	Origins and molecular pathology of ovarian cancer.	Modern pathology 	2005	100
15973414	1499	Batlle E	EphB receptor activity suppresses colorectal cancer progression.	Nature	2005	110
16230409	1499	Thomson S	Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.	Cancer research	2005	193
16239965	1499	Balint K	Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression.	The Journal of clinical investigation	2005	94
16258095	1499	Ellison DW	beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee.	Journal of clinical oncology 	2005	68
16449977	1499	Patrawala L	Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells.	Oncogene	2006	284
16670761	1499	Krishnan V	Regulation of bone mass by Wnt signaling.	The Journal of clinical investigation	2006	266
16756720	1499	Zeng G	Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma.	Neoplasia	2006	75
16799620	1499	Breuhahn K	Dysregulation of growth factor signaling in human hepatocellular carcinoma.	Oncogene	2006	99
16799625	1499	Levrero M	Viral hepatitis and liver cancer: the case of hepatitis C.	Oncogene	2006	107
16823493	1499	Garcia-Gras E	Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy.	The Journal of clinical investigation	2006	135
16857785	1499	Yang AD	Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines.	Clinical cancer research 	2006	132
16964294	1499	Zucman-Rossi J	Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas.	Oncogene	2007	59
17079465	1499	Kurayoshi M	Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion.	Cancer research	2006	122
17145894	1499	Wang Y	Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice.	Cancer research	2006	66
17287208	1499	Fang D	Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity.	The Journal of biological chemistry	2007	220
17295177	1499	Villanueva A	Genomics and signaling pathways in hepatocellular carcinoma.	Seminars in liver disease	2007	150
17371942	1499	Giuliani N	The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients.	Blood	2007	56
17413031	1499	Ross AJ	Transcriptional profiling of mucociliary differentiation in human airway epithelial cells.	American journal of respiratory cell and molecular biology	2007	80
17452641	1499	Sukhdeo K	Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma.	Proceedings of the National Academy of Sciences of the United States of America	2007	60
17464972	1499	Thompson MD	WNT/beta-catenin signaling in liver health and disease.	Hepatology	2007	126
17638895	1499	Vignjevic D	Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer.	Cancer research	2007	73
17785413	1499	Tward AD	Distinct pathways of genomic progression to benign and malignant tumors of the liver.	Proceedings of the National Academy of Sciences of the United States of America	2007	64
17854061	1499	Gavert N	beta-Catenin signaling in biological control and cancer.	Journal of cellular biochemistry	2007	59
17979879	1499	Mimeault M	Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers.	Journal of cellular and molecular medicine	2007	59
18339862	1499	Li H	PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells.	Cancer research	2008	76
18364678	1499	Qiao L	Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model.	Cell research	2008	76
18381440	1499	Sawada K	Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target.	Cancer research	2008	104
18385740	1499	Malanchi I	Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling.	Nature	2008	169
18519688	1499	Yang W	Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells.	Cancer research	2008	101
18577996	1499	Bengochea A	Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma.	British journal of cancer	2008	53
18679417	1499	Chang YM	Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.	Oncogene	2008	55
18718806	1499	Sabbah M	Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.	Drug resistance updates 	2008	98
18769486	1499	Kool M	Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features.	PloS one	2008	203
18791199	1499	Cannito S	Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells.	Carcinogenesis	2008	87
18832571	1499	Lazar AJ	Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors.	The American journal of pathology	2008	55
18949017	1499	Pu P	Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth.	Cancer gene therapy	2009	58
18987168	1499	Smallridge RC	Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.	Endocrine-related cancer	2009	84
19047049	1499	Bourguignon LY	Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells.	The Journal of biological chemistry	2009	47
19144919	1499	Chien AJ	Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model.	Proceedings of the National Academy of Sciences of the United States of America	2009	106
19365403	1499	Bisson I	WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics.	Cell research	2009	89
19492080	1499	Korkaya H	Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling.	PLoS biology	2009	184
19703993	1499	Saydam O	Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.	Molecular and cellular biology	2009	83
19723656	1499	Hoshida Y	Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.	Cancer research	2009	176
19797115	1499	Dennler S	Cloning of the human GLI2 Promoter: transcriptional activation by transforming growth factor-beta via SMAD3/beta-catenin cooperation.	The Journal of biological chemistry	2009	48
19852728	1499	van Zijl F	Epithelial-mesenchymal transition in hepatocellular carcinoma.	Future oncology	2009	78
19882675	1499	Cai Y	Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma.	The Journal of pathology	2010	42
19915524	1499	Liu LK	Upregulation of vimentin and aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome.	Modern pathology 	2010	47
20018914	1499	Ghosh AK	Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression.	Blood	2010	61
20227366	1499	Tauriello DV	Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl.	Molecular cell	2010	46
20348907	1499	Zhang L	Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis.	Nature	2010	41
20395444	1499	Khramtsov AI	Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome.	The American journal of pathology	2010	108
20603725	1499	Lucero OM	A re-evaluation of the "oncogenic" nature of Wnt/beta-catenin signaling in melanoma and other cancers.	Current oncology reports	2010	44
20610629	1499	Gu Y	GlcNAcylation plays an essential role in breast cancer metastasis.	Cancer research	2010	44
20691072	1499	Kanwar SS	The Wnt/beta-catenin pathway regulates growth and maintenance of colonospheres.	Molecular cancer	2010	86
20713706	1499	Ettenberg SA	Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies.	Proceedings of the National Academy of Sciences of the United States of America	2010	45
20716670	1499	Mimeault M	Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies.	Pharmacological reviews	2010	42
20921458	1499	Ellison DW	Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.	Journal of clinical oncology 	2011	63
20978119	1499	He BC	Tetrandrine inhibits Wnt/β-catenin signaling and suppresses tumor growth of human colorectal cancer.	Molecular pharmacology	2011	43
21108734	1499	Marchand A	The Wnt/beta-catenin pathway is activated during advanced arterial aging in humans.	Aging cell	2011	35
21156284	1499	Yeung J	β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells.	Cancer cell	2010	66
21199802	1499	Waaler J	Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth.	Cancer research	2011	35
21346776	1499	Syed DN	Inhibition of human melanoma cell growth by the dietary flavonoid fisetin is associated with disruption of Wnt/β-catenin signaling and decreased Mitf levels.	The Journal of investigative dermatology	2011	39
21386792	1499	Fassnacht M	Adrenocortical carcinoma: a clinician's update.	Nature reviews. Endocrinology	2011	49
21531761	1499	Osada T	Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations.	Cancer research	2011	54
21636786	1499	Gaston-Massuet C	Increased Wingless (Wnt) signaling in pituitary progenitor/stem cells gives rise to pituitary tumors in mice and humans.	Proceedings of the National Academy of Sciences of the United States of America	2011	41
21704588	1499	Froeling FE	Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression.	Gastroenterology	2011	57
21788521	1499	Lu D	Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells.	Proceedings of the National Academy of Sciences of the United States of America	2011	84
21880956	1499	Zemans RL	Neutrophil transmigration triggers repair of the lung epithelium via beta-catenin signaling.	Proceedings of the National Academy of Sciences of the United States of America	2011	41
22007144	1499	Tian X	E-cadherin/β-catenin complex and the epithelial barrier.	Journal of biomedicine and biotechnology	2011	56
22095546	1499	Mackinnon AC	Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3.	American journal of respiratory and critical care medicine	2012	42
22095947	1499	He W	Matrix metalloproteinase-7 as a surrogate marker predicts renal Wnt/β-catenin activity in CKD.	Journal of the American Society of Nephrology 	2012	40
22115830	1499	Freeman TJ	Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of β-catenin.	Gastroenterology	2012	39
22142829	1499	Shukla N	Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.	Clinical cancer research 	2012	62
22158988	1499	Wu J	Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways.	Proceedings of the National Academy of Sciences of the United States of America	2011	120
22234612	1499	Biechele TL	Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma.	Science signaling	2012	50
22328737	1499	Beyer C	β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis.	Annals of the rheumatic diseases	2012	40
22430211	1499	Yeramian A	Endometrial carcinoma: molecular alterations involved in tumor development and progression.	Oncogene	2013	26
22459450	1499	Sun JY	MicroRNA-320a suppresses human colon cancer cell proliferation by directly targeting β-catenin.	Biochemical and biophysical research communications	2012	45
22484120	1499	Zhang J	MicroRNA-26a promotes cholangiocarcinoma growth by activating β-catenin.	Gastroenterology	2012	47
22610277	1499	Tenbaum SP	β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer.	Nature medicine	2012	82
22653804	1499	McConechy MK	Use of mutation profiles to refine the classification of endometrial carcinomas.	The Journal of pathology	2012	45
22851508	1499	Ibrahim EE	Embryonic NANOG activity defines colorectal cancer stem cells and modulates through AP1- and TCF-dependent mechanisms.	Stem cells	2012	35
22914623	1499	Takada K	Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling.	Science translational medicine	2012	48
23034650	1499	Grivennikov SI	Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth.	Nature	2012	215
23139209	1499	Gong A	FoxM1 and Wnt/β-catenin signaling in glioma stem cells.	Cancer research	2012	34
23178882	1499	Youssef KK	Adult interfollicular tumour-initiating cells are reprogrammed into an embryonic hair follicle progenitor-like fate during basal cell carcinoma initiation.	Nature cell biology	2012	32
23188675	1499	Hsieh IS	MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway.	Carcinogenesis	2013	66
23291185	1499	Ma Y	Inhibition of the Wnt-β-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy.	Biochemical and biophysical research communications	2013	26
23300485	1499	Francis JC	β-catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinoma.	PLoS genetics	2013	28
23307470	1499	Wend P	WNT10B/β-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer.	EMBO molecular medicine	2013	36
23325582	1499	Peeters M	Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.	Clinical cancer research 	2013	56
23333633	1499	Chiang CH	Up-regulation of miR-182 by β-catenin in breast cancer increases tumorigenicity and invasiveness by targeting the matrix metalloproteinase inhibitor RECK.	Biochimica et biophysica acta	2013	33
23337059	1499	Wangefjord S	Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer.	Diagnostic pathology	2013	27
23354045	1499	Kim C	Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs.	Nature	2013	98
23359139	1499	Kadaba R	Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes.	The Journal of pathology	2013	28
23539445	1499	Xu C	β-Catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma.	Cancer research	2013	28
23755105	1499	Papafragkou E	Challenges of culturing human norovirus in three-dimensional organoid intestinal cell culture models.	PloS one	2014	24
23765252	1499	McConechy MK	Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.	Modern pathology 	2014	25
23780408	1499	Bashashati A	Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.	The Journal of pathology	2013	80
23887712	1499	Nault JC	High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.	Nature communications	2013	82
23945276	1499	Pegoraro S	HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness.	Oncotarget	2013	33
23979959	1499	Nikiforova MN	Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer.	The Journal of clinical endocrinology and metabolism	2013	52
24209998	1499	Dey N	Wnt signaling in triple negative breast cancer is associated with metastasis.	BMC cancer	2013	29
24244343	1499	Ji Q	Resveratrol inhibits invasion and metastasis of colorectal cancer cells via MALAT1 mediated Wnt/β-catenin signal pathway.	PloS one	2013	49
24282295	1499	Stoyanova T	Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells.	Proceedings of the National Academy of Sciences of the United States of America	2013	40
24335145	1499	Tang X	Glycogen synthase kinase 3 beta inhibits microRNA-183-96-182 cluster via the β-Catenin/TCF/LEF-1 pathway in gastric cancer cells.	Nucleic acids research	2014	21
24347249	1499	Ramteke A	Exosomes secreted under hypoxia enhance invasiveness and stemness of prostate cancer cells by targeting adherens junction molecules.	Molecular carcinogenesis	2015	29
24413733	1499	Brastianos PK	Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.	Nature genetics	2014	36
24416618	1499	James AW	Review of Signaling Pathways Governing MSC Osteogenic and Adipogenic Differentiation.	Scientifica	2013	64
24429522	1499	Kode A	Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts.	Nature	2014	80
24436047	1499	Shern JF	Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.	Cancer discovery	2014	82
24582836	1499	Lau CC	Viral-human chimeric transcript predisposes risk to liver cancer development and progression.	Cancer cell	2014	43
24614104	1499	Tucci V	Dominant β-catenin mutations cause intellectual disability with recognizable syndromic features.	The Journal of clinical investigation	2014	26
24706870	1499	Chen EY	Glycogen synthase kinase 3 inhibitors induce the canonical WNT/β-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma.	Proceedings of the National Academy of Sciences of the United States of America	2014	26
24736023	1499	Arend RC	Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.	Gynecologic oncology	2014	32
24837430	1499	Amini-Nik S	β-Catenin-regulated myeloid cell adhesion and migration determine wound healing.	The Journal of clinical investigation	2014	23
24837480	1499	Tao J	Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice.	Gastroenterology	2014	34
24859161	1499	Li L	Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.	Gastroenterology	2014	27
24975608	1499	Saretzki G	Extra-telomeric functions of human telomerase: cancer, mitochondria and oxidative stress.	Current pharmaceutical design	2014	21
25248380	1499	Friemel J	Intratumor heterogeneity in hepatocellular carcinoma.	Clinical cancer research 	2015	28
25444902	1499	Zhang J	EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma.	Cancer letters	2015	18
25449213	1499	Cao C	The long intergenic noncoding RNA UFC1, a target of MicroRNA 34a, interacts with the mRNA stabilizing protein HuR to increase levels of β-catenin in HCC cells.	Gastroenterology	2015	37
25490274	1499	Juhlin CC	Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma.	The Journal of clinical endocrinology and metabolism	2015	17
25500543	1499	Lemieux E	Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer.	Oncogene	2015	27
25600645	1499	Hirata H	Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205.	Cancer research	2015	81
25608619	1499	Zhang Z	microRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma.	Molecular cancer	2015	18
25670168	1499	Cojoc M	Aldehyde Dehydrogenase Is Regulated by β-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells.	Cancer research	2015	25
25720322	1499	Stelloo E	Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.	Modern pathology 	2015	16
25813403	1499	Leung WK	Wnt/β-Catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion.	Cancer letters	2015	23
25820276	1499	Bol GM	Targeting DDX3 with a small molecule inhibitor for lung cancer therapy.	EMBO molecular medicine	2015	22
26025765	1499	Ghahhari NM	Interplay between microRNAs and WNT/β-catenin signalling pathway regulates epithelial-mesenchymal transition in cancer.	European journal of cancer	2015	19
26202299	1499	Jang GB	Blockade of Wnt/β-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype.	Scientific reports	2015	25
26364599	1499	Zhou L	Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.	Oncogene	2016	25
26684358	1499	Zheng H	MicroRNA-1225-5p inhibits proliferation and metastasis of gastric carcinoma through repressing insulin receptor substrate-1 and activation of β-catenin signaling.	Oncotarget	2016	13
26811628	1499	Vilchez V	Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment.	World journal of gastroenterology	2016	13
27042933	1499	Kaur A	sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.	Nature	2016	27
27378147	1499	Marchetto MC	Altered proliferation and networks in neural cells derived from idiopathic autistic individuals.	Molecular psychiatry	2017	12
10888772	1509	Fitzgibbons PL	Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.	Archives of pathology and laboratory medicine	2000	147
11007884	1509	Kegel KB	Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy.	The Journal of neuroscience 	2000	102
12615733	1509	Krishnamachary B	Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1.	Cancer research	2003	115
12649263	1509	Kostin S	Myocytes die by multiple mechanisms in failing human hearts.	Circulation research	2003	128
16670177	1509	Siintola E	Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis.	Brain 	2006	67
17363733	1509	Carew JS	Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance.	Blood	2007	176
17954709	1509	Harris L	American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.	Journal of clinical oncology 	2007	468
19203374	1509	Cullen V	Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo.	Molecular brain	2009	63
19288297	1509	Achim CL	Increased accumulation of intraneuronal amyloid beta in HIV-infected patients.	Journal of neuroimmune pharmacology 	2009	55
19505575	1509	Chu Y	Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.	Neurobiology of disease	2009	82
20406898	1509	Geng Y	Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent.	Neuro-oncology	2010	50
22563482	1509	Martino L	Palmitate activates autophagy in INS-1E β-cells and in isolated rat and human pancreatic islets.	PloS one	2012	31
24401568	1509	Liu B	Hepatitis B virus X protein inhibits autophagic degradation by impairing lysosomal maturation.	Autophagy	2014	23
24418614	1509	Coffey EE	Lysosomal alkalization and dysfunction in human fibroblasts with the Alzheimer's disease-linked presenilin 1 A246E mutation can be reversed with cAMP.	Neuroscience	2014	25
26062630	1509	Goetzl EJ	Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease.	Neurology	2015	31
15955905	1649	Sehn LH	Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.	Journal of clinical oncology 	2005	135
16230674	1649	Fisher RI	New treatment options have changed the survival of patients with follicular lymphoma.	Journal of clinical oncology 	2005	68
16357160	1649	Nawrocki ST	Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells.	Cancer research	2005	79
17105812	1649	Sehn LH	The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.	Blood	2007	160
17268797	1649	Laybutt DR	Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes.	Diabetologia	2007	213
17548474	1649	Rahmani M	The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress.	Molecular and cellular biology	2007	73
17586092	1649	Grosso F	Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.	The Lancet. Oncology	2007	83
17686866	1649	Medigeshi GR	West Nile virus infection activates the unfolded protein response, leading to CHOP induction and apoptosis.	Journal of virology	2007	80
17942911	1649	Pyrko P	The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.	Cancer research	2007	116
18226581	1649	Pfreundschuh M	Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).	The Lancet. Oncology	2008	138
18544678	1649	Rimsza LM	Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.	Blood	2008	50
18559892	1649	Cunha DA	Initiation and execution of lipotoxic ER stress in pancreatic beta-cells.	Journal of cell science	2008	142
19038878	1649	Lenz G	Stromal gene signatures in large-B-cell lymphomas.	The New England journal of medicine	2008	321
19420259	1649	Di Nardo A	Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner.	The Journal of neuroscience 	2009	60
19723703	1649	Senkal CE	Antiapoptotic roles of ceramide-synthase-6-generated C16-ceramide via selective regulation of the ATF6/CHOP arm of ER-stress-response pathways.	FASEB journal 	2010	79
21135273	1649	Meyer PN	Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.	Journal of clinical oncology 	2011	73
21189393	1649	Ruan J	Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.	Journal of clinical oncology 	2011	54
21949742	1649	Merquiol E	HCV causes chronic endoplasmic reticulum stress leading to adaptation and interference with the unfolded protein response.	PloS one	2011	41
22434142	1649	Gorbatyuk MS	Glucose regulated protein 78 diminishes α-synuclein neurotoxicity in a rat model of Parkinson disease.	Molecular therapy 	2012	38
22699564	1649	Marhfour I	Expression of endoplasmic reticulum stress markers in the islets of patients with type 1 diabetes.	Diabetologia	2012	45
22911837	1649	Li ZM	Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP.	PloS one	2012	32
23530110	1649	Federico M	R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.	Journal of clinical oncology 	2013	28
23670030	1649	Li T	Salinomycin induces cell death with autophagy through activation of endoplasmic reticulum stress in human cancer cells.	Autophagy	2013	28
24336156	1649	Tzankov A	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.	Modern pathology 	2014	23
24506200	1649	Perry AM	MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.	British journal of haematology	2014	25
24691439	1649	Zode GS	Ocular-specific ER stress reduction rescues glaucoma in murine glucocorticoid-induced glaucoma.	The Journal of clinical investigation	2014	20
24732592	1649	Rossille D	High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial.	Leukemia	2014	32
24743734	1649	González-Rodríguez A	Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD.	Cell death and disease	2014	49
24943107	1649	Oki Y	Double hit lymphoma: the MD Anderson Cancer Center clinical experience.	British journal of haematology	2014	26
25499448	1649	Sehn LH	Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity.	Blood	2015	36
25867072	1649	He K	mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation.	Oncogene	2016	13
26240231	1649	Scott DW	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.	Journal of clinical oncology 	2015	19
2937395	1674	Jonasson L	Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque.	Arteriosclerosis	1986	176
9679048	1674	Bachem MG	Identification, culture, and characterization of pancreatic stellate cells in rats and humans.	Gastroenterology	1998	166
14581350	1674	Ayala G	Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer.	Clinical cancer research 	2003	95
14707860	1674	Folpe AL	Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature.	The American journal of surgical pathology	2004	76
15613856	1674	Miettinen M	Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up.	The American journal of surgical pathology	2005	174
15781488	1674	Blay JY	Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.	Annals of oncology 	2005	123
16327428	1674	Folpe AL	Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature.	The American journal of surgical pathology	2005	106
16720851	1674	Bernstein M	Ewing's sarcoma family of tumors: current management.	The oncologist	2006	76
21173249	1674	Österreicher CH	Fibroblast-specific protein 1 identifies an inflammatory subpopulation of macrophages in the liver.	Proceedings of the National Academy of Sciences of the United States of America	2011	69
21388673	1674	Raya-Rivera A	Tissue-engineered autologous urethras for patients who need reconstruction: an observational study.	Lancet	2011	53
23143191	1674	Clemen CS	Desminopathies: pathology and mechanisms.	Acta neuropathologica	2013	28
9563954	1756	Olson TM	Actin mutations in dilated cardiomyopathy, a heritable form of heart failure.	Science	1998	110
12415109	1756	Haslett JN	Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle.	Proceedings of the National Academy of Sciences of the United States of America	2002	90
12589117	1756	Finsterer J	The heart in human dystrophinopathies.	Cardiology	2003	92
16025101	1756	Yasuda S	Dystrophic heart failure blocked by membrane sealant poloxamer.	Nature	2005	87
17095633	1756	Tidball JG	The role of free radicals in the pathophysiology of muscular dystrophy.	Journal of applied physiology	2007	60
17108972	1756	Sampaolesi M	Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs.	Nature	2006	206
20517298	1756	Kornegay JN	Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs.	Molecular therapy 	2010	57
20517938	1756	Malik V	Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy.	Annals of neurology	2010	71
21212803	1756	Cacchiarelli D	miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy.	EMBO reports	2011	48
21425469	1756	Cacchiarelli D	miRNAs as serum biomarkers for Duchenne muscular dystrophy.	EMBO molecular medicine	2011	65
21468001	1756	Pichavant C	Current status of pharmaceutical and genetic therapeutic approaches to treat DMD.	Molecular therapy 	2011	54
23521559	1756	Koo T	Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy.	Human gene therapy	2013	32
23671309	1756	Rahimov F	The cell biology of disease: cellular and molecular mechanisms underlying muscular dystrophy.	The Journal of cell biology	2013	56
23907995	1756	Mendell JR	Eteplirsen for the treatment of Duchenne muscular dystrophy.	Annals of neurology	2013	111
24434629	1756	Guan X	Dystrophin-deficient cardiomyocytes derived from human urine: new biologic reagents for drug discovery.	Stem cell research	2014	23
24793134	1756	Wang Y	Dystrophin is a tumor suppressor in human cancers with myogenic programs.	Nature genetics	2014	27
24877152	1756	Kharraz Y	Understanding the process of fibrosis in Duchenne muscular dystrophy.	BioMed research international	2014	23
25322757	1756	Mendell JR	A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy.	Molecular therapy 	2015	34
25492562	1756	Ousterout DG	Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases.	Molecular therapy 	2015	29
25791035	1756	Lin B	Modeling and study of the mechanism of dilated cardiomyopathy using induced pluripotent stem cells derived from individuals with Duchenne muscular dystrophy.	Disease models and mechanisms	2015	19
25859012	1756	Chen Y	Functional disruption of the dystrophin gene in rhesus monkey using CRISPR/Cas9.	Human molecular genetics	2015	30
26048046	1756	Guiraud S	The Pathogenesis and Therapy of Muscular Dystrophies.	Annual review of genomics and human genetics	2015	26
26877224	1756	Young CS	A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells.	Cell stem cell	2016	26
3477813	1956	Wong AJ	Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification.	Proceedings of the National Academy of Sciences of the United States of America	1987	173
3798106	1956	Slamon DJ	Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.	Science	1987	1881
9006938	1956	Huang HS	The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling.	The Journal of biological chemistry	1997	162
9403702	1956	Petit AM	Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.	The American journal of pathology	1997	115
9831867	1956	Ross JS	The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.	Stem cells	1998	109
10722725	1956	Jo M	Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells.	The Journal of biological chemistry	2000	104
10728703	1956	Frederick L	Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.	Cancer research	2000	153
10760290	1956	Grandis JR	Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2000	149
10815932	1956	Ciardiello F	Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.	Clinical cancer research 	2000	107
10873065	1956	Huang SM	Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.	Clinical cancer research 	2000	98
10877829	1956	Puddicombe SM	Involvement of the epidermal growth factor receptor in epithelial repair in asthma.	FASEB journal 	2000	109
11156248	1956	Sirotnak FM	Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.	Clinical cancer research 	2000	94
11159180	1956	Specht K	Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue.	The American journal of pathology	2001	91
11420660	1956	Garcia R	Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.	Oncogene	2001	164
11431323	1956	Sonoda Y	Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma.	Cancer research	2001	86
11431346	1956	Viloria-Petit A	Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.	Cancer research	2001	110
11504770	1956	Smith JS	PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.	Journal of the National Cancer Institute	2001	100
11585753	1956	Moasser MM	The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.	Cancer research	2001	87
12124174	1956	Liu D	EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma.	Cancer cell	2002	103
12183421	1956	Wedge SR	ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.	Cancer research	2002	158
12359858	1956	Wang F	Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts.	Journal of the National Cancer Institute	2002	111
12429632	1956	Di Lorenzo G	Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.	Clinical cancer research 	2002	88
12499279	1956	Ang KK	Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.	Cancer research	2002	224
12743152	1956	Cohen EE	Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.	Journal of clinical oncology 	2003	98
12824187	1956	Buchanan FG	Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor.	The Journal of biological chemistry	2003	104
12860957	1956	Mendelsohn J	Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.	Journal of clinical oncology 	2003	184
12953099	1956	Hirsch FR	Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.	Journal of clinical oncology 	2003	238
14583498	1956	Shinojima N	Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.	Cancer research	2003	158
14638850	1956	Rich JN	Phase II trial of gefitinib in recurrent glioblastoma.	Journal of clinical oncology 	2004	122
14641026	1956	Fischer OM	EGFR signal transactivation in cancer cells.	Biochemical Society transactions	2003	95
14701768	1956	Soulieres D	Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.	Journal of clinical oncology 	2004	145
14769856	1956	Liu H	Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells.	The Journal of cell biology	2004	93
15059883	1956	Nahta R	The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.	Cancer research	2004	112
15084238	1956	Arpino G	Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.	Breast cancer research 	2004	105
15226328	1956	Xiong HQ	Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.	Journal of clinical oncology 	2004	91
15269313	1956	Cunningham D	Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.	The New England journal of medicine	2004	891
15310767	1956	Pérez-Soler R	Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.	Journal of clinical oncology 	2004	151
15328174	1956	Nielsen TO	Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.	Clinical cancer research 	2004	595
15492241	1956	Tracy S	Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.	Cancer research	2004	86
15598946	1956	Spano JP	Impact of EGFR expression on colorectal cancer patient prognosis and survival.	Annals of oncology 	2005	70
15604253	1956	Kosaka T	Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.	Cancer research	2004	233
15665312	1956	Lo HW	Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer.	Cancer research	2005	92
15677699	1956	Chung KY	Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.	Journal of clinical oncology 	2005	200
15681531	1956	Marchetti A	EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.	Journal of clinical oncology 	2005	149
15709185	1956	Tokumo M	The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.	Clinical cancer research 	2005	94
15710947	1956	Han SW	Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.	Journal of clinical oncology 	2005	135
15728811	1956	Kobayashi S	EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.	The New England journal of medicine	2005	832
15731348	1956	Engelman JA	ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.	Proceedings of the National Academy of Sciences of the United States of America	2005	148
15735034	1956	Stabile LP	Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.	Cancer research	2005	82
15738541	1956	Mitsudomi T	Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.	Journal of clinical oncology 	2005	175
15741570	1956	Shigematsu H	Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.	Journal of the National Cancer Institute	2005	439
15746047	1956	Heimberger AB	Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.	Clinical cancer research 	2005	134
15753357	1956	Shigematsu H	Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.	Cancer research	2005	142
15753462	1956	Herbst RS	Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.	Journal of clinical oncology 	2005	86
15814656	1956	Shimizu M	(-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells.	Clinical cancer research 	2005	65
15831234	1956	Giannini C	Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.	Neuro-oncology	2005	158
15920544	1956	Bhargava R	EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.	Modern pathology 	2005	76
15939921	1956	Baselga J	Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.	Journal of clinical oncology 	2005	77
15956649	1956	Haas-Kogan DA	Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.	Journal of the National Cancer Institute	2005	132
16020518	1956	Means AL	Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates.	Development	2005	106
16033833	1956	Lakhani SR	Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.	Clinical cancer research 	2005	149
16043828	1956	Eberhard DA	Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.	Journal of clinical oncology 	2005	344
16043829	1956	Herbst RS	TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2005	275
16051952	1956	Cappuzzo F	Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.	Journal of clinical oncology 	2005	69
16115926	1956	Psyrri A	Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis.	Clinical cancer research 	2005	90
16161046	1956	Hanawa M	EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus.	International journal of cancer	2006	67
16170173	1956	Philip PA	Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.	Journal of clinical oncology 	2005	94
16204011	1956	Bell DW	Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.	Journal of clinical oncology 	2005	119
16230383	1956	Baird K	Gene expression profiling of human sarcomas: insights into sarcoma biology.	Cancer research	2005	85
16314626	1956	Burtness B	Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.	Journal of clinical oncology 	2005	166
16322287	1956	Haura EB	Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.	Clinical cancer research 	2005	70
16333527	1956	Hiscox S	Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.	Breast cancer research and treatment	2006	64
16361555	1956	Yauch RL	Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.	Clinical cancer research 	2005	161
16397019	1956	Diaz N	Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression.	Clinical cancer research 	2006	78
16424029	1956	Witta SE	Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.	Cancer research	2006	137
16452222	1956	Konecny GE	Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.	Cancer research	2006	213
16533778	1956	Rodríguez-Pinilla SM	Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas.	Clinical cancer research 	2006	68
16533793	1956	Tam IY	Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.	Clinical cancer research 	2006	112
16540667	1956	Alvarez JV	Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.	Cancer research	2006	61
16549822	1956	Takeuchi T	Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors.	Journal of clinical oncology 	2006	64
16565487	1956	Li YC	Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents.	The American journal of pathology	2006	96
16730237	1956	Ji H	The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.	Cancer cell	2006	125
16740687	1956	Song L	Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.	Cancer research	2006	73
16757721	1956	Carey LA	Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.	JAMA	2006	957
16763281	1956	Kalyankrishna S	Epidermal growth factor receptor biology in head and neck cancer.	Journal of clinical oncology 	2006	160
16785471	1956	Inoue A	Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.	Journal of clinical oncology 	2006	116
16837691	1956	Zakowski MF	EGFR mutations in small-cell lung cancers in patients who have never smoked.	The New England journal of medicine	2006	65
16912159	1956	Wang MY	Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.	Cancer research	2006	96
16931954	1956	Hicks DG	Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.	The American journal of surgical pathology	2006	68
16938528	1956	Kim MJ	Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.	Human pathology	2006	82
17047074	1956	Morgillo F	Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.	Cancer research	2006	101
17047648	1956	Asahina H	A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.	British journal of cancer	2006	67
17050875	1956	Lenz HJ	Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.	Journal of clinical oncology 	2006	90
17085664	1956	Balak MN	Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.	Clinical cancer research 	2006	195
17218988	1956	Kenny PA	Targeting TACE-dependent EGFR ligand shedding in breast cancer.	The Journal of clinical investigation	2007	72
17251932	1956	Ventura A	Restoration of p53 function leads to tumour regression in vivo.	Nature	2007	502
17308052	1956	Buck E	Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition.	Molecular cancer therapeutics	2007	70
17308062	1956	Nahta R	Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.	Molecular cancer therapeutics	2007	67
17403429	1956	Smith HO	GPR30: a novel indicator of poor survival for endometrial carcinoma.	American journal of obstetrics and gynecology	2007	74
17404082	1956	Shaffer DR	Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.	Clinical cancer research 	2007	98
17440163	1956	Farnie G	Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways.	Journal of the National Cancer Institute	2007	98
17452677	1956	Moore MJ	Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.	Journal of clinical oncology 	2007	820
17470858	1956	Van Cutsem E	Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.	Journal of clinical oncology 	2007	381
17474783	1956	Huang X	Cancer cells assemble and align gold nanorods conjugated to antibodies to produce highly enhanced, sharp, and polarized surface Raman spectra: a potential cancer diagnostic marker.	Nano letters	2007	58
17483330	1956	Palmieri D	Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain.	Cancer research	2007	101
17623837	1956	Thomas MB	Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.	Cancer	2007	69
17663798	1956	Hoadley KA	EGFR associated expression profiles vary with breast tumor subtype.	BMC genomics	2007	101
17670948	1956	Franovic A	Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer.	Proceedings of the National Academy of Sciences of the United States of America	2007	68
17785346	1956	Krex D	Long-term survival with glioblastoma multiforme.	Brain 	2007	171
17888036	1956	Mitsudomi T	Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.	Cancer science	2007	121
17894407	1956	De Luca A	The role of the EGFR signaling in tumor microenvironment.	Journal of cellular physiology	2008	89
17896140	1956	Lieto E	Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients.	Annals of surgical oncology	2008	52
17922188	1956	Tan DS	Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients.	Breast cancer research and treatment	2008	60
17947225	1956	Rosell R	Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.	Annals of oncology 	2008	60
17974556	1956	Cappuzzo F	EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.	Annals of oncology 	2008	66
17974918	1956	Okawa T	The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation.	Genes and development	2007	65
18060032	1956	Gao SP	Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.	The Journal of clinical investigation	2007	193
18087285	1956	Yoshikawa D	Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma.	British journal of cancer	2008	79
18236164	1956	Barr S	Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions.	Clinical and experimental metastasis	2008	70
18272912	1956	Tol J	A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.	Annals of oncology 	2008	56
18281673	1956	Eberhard DA	Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.	Journal of clinical oncology 	2008	67
18297114	1956	Wheeler DL	Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.	Oncogene	2008	159
18303429	1956	Marks JL	Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.	Journal of thoracic oncology 	2008	71
18316557	1956	Cheang MC	Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.	Clinical cancer research 	2008	299
18339877	1956	Jhawer M	PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.	Cancer research	2008	130
18362333	1956	Diehn M	Identification of noninvasive imaging surrogates for brain tumor gene-expression modules.	Proceedings of the National Academy of Sciences of the United States of America	2008	85
18381447	1956	Fuchs BC	Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.	Cancer research	2008	86
18390971	1956	Sobrero AF	EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2008	168
18391747	1956	Motoi N	Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.	The American journal of surgical pathology	2008	77
18397279	1956	Kim MA	EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number.	Histopathology	2008	67
18408761	1956	Li D	BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.	Oncogene	2008	267
18413800	1956	Godin-Heymann N	The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.	Molecular cancer therapeutics	2008	58
18421051	1956	Lin NU	Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.	Journal of clinical oncology 	2008	97
18425114	1956	Al-Nedawi K	Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells.	Nature cell biology	2008	350
18437168	1956	Ladanyi M	Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond.	Modern pathology 	2008	71
18452692	1956	Molina JR	Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.	Mayo Clinic proceedings	2008	357
18458038	1956	Sequist LV	First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.	Journal of clinical oncology 	2008	233
18486742	1956	Argiris A	Head and neck cancer.	Lancet	2008	285
18509184	1956	Yang CH	Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.	Journal of clinical oncology 	2008	56
18565887	1956	Murat A	Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.	Journal of clinical oncology 	2008	213
18596266	1956	Maheswaran S	Detection of mutations in EGFR in circulating lung-cancer cells.	The New England journal of medicine	2008	402
18604200	1956	Kolev V	EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer.	Nature cell biology	2008	67
18612148	1956	Anders CK	Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.	Journal of clinical oncology 	2008	140
18612151	1956	Hirsch FR	Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.	Journal of clinical oncology 	2008	65
18632642	1956	Lee-Hoeflich ST	A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.	Cancer research	2008	168
18802721	1956	van Krieken JH	KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.	Virchows Archiv 	2008	73
18836087	1956	Cappuzzo F	MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.	Annals of oncology 	2009	80
18839307	1956	Viale G	Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity.	Breast cancer research and treatment	2009	51
18922904	1956	Buck E	Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.	Cancer research	2008	82
18927285	1956	Fichtner I	Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.	Clinical cancer research 	2008	85
18955454	1956	Di Leo A	Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.	Journal of clinical oncology 	2008	92
18978815	1956	Pickl M	Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab.	Oncogene	2009	84
19027483	1956	Kim ES	Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.	Lancet	2008	258
19047149	1956	Saxena NK	Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor.	Cancer research	2008	65
19058255	1956	Xia W	Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer.	Molecular carcinogenesis	2009	67
19073608	1956	Webster RJ	Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7.	The Journal of biological chemistry	2009	138
19096300	1956	Onozato R	Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.	Journal of thoracic oncology 	2009	61
19109410	1956	Graner MW	Proteomic and immunologic analyses of brain tumor exosomes.	FASEB journal 	2009	101
19117999	1956	Huang F	The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.	Cancer research	2009	63
19150933	1956	Corkery B	Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.	Annals of oncology 	2009	66
19169683	1956	Ramanathan RK	A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.	Cancer chemotherapy and pharmacology	2009	59
19170230	1956	Wong DW	The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.	Cancer	2009	157
19228746	1956	Lin NU	Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.	Clinical cancer research 	2009	105
19234440	1956	Inamura K	EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.	Modern pathology 	2009	103
19238632	1956	Tang Z	Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.	British journal of cancer	2008	57
19252415	1956	Golding SE	Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells.	Cancer biology and therapy	2009	49
19276389	1956	Narayan M	Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells.	Cancer research	2009	69
19276677	1956	Wheeler DL	Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.	Cancer biology and therapy	2009	55
19332730	1956	Natale RB	Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.	Journal of clinical oncology 	2009	51
19346299	1956	Ross JS	The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.	The oncologist	2009	199
19366827	1956	Yu J	Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer.	Clinical cancer research 	2009	54
19410716	1956	Pirker R	Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.	Lancet	2009	294
19414683	1956	Bai H	Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.	Journal of clinical oncology 	2009	84
19421193	1956	Bos PD	Genes that mediate breast cancer metastasis to the brain.	Nature	2009	433
19421880	1956	Dembinski JL	Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma.	Clinical and experimental metastasis	2009	60
19433789	1956	O'Keeffe GC	Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF.	Proceedings of the National Academy of Sciences of the United States of America	2009	47
19447865	1956	Naumov GN	Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.	Clinical cancer research 	2009	55
19480968	1956	Kuremsky JG	Biomarkers for response to neoadjuvant chemoradiation for rectal cancer.	International journal of radiation oncology, biology, physics	2009	56
19544433	1956	Kelly JJ	Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.	Stem cells	2009	62
19549916	1956	Di Vizio D	Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease.	Cancer research	2009	77
19584155	1956	Schmid K	EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.	Clinical cancer research 	2009	66
19596646	1956	Anders CK	Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.	Clinical breast cancer	2009	104
19625624	1956	Guo D	The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2009	81
19636327	1956	Normanno N	Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.	Nature reviews. Clinical oncology	2009	107
19667264	1956	Shaw AT	Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.	Journal of clinical oncology 	2009	383
19680293	1956	Gazdar AF	Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.	Oncogene	2009	163
19690143	1956	Lu KV	Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.	Cancer research	2009	55
19738166	1956	Siena S	Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.	Journal of the National Cancer Institute	2009	144
19738203	1956	Huang PH	Oncogenic EGFR signaling networks in glioma.	Science signaling	2009	92
19775602	1956	Dawson SJ	Triple negative breast cancers: clinical and prognostic implications.	European journal of cancer	2009	55
19786658	1956	Johnston S	Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.	Journal of clinical oncology 	2009	191
19826477	1956	Soh J	Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.	PloS one	2009	66
19917871	1956	Azzoli CG	American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.	Journal of clinical oncology 	2009	139
19920198	1956	Gravendeel LA	Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology.	Cancer research	2009	128
19942479	1956	Folprecht G	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.	The Lancet. Oncology	2010	131
20012924	1956	McConkey DJ	Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer.	Cancer metastasis reviews	2009	81
20018733	1956	Chan G	Activation of EGFR on monocytes is required for human cytomegalovirus entry and mediates cellular motility.	Proceedings of the National Academy of Sciences of the United States of America	2009	56
20065189	1956	Wells SA Jr	Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.	Journal of clinical oncology 	2010	95
20082448	1956	Rimawi MF	Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes.	Cancer	2010	45
20100958	1956	Khambata-Ford S	Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	63
20100966	1956	Lynch TJ	Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.	Journal of clinical oncology 	2010	103
20103678	1956	Baldus SE	Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.	Clinical cancer research 	2010	109
20108024	1956	Suda K	Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.	Cancer metastasis reviews	2010	44
20146086	1956	Clarke JL	High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.	Journal of neuro-oncology	2010	50
20183914	1956	Takahashi T	Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.	Annals of surgical oncology	2010	80
20194857	1956	Voduc KD	Breast cancer subtypes and the risk of local and regional relapse.	Journal of clinical oncology 	2010	212
20351699	1956	Harris TJ	The molecular pathology of cancer.	Nature reviews. Clinical oncology	2010	57
20399983	1956	Tol J	Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.	Clinical therapeutics	2010	50
20431034	1956	Tsiatis AC	Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications.	The Journal of molecular diagnostics 	2010	105
20431349	1956	Witkiewicz AK	Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers.	Cancer biology and therapy	2010	57
20479403	1956	Sequist LV	Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	96
20501798	1956	O'Brien NA	Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.	Molecular cancer therapeutics	2010	83
20515495	1956	Krakstad C	Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics.	Molecular cancer	2010	65
20520800	1956	Blows FM	Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies.	PLoS medicine	2010	185
20551945	1956	Janku F	Targeted therapy in non-small-cell lung cancer--is it becoming a reality?	Nature reviews. Clinical oncology	2010	61
20562913	1956	Gan Y	Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.	Oncogene	2010	73
20570559	1956	Herbst RS	Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.	The Lancet. Oncology	2010	99
20573926	1956	Maemondo M	Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.	The New England journal of medicine	2010	979
20595147	1956	Porta R	Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.	The European respiratory journal	2011	60
20621056	1956	Curtis SJ	Primary tumor genotype is an important determinant in identification of lung cancer propagating cells.	Cell stem cell	2010	50
20624322	1956	Zhang X	Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.	Molecular cancer	2010	79
20627894	1956	Eichler AF	EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.	Neuro-oncology	2010	48
20647323	1956	Hadjipanayis CG	EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma.	Cancer research	2010	82
20671236	1956	Zhu WZ	Neuregulin/ErbB signaling regulates cardiac subtype specification in differentiating human embryonic stem cells.	Circulation research	2010	59
20716591	1956	Sathornsumetee S	Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.	Neuro-oncology	2010	48
20798686	1956	Li QQ	Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells.	Cell death and differentiation	2011	40
20824720	1956	da Cunha Santos G	Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.	Cancer	2010	42
20855820	1956	Johnson FM	Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	53
20858720	1956	Mazzoleni S	Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis.	Cancer research	2010	65
20861192	1956	Hochgräfe F	Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.	Cancer research	2010	56
20874002	1956	Katakowski M	MiR-146b-5p suppresses EGFR expression and reduces in vitro migration and invasion of glioma.	Cancer investigation	2010	47
20887192	1956	da Cunha Santos G	EGFR mutations and lung cancer.	Annual review of pathology	2011	65
20921462	1956	Peeters M	Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2010	181
20921465	1956	Douillard JY	Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.	Journal of clinical oncology 	2010	342
20943624	1956	Vermorken JB	Optimal treatment for recurrent/metastatic head and neck cancer.	Annals of oncology 	2010	51
21030498	1956	Heon S	Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.	Clinical cancer research 	2010	44
21048039	1956	Licitra L	Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.	Annals of oncology 	2011	54
21062932	1956	Camidge DR	Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.	Clinical cancer research 	2010	75
21062933	1956	Suda K	Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.	Clinical cancer research 	2010	47
21081655	1956	John T	The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer.	Clinical cancer research 	2011	38
21160525	1956	Leemans CR	The molecular biology of head and neck cancer.	Nature reviews. Cancer	2011	466
21163703	1956	De Roock W	KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.	The Lancet. Oncology	2011	125
21168239	1956	Chung JH	Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.	Lung cancer	2011	39
21220474	1956	Donev IS	Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.	Clinical cancer research 	2011	37
21220480	1956	Osborne CK	Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.	Clinical cancer research 	2011	52
21248300	1956	Arcila ME	Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.	Clinical cancer research 	2011	120
21248303	1956	Janjigian YY	Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.	Clinical cancer research 	2011	45
21258250	1956	Ludovini V	Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.	Journal of thoracic oncology 	2011	44
21303969	1956	Ramalingam SS	Lung cancer: New biological insights and recent therapeutic advances.	CA	2011	87
21408138	1956	van Eijk R	Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR.	PloS one	2011	43
21430269	1956	Sequist LV	Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.	Science translational medicine	2011	619
21430781	1956	Bivona TG	FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.	Nature	2011	99
21502544	1956	Van Cutsem E	Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.	Journal of clinical oncology 	2011	350
21576636	1956	Spigel DR	Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	40
21597390	1956	Suda K	Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.	Journal of thoracic oncology 	2011	69
21641636	1956	Maughan TS	Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.	Lancet	2011	199
21653320	1956	Wang X	A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.	Blood	2011	95
21670455	1956	Fukuoka M	Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).	Journal of clinical oncology 	2011	294
21690342	1956	Jin K	The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway.	Proceedings of the National Academy of Sciences of the United States of America	2012	30
21720997	1956	Kim HR	Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.	Cancer	2012	33
21730270	1956	Yatabe Y	Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma.	Journal of clinical oncology 	2011	46
21764376	1956	Yasuda H	EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.	The Lancet. Oncology	2012	79
21768463	1956	Sequist LV	Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.	Journal of clinical oncology 	2011	120
21775534	1956	Oxnard GR	New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.	Clinical cancer research 	2011	83
21778164	1956	Heijink IH	Cigarette smoke impairs airway epithelial barrier function and cell-cell contact recovery.	The European respiratory journal	2012	39
21788562	1956	Zhou Q	Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	61
21830014	1956	Tamimi RM	Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer.	Breast cancer research and treatment	2012	47
21865399	1956	Grommes C	"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.	Neuro-oncology	2011	57
21886163	1956	Breitbach CJ	Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.	Nature	2011	138
21893191	1956	Wertheimer E	Rac signaling in breast cancer: a tale of GEFs and GAPs.	Cellular signalling	2012	62
21909139	1956	Yue P	Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.	Oncogene	2012	36
21914172	1956	Sihto H	Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.	Breast cancer research 	2011	40
21926387	1956	Travis WD	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary.	Proceedings of the American Thoracic Society	2011	71
21990576	1956	Terwisscha van Scheltinga AG	Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies.	Journal of nuclear medicine 	2011	51
22020299	1956	Low-Nam ST	ErbB1 dimerization is promoted by domain co-confinement and stabilized by ligand binding.	Nature structural and molecular biology	2011	73
22025146	1956	Wells SA Jr	Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.	Journal of clinical oncology 	2012	186
22042947	1956	Lennerz JK	MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.	Journal of clinical oncology 	2011	116
22054879	1956	Travis WD	Pathology of lung cancer.	Clinics in chest medicine	2011	59
22056021	1956	Pirker R	EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.	The Lancet. Oncology	2012	132
22065080	1956	Koul D	Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.	Clinical cancer research 	2012	44
22119437	1956	Soria JC	EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.	Cancer treatment reviews	2012	35
22137795	1956	Snuderl M	Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.	Cancer cell	2011	184
22139077	1956	Bonavia R	EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway.	Oncogene	2012	52
22140546	1956	Li C	Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers.	PloS one	2011	54
22173549	1956	Vermaat JS	Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment.	Clinical cancer research 	2012	44
22173704	1956	Krebs MG	Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.	Journal of thoracic oncology 	2012	101
22178589	1956	Andersen JB	Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.	Gastroenterology	2012	76
22189713	1956	Deng XS	Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers.	Cell cycle	2012	48
22207554	1956	Park S	High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.	Histology and histopathology	2012	35
22209049	1956	O'Flaherty JD	Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer.	Lung cancer	2012	44
22228640	1956	Rekhtman N	Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.	Clinical cancer research 	2012	73
22228822	1956	Kim Y	The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor.	Molecular cancer therapeutics	2012	34
22237264	1956	Sun PL	High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.	Journal of thoracic oncology 	2012	34
22261334	1956	Han W	Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations.	Cancer letters	2012	64
22281684	1956	Prahallad A	Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.	Nature	2012	392
22282308	1956	Cheng L	Molecular pathology of lung cancer: key to personalized medicine.	Modern pathology 	2012	41
22285168	1956	Rosell R	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.	The Lancet. Oncology	2012	876
22305568	1956	Spike BT	A mammary stem cell population identified and characterized in late embryogenesis reveals similarities to human breast cancer.	Cell stem cell	2012	56
22317764	1956	Zhang Y	Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.	Clinical cancer research 	2012	46
22370318	1956	Lee JS	Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).	Journal of clinical oncology 	2012	70
22407829	1956	Perez-Moreno P	Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities.	Clinical cancer research 	2012	48
22414764	1956	Blivet-Van Eggelpoël MJ	Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.	Journal of hepatology	2012	37
22418700	1956	Lin NU	A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.	Breast cancer research and treatment	2012	44
22440336	1956	Scagliotti GV	Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.	Clinical lung cancer	2012	44
22448344	1956	Corcoran RB	EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.	Cancer discovery	2012	179
22454081	1956	Gallardo A	Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.	British journal of cancer	2012	55
22505743	1956	Navani N	Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients.	American journal of respiratory and critical care medicine	2012	53
22535374	1956	De Boeck A	Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling.	Gut	2013	34
22579283	1956	Lee MJ	Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.	Cell	2012	180
22590557	1956	Wilkerson MD	Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation.	PloS one	2012	45
22591372	1956	Gorges TM	Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.	BMC cancer	2012	110
22611028	1956	Roselli M	Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer.	Clinical cancer research 	2012	36
22677429	1956	Park SJ	Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.	Lung cancer	2012	50
22722830	1956	Misale S	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.	Nature	2012	333
22722843	1956	Diaz LA Jr	The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.	Nature	2012	379
22751098	1956	Zhang Z	Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.	Nature genetics	2012	263
22753918	1956	Ramalingam SS	Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2012	63
22768234	1956	An SJ	Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.	PloS one	2012	50
22778317	1956	Gridelli C	First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.	Journal of clinical oncology 	2012	54
22780919	1956	Morgan RA	Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.	Human gene therapy	2012	71
22797485	1956	Zhao X	Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.	Respiration; international review of thoracic diseases	2013	30
22801742	1956	Doecke JD	Blood-based protein biomarkers for diagnosis of Alzheimer disease.	Archives of neurology	2012	65
22806307	1956	Togashi Y	Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.	Cancer chemotherapy and pharmacology	2012	34
22810899	1956	Johnson ML	Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.	Cancer	2013	32
22826274	1956	Bai H	Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.	Journal of clinical oncology 	2012	60
22847020	1956	Phuphanich S	Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma.	Cancer immunology, immunotherapy 	2013	68
22898037	1956	Argiris A	Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.	Annals of oncology 	2013	34
22898678	1956	Leboulleux S	Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.	The Lancet. Oncology	2012	56
22949147	1956	Van Cutsem E	Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.	Journal of clinical oncology 	2012	183
22977193	1956	Terashima M	Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.	Clinical cancer research 	2012	59
23000897	1956	Cancer Genome Atlas Network.	Comprehensive molecular portraits of human breast tumours.	Nature	2012	2327
23012302	1956	André F	Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents.	Annals of oncology 	2012	58
23014527	1956	Dogan S	Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.	Clinical cancer research 	2012	74
23052255	1956	Suehara Y	Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.	Clinical cancer research 	2012	35
23073759	1956	Masuda H	Role of epidermal growth factor receptor in breast cancer.	Breast cancer research and treatment	2012	81
23084121	1956	Nielsen DL	Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.	Breast	2013	26
23091115	1956	Byers LA	An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.	Clinical cancer research 	2013	176
23123196	1956	Yang W	EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis.	Molecular cell	2012	55
23129122	1956	Wu YL	Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).	Annals of oncology 	2013	36
23149820	1956	Singh JK	Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.	Clinical cancer research 	2013	49
23154552	1956	Weickhardt AJ	Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.	Journal of thoracic oncology 	2012	80
23154553	1956	D'Angelo SP	Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.	Journal of thoracic oncology 	2012	36
23172555	1956	Ellison G	EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples.	Journal of clinical pathology	2013	49
23233388	1956	Mostert B	KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.	International journal of cancer	2013	30
23242438	1956	Yoshizawa A	Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.	Journal of thoracic oncology 	2013	67
23242808	1956	Girotti MR	Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.	Cancer discovery	2013	99
23280481	1956	Chen CL	Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer.	The Prostate	2013	44
23319610	1956	Ferraro DA	Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR.	Proceedings of the National Academy of Sciences of the United States of America	2013	26
23333074	1956	Zaiss DM	Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor.	Immunity	2013	49
23341526	1956	Welsh JW	Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.	Journal of clinical oncology 	2013	71
23341890	1956	Li Y	Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.	PloS one	2013	41
23344264	1956	Yeh P	DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.	Clinical cancer research 	2013	35
23358903	1956	Bayraktar S	Molecularly targeted therapies for metastatic triple-negative breast cancer.	Breast cancer research and treatment	2013	31
23361103	1956	Gonzalez de Castro D	Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance.	Clinical pharmacology and therapeutics	2013	47
23362162	1956	Tuononen K	Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.	Genes, chromosomes and cancer	2013	34
23370315	1956	Hirsch FR	Epidermal growth factor receptor inhibition in lung cancer: status 2012.	Journal of thoracic oncology 	2013	26
23375249	1956	Heinemann V	Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action.	Cancer treatment reviews	2013	28
23391413	1956	Voss JS	Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.	Human pathology	2013	38
23401433	1956	Li T	Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.	Journal of clinical oncology 	2013	86
23401443	1956	Travis WD	New pathologic classification of lung cancer: relevance for clinical practice and clinical trials.	Journal of clinical oncology 	2013	68
23401451	1956	Ohashi K	Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.	Journal of clinical oncology 	2013	103
23404247	1956	Valtorta E	KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy.	International journal of cancer	2013	34
23407558	1956	Yu HA	Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.	Journal of thoracic oncology 	2013	48
23470965	1956	Yu HA	Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.	Clinical cancer research 	2013	251
23486266	1956	Russell PA	Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.	Journal of thoracic oncology 	2013	29
23551194	1956	Lindeman NI	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.	Archives of pathology and laboratory medicine	2013	68
23552377	1956	Lindeman NI	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.	Journal of thoracic oncology 	2013	124
23553849	1956	Socinski MA	A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.	Clinical cancer research 	2013	70
23555746	1956	Luca AC	Impact of the 3D microenvironment on phenotype, gene expression, and EGFR inhibition of colorectal cancer cell lines.	PloS one	2013	36
23562183	1956	Lindeman NI	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.	The Journal of molecular diagnostics 	2013	60
23563269	1956	Murtaza M	Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.	Nature	2013	259
23576557	1956	Keysar SB	Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.	Cancer research	2013	26
23584089	1956	Sadanandam A	A colorectal cancer classification system that associates cellular phenotype and responses to therapy.	Nature medicine	2013	186
23584090	1956	De Sousa E Melo F	Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions.	Nature medicine	2013	132
23636329	1956	Shen J	EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2.	Nature	2013	100
23653350	1956	Balanis N	Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway.	The Journal of biological chemistry	2013	29
23723294	1956	Dearden S	Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).	Annals of oncology 	2013	58
23729361	1956	Gainor JF	ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.	Clinical cancer research 	2013	85
23729478	1956	Bardelli A	Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.	Cancer discovery	2013	126
23733761	1956	Baselga J	Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.	Journal of clinical oncology 	2013	66
23777544	1956	Gan HK	The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered.	The FEBS journal	2013	46
23814043	1956	Gainor JF	Novel targets in non-small cell lung cancer: ROS1 and RET fusions.	The oncologist	2013	35
23816960	1956	Sequist LV	Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.	Journal of clinical oncology 	2013	383
23816963	1956	Katakami N	LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.	Journal of clinical oncology 	2013	63
23816967	1956	Yang JC	Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.	Journal of clinical oncology 	2013	49
23833300	1956	Cardarella S	Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.	Clinical cancer research 	2013	34
23872583	1956	Kanda R	Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt-driven bypass signaling.	Cancer research	2013	28
23888061	1956	Liu X	The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies.	Journal of clinical pathology	2013	29
23891509	1956	Tsuta K	The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations.	Lung cancer	2013	35
23894143	1956	Li R	Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.	Molecular cancer therapeutics	2013	32
23931927	1956	Gridelli C	ALK inhibitors in the treatment of advanced NSCLC.	Cancer treatment reviews	2014	34
23980091	1956	Goss GD	Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.	Journal of clinical oncology 	2013	40
24021541	1956	Iuchi T	Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.	Lung cancer	2013	31
24026012	1956	Giles KM	Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.	Molecular cancer therapeutics	2013	29
24065731	1956	Walter AO	Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.	Cancer discovery	2013	122
24098024	1956	Pichler M	miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.	Journal of clinical pathology	2014	26
24105277	1956	Hata A	Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.	Cancer	2013	38
24122263	1956	Cummings MC	Metastatic progression of breast cancer: insights from 50 years of autopsies.	The Journal of pathology	2014	25
24122793	1956	Troiani T	Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.	Clinical cancer research 	2013	36
24141978	1956	Zhang L	A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.	Scientific reports	2013	28
24165158	1956	Rho JK	MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.	Cancer research	2014	29
24174329	1956	Clinical Lung Cancer Genome Project (CLCGP).	A genomics-based classification of human lung tumors.	Science translational medicine	2013	74
24199791	1956	Ahmad A	Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.	Journal of hematology and oncology	2013	29
24236184	1956	Scarpa A	Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel.	PloS one	2013	28
24248375	1956	Drake JM	Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets.	Proceedings of the National Academy of Sciences of the United States of America	2013	28
24335959	1956	Huang WC	miRNA-491-5p and GIT1 serve as modulators and biomarkers for oral squamous cell carcinoma invasion and metastasis.	Cancer research	2014	31
24366937	1956	Vergote IB	Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.	Journal of clinical oncology 	2014	23
24378644	1956	Siegelin MD	Epidermal growth factor receptor mutations in lung adenocarcinoma.	Laboratory investigation; a journal of technical methods and pathology	2014	40
24390343	1956	Scafidi J	Intranasal epidermal growth factor treatment rescues neonatal brain injury.	Nature	2014	43
24406864	1956	Park HS	High EGFR gene copy number predicts poor outcome in triple-negative breast cancer.	Modern pathology 	2014	33
24419411	1956	Shi Y	A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).	Journal of thoracic oncology 	2014	113
24425048	1956	Kim J	microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma.	Cancer research	2014	25
24439929	1956	Wu YL	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2014	223
24443522	1956	Yang JJ	Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.	Clinical cancer research 	2014	29
24448239	1956	Luraghi P	MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.	Cancer research	2014	23
24458568	1956	Suda K	The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.	International journal of cancer	2014	22
24470557	1956	Wen PY	Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.	Neuro-oncology	2014	23
24508104	1956	André F	Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).	The Lancet. Oncology	2014	55
24513263	1956	Vanderlaan PA	Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.	Lung cancer	2014	20
24550739	1956	Borad MJ	Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.	PLoS genetics	2014	55
24553385	1956	Bettegowda C	Detection of circulating tumor DNA in early- and late-stage human malignancies.	Science translational medicine	2014	385
24621885	1956	Zhang Y	MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET.	PloS one	2014	21
24626858	1956	Nagatsuma AK	Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.	Gastric cancer 	2015	24
24644001	1956	Li L	Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.	Clinical cancer research 	2014	43
24652789	1956	Lu JL	Association of body mass index with outcomes in patients with CKD.	Journal of the American Society of Nephrology 	2014	33
24656976	1956	Yan M	HER2 aberrations in cancer: implications for therapy.	Cancer treatment reviews	2014	40
24666267	1956	Therkildsen C	The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.	Acta oncologica	2014	56
24670642	1956	Sun C	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.	Nature	2014	139
24677197	1956	Fuchs BC	Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma.	Hepatology	2014	60
24685132	1956	Sun C	Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.	Cell reports	2014	43
24687833	1956	Schwartzberg LS	PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.	Journal of clinical oncology 	2014	99
24687921	1956	Koeppen H	Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.	Clinical cancer research 	2014	26
24743704	1956	Li S	Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.	British journal of cancer	2014	25
24747441	1956	Seguin L	An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.	Nature cell biology	2014	58
24773774	1956	Weber B	Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays.	BMC cancer	2014	25
24816687	1956	Zhou X	MicroRNA-7 inhibits tumor metastasis and reverses epithelial-mesenchymal transition through AKT/ERK1/2 inactivation by targeting EGFR in epithelial ovarian cancer.	PloS one	2014	24
24831979	1956	Gregorc V	Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.	The Lancet. Oncology	2014	39
24857062	1956	Abrams J	National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting	2014	32
24886126	1956	Ma J	Targeting of erbB3 receptor to overcome resistance in cancer treatment.	Molecular cancer	2014	28
24895374	1956	Rohan TE	Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer.	Journal of the National Cancer Institute	2014	33
24904092	1956	Irazabal MV	Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.	Journal of the American Society of Nephrology 	2015	24
24919569	1956	Van Cutsem E	Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.	Clinical cancer research 	2014	22
24919575	1956	Yoshida T	Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.	Clinical cancer research 	2014	20
24939055	1956	Qu Y	Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.	Journal of experimental and clinical cancer research 	2014	22
25009014	1956	Azuma K	Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.	Annals of oncology 	2014	66
25009231	1956	Rebouissou S	EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype.	Science translational medicine	2014	33
25013125	1956	Couraud S	Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.	Clinical cancer research 	2014	40
25031274	1956	Lee SM	Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.	Journal of the National Cancer Institute	2014	22
25057166	1956	Missiaglia E	Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features.	Annals of oncology 	2014	38
25079552	1956	Cancer Genome Atlas Research Network.	Comprehensive molecular profiling of lung adenocarcinoma.	Nature	2014	567
25080476	1956	Müller C	Hematogenous dissemination of glioblastoma multiforme.	Science translational medicine	2014	27
25091798	1956	Masterson L	De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials.	European journal of cancer	2014	30
25136066	1956	Brand TM	AXL mediates resistance to cetuximab therapy.	Cancer research	2014	27
25137181	1956	Marchetti A	Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.	PloS one	2014	33
25150284	1956	Labussière M	Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.	Neurology	2014	29
25164765	1956	Brannon AR	Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.	Genome biology	2014	54
25175099	1956	Seto T	Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.	The Lancet. Oncology	2014	67
25247337	1956	Hoffknecht P	Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.	Journal of thoracic oncology 	2015	25
25248381	1956	Laurent-Puig P	Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.	Clinical cancer research 	2015	30
25311215	1956	Leighl NB	Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.	Journal of clinical oncology 	2014	42
25345567	1956	Hagemann IS	Clinical next-generation sequencing in patients with non-small cell lung cancer.	Cancer	2015	29
25349291	1956	Iyengar P	Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.	Journal of clinical oncology 	2014	23
25349974	1956	D'Incecco A	PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.	British journal of cancer	2015	69
25394791	1956	Crystal AS	Patient-derived models of acquired resistance can identify effective drug combinations for cancer.	Science	2014	120
25405368	1956	Chiyomaru T	Dual regulation of receptor tyrosine kinase genes EGFR and c-Met by the tumor-suppressive microRNA-23b/27b cluster in bladder cancer.	International journal of oncology	2015	22
25409146	1956	Cheng CJ	MicroRNA silencing for cancer therapy targeted to the tumour microenvironment.	Nature	2015	97
25444907	1956	Hao C	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.	Cancer letters	2015	18
25468223	1956	Cohen AL	Glioma biology and molecular markers.	Cancer treatment and research	2015	26
25492084	1956	Keck MK	Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes.	Clinical cancer research 	2015	30
25556173	1956	Loupy A	Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts.	Journal of the American Society of Nephrology 	2015	20
25567908	1956	Drilon A	Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.	Clinical cancer research 	2015	30
25573908	1956	Kopp JB	Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial.	Journal of the American Society of Nephrology 	2015	22
25579803	1956	Gustavsson B	A review of the evolution of systemic chemotherapy in the management of colorectal cancer.	Clinical colorectal cancer	2015	29
25589191	1956	Yang JC	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.	The Lancet. Oncology	2015	173
25589621	1956	Yaeger R	Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.	Clinical cancer research 	2015	39
25593032	1956	Linnekamp JF	Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes.	Cancer research	2015	21
25593300	1956	Cani AK	Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.	Molecular cancer research 	2015	18
25596659	1956	Giralt J	Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.	The Lancet. Oncology	2015	21
25605843	1956	Van Cutsem E	Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.	Journal of clinical oncology 	2015	74
25623215	1956	Arena S	Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.	Clinical cancer research 	2015	24
25628445	1956	Morelli MP	Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.	Annals of oncology 	2015	22
25629630	1956	Fillmore CM	EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.	Nature	2015	49
25629635	1956	Wu C	High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.	Journal of thoracic oncology 	2015	16
25639985	1956	Mao C	Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.	Scientific reports	2015	19
25649416	1956	Stahl P	Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer.	BMC gastroenterology	2015	17
25662388	1956	Kim MY	Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.	Lung cancer	2015	25
25673558	1956	Pietrantonio F	Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.	European journal of cancer	2015	37
25673644	1956	Ahronian LG	Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.	Cancer discovery	2015	46
25682441	1956	Fuse N	Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.	Gastric cancer 	2016	19
25689095	1956	Kumarakulasinghe NB	Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).	Respirology	2015	16
25714397	1956	Stahlhut C	Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation.	Cell cycle	2015	21
25738220	1956	Sholl LM	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.	Journal of thoracic oncology 	2015	37
25758528	1956	Niederst MJ	RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.	Nature communications	2015	45
25807485	1956	Obenauf AC	Therapy-induced tumour secretomes promote resistance and tumour progression.	Nature	2015	63
25807554	1956	Tang MC	Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.	PloS one	2015	15
25832655	1956	Jie HB	CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.	Cancer research	2015	33
25843712	1956	Blakely CM	NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.	Cell reports	2015	22
25873175	1956	Elkabets M	AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.	Cancer cell	2015	35
25882755	1956	Watanabe M	Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR.	Clinical cancer research 	2015	37
25892145	1956	Machiels JP	Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head &amp;amp; Neck 1): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2015	39
25895031	1956	Tang Y	The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs.	Oncotarget	2015	32
25904751	1956	Rosenthal EL	Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer.	Clinical cancer research 	2015	33
25923550	1956	Sequist LV	Rociletinib in EGFR-mutated non-small-cell lung cancer.	The New England journal of medicine	2015	125
25943888	1956	Aldape K	Glioblastoma: pathology, molecular mechanisms and markers.	Acta neuropathologica	2015	25
25956936	1956	Rizzo S	CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.	European radiology	2016	12
25979833	1956	Brulé SY	Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.	European journal of cancer	2015	22
25989278	1956	Rowland A	Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.	British journal of cancer	2015	21
26014294	1956	Zhou C	BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2015	26
26024796	1956	Cooper WA	PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.	Lung cancer	2015	29
26030179	1956	Siravegna G	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.	Nature medicine	2015	58
26040904	1956	Solé C	miR-29c in urinary exosomes as predictor of early renal fibrosis in lupus nephritis.	Nephrology, dialysis, transplantation 	2015	21
26045340	1956	Thatcher N	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.	The Lancet. Oncology	2015	52
26051236	1956	Yang JC	Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.	The Lancet. Oncology	2015	39
26121317	1956	Stewart RL	Clinical significance of the integrin α6β4 in human malignancies.	Laboratory investigation; a journal of technical methods and pathology	2015	24
26149886	1956	Devarakonda S	Genomic alterations in lung adenocarcinoma.	The Lancet. Oncology	2015	20
26159065	1956	Soria JC	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.	The Lancet. Oncology	2015	49
26169611	1956	Scagliotti G	Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2015	34
26184520	1956	Tabernero J	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.	The Lancet. Oncology	2015	37
26206882	1956	Uchida J	Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA.	Clinical chemistry	2015	25
26243863	1956	Kavuri SM	HER2 activating mutations are targets for colorectal cancer treatment.	Cancer discovery	2015	18
26267324	1956	Riquelme I	Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy.	Oncotarget	2015	18
26269204	1956	Planchard D	EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.	Annals of oncology 	2015	26
26308162	1956	Russo A	A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.	Oncotarget	2015	30
26318427	1956	Bronte G	New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?	Oncotarget	2015	16
26324367	1956	Masters GA	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.	Journal of clinical oncology 	2015	47
26330164	1956	Caruso HG	Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.	Cancer research	2015	36
26351341	1956	Sacco AG	Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.	Journal of clinical oncology 	2015	22
26354927	1956	Dubbink HJ	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.	Neuro-oncology	2016	14
26358176	1956	Dietel M	A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.	Cancer gene therapy	2015	25
26370354	1956	Tan CS	Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.	The Lancet. Oncology	2015	35
26392303	1956	Misale S	Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers.	Nature communications	2015	17
26392535	1956	Kamburov A	Comprehensive assessment of cancer missense mutation clustering in protein structures.	Proceedings of the National Academy of Sciences of the United States of America	2015	26
26410082	1956	Brastianos PK	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.	Cancer discovery	2015	51
26416997	1956	Cai W	Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.	Journal of clinical oncology 	2015	21
26434585	1956	Schneider MR	The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors.	Oncogene	2016	12
26446944	1956	Sundaresan TK	Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.	Clinical cancer research 	2016	45
26459174	1956	Paweletz CP	Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.	Clinical cancer research 	2016	19
26460303	1956	Kopetz S	Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.	Journal of clinical oncology 	2015	41
26477306	1956	Schabath MB	Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.	Oncogene	2016	11
26525104	1956	Best MG	RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics.	Cancer cell	2015	34
26537995	1956	Minguet J	Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.	International journal of cancer	2016	19
26582655	1956	Xu S	Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients.	Cancer letters	2016	12
26598545	1956	Gebhart G	Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.	Annals of oncology 	2016	19
26637667	1956	Lastwika KJ	Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.	Cancer research	2016	31
26644315	1956	Russo M	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.	Cancer discovery	2016	23
26690310	1956	Richman SD	HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.	The Journal of pathology	2016	11
26724471	1956	Lin JJ	Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.	Journal of thoracic oncology 	2016	12
26727163	1956	Quoix E	TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.	The Lancet. Oncology	2016	17
26729443	1956	Awad MM	MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.	Journal of clinical oncology 	2016	33
26735353	1956	Bournet B	Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.	European journal of cancer	2016	16
26789630	1956	Yoshida T	ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.	PloS one	2016	13
26799287	1956	Del Re M	Contribution of KRAS mutations and c.2369C &amp;gt; T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.	Oncotarget	2017	9
26823294	1956	Schuler M	First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.	Journal of thoracic oncology 	2016	12
26828195	1956	Hata AN	Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.	Nature medicine	2016	57
26832883	1956	Mukai S	Overexpression of Transmembrane Protein BST2 is Associated with Poor Survival of Patients with Esophageal, Gastric, or Colorectal Cancer.	Annals of surgical oncology	2017	5
26844548	1956	Hedner C	Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma.	PloS one	2016	11
26867973	1956	Zheng D	Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.	Scientific reports	2016	29
26874901	1956	Chan A	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.	The Lancet. Oncology	2016	13
26898616	1956	Tan CS	Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.	Lung cancer	2016	17
26926684	1956	Desmedt C	Genomic Characterization of Primary Invasive Lobular Breast Cancer.	Journal of clinical oncology 	2016	12
26942675	1956	Li X	Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis.	Molecular cell	2016	14
26968708	1956	Feng K	Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer.	Science China. Life sciences	2016	14
27071706	1956	Wang S	Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.	Journal of hematology and oncology	2016	29
27083334	1956	Park K	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.	The Lancet. Oncology	2016	46
27117702	1956	Lin S	The m(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells.	Molecular cell	2016	23
17518741	2006	Falanga V	Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds.	Tissue engineering	2007	138
17601538	2006	O'Rourke MF	Mechanical factors in arterial aging: a clinical perspective.	Journal of the American College of Cardiology	2007	149
18723672	2006	van Rooij E	Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis.	Proceedings of the National Academy of Sciences of the United States of America	2008	476
19747980	2006	Booij JC	The dynamic nature of Bruch's membrane.	Progress in retinal and eye research	2010	70
22729285	2006	Wu W	Fast-degrading elastomer enables rapid remodeling of a cell-free synthetic graft into a neoartery.	Nature medicine	2012	53
23536538	2006	Tsamis A	Elastin and collagen fibre microstructure of the human aorta in ageing and disease: a review.	Journal of the Royal Society, Interface	2013	31
25638205	2006	Zhang J	Exosomes released from human induced pluripotent stem cells-derived MSCs facilitate cutaneous wound healing by promoting collagen synthesis and angiogenesis.	Journal of translational medicine	2015	29
10934146	2034	Talks KL	The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages.	The American journal of pathology	2000	240
16418497	2034	Koukourakis MI	Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial.	Journal of clinical oncology 	2006	63
18182667	2034	Sathornsumetee S	Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.	Journal of clinical oncology 	2008	74
18316553	2034	Camps C	hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer.	Clinical cancer research 	2008	210
18371555	2034	Sluimer JC	Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis.	Journal of the American College of Cardiology	2008	66
19372578	2034	McCord AM	Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro.	Molecular cancer research 	2009	66
19494350	2034	Semenza GL	Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis.	Blood	2009	53
19706526	2034	Bertout JA	HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses.	Proceedings of the National Academy of Sciences of the United States of America	2009	57
20206201	2034	Ralph SJ	The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy.	Molecular aspects of medicine	2010	82
20939709	2034	Lee FS	The HIF pathway and erythrocytosis.	Annual review of pathology	2011	46
21466972	2034	Rohwer N	Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.	Drug resistance updates 	2011	89
22169972	2034	Keith B	HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression.	Nature reviews. Cancer	2011	351
22642602	2034	Liang D	The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells.	BMC cancer	2012	33
23297826	2034	Agani F	Oxygen-independent regulation of HIF-1: novel involvement of PI3K/AKT/mTOR pathway in cancer.	Current cancer drug targets	2013	32
24997364	2034	Slominski A	The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1α expression and HIF-dependent attendant pathways.	Archives of biochemistry and biophysics	2014	31
25319824	2034	Bigham AW	Human high-altitude adaptation: forward genetics meets the HIF pathway.	Genes and development	2014	29
25417700	2034	Choudhry H	Tumor hypoxia induces nuclear paraspeckle formation through HIF-2α dependent transcriptional activation of NEAT1 leading to cancer cell survival.	Oncogene	2015	26
25456395	2034	Kim Y	Expression of lactate/H⁺ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses.	Human pathology	2015	20
26409567	2034	Cockle JV	Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling.	Neuro-oncology	2016	13
27001847	2034	Zhang C	Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m⁶A-demethylation of NANOG mRNA.	Proceedings of the National Academy of Sciences of the United States of America	2016	21
9504686	2064	Allred DC	Prognostic and predictive factors in breast cancer by immunohistochemical analysis.	Modern pathology 	1998	386
10223227	2064	Nakajima M	The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas.	Cancer	1999	113
10713699	2064	Cogswell PC	Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3.	Oncogene	2000	118
11158614	2064	Welsh JB	Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer.	Proceedings of the National Academy of Sciences of the United States of America	2001	125
11248153	2064	Slamon DJ	Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.	The New England journal of medicine	2001	1654
11751413	2064	Moulder SL	Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.	Cancer research	2001	96
11948130	2064	Park JW	Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.	Clinical cancer research 	2002	101
12060624	2064	Schindl M	Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer.	Clinical cancer research 	2002	96
12432043	2064	Keyomarsi K	Cyclin E and survival in patients with breast cancer.	The New England journal of medicine	2002	116
12529347	2064	Konecny G	Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.	Journal of the National Cancer Institute	2003	87
12627523	2064	Bos R	Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.	Cancer	2003	135
12646923	2064	Vermeer PD	Segregation of receptor and ligand regulates activation of epithelial growth factor receptor.	Nature	2003	121
12784331	2064	Bendell JC	Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.	Cancer	2003	119
12897328	2064	Ross JS	The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.	The oncologist	2003	91
14578209	2064	Lin EY	Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases.	The American journal of pathology	2003	327
14647146	2064	Schlieman MG	Incidence, mechanism and prognostic value of activated AKT in pancreas cancer.	British journal of cancer	2003	76
15194824	2064	Meng S	HER-2 gene amplification can be acquired as breast cancer progresses.	Proceedings of the National Academy of Sciences of the United States of America	2004	119
15220474	2064	Biswas DK	NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis.	Proceedings of the National Academy of Sciences of the United States of America	2004	102
15324695	2064	Nagata Y	PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.	Cancer cell	2004	432
15355889	2064	Gennari R	Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2.	Clinical cancer research 	2004	100
15385631	2064	Austin CD	Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin.	Molecular biology of the cell	2004	113
15455388	2064	Lengyel E	C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.	International journal of cancer	2005	85
15501983	2064	Mondesire WH	Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells.	Clinical cancer research 	2004	86
15534099	2064	Camp RL	X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.	Clinical cancer research 	2004	274
15542430	2064	Li YM	Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis.	Cancer cell	2004	144
15545664	2064	Winer EP	American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.	Journal of clinical oncology 	2005	139
15561805	2064	Cianfrocca M	Prognostic and predictive factors in early-stage breast cancer.	The oncologist	2004	94
15641021	2064	Simpson PT	Molecular evolution of breast cancer.	The Journal of pathology	2005	94
15818618	2064	Abd El-Rehim DM	High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses.	International journal of cancer	2005	106
15897907	2064	Farmer P	Identification of molecular apocrine breast tumours by microarray analysis.	Oncogene	2005	204
16000569	2064	De Laurentiis M	A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.	Clinical cancer research 	2005	73
16019138	2064	Chen DC	Serum adiponectin and leptin levels in Taiwanese breast cancer patients.	Cancer letters	2006	84
16088978	2064	Kirkegaard T	AKT activation predicts outcome in breast cancer patients treated with tamoxifen.	The Journal of pathology	2005	74
16115903	2064	Rouzier R	Breast cancer molecular subtypes respond differently to preoperative chemotherapy.	Clinical cancer research 	2005	346
16148022	2064	Goldhirsch A	Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.	Annals of oncology 	2005	137
16166438	2064	Press MF	Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.	Clinical cancer research 	2005	69
16192626	2064	Weil RJ	Breast cancer metastasis to the central nervous system.	The American journal of pathology	2005	94
16344916	2064	Salvucci O	The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.	Breast cancer research and treatment	2006	67
16368942	2064	McCabe A	Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis.	Journal of the National Cancer Institute	2005	77
16404427	2064	Arnould L	Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?	British journal of cancer	2006	109
16603601	2064	Pestalozzi BC	Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).	Annals of oncology 	2006	69
16611412	2064	Ghebeh H	The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.	Neoplasia	2006	129
16682622	2064	Xia W	A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2006	110
16682724	2064	Linden HM	Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.	Journal of clinical oncology 	2006	65
16683005	2064	Nahta R	Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.	Nature clinical practice. Oncology	2006	220
16782917	2064	Robert N	Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.	Journal of clinical oncology 	2006	94
16809727	2064	Perez EA	HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.	Journal of clinical oncology 	2006	84
16846532	2064	Calza S	Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients.	Breast cancer research 	2006	81
16868827	2064	Park DI	HER-2/neu amplification is an independent prognostic factor in gastric cancer.	Digestive diseases and sciences	2006	70
17085646	2064	Filardo EJ	Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression.	Clinical cancer research 	2006	97
17116942	2064	Haffty BG	Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.	Journal of clinical oncology 	2006	205
17157792	2064	Chin K	Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.	Cancer cell	2006	472
17159499	2064	Stemmler HJ	Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.	Anti-cancer drugs	2007	57
17332353	2064	Huang F	Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection.	Cancer research	2007	101
17347129	2064	Chapman C	Autoantibodies in breast cancer: their use as an aid to early diagnosis.	Annals of oncology 	2007	62
17363517	2064	Lin NU	Brain metastases: the HER2 paradigm.	Clinical cancer research 	2007	81
17377838	2064	Soerjomataram I	An overview of prognostic factors for long-term survivors of breast cancer.	Breast cancer research and treatment	2008	84
17409397	2064	Pick E	High HSP90 expression is associated with decreased survival in breast cancer.	Cancer research	2007	73
17438091	2064	Carey LA	The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.	Clinical cancer research 	2007	429
17470737	2064	Arpino G	Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.	Journal of the National Cancer Institute	2007	58
17530017	2064	Nahta R	Trastuzumab: triumphs and tribulations.	Oncogene	2007	77
17606733	2064	Marangoni E	A new model of patient tumor-derived breast cancer xenografts for preclinical assays.	Clinical cancer research 	2007	106
17620276	2064	Morris GJ	Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database.	Cancer	2007	132
17671126	2064	Dent R	Triple-negative breast cancer: clinical features and patterns of recurrence.	Clinical cancer research 	2007	677
17686164	2064	Viani GA	Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.	BMC cancer	2007	74
17967430	2064	Ahmed KM	NF-kappa B-mediated adaptive resistance to ionizing radiation.	Free radical biology and medicine	2008	56
18037158	2064	Tomsová M	Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.	Gynecologic oncology	2008	60
18048329	2064	Gupta GP	ID genes mediate tumor reinitiation during breast cancer lung metastasis.	Proceedings of the National Academy of Sciences of the United States of America	2007	89
18089790	2064	Sempere LF	Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer.	Cancer research	2007	204
18159072	2064	Gennari A	HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.	Journal of the National Cancer Institute	2008	68
18223211	2064	Allred DC	Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution.	Clinical cancer research 	2008	91
18227529	2064	Dowsett M	Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.	Journal of clinical oncology 	2008	80
18250347	2064	Liedtke C	Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.	Journal of clinical oncology 	2008	411
18285604	2064	Kyndi M	Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.	Journal of clinical oncology 	2008	79
18297396	2064	Lu X	Predicting features of breast cancer with gene expression patterns.	Breast cancer research and treatment	2008	83
18316611	2064	Shattuck DL	Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells.	Cancer research	2008	112
18339869	2064	Yamaguchi N	NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells.	Cancer research	2008	54
18398844	2064	Bertucci F	How basal are triple-negative breast cancers?	International journal of cancer	2008	112
18413639	2064	Nguyen PL	Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.	Journal of clinical oncology 	2008	147
18422971	2064	Hofmann M	Assessment of a HER2 scoring system for gastric cancer: results from a validation study.	Histopathology	2008	202
18441328	2064	Gravalos C	HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.	Annals of oncology 	2008	179
18455127	2064	Stoecklein NH	Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer.	Cancer cell	2008	56
18469855	2064	Osipo C	ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.	Oncogene	2008	59
18487574	2064	Rakha EA	Basal-like breast cancer: a critical review.	Journal of clinical oncology 	2008	213
18505968	2064	Martín M	Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.	Journal of the National Cancer Institute	2008	51
18543098	2064	Dent R	Pattern of metastatic spread in triple-negative breast cancer.	Breast cancer research and treatment	2009	79
18591932	2064	Korkaya H	HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion.	Oncogene	2008	203
18592370	2064	Jones RL	The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer.	Breast cancer research and treatment	2009	49
18625725	2064	Wang SE	Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab.	Molecular and cellular biology	2008	61
18698033	2064	Desmedt C	Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.	Clinical cancer research 	2008	223
18720457	2064	Weigelt B	Refinement of breast cancer classification by molecular characterization of histological special types.	The Journal of pathology	2008	100
18841463	2064	Tan AR	Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?	Breast cancer research and treatment	2009	48
18973228	2064	Ferretti E	MicroRNA profiling in human medulloblastoma.	International journal of cancer	2009	85
19001334	2064	Chia S	Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.	Journal of clinical oncology 	2008	52
19005469	2064	Hurtado A	Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen.	Nature	2008	96
19074892	2064	Law JH	Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.	Cancer research	2008	112
19116383	2064	Sieuwerts AM	Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells.	Journal of the National Cancer Institute	2009	131
19156142	2064	Barros-Silva JD	Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients.	British journal of cancer	2009	50
19179558	2064	Blackwell KL	Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.	Annals of oncology 	2009	48
19204205	2064	Hugh J	Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.	Journal of clinical oncology 	2009	107
19204209	2064	Sauter G	Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.	Journal of clinical oncology 	2009	106
19218427	2064	Ben-Kasus T	Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis.	Proceedings of the National Academy of Sciences of the United States of America	2009	58
19266279	2064	Chen DT	Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue.	Breast cancer research and treatment	2010	58
19276373	2064	Iorio MV	microRNA-205 regulates HER3 in human breast cancer.	Cancer research	2009	112
19289619	2064	von Minckwitz G	Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.	Journal of clinical oncology 	2009	134
19318578	2064	Neal CL	14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival.	Cancer research	2009	55
19320967	2064	Stead LA	Triple-negative breast cancers are increased in black women regardless of age or body mass index.	Breast cancer research 	2009	74
19366799	2064	Elsheikh SE	Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome.	Cancer research	2009	76
19380452	2064	Penault-Llorca F	Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.	Journal of clinical oncology 	2009	49
19436038	2064	Cheang MC	Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.	Journal of the National Cancer Institute	2009	409
19562338	2064	Reuschenbach M	A systematic review of humoral immune responses against tumor antigens.	Cancer immunology, immunotherapy 	2009	60
19574486	2064	Onitilo AA	Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival.	Clinical medicine and research	2009	153
19589136	2064	Aktas B	Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients.	Breast cancer research 	2009	184
19596702	2064	Liedtke C	Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.	Annals of oncology 	2009	69
19597704	2064	Pestrin M	Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.	Breast cancer research and treatment	2009	56
19617568	2064	Ponzo MG	Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2009	76
19633047	2064	Kataoka Y	Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.	Annals of oncology 	2010	56
19664291	2064	Fehm T	Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells.	Breast cancer research 	2009	59
19668225	2064	Zhao YH	Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth.	Oncogene	2009	51
19671800	2064	Liu L	Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.	Cancer research	2009	114
19687332	2064	Ellard SL	Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.	Journal of clinical oncology 	2009	55
19720923	2064	Disis ML	Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.	Journal of clinical oncology 	2009	78
19732720	2064	Lu J	14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition.	Cancer cell	2009	70
19735549	2064	Behbod F	An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ.	Breast cancer research 	2009	60
19764994	2064	Parise CA	Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.	The breast journal	2009	68
19786670	2064	Kaufman B	Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.	Journal of clinical oncology 	2009	136
19858088	2064	Aitken SJ	Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases.	Annals of oncology 	2010	40
19884543	2064	Gonzalez-Angulo AM	High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.	Journal of clinical oncology 	2009	66
19884557	2064	Joensuu H	Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.	Journal of clinical oncology 	2009	85
19887463	2064	Park S	Expression of androgen receptors in primary breast cancer.	Annals of oncology 	2010	67
19917839	2064	Spielmann M	Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.	Journal of clinical oncology 	2009	56
19933921	2064	Dawood S	Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.	Journal of clinical oncology 	2010	128
20068073	2064	Ahmed N	HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.	Clinical cancer research 	2010	72
20113825	2064	Gianni L	Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.	Lancet	2010	165
20124182	2064	Baselga J	Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.	Journal of clinical oncology 	2010	135
20124187	2064	Blackwell KL	Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.	Journal of clinical oncology 	2010	176
20181526	2064	Weigelt B	Breast cancer molecular profiling with single sample predictors: a retrospective analysis.	The Lancet. Oncology	2010	97
20208134	2064	Grabsch H	HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series.	Cellular oncology 	2010	63
20231686	2064	Staaf J	Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.	Journal of clinical oncology 	2010	54
20308670	2064	Untch M	Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.	Journal of clinical oncology 	2010	88
20339913	2064	Barrios CH	Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.	Breast cancer research and treatment	2010	50
20348949	2064	Bafna S	Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells.	Oncogene	2010	95
20371474	2064	Amin DN	Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.	Science translational medicine	2010	63
20406831	2064	Riethdorf S	Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial.	Clinical cancer research 	2010	104
20410336	2064	Shah MA	Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease.	Journal of the National Comprehensive Cancer Network 	2010	48
20421541	2064	Krop IE	Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.	Journal of clinical oncology 	2010	102
20436504	2064	Schnitt SJ	Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy.	Modern pathology 	2010	66
20484419	2064	Baum RP	Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules.	Journal of nuclear medicine 	2010	57
20498394	2064	Kennecke H	Metastatic behavior of breast cancer subtypes.	Journal of clinical oncology 	2010	290
20498403	2064	Miles DW	Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.	Journal of clinical oncology 	2010	187
20535745	2064	Toullec A	Oxidative stress promotes myofibroblast differentiation and tumour spreading.	EMBO molecular medicine	2010	65
20537966	2064	Podo F	Triple-negative breast cancer: present challenges and new perspectives.	Molecular oncology	2010	61
20576095	2064	Jönsson G	Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics.	Breast cancer research 	2010	65
20629078	2064	Stark A	African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study.	Cancer	2010	50
20647302	2064	Weigel MT	Current and emerging biomarkers in breast cancer: prognosis and prediction.	Endocrine-related cancer	2010	89
20665045	2064	Rüschoff J	HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing.	Virchows Archiv 	2010	85
20697084	2064	Perez EA	HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.	Journal of clinical oncology 	2010	51
20697801	2064	Huober J	Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.	Breast cancer research and treatment	2010	44
20711231	2064	Arias-Romero LE	A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells.	Oncogene	2010	52
20730488	2064	Junttila TT	Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.	Breast cancer research and treatment	2011	61
20832293	2064	Dedes KJ	Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer.	European journal of cancer	2011	44
20837693	2064	Nielsen TO	A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.	Clinical cancer research 	2010	165
20859679	2064	Fehm T	HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.	Breast cancer research and treatment	2010	74
20861225	2064	Toft DJ	Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies.	Molecular endocrinology	2011	38
20863372	2064	Hoefnagel LD	Receptor conversion in distant breast cancer metastases.	Breast cancer research 	2010	49
20876285	2064	Cittelly DM	Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors.	Carcinogenesis	2010	50
20877296	2064	Carey L	Triple-negative breast cancer: disease entity or title of convenience?	Nature reviews. Clinical oncology	2010	180
21057787	2064	Groheux D	Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.	European journal of nuclear medicine and molecular imaging	2011	39
21059212	2064	Thompson AM	Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).	Breast cancer research 	2010	59
21109570	2064	Tamura K	FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer.	Annals of oncology 	2011	41
21115860	2064	Valero V	Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.	Journal of clinical oncology 	2011	43
21147047	2064	Prat A	Deconstructing the molecular portraits of breast cancer.	Molecular oncology	2011	261
21172893	2064	Burris HA 3rd	Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.	Journal of clinical oncology 	2011	115
21191116	2064	Iwamoto T	Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.	Journal of the National Cancer Institute	2011	64
21204711	2064	Gutierrez C	HER2: biology, detection, and clinical implications.	Archives of pathology and laboratory medicine	2011	50
21264346	2064	Ignatiadis M	HER2-positive circulating tumor cells in breast cancer.	PloS one	2011	50
21270527	2064	Radojicic J	MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer.	Cell cycle	2011	72
21298334	2064	Raimondi C	Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients.	Breast cancer research and treatment	2011	72
21310941	2064	Al-Ejeh F	Breast cancer stem cells: treatment resistance and therapeutic opportunities.	Carcinogenesis	2011	36
21342044	2064	Gajria D	HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.	Expert review of anticancer therapy	2011	73
21354370	2064	Gianni L	Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.	The Lancet. Oncology	2011	107
21356373	2064	Conklin MW	Aligned collagen is a prognostic signature for survival in human breast carcinoma.	The American journal of pathology	2011	192
21368164	2064	Chakrabarty A	Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.	Proceedings of the National Academy of Sciences of the United States of America	2012	116
21373875	2064	Glück S	TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.	Breast cancer research and treatment	2012	58
21376385	2064	Cortes J	Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.	Lancet	2011	129
21387260	2064	Lara-Medina F	Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity.	Cancer	2011	41
21422418	2064	Desmedt C	Multifactorial approach to predicting resistance to anthracyclines.	Journal of clinical oncology 	2011	43
21437909	2064	Ladoire S	In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival.	The Journal of pathology	2011	47
21469140	2064	Andreopoulou E	Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system.	International journal of cancer	2012	43
21497451	2064	Sperduto PW	Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases.	International journal of radiation oncology, biology, physics	2012	37
21501481	2064	Kao KJ	Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization.	BMC cancer	2011	74
21505063	2064	Sieuwerts AM	mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients.	Clinical cancer research 	2011	59
21509760	2064	Musolino A	Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.	Cancer	2011	35
21555689	2064	Ellis MJ	Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.	Journal of clinical oncology 	2011	82
21558407	2064	Modi S	HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.	Clinical cancer research 	2011	100
21562709	2064	Ono M	Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.	Breast cancer research and treatment	2012	53
21671017	2064	Harrell JC	Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse.	Breast cancer research and treatment	2012	73
21699723	2064	Giuliano M	Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.	Breast cancer research 	2011	42
21709140	2064	Goldhirsch A	Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.	Annals of oncology 	2011	560
21709195	2064	Begnami MD	Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.	Journal of clinical oncology 	2011	61
21717105	2064	Liu F	CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes.	Breast cancer research and treatment	2011	42
21768129	2064	Brufsky AM	Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.	Clinical cancer research 	2011	52
21788566	2064	Untch M	Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.	Journal of clinical oncology 	2011	65
21795664	2064	Yaghjyan L	Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics.	Journal of the National Cancer Institute	2011	41
21807638	2064	Filipits M	A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.	Clinical cancer research 	2011	79
21847123	2064	Pandya K	Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence.	British journal of cancer	2011	45
21859480	2064	Li J	A nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China.	BMC cancer	2011	41
21862872	2064	Liu B	Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.	Cell cycle	2011	38
21884641	2064	Holliday DL	Choosing the right cell line for breast cancer research.	Breast cancer research 	2011	189
21900114	2064	Arvold ND	Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy.	Journal of clinical oncology 	2011	54
21908711	2064	Kristensen VN	Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling.	Proceedings of the National Academy of Sciences of the United States of America	2012	62
21965473	2064	Giordano A	Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy.	Annals of oncology 	2012	32
21990397	2064	Brufsky AM	RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.	Journal of clinical oncology 	2011	82
22049225	2064	Mahmoud SM	Tumour-infiltrating macrophages and clinical outcome in breast cancer.	Journal of clinical pathology	2012	43
22124109	2064	Niikura N	Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors.	Journal of clinical oncology 	2012	67
22149875	2064	Baselga J	Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.	The New England journal of medicine	2012	394
22153890	2064	Gianni L	Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2012	239
22178456	2064	Amir E	Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies.	Cancer treatment reviews	2012	32
22222640	2064	Rüschoff J	HER2 testing in gastric cancer: a practical approach.	Modern pathology 	2012	80
22248472	2064	McDonagh CF	Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.	Molecular cancer therapeutics	2012	70
22257523	2064	Untch M	Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.	The Lancet. Oncology	2012	65
22257673	2064	Baselga J	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.	Lancet	2012	207
22264265	2064	Kasimir-Bauer S	Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells.	Breast cancer research 	2012	66
22276821	2064	Bear HD	Bevacizumab added to neoadjuvant chemotherapy for breast cancer.	The New England journal of medicine	2012	94
22331459	2064	Stevens KN	19p13.1 is a triple-negative-specific breast cancer susceptibility locus.	Cancer research	2012	44
22331954	2064	Bergh J	First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.	Journal of clinical oncology 	2012	53
22370716	2064	Jung EJ	Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients.	Cancer	2012	61
22377126	2064	Pierga JY	Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.	The Lancet. Oncology	2012	31
22388088	2064	Aceto N	Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.	Nature medicine	2012	65
22388760	2064	Seol H	Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance.	Modern pathology 	2012	36
22393084	2064	Cortés J	Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.	Journal of clinical oncology 	2012	52
22400902	2064	Wu X	De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer.	Journal of translational medicine	2012	46
22407832	2064	García-García C	Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.	Clinical cancer research 	2012	49
22412143	2064	Baselga J	Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.	Journal of clinical oncology 	2012	36
22461643	2064	Stern HM	Improving treatment of HER2-positive cancers: opportunities and challenges.	Science translational medicine	2012	42
22495314	2064	Shah SP	The clonal and mutational evolution spectrum of primary triple-negative breast cancers.	Nature	2012	499
22508812	2064	von Minckwitz G	Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.	Journal of clinical oncology 	2012	250
22513938	2064	Moja L	Trastuzumab containing regimens for early breast cancer.	The Cochrane database of systematic reviews	2012	73
22544643	2064	Lin NU	Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.	Cancer	2012	50
22565002	2064	Bachelot T	Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.	Journal of clinical oncology 	2012	120
22586653	2064	Bertotti A	A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.	Cancer discovery	2011	125
22649126	2064	Krop IE	A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.	Journal of clinical oncology 	2012	58
22665540	2064	Ebb D	Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group.	Journal of clinical oncology 	2012	41
22677156	2064	Lucci A	Circulating tumour cells in non-metastatic breast cancer: a prospective study.	The Lancet. Oncology	2012	96
22689179	2064	Janjigian YY	Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.	Annals of oncology 	2012	46
22689798	2064	Chlebowski RT	Diabetes, metformin, and breast cancer in postmenopausal women.	Journal of clinical oncology 	2012	48
22689807	2064	Blackwell KL	Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.	Journal of clinical oncology 	2012	105
22711706	2064	Chia SK	A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen.	Clinical cancer research 	2012	48
22761469	2064	Arcila ME	Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.	Clinical cancer research 	2012	53
22773826	2064	Clarke CA	Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.	Journal of the National Cancer Institute	2012	54
22817698	2064	Byrski T	Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.	Breast cancer research 	2012	36
22884505	2064	Ismael G	Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.	The Lancet. Oncology	2012	40
22894854	2064	Müller V	Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.	Breast cancer research 	2012	35
22899400	2064	Anglesio MS	Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.	The Journal of pathology	2013	31
22967996	2064	Awada A	Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.	Annals of oncology 	2013	26
22973057	2064	Giordano A	Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.	Molecular cancer therapeutics	2012	58
22987084	2064	Romond EH	Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.	Journal of clinical oncology 	2012	60
23000189	2064	Park EJ	Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model.	Journal of controlled release 	2012	37
23020162	2064	Verma S	Trastuzumab emtansine for HER2-positive advanced breast cancer.	The New England journal of medicine	2012	381
23034170	2064	Ma C	Tumor-infiltrating γδ T lymphocytes predict clinical outcome in human breast cancer.	Journal of immunology	2012	37
23035882	2064	Bastien RR	PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.	BMC medical genomics	2012	64
23122784	2064	Bachelot T	Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.	The Lancet. Oncology	2013	72
23129208	2064	Bidard FC	Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials.	Cancer metastasis reviews	2013	61
23136233	2064	Eiermann W	The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.	Annals of oncology 	2013	30
23139264	2064	Warneke VS	Her2/neu testing in gastric cancer: evaluating the risk of sampling errors.	Annals of oncology 	2013	27
23220880	2064	Bose R	Activating HER2 mutations in HER2 gene amplification negative breast cancer.	Cancer discovery	2013	135
23233704	2064	Prat A	Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.	Journal of clinical oncology 	2013	87
23246022	2064	Mackey JR	Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.	The Lancet. Oncology	2013	41
23271327	2064	Wallwiener M	The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.	Breast cancer research and treatment	2013	27
23302230	2064	Alkins R	Focused ultrasound delivers targeted immune cells to metastatic brain tumors.	Cancer research	2013	32
23341518	2064	Loi S	Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.	Journal of clinical oncology 	2013	199
23382472	2064	Hurvitz SA	Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.	Journal of clinical oncology 	2013	69
23396049	2064	Van Laere SJ	Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets.	Clinical cancer research 	2013	28
23422754	2064	Miles DW	Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.	British journal of cancer	2013	34
23436929	2064	O'Toole SA	Therapeutic targets in triple negative breast cancer.	Journal of clinical pathology	2013	37
23442322	2064	Ithimakin S	HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.	Cancer research	2013	55
23475636	2064	Swain SM	Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.	The oncologist	2013	28
23519125	2064	Wang S	Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells.	Cell death and disease	2013	26
23569311	2064	Gianni L	AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.	Journal of clinical oncology 	2013	46
23593079	2064	Lee HJ	Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients.	Journal of breast cancer	2013	26
23602601	2064	Swain SM	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.	The Lancet. Oncology	2013	145
23610105	2064	Mazières J	Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.	Journal of clinical oncology 	2013	82
23627572	2064	Müller BM	Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression.	BMC cancer	2013	35
23650412	2064	Perez EA	Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.	Journal of clinical oncology 	2013	35
23667204	2064	Ajani JA	Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines.	Journal of the National Comprehensive Cancer Network 	2013	103
23737486	2064	Zhang X	A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models.	Cancer research	2013	71
23738752	2064	Chen WC	Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor.	Histopathology	2013	31
23748853	2064	Eichelser C	Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression.	Clinical chemistry	2013	35
23756627	2064	Muenst S	The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer.	Breast cancer research and treatment	2013	49
23757357	2064	Sessa C	First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors.	Clinical cancer research 	2013	33
23807776	2064	Hanna WM	HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.	Modern pathology 	2014	31
23901018	2064	Engstrøm MJ	Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients.	Breast cancer research and treatment	2013	32
23965851	2064	Cufí S	The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in HER2-positive breast cancer.	Scientific reports	2013	27
23970015	2064	Denkert C	Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.	Annals of oncology 	2013	28
24002511	2064	von Minckwitz G	Response-guided neoadjuvant chemotherapy for breast cancer.	Journal of clinical oncology 	2013	32
24029656	2064	Tamura K	64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer.	Journal of nuclear medicine 	2013	32
24041156	2064	Singh JK	Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells.	Breast cancer research 	2013	34
24056965	2064	Nair R	c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer.	Oncogene	2014	32
24080156	2064	Kümler I	A systematic review of dual targeting in HER2-positive breast cancer.	Cancer treatment reviews	2014	33
24095300	2064	Robidoux A	Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2013	54
24099077	2064	Wolff AC	Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.	Archives of pathology and laboratory medicine	2014	99
24101045	2064	Wolff AC	Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.	Journal of clinical oncology 	2013	434
24130112	2064	Walsh AJ	Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer.	Cancer research	2013	43
24148764	2064	Leivonen SK	High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth.	Molecular oncology	2014	39
24157828	2064	Dubsky P	The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.	British journal of cancer	2013	35
24162158	2064	Prat A	Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.	Breast cancer research and treatment	2013	48
24239210	2064	Buzdar AU	Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.	The Lancet. Oncology	2013	27
24269135	2064	Aurilio G	A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases.	European journal of cancer	2014	26
24297508	2064	Chung SS	STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits.	International journal of oncology	2014	30
24298071	2064	Lin NU	CNS metastases in breast cancer: old challenge, new frontiers.	Clinical cancer research 	2013	33
24337597	2064	Auvinen P	Hyaluronan synthases (HAS1-3) in stromal and malignant cells correlate with breast cancer grade and predict patient survival.	Breast cancer research and treatment	2014	20
24337604	2064	Mortimer JE	Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.	Journal of nuclear medicine 	2014	28
24360619	2064	Figueroa-Magalhães MC	Treatment of HER2-positive breast cancer.	Breast	2014	21
24443618	2064	Prat A	Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study.	Clinical cancer research 	2014	23
24448237	2064	Almendro V	Genetic and phenotypic diversity in breast tumor metastases.	Cancer research	2014	39
24463450	2064	Santagata S	Taxonomy of breast cancer based on normal cell phenotype predicts outcome.	The Journal of clinical investigation	2014	55
24470511	2064	Saura C	Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.	Clinical cancer research 	2014	25
24477977	2064	Anderson KN	Reproductive risk factors and breast cancer subtypes: a review of the literature.	Breast cancer research and treatment	2014	47
24480556	2064	Bianchini G	The immune system and response to HER2-targeted treatment in breast cancer.	The Lancet. Oncology	2014	29
24521995	2064	Sweeney C	Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.	Cancer epidemiology, biomarkers and prevention 	2014	24
24523301	2064	Gross MI	Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.	Molecular cancer therapeutics	2014	85
24529560	2064	Cortazar P	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.	Lancet	2014	220
24532163	2064	Dirican A	Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer?	International journal of clinical oncology	2015	20
24569463	2064	Yoshida T	Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.	British journal of cancer	2014	36
24608200	2064	Loi S	Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.	Annals of oncology 	2014	129
24657003	2064	Gianni L	Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.	The Lancet. Oncology	2014	35
24665085	2064	Sörensen J	First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule.	Journal of nuclear medicine 	2014	36
24721646	2064	Chittaranjan S	Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer.	Clinical cancer research 	2014	22
24722644	2064	Soussan M	Relationship between tumor heterogeneity measured on FDG-PET/CT and pathological prognostic factors in invasive breast cancer.	PloS one	2014	30
24727284	2064	Geng SQ	Breast cancer stem cells: Multiple capacities in tumor metastasis.	Cancer letters	2014	22
24739973	2064	Godinho SA	Oncogene-like induction of cellular invasion from centrosome amplification.	Nature	2014	60
24794243	2064	von Minckwitz G	Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.	The Lancet. Oncology	2014	77
24799465	2064	Giordano SH	Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.	Journal of clinical oncology 	2014	45
24842267	2064	Muenst S	Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer.	Breast cancer research and treatment	2014	78
24868024	2064	Satoh T	Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.	Journal of clinical oncology 	2014	79
24887180	2064	Barok M	Trastuzumab emtansine: mechanisms of action and drug resistance.	Breast cancer research 	2014	31
24912899	2064	de Azambuja E	Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).	Journal of clinical oncology 	2014	31
24915873	2064	Ali HR	Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.	Annals of oncology 	2014	49
24960601	2064	Choi W	Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.	Nature reviews. Urology	2014	30
24967588	2064	Ferrari N	Expression of RUNX1 correlates with poor patient prognosis in triple negative breast cancer.	PloS one	2014	20
25038874	2064	Van Cutsem E	HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.	Gastric cancer 	2015	23
25049332	2064	Ades F	Luminal B breast cancer: molecular characterization, clinical management, and future perspectives.	Journal of clinical oncology 	2014	51
25086636	2064	Müller V	Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.	Breast cancer research and treatment	2014	25
25130998	2064	de Azambuja E	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.	The Lancet. Oncology	2014	44
25185096	2064	Partridge AH	Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.	Journal of clinical oncology 	2014	33
25185099	2064	Mackey JR	Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.	Journal of clinical oncology 	2015	17
25224496	2064	Palmer JR	Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium.	Journal of the National Cancer Institute	2014	34
25273342	2064	von Minckwitz G	Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2014	24
25358515	2064	Polzer B	Molecular profiling of single circulating tumor cells with diagnostic intention.	EMBO molecular medicine	2014	45
25373520	2064	Schönfeld K	Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.	Molecular therapy 	2015	30
25559818	2064	Majewski IJ	PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.	Journal of clinical oncology 	2015	38
25605838	2064	Pivot X	CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.	Journal of clinical oncology 	2015	19
25605862	2064	Kaufman PA	Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.	Journal of clinical oncology 	2015	45
25636205	2064	Groenendijk FH	ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.	European urology	2016	15
25682074	2064	Wong-Brown MW	Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.	Breast cancer research and treatment	2015	17
25693012	2064	Swain SM	Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.	The New England journal of medicine	2015	132
25713166	2064	Ng CK	Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights.	Journal of the National Cancer Institute	2015	20
25805799	2064	Basu B	First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.	Clinical cancer research 	2015	21
25825511	2064	Kohler BA	Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State.	Journal of the National Cancer Institute	2015	103
25825707	2064	Tang H	Decreased &lt;i&gt;BECN1&lt;/i&gt; mRNA Expression in Human Breast Cancer is Associated with Estrogen Receptor-Negative Subtypes and Poor Prognosis.	EBioMedicine	2015	19
25847929	2064	Telli ML	Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.	Journal of clinical oncology 	2015	27
25849106	2064	McCart Reed AE	Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics.	Breast cancer research 	2015	19
25895611	2064	Zardavas D	Clinical management of breast cancer heterogeneity.	Nature reviews. Clinical oncology	2015	34
25896973	2064	Chantrill LA	Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial.	Clinical cancer research 	2015	25
25918288	2064	Shah MA	Update on metastatic gastric and esophageal cancers.	Journal of clinical oncology 	2015	19
25939896	2064	Coates AS	Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.	Annals of oncology 	2015	139
25959051	2064	Acerbi I	Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration.	Integrative biology 	2015	45
25995301	2064	Dieci MV	Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.	Annals of oncology 	2015	21
26092818	2064	Hurvitz SA	Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.	The Lancet. Oncology	2015	41
26093818	2064	Mazel M	Frequent expression of PD-L1 on circulating breast cancer cells.	Molecular oncology	2015	23
26181252	2064	Salgado R	Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.	JAMA oncology	2015	37
26211827	2064	Early Breast Cancer Trialists' Collaborative Group (EBCTCG).	Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.	Lancet	2015	34
26253814	2064	Prat A	Clinical implications of the intrinsic molecular subtypes of breast cancer.	Breast	2015	32
26317899	2064	Barrett MT	Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.	Oncotarget	2015	19
26422389	2064	Nuciforo P	High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.	Molecular oncology	2016	11
26469139	2064	Perez EA	Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.	JAMA oncology	2016	12
26530965	2064	Murtaza M	Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.	Nature communications	2015	33
26549855	2064	Sun J	A potential prognostic long non-coding RNA signature to predict metastasis-free survival of breast cancer patients.	Scientific reports	2015	24
26578779	2064	Tolaney SM	Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.	Proceedings of the National Academy of Sciences of the United States of America	2015	19
26598540	2064	Pruneri G	Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer.	Annals of oncology 	2016	12
26598744	2064	Piccart-Gebhart M	Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.	Journal of clinical oncology 	2016	17
26598746	2064	Levine MN	Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.	Journal of clinical oncology 	2016	12
26628478	2064	Hecht JR	Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.	Journal of clinical oncology 	2016	58
26667975	2064	Savas P	Clinical relevance of host immunity in breast cancer: from TILs to the clinic.	Nature reviews. Clinical oncology	2016	32
26855592	2064	Xu H	Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis.	OncoTargets and therapy	2016	12
26858339	2064	Harris LN	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.	Journal of clinical oncology 	2016	34
26869049	2064	Untch M	Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.	The Lancet. Oncology	2016	17
26874951	2064	Shoda K	Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer.	Gastric cancer 	2017	6
26928228	2064	Dunning AM	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.	Nature genetics	2016	12
26995633	2064	Yang SX	New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.	Cancer treatment reviews	2016	15
27108243	2064	Sartore-Bianchi A	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2016	32
27156933	2064	Van Cutsem E	Gastric cancer.	Lancet	2016	35
9371488	2099	Clarke RB	Dissociation between steroid receptor expression and cell proliferation in the human breast.	Cancer research	1997	155
9662379	2099	Kononen J	Tissue microarrays for high-throughput molecular profiling of tumor specimens.	Nature medicine	1998	753
11289127	2099	Roger P	Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.	Cancer research	2001	91
11438457	2099	Leav I	Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma.	The American journal of pathology	2001	90
11929836	2099	Stabile LP	Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen.	Cancer research	2002	101
12743151	2099	Bardou VJ	Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.	Journal of clinical oncology 	2003	115
15221988	2099	Giordano SH	Breast carcinoma in men: a population-based study.	Cancer	2004	103
15223047	2099	Dontu G	Breast cancer, stem/progenitor cells and the estrogen receptor.	Trends in endocrinology and metabolism	2004	90
15310774	2099	Fink AK	Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer.	Journal of clinical oncology 	2004	72
15342389	2099	Kubo M	Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer.	Cancer research	2004	103
15591335	2099	Paik S	A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.	The New England journal of medicine	2004	1227
15897552	2099	Mamounas EP	Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.	Journal of clinical oncology 	2005	98
15899795	2099	Dai H	A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients.	Cancer research	2005	89
16478745	2099	Sotiriou C	Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.	Journal of the National Cancer Institute	2006	534
16609087	2099	Berry DA	Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.	JAMA	2006	137
16954471	2099	Buyse M	Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.	Journal of the National Cancer Institute	2006	242
16980581	2099	Eeckhoute J	A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer.	Genes and development	2006	100
17113977	2099	Russo J	The role of estrogen in the initiation of breast cancer.	The Journal of steroid biochemistry and molecular biology	2006	72
17135638	2099	Bates GJ	Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.	Journal of clinical oncology 	2006	214
17372279	2099	Tworoger SS	A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer.	Journal of clinical oncology 	2007	61
17417639	2099	Holst F	Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.	Nature genetics	2007	75
17586727	2099	Sasser AK	Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer.	FASEB journal 	2007	60
17652280	2099	Glass AG	Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.	Journal of the National Cancer Institute	2007	93
18071188	2099	Owusu C	Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer.	Journal of clinical oncology 	2008	74
18347134	2099	Sun M	Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells.	Molecular cancer therapeutics	2008	104
18443585	2099	Ben-Porath I	An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors.	Nature genetics	2008	775
18505969	2099	Setlur SR	Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.	Journal of the National Cancer Institute	2008	106
18509175	2099	Azim AA	Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.	Journal of clinical oncology 	2008	72
18515733	2099	Ross JS	Commercialized multigene predictors of clinical outcome for breast cancer.	The oncologist	2008	52
18574464	2099	Ramsay RG	MYB function in normal and cancer cells.	Nature reviews. Cancer	2008	146
18593897	2099	Kondo N	miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer.	Cancer research	2008	97
18593923	2099	Rizzo P	Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches.	Cancer research	2008	103
19027010	2099	Liu WH	MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells.	Gastroenterology	2009	63
19112174	2099	Yamnik RL	S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation.	The Journal of biological chemistry	2009	58
19116762	2099	Toh Y	The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications.	Clinical and experimental metastasis	2009	63
19275906	2099	Solomon MB	Sex differences in psychopathology: of gonads, adrenals and mental illness.	Physiology and behavior	2009	60
19317994	2099	Gnerlich JL	Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease.	Journal of the American College of Surgeons	2009	61
19487384	2099	Shi L	Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer.	Journal of clinical oncology 	2009	48
19567422	2099	Milne RL	Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042.	Journal of the National Cancer Institute	2009	52
19730444	2099	Spizzo R	miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells.	Cell death and differentiation	2010	76
20065188	2099	Mamounas EP	Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.	Journal of clinical oncology 	2010	67
20080637	2099	Lovén J	MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma.	Proceedings of the National Academy of Sciences of the United States of America	2010	44
20081107	2099	Rajkumar R	Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension.	American journal of physiology. Heart and circulatory physiology	2010	54
20104427	2099	Bulun SE	Estrogen receptor-beta, estrogen receptor-alpha, and progesterone resistance in endometriosis.	Seminars in reproductive medicine	2010	44
20663194	2099	Tuominen VJ	ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67.	Breast cancer research 	2010	123
20805453	2099	Bianchini G	Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.	Journal of clinical oncology 	2010	59
21123450	2099	Rhodes LV	Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.	Cancer research	2011	55
21362200	2099	Sanchez CG	Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.	Breast cancer research 	2011	46
21483002	2099	Mahmoud SM	Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.	Journal of clinical oncology 	2011	251
21846820	2099	Palmer JR	Parity and lactation in relation to estrogen receptor negative breast cancer in African American women.	Cancer epidemiology, biomarkers and prevention 	2011	50
21878914	2099	Kong SL	Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state.	Molecular systems biology	2011	49
22125492	2099	Magnani L	PBX1 genomic pioneer function drives ERα signaling underlying progression in breast cancer.	PLoS genetics	2011	47
22151962	2099	West NR	Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.	Breast cancer research 	2011	78
22301780	2099	Baumgarten SC	Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers.	Molecular endocrinology	2012	42
22986741	2099	Jerby L	Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer.	Cancer research	2012	30
23251644	2099	Budczies J	Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization.	PloS one	2012	122
23535733	2099	Garcia-Closas M	Genome-wide association studies identify four ER negative-specific breast cancer risk loci.	Nature genetics	2013	151
23690420	2099	Hughes KS	Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.	Journal of clinical oncology 	2013	65
23845444	2099	Vaillant F	Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer.	Cancer cell	2013	62
23965901	2099	Gucalp A	Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.	Clinical cancer research 	2013	86
23985562	2099	-	Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society.	Menopause	2013	47
24055055	2099	Li S	Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.	Cell reports	2013	117
24185510	2099	Robinson DR	Activating ESR1 mutations in hormone-resistant metastatic breast cancer.	Nature genetics	2013	157
24210818	2099	Wu Q	27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth.	Cell reports	2013	48
24217577	2099	Merenbakh-Lamin K	D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer.	Cancer research	2013	56
24273215	2099	Vera-Badillo FE	Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis.	Journal of the National Cancer Institute	2014	45
24343304	2099	Palmer JR	A collaborative study of the etiology of breast cancer subtypes in African American women: the AMBER consortium.	Cancer causes and control 	2014	24
24398047	2099	Jeselsohn R	Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.	Clinical cancer research 	2014	76
24451109	2099	Cochrane DR	Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.	Breast cancer research 	2014	46
24469049	2099	Cyr AR	TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis.	Oncogene	2015	18
24663045	2099	Mayer IA	Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.	Journal of clinical oncology 	2014	41
24858917	2099	Ohba K	In vivo and in vitro studies suggest a possible involvement of HPV infection in the early stage of breast carcinogenesis via APOBEC3B induction.	PloS one	2014	23
25013076	2099	Yu M	Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility.	Science	2014	133
25417601	2099	Schuler KM	Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer.	Cancer medicine	2015	20
25529635	2099	Glubb DM	Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1.	American journal of human genetics	2015	19
25855707	2099	Mavaddat N	Prediction of breast cancer risk based on profiling with common genetic variants.	Journal of the National Cancer Institute	2015	57
25879485	2099	Lai A	Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.	Journal of medicinal chemistry	2015	24
25979954	2099	Guttery DS	Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.	Clinical chemistry	2015	22
26124144	2099	Honda S	Sex hormone-dependent tRNA halves enhance cell proliferation in breast and prostate cancers.	Proceedings of the National Academy of Sciences of the United States of America	2015	24
26261103	2099	Chu D	ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.	Clinical cancer research 	2016	22
26317216	2099	Butler TM	Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease.	PloS one	2015	17
26500237	2099	Wang P	Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.	Clinical cancer research 	2016	22
26541326	2099	Baptista MZ	Prognostic significance of PD-L1 and PD-L2 in breast cancer.	Human pathology	2016	18
26563128	2099	Ma CX	A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.	Clinical cancer research 	2016	13
26947176	2099	Sflomos G	A Preclinical Model for ERα-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response.	Cancer cell	2016	14
27513155	2099	Giuliano AE	Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.	Annals of surgery	2016	14
27532364	2099	Chandarlapaty S	Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.	JAMA oncology	2016	18
14500907	2146	Kleer CG	EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.	Proceedings of the National Academy of Sciences of the United States of America	2003	463
16330673	2146	Bachmann IM	EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.	Journal of clinical oncology 	2006	183
16734726	2146	Matsukawa Y	Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer.	Cancer science	2006	65
16738054	2146	Shumaker DK	Mutant nuclear lamin A leads to progressive alterations of epigenetic control in premature aging.	Proceedings of the National Academy of Sciences of the United States of America	2006	189
18006806	2146	Yu J	A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.	Cancer research	2007	111
18176935	2146	Wei Y	Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.	Molecular carcinogenesis	2008	80
18430739	2146	Fujii S	Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation.	The Journal of biological chemistry	2008	66
19008416	2146	Varambally S	Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.	Science	2008	327
19079346	2146	Gonzalez ME	Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1.	Oncogene	2009	70
19351856	2146	Hussain M	Tobacco smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer cells.	Cancer research	2009	54
20946108	2146	Orzan F	Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.	Neuropathology and applied neurobiology	2011	38
20952513	2146	Zhang B	Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer.	Carcinogenesis	2011	63
21216927	2146	Rizzo S	Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2.	Molecular cancer therapeutics	2011	61
21270667	2146	Zhang JG	MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.	Journal of thoracic oncology 	2011	52
21321380	2146	Smits M	miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis.	Oncotarget	2010	76
21512140	2146	Cheng AS	EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.	Cancer research	2011	55
21672940	2146	Zheng F	The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.	Gut	2012	106
21685935	2146	Tong ZT	EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin.	Oncogene	2012	54
22086681	2146	Bao B	Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.	Cancer prevention research	2012	91
22108826	2146	Bao B	Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression.	Cancer research	2012	87
22237151	2146	Ntziachristos P	Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia.	Nature medicine	2012	127
22272343	2146	Shin YJ	The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells.	PloS one	2012	34
22370893	2146	Au SL	Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.	Hepatology	2012	62
22442719	2146	Kong D	Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM.	PloS one	2012	59
22505648	2146	Ren G	Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.	Cancer research	2012	60
22930729	2146	Börno ST	Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation.	Cancer discovery	2012	31
22948084	2146	Asangani IA	Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma.	Oncotarget	2012	45
22952749	2146	Bao B	Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF.	PloS one	2012	42
23354591	2146	Luo M	Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression.	Cancer letters	2013	117
23568486	2146	Ronan JL	From neural development to cognition: unexpected roles for chromatin.	Nature reviews. Genetics	2013	122
23764001	2146	Tiwari N	Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming.	Cancer cell	2013	82
24052547	2146	Bödör C	EZH2 mutations are frequent and represent an early event in follicular lymphoma.	Blood	2013	30
24097870	2146	Behrens C	EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.	Clinical cancer research 	2013	33
24211739	2146	Xu L	MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.	Journal of hepatology	2014	30
24516139	2146	Gonzalez ME	EZH2 expands breast stem cells through activation of NOTCH1 signaling.	Proceedings of the National Academy of Sciences of the United States of America	2014	37
24612432	2146	Liu L	Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.	BJU international	2016	17
25153722	2146	Konno Y	MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells.	Oncotarget	2014	46
25457180	2146	Bradley WD	EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.	Chemistry and biology	2014	31
25601206	2146	Kim SH	EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner.	Stem cell reports	2015	26
25644061	2146	Koumangoye RB	SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells.	Molecular cancer	2015	16
25653233	2146	Toden S	Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer.	Carcinogenesis	2015	17
25693145	2146	Zheng F	Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in vivo by repressing multiple targets.	PLoS genetics	2015	19
25762643	2146	Zheng M	Snail and Slug collaborate on EMT and tumor metastasis through miR-101-mediated EZH2 axis in oral tongue squamous cell carcinoma.	Oncotarget	2015	18
25965569	2146	Kim E	SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition.	Cancer cell	2015	49
26424790	2146	Dudakovic A	Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2.	The Journal of biological chemistry	2015	16
26501191	2146	Huang L	Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids.	Nature medicine	2015	19
26516927	2146	Wang D	LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer.	Oncotarget	2015	18
26523864	2146	Zhao E	Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction.	Nature immunology	2016	29
26755663	2146	Agarwal P	Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.	Oncotarget	2016	11
7664263	2247	Takahashi Y	Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.	Cancer research	1995	196
9214605	2247	Bello D	Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18.	Carcinogenesis	1997	126
12203386	2247	Ignatova TN	Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro.	Glia	2002	250
15166270	2247	Esposito I	Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma.	Journal of clinical pathology	2004	73
15749926	2247	Xu C	Basic fibroblast growth factor supports undifferentiated human embryonic stem cell growth without conditioned medium.	Stem cells	2005	75
16540670	2247	Xie TX	Activation of stat3 in human melanoma promotes brain metastasis.	Cancer research	2006	103
16697959	2247	Lee J	Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.	Cancer cell	2006	670
16762629	2247	Danese S	Angiogenesis as a novel component of inflammatory bowel disease pathogenesis.	Gastroenterology	2006	88
18323556	2247	Yao JC	Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.	Journal of clinical oncology 	2008	79
19197140	2247	Izikki M	Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents.	The Journal of clinical investigation	2009	49
19232461	2247	Qiang L	Isolation and characterization of cancer stem like cells in human glioblastoma cell lines.	Cancer letters	2009	55
20569691	2247	Buecker C	A murine ESC-like state facilitates transgenesis and homologous recombination in human pluripotent stem cells.	Cell stem cell	2010	75
20616342	2247	Johansson A	Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy.	The American journal of pathology	2010	43
20643952	2247	Evseenko D	Mapping the first stages of mesoderm commitment during differentiation of human embryonic stem cells.	Proceedings of the National Academy of Sciences of the United States of America	2010	65
21712446	2247	Sharpe R	FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo.	Clinical cancer research 	2011	38
22134360	2247	Xie G	IL-6-induced epithelial-mesenchymal transition promotes the generation of breast cancer stem-like cells analogous to mammosphere cultures.	International journal of oncology	2012	33
23060229	2247	Ellman MB	Fibroblast growth factor control of cartilage homeostasis.	Journal of cellular biochemistry	2013	28
23536707	2247	Terai H	Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC.	Molecular cancer research 	2013	41
23863927	2247	Katoh M	Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review).	International journal of molecular medicine	2013	27
24481949	2247	Ricard N	Increased pericyte coverage mediated by endothelial-derived fibroblast growth factor-2 and interleukin-6 is a source of smooth muscle-like cells in pulmonary hypertension.	Circulation	2014	23
24960162	2247	Bertero T	Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension.	The Journal of clinical investigation	2014	43
1279432	2321	Plate KH	Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.	Nature	1992	334
11734454	2321	Bhatt AJ	Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia.	American journal of respiratory and critical care medicine	2001	115
17550303	2321	Lee TH	Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1.	PLoS medicine	2007	87
18541897	2321	Cohen EE	Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.	Journal of clinical oncology 	2008	149
19597027	2321	Schiller JH	Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.	Journal of clinical oncology 	2009	45
19826113	2321	Matulonis UA	Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.	Journal of clinical oncology 	2009	55
19834490	2321	Zhang Z	VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2.	Cell death and differentiation	2010	50
20200024	2321	Iwamoto FM	Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).	Neuro-oncology	2010	43
20921924	2321	Hecht JL	Relationship Between Neonatal Blood Protein Concentrations and Placenta Histologic Characteristics in Extremely Low GA Newborns.	Pediatric research	2011	37
21212411	2321	Frank NY	VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth.	Cancer research	2011	49
21238986	2321	Leviton A	The relationship between early concentrations of 25 blood proteins and cerebral white matter injury in preterm newborns: the ELGAN study.	The Journal of pediatrics	2011	44
21306953	2321	Kindler HL	Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.	The Lancet. Oncology	2011	95
22159180	2321	Schwarzenberg J	3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab.	Journal of nuclear medicine 	2012	31
24019545	2321	Motzer RJ	Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.	Journal of clinical oncology 	2013	55
25218906	2321	Liu JF	Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.	The Lancet. Oncology	2014	58
1862087	2335	Broekelmann TJ	Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis.	Proceedings of the National Academy of Sciences of the United States of America	1991	161
2589440	2335	Roberts JM	Preeclampsia: an endothelial cell disorder.	American journal of obstetrics and gynecology	1989	178
9111868	2335	Naor D	CD44: structure, function, and association with the malignant process.	Advances in cancer research	1997	183
9520466	2335	Azizi SA	Engraftment and migration of human bone marrow stromal cells implanted in the brains of albino rats--similarities to astrocyte grafts.	Proceedings of the National Academy of Sciences of the United States of America	1998	136
10051240	2335	Salvi S	Acute inflammatory responses in the airways and peripheral blood after short-term exposure to diesel exhaust in healthy human volunteers.	American journal of respiratory and critical care medicine	1999	168
10353737	2335	Brown LF	Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast.	Clinical cancer research 	1999	96
12235007	2335	Gillan L	Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility.	Cancer research	2002	147
12451003	2335	Tepper OM	Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures.	Circulation	2002	300
15020515	2335	Boldt A	Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease.	Heart	2004	75
16436674	2335	McDaniel SM	Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis.	The American journal of pathology	2006	65
16832052	2335	Zaman MH	Migration of tumor cells in 3D matrices is governed by matrix stiffness along with cell-matrix adhesion and proteolysis.	Proceedings of the National Academy of Sciences of the United States of America	2006	347
17234776	2335	Yao ES	Increased beta1 integrin is associated with decreased survival in invasive breast cancer.	Cancer research	2007	63
17406031	2335	Mahadevan D	Tumor-stroma interactions in pancreatic ductal adenocarcinoma.	Molecular cancer therapeutics	2007	159
17546601	2335	Kenny HA	Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum.	International journal of cancer	2007	72
18235537	2335	Riley G	Tendinopathy--from basic science to treatment.	Nature clinical practice. Rheumatology	2008	69
18468901	2335	Stylli SS	Invadopodia: at the cutting edge of tumour invasion.	Journal of clinical neuroscience 	2008	63
19079190	2335	Blanchard C	Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses.	Mucosal immunology	2008	68
19819674	2335	Fairweather D	Alternatively activated macrophages in infection and autoimmunity.	Journal of autoimmunity	2009	70
19875671	2335	Karamichos D	Human corneal fibrosis: an in vitro model.	Investigative ophthalmology and visual science	2010	49
20530259	2335	Solinas G	Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility.	Journal of immunology	2010	76
22169009	2335	Sanchez-Niño MD	Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy.	American journal of physiology. Renal physiology	2012	37
22293174	2335	Salmon H	Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors.	The Journal of clinical investigation	2012	37
22465212	2335	Kagalwalla AF	Eosinophilic esophagitis: epithelial mesenchymal transition contributes to esophageal remodeling and reverses with treatment.	The Journal of allergy and clinical immunology	2012	39
22472177	2335	DeLay M	Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy.	Clinical cancer research 	2012	36
22894573	2335	Stalmans P	Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.	The New England journal of medicine	2012	75
23047680	2335	Reticker-Flynn NE	A combinatorial extracellular matrix platform identifies cell-extracellular matrix interactions that correlate with metastasis.	Nature communications	2012	47
23430739	2335	Thompson CA	Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes.	The Journal of biological chemistry	2013	59
24117661	2335	Fernandez-Garcia B	Expression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis.	Histopathology	2014	23
25107915	2335	Jung HY	Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis.	Clinical cancer research 	2015	31
25794655	2335	Beuran M	The epithelial to mesenchymal transition in pancreatic cancer: A systematic review.	Pancreatology 	2015	17
26811325	2335	Oudin MJ	Tumor Cell-Driven Extracellular Matrix Remodeling Drives Haptotaxis during Metastatic Progression.	Cancer discovery	2016	13
15653324	2475	Harrington LS	Restraining PI3K: mTOR signalling goes back to the membrane.	Trends in biochemical sciences	2005	125
15916903	2475	Fuchs BC	Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?	Seminars in cancer biology	2005	115
15955899	2475	Chan S	Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.	Journal of clinical oncology 	2005	103
16341243	2475	Thomas GV	Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.	Nature medicine	2006	163
16724053	2475	Shaw RJ	Ras, PI(3)K and mTOR signalling controls tumour cell growth.	Nature	2006	545
16769083	2475	Khan S	Rapamycin confers preconditioning-like protection against ischemia-reperfusion injury in isolated mouse heart and cardiomyocytes.	Journal of molecular and cellular cardiology	2006	64
17031397	2475	Duran I	A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas.	British journal of cancer	2006	72
17041628	2475	Easton JB	mTOR and cancer therapy.	Oncogene	2006	120
17275731	2475	Tsang CK	Targeting mammalian target of rapamycin (mTOR) for health and diseases.	Drug discovery today	2007	106
17360704	2475	Roux PP	RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation.	The Journal of biological chemistry	2007	202
17463046	2475	Roos S	Mammalian target of rapamycin in the human placenta regulates leucine transport and is down-regulated in restricted fetal growth.	The Journal of physiology	2007	68
17911267	2475	Zhou J	Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance.	Proceedings of the National Academy of Sciences of the United States of America	2007	188
17913600	2475	Swiech L	Role of mTOR in physiology and pathology of the nervous system.	Biochimica et biophysica acta	2008	96
18006825	2475	Dowling RJ	Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.	Cancer research	2007	250
18184959	2475	Bissler JJ	Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.	The New England journal of medicine	2008	278
18393362	2475	Yin XM	Autophagy in the liver.	Hepatology	2008	69
18559509	2475	Wang L	Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells.	Cancer research	2008	59
18636076	2475	Sarkar S	Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies.	Cell death and differentiation	2009	124
18653228	2475	Motzer RJ	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.	Lancet	2008	647
18722121	2475	Carrière A	Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation.	Current biology 	2008	116
18787170	2475	Mao JH	FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.	Science	2008	130
18829560	2475	Serra V	NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.	Cancer research	2008	251
18846101	2475	Wouters BG	Hypoxia signalling through mTOR and the unfolded protein response in cancer.	Nature reviews. Cancer	2008	232
18929564	2475	Villanueva A	Pivotal role of mTOR signaling in hepatocellular carcinoma.	Gastroenterology	2008	182
19223493	2475	Yu G	Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer.	Clinical cancer research 	2009	47
19264150	2475	Foster DA	Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells.	Biochimica et biophysica acta	2009	73
19357233	2475	Trendelenburg AU	Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size.	American journal of physiology. Cell physiology	2009	156
19372546	2475	Breuleux M	Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.	Molecular cancer therapeutics	2009	68
19501590	2475	Mueller MT	Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer.	Gastroenterology	2009	80
19543393	2475	Strauss L	Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin.	PloS one	2009	56
19822355	2475	Cantrell LA	Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy.	Gynecologic oncology	2010	65
19860903	2475	Yuan R	Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.	Journal of hematology and oncology	2009	58
20068094	2475	Manara MC	NVP-BEZ235 as a new therapeutic option for sarcomas.	Clinical cancer research 	2010	50
20081105	2475	Nagaraja AK	A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.	Molecular endocrinology	2010	76
20089925	2475	Malagelada C	Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease.	The Journal of neuroscience 	2010	103
20231677	2475	Doi T	Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer.	Journal of clinical oncology 	2010	53
20368560	2475	Hainsworth JD	Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.	Journal of clinical oncology 	2010	46
20386866	2475	Ost A	Attenuated mTOR signaling and enhanced autophagy in adipocytes from obese patients with type 2 diabetes.	Molecular medicine	2010	57
20388847	2475	Rozengurt E	Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer.	Clinical cancer research 	2010	71
20484036	2475	Doghman M	Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors.	Cancer research	2010	64
20491627	2475	Zhou H	The complexes of mammalian target of rapamycin.	Current protein and peptide science	2010	42
20501828	2475	Fornari F	MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells.	Cancer research	2010	120
20530877	2475	Miller TW	Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.	The Journal of clinical investigation	2010	104
20581391	2475	Serra AL	Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.	The New England journal of medicine	2010	116
20581392	2475	Walz G	Everolimus in patients with autosomal dominant polycystic kidney disease.	The New England journal of medicine	2010	125
20615870	2475	Abe N	Mammalian target of rapamycin (mTOR) activation increases axonal growth capacity of injured peripheral nerves.	The Journal of biological chemistry	2010	46
20664473	2475	Boudreaux JP	The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum.	Pancreas	2010	53
20668229	2475	Green AS	The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation.	Blood	2010	45
20685255	2475	Wolff D	Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease.	Biology of blood and marrow transplantation 	2011	37
20857497	2475	Sunayama J	Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.	Stem cells	2010	56
21047224	2475	Krueger DA	Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.	The New England journal of medicine	2010	206
21071439	2475	Carriere A	ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1).	The Journal of biological chemistry	2011	68
21145759	2475	Procaccini C	An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness.	Immunity	2010	92
21177764	2475	Quek R	Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.	Clinical cancer research 	2011	64
21228155	2475	Rieker C	Nucleolar disruption in dopaminergic neurons leads to oxidative damage and parkinsonism through repression of mammalian target of rapamycin signaling.	The Journal of neuroscience 	2011	39
21331075	2475	Evangelisti C	Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.	Leukemia	2011	35
21346035	2475	Finley DS	Tumor biology and prognostic factors in renal cell carcinoma.	The oncologist	2011	35
21372221	2475	Santiskulvong C	Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.	Clinical cancer research 	2011	42
21430067	2475	Gulhati P	mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways.	Cancer research	2011	153
21606591	2475	Gödel M	Role of mTOR in podocyte function and diabetic nephropathy in humans and mice.	The Journal of clinical investigation	2011	124
21613612	2475	Pirkmajer S	Serum starvation: caveat emptor.	American journal of physiology. Cell physiology	2011	36
21690594	2475	Taveira-DaSilva AM	Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.	Annals of internal medicine	2011	38
21750201	2475	Naing A	Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.	Clinical cancer research 	2011	44
21890410	2475	Crino PB	mTOR: A pathogenic signaling pathway in developmental brain malformations.	Trends in molecular medicine	2011	51
21907221	2475	Duman RS	Signaling pathways underlying the rapid antidepressant actions of ketamine.	Neuropharmacology	2012	85
21952069	2475	Coppin C	Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.	BJU international	2011	49
21975930	2475	Patel V	Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer.	Cancer research	2011	49
22067397	2475	Chawla SP	Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.	Journal of clinical oncology 	2012	56
22080480	2475	Gupta M	Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies.	Blood	2012	33
22098780	2475	Khan MI	Induction of ROS, mitochondrial damage and autophagy in lung epithelial cancer cells by iron oxide nanoparticles.	Biomaterials	2012	44
22119496	2475	Pavel ME	Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.	Lancet	2011	136
22171948	2475	Deng W	Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition.	Pigment cell and melanoma research	2012	35
22340590	2475	Pei Y	An animal model of MYC-driven medulloblastoma.	Cancer cell	2012	81
22367541	2475	Hsieh AC	The translational landscape of mTOR signalling steers cancer initiation and metastasis.	Nature	2012	296
22378068	2475	Shi WY	Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy.	Cell death and disease	2012	50
22397650	2475	Gerlinger M	Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.	The New England journal of medicine	2012	1540
22409888	2475	Molinolo AA	mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas.	Clinical cancer research 	2012	36
22500211	2475	Song CW	Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells.	Scientific reports	2012	62
22562464	2475	Luo Z	The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth.	Cancer research	2012	60
22612226	2475	van Vliet EA	Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood-brain barrier leakage but not microglia activation.	Epilepsia	2012	33
22674982	2475	Shrivastava S	Hepatitis C virus upregulates Beclin1 for induction of autophagy and activates mTOR signaling.	Journal of virology	2012	38
22685175	2475	Tasian SK	Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.	Blood	2012	42
22734070	2475	Payne EM	L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway.	Blood	2012	42
22759480	2475	Tran HT	Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.	The Lancet. Oncology	2012	73
22848625	2475	Bray K	Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibition.	PloS one	2012	43
22919032	2475	McInturff AM	Mammalian target of rapamycin regulates neutrophil extracellular trap formation via induction of hypoxia-inducible factor 1 α.	Blood	2012	43
22958932	2475	Iglesias-Bartolome R	mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis.	Cell stem cell	2012	75
22980985	2475	Lu P	Long-distance growth and connectivity of neural stem cells after severe spinal cord injury.	Cell	2012	127
22983984	2475	Iwaya T	Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway.	Carcinogenesis	2012	41
22994652	2475	Welker MW	Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge.	Transplant international 	2013	29
23012248	2475	Acquaviva J	Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.	Molecular cancer therapeutics	2012	32
23150676	2475	Jansson N	Activation of placental mTOR signaling and amino acid transporters in obese women giving birth to large babies.	The Journal of clinical endocrinology and metabolism	2013	43
23233719	2475	Wolff AC	Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.	Journal of clinical oncology 	2013	55
23246963	2475	Montero JC	Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.	Oncogene	2014	26
23271044	2475	Chiarini F	A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.	Oncotarget	2012	33
23272949	2475	Schlicker A	Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines.	BMC medical genomics	2012	37
23325216	2475	Johnson SC	mTOR is a key modulator of ageing and age-related disease.	Nature	2013	288
23454761	2475	Lamming DW	Rapalogs and mTOR inhibitors as anti-aging therapeutics.	The Journal of clinical investigation	2013	104
23477833	2475	Schwartz GK	Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2013	42
23549875	2475	Coffee EM	Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.	Clinical cancer research 	2013	28
23619167	2475	Lui VW	Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.	Cancer discovery	2013	106
23633458	2475	von Roemeling CA	Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.	Clinical cancer research 	2013	38
23708729	2475	Ryter SW	Autophagy: a critical regulator of cellular metabolism and homeostasis.	Molecules and cells	2013	43
23818640	2475	Meckes DG Jr	Modulation of B-cell exosome proteins by gamma herpesvirus infection.	Proceedings of the National Academy of Sciences of the United States of America	2013	44
23832089	2475	Pajvani UB	Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability.	Nature medicine	2013	32
23929677	2475	Sinha RA	Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice.	Hepatology	2014	36
24024901	2475	Santulli G	Tailoring mTOR-based therapy: molecular evidence and clinical challenges.	Pharmacogenomics	2013	27
24055054	2475	Villanueva J	Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.	Cell reports	2013	43
24055102	2475	Lee JH	Sestrins orchestrate cellular metabolism to attenuate aging.	Cell metabolism	2013	53
24059496	2475	Sarkar S	Regulation of autophagy by mTOR-dependent and mTOR-independent pathways: autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers.	Biochemical Society transactions	2013	56
24100461	2475	Perl A	Oxidative stress in the pathology and treatment of systemic lupus erythematosus.	Nature reviews. Rheumatology	2013	41
24185040	2475	Francipane MG	Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1.	Oncotarget	2013	28
24204632	2475	Lonardo E	Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells.	PloS one	2013	41
24270265	2475	Goncharov DA	Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension.	Circulation	2014	32
24390152	2475	Freret T	Mechanisms underlying the neuroprotective effect of brain reserve against late life depression.	Journal of neural transmission	2015	22
24474794	2475	Liu X	Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK.	Proceedings of the National Academy of Sciences of the United States of America	2014	56
24481845	2475	Sciarretta S	Mammalian target of rapamycin signaling in cardiac physiology and disease.	Circulation research	2014	66
24508508	2475	Li J	Rapamycin: one drug, many effects.	Cell metabolism	2014	66
24534455	2475	Martinet W	mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques.	Atherosclerosis	2014	22
24553191	2475	Li X	LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway.	Oncotarget	2014	21
24569374	2475	Ma XH	Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.	The Journal of clinical investigation	2014	77
24622468	2475	Voss MH	Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy.	Clinical cancer research 	2014	37
24625776	2475	Wagle N	Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.	Cancer discovery	2014	70
24651621	2475	Zhang Y	Cartilage-specific deletion of mTOR upregulates autophagy and protects mice from osteoarthritis.	Annals of the rheumatic diseases	2015	36
24662833	2475	Nguyen HG	Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model.	Oncogene	2014	26
24789445	2475	Pickard MR	Regulation of apoptosis by long non-coding RNA GAS5 in breast cancer cells: implications for chemotherapy.	Breast cancer research and treatment	2014	30
24810336	2475	Minna E	miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma.	Oncotarget	2014	29
24821879	2475	Brugarolas J	Molecular genetics of clear-cell renal cell carcinoma.	Journal of clinical oncology 	2014	37
24899720	2475	Caccamo A	Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature.	The Journal of neuroscience 	2014	30
24991838	2475	Rangwala R	Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.	Autophagy	2014	80
25103565	2475	Lehmann BD	PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.	Breast cancer research 	2014	32
25203323	2475	Wang Y	The splicing factor RBM4 controls apoptosis, proliferation, and migration to suppress tumor progression.	Cancer cell	2014	28
25282103	2475	Wood AR	Defining the role of common variation in the genomic and biological architecture of adult human height.	Nature genetics	2014	268
25295501	2475	Wagle N	Response and acquired resistance to everolimus in anaplastic thyroid cancer.	The New England journal of medicine	2014	61
25326666	2475	Ronan B	A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy.	Nature chemical biology	2014	46
25341517	2475	Johnson SC	Modulating mTOR in aging and health.	Interdisciplinary topics in gerontology	2015	21
25351205	2475	Scelo G	Variation in genomic landscape of clear cell renal cell carcinoma across Europe.	Nature communications	2014	24
25385035	2475	Favier J	Paraganglioma and phaeochromocytoma: from genetics to personalized medicine.	Nature reviews. Endocrinology	2015	26
25432176	2475	Kolev VN	PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells.	Cancer research	2015	33
25446280	2475	Wagner LM	Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group.	Pediatric blood and cancer	2015	17
25498219	2475	Grignani G	Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.	The Lancet. Oncology	2015	30
25512523	2475	Perry JA	Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.	Proceedings of the National Academy of Sciences of the United States of America	2014	46
25671304	2475	Lamb R	Targeting tumor-initiating cells: eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction.	Oncotarget	2015	16
25749036	2475	Yang H	FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells.	Oncotarget	2015	17
25813405	2475	Wang Y	CRNDE, a long-noncoding RNA, promotes glioma cell growth and invasion through mTOR signaling.	Cancer letters	2015	33
25867026	2475	Sesen J	Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response.	PloS one	2015	18
25902704	2475	Longo VD	Interventions to Slow Aging in Humans: Are We Ready?	Aging cell	2015	58
25913192	2475	Venkatesh HS	Neuronal Activity Promotes Glioma Growth through Neuroligin-3 Secretion.	Cell	2015	38
26004684	2475	Han B	Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.	Cancer cell	2015	20
26018084	2475	Nakashima M	Somatic Mutations in the MTOR gene cause focal cortical dysplasia type IIb.	Annals of neurology	2015	19
26117819	2475	Yap TA	Drugging PI3K in cancer: refining targets and therapeutic strategies.	Current opinion in pharmacology	2015	30
26156073	2475	Bissler JJ	Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.	Nephrology, dialysis, transplantation 	2016	17
26190651	2475	Fu X	2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling.	Cell metabolism	2015	15
26277543	2475	Hsieh AL	MYC and metabolism on the path to cancer.	Seminars in cell and developmental biology	2015	25
26293922	2475	Liu P	PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex.	Cancer discovery	2015	30
26482279	2475	Motzer RJ	Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.	The Lancet. Oncology	2015	57
26627594	2475	Qian P	The Dlk1-Gtl2 Locus Preserves LT-HSC Function by Inhibiting the PI3K-mTOR Pathway to Restrict Mitochondrial Metabolism.	Cell stem cell	2016	13
26794930	2475	Armstrong AJ	Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.	The Lancet. Oncology	2016	16
27279227	2475	Rodrik-Outmezguine VS	Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.	Nature	2016	19
27279544	2475	Choueiri TK	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.	The Lancet. Oncology	2016	35
27615548	2475	Hsieh JJ	Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer.	Seminars in cell and developmental biology	2017	7
9425002	2670	Wolswijk G	Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells.	The Journal of neuroscience 	1998	105
11138011	2670	Brenner M	Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease.	Nature genetics	2001	112
12853570	2670	Curtis MA	Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain.	Proceedings of the National Academy of Sciences of the United States of America	2003	116
15280535	2670	Kelly S	Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex.	Proceedings of the National Academy of Sciences of the United States of America	2004	155
15367883	2670	Apte MV	Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells.	Pancreas	2004	119
15495269	2670	Pekny M	Astrocyte intermediate filaments in CNS pathologies and regeneration.	The Journal of pathology	2004	77
17405762	2670	Misu T	Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.	Brain 	2007	115
17491094	2670	Thannickal TC	Hypocretin (orexin) cell loss in Parkinson's disease.	Brain 	2007	75
18240313	2670	Lee Y	GFAP promoter elements required for region-specific and astrocyte-specific expression.	Glia	2008	62
18927145	2670	Gouw AA	Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology.	Brain 	2008	68
19638961	2670	Lawlor PA	Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates.	Molecular therapy 	2009	53
20140958	2670	Olabarria M	Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease.	Glia	2010	53
21219963	2670	Middeldorp J	GFAP in health and disease.	Progress in neurobiology	2011	140
21280078	2670	Gunnarsson M	Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.	Annals of neurology	2011	41
21702960	2670	Mondello S	Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study.	Critical care	2011	52
21930157	2670	Kane MJ	A mouse model of human repetitive mild traumatic brain injury.	Journal of neuroscience methods	2012	42
23469922	2670	Rajkowska G	Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue.	Current drug targets	2013	55
23579868	2670	Misu T	Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica.	Acta neuropathologica	2013	42
23769173	2670	Yuan T	Human induced pluripotent stem cell-derived neural stem cells survive, migrate, differentiate, and improve neurologic function in a rat model of middle cerebral artery occlusion.	Stem cell research and therapy	2013	25
24269023	2670	Kamphuis W	Glial fibrillary acidic protein isoform expression in plaque related astrogliosis in Alzheimer's disease.	Neurobiology of aging	2014	20
24332821	2670	Chalak LF	Biomarkers for severity of neonatal hypoxic-ischemic encephalopathy and outcomes in newborns receiving hypothermia therapy.	The Journal of pediatrics	2014	22
24419315	2670	Williams EC	Mutant astrocytes differentiated from Rett syndrome patients-specific iPSCs have adverse effects on wild-type neurons.	Human molecular genetics	2014	38
24501367	2670	Sosunov AA	Phenotypic heterogeneity and plasticity of isocortical and hippocampal astrocytes in the human brain.	The Journal of neuroscience 	2014	23
24667434	2670	Zhang Z	Human traumatic brain injury induces autoantibody response against glial fibrillary acidic protein and its breakdown products.	PloS one	2014	24
25034944	2670	Chen C	Role of astroglia in Down's syndrome revealed by patient-derived human-induced pluripotent stem cells.	Nature communications	2014	35
15132968	2735	Fan L	Hedgehog signaling promotes prostate xenograft tumor growth.	Endocrinology	2004	75
15314219	2735	Sanchez P	Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling.	Proceedings of the National Academy of Sciences of the United States of America	2004	145
17332349	2735	Feldmann G	Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers.	Cancer research	2007	236
17494766	2735	Lauth M	Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.	Proceedings of the National Academy of Sciences of the United States of America	2007	196
18756266	2735	Ferretti E	Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells.	The EMBO journal	2008	96
18790753	2735	Feldmann G	An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer.	Molecular cancer therapeutics	2008	84
19028702	2735	Liao X	Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation.	Carcinogenesis	2009	62
19214186	2735	Stecca B	A GLI1-p53 inhibitory loop controls neural stem cell and tumour cell numbers.	The EMBO journal	2009	75
19351822	2735	Northcott PA	The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors.	Cancer research	2009	108
19445942	2735	Kolterud A	Paracrine Hedgehog signaling in stomach and intestine: new roles for hedgehog in gastrointestinal patterning.	Gastroenterology	2009	50
20049737	2735	Varnat F	Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion.	EMBO molecular medicine	2009	130
20083481	2735	Stecca B	Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals.	Journal of molecular cell biology	2010	89
20581802	2735	Zbinden M	NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53.	The EMBO journal	2010	98
21135115	2735	Mazumdar T	Hedgehog signaling drives cellular survival in human colon carcinoma cells.	Cancer research	2011	53
21169257	2735	Schreck KC	The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance.	Clinical cancer research 	2010	50
21183792	2735	Beauchamp EM	Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway.	The Journal of clinical investigation	2011	66
21300762	2735	LoRusso PM	Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.	Clinical cancer research 	2011	131
21632555	2735	O'Toole SA	Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer.	Cancer research	2011	38
21796625	2735	Tang SN	Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics.	International journal of cancer	2012	47
22087285	2735	Singh BN	Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms.	PloS one	2011	54
22730244	2735	Santini R	Hedgehog-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells.	Stem cells	2012	40
24493717	2735	Kim DJ	Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma.	Journal of clinical oncology 	2014	38
24523439	2735	Rodon J	A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.	Clinical cancer research 	2014	37
24870236	2735	Zahreddine HA	The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.	Nature	2014	41
25278454	2735	Kim EJ	Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma.	Clinical cancer research 	2014	31
9819447	2875	Davis GL	Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.	The New England journal of medicine	1998	152
10210705	2875	Kenny-Walsh E	Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group.	The New England journal of medicine	1999	144
11438497	2875	Dixon JB	Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.	Gastroenterology	2001	176
12512031	2875	Ruhl CE	Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States.	Gastroenterology	2003	118
12606734	2875	Hadziyannis SJ	Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.	The New England journal of medicine	2003	131
12897283	2875	van den Hout HM	The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature.	Pediatrics	2003	81
14512888	2875	Neuschwander-Tetri BA	Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.	Hepatology	2003	99
14960526	2875	Hickman IJ	Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life.	Gut	2004	72
15639293	2875	Janssen HL	Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.	Lancet	2005	150
17087951	2875	Hadziyannis SJ	Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.	Gastroenterology	2006	145
17439526	2875	Coco B	Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases.	Journal of viral hepatitis	2007	108
18095306	2875	Arena U	Acute viral hepatitis increases liver stiffness values measured by transient elastography.	Hepatology	2008	107
18673426	2875	Chan HL	Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B.	Journal of viral hepatitis	2009	66
18752331	2875	Fracanzani AL	Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.	Hepatology	2008	95
19585618	2875	Feldstein AE	Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.	Hepatology	2009	123
19877169	2875	Ratziu V	Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial.	Hepatology	2010	52
20858492	2875	Williams CD	Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.	Gastroenterology	2011	346
21688282	2875	Bhala N	The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study.	Hepatology	2011	78
21953442	2875	Kowdley KV	Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.	Hepatology	2012	65
21971536	2875	Rizzo L	Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C.	The American journal of gastroenterology	2011	39
22183689	2875	Lomonaco R	Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease.	Hepatology	2012	52
22266604	2875	Antoine DJ	Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity.	Journal of hepatology	2012	103
22894884	2875	Di Giacomo AM	Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.	The Lancet. Oncology	2012	46
23696515	2875	Noureddin M	Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials.	Hepatology	2013	53
24316260	2875	Lambert JE	Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease.	Gastroenterology	2014	63
24569542	2875	Chiu S	Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials.	European journal of clinical nutrition	2014	28
25311610	2875	Faghihzadeh F	Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.	Nutrition research	2014	24
25601341	2875	Ryan CJ	Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.	The Lancet. Oncology	2015	85
25873639	2875	Kwok R	Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study.	Gut	2016	13
27247226	2875	Seiwert TY	Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.	The Lancet. Oncology	2016	52
10544223	2956	Lynch HT	Genetic susceptibility to non-polyposis colorectal cancer.	Journal of medical genetics	1999	131
11257106	2956	Peltomäki P	Deficient DNA mismatch repair: a common etiologic factor for colon cancer.	Human molecular genetics	2001	94
15872200	2956	Hampel H	Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).	The New England journal of medicine	2005	244
17327285	2956	Vasen HF	Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer).	Journal of medical genetics	2007	103
17404084	2956	Cahill DP	Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.	Clinical cancer research 	2007	83
18556767	2956	Shia J	Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry.	The Journal of molecular diagnostics 	2008	71
19584161	2956	Yip S	MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.	Clinical cancer research 	2009	75
19622357	2956	Stoffel E	Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome.	Gastroenterology	2009	77
22355048	2956	Beamer LC	Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results.	Journal of clinical oncology 	2012	35
24362816	2956	Thompson BA	Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database.	Nature genetics	2014	80
24844595	2956	Meng B	POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.	Gynecologic oncology	2014	22
25194673	2956	Haraldsdottir S	Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations.	Gastroenterology	2014	35
25305506	2956	Sinicrope FA	Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.	Gastroenterology	2015	42
26031544	2956	Kawakami H	Microsatellite instability testing and its role in the management of colorectal cancer.	Current treatment options in oncology	2015	17
26720728	2956	Norquist BM	Inherited Mutations in Women With Ovarian Carcinoma.	JAMA oncology	2016	24
26880610	2956	Dudley JC	Microsatellite Instability as a Biomarker for PD-1 Blockade.	Clinical cancer research 	2016	28
9267033	3064	Davies SW	Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.	Cell	1997	452
9768849	3064	Jackson GR	Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons.	Neuron	1998	133
10087066	3064	Gutekunst CA	Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology.	The Journal of neuroscience 	1999	184
12881722	3064	Zuccato C	Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes.	Nature genetics	2003	216
14978262	3064	Lee WC	Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease.	Proceedings of the National Academy of Sciences of the United States of America	2004	95
15340079	3064	Trushina E	Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro.	Molecular and cellular biology	2004	138
17041811	3064	Borrell-Pagès M	Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies.	Cellular and molecular life sciences 	2006	62
17687326	3064	Bennett EJ	Global changes to the ubiquitin system in Huntington's disease.	Nature	2007	175
18488016	3064	Yang SH	Towards a transgenic model of Huntington's disease in a non-human primate.	Nature	2008	108
18550760	3064	Gray M	Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice.	The Journal of neuroscience 	2008	183
18625748	3064	Björkqvist M	A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease.	The Journal of experimental medicine	2008	126
19460373	3064	Sassone J	Huntington's disease: the current state of research with peripheral tissues.	Experimental neurology	2009	45
19487684	3064	Nekooki-Machida Y	Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity.	Proceedings of the National Academy of Sciences of the United States of America	2009	78
19646924	3064	Tabrizi SJ	Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.	The Lancet. Neurology	2009	156
20383138	3064	Martinez-Vicente M	Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease.	Nature neuroscience	2010	180
20923788	3064	Nopoulos PC	Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment.	Brain 	2011	38
21130037	3064	Tabrizi SJ	Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.	The Lancet. Neurology	2011	121
21257639	3064	Shirendeb U	Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage.	Human molecular genetics	2011	78
21395858	3064	Winner B	Neurodegenerative disease and adult neurogenesis.	The European journal of neuroscience	2011	114
21971427	3064	Carroll JB	Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.	Molecular therapy 	2011	69
21997870	3064	Shirendeb UP	Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease.	Human molecular genetics	2012	60
22031240	3064	McBride JL	Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease.	Molecular therapy 	2011	57
22137354	3064	Tabrizi SJ	Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.	The Lancet. Neurology	2012	78
22187000	3064	Harris H	Control of autophagy as a therapy for neurodegenerative disease.	Nature reviews. Neurology	2011	131
22446390	3064	Costa V	Shaping the role of mitochondria in the pathogenesis of Huntington's disease.	The EMBO journal	2012	35
22613578	3064	Juopperi TA	Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells.	Molecular brain	2012	62
22709585	3064	Siddiqui A	Mitochondrial DNA damage is associated with reduced mitochondrial bioenergetics in Huntington's disease.	Free radical biology and medicine	2012	32
22748967	3064	An MC	Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells.	Cell stem cell	2012	81
23160193	3064	Kwan W	Mutant huntingtin impairs immune cell migration in Huntington disease.	The Journal of clinical investigation	2012	33
23664844	3064	Tabrizi SJ	Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.	The Lancet. Neurology	2013	98
24459107	3064	Träger U	HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation.	Brain 	2014	32
24584051	3064	Crotti A	Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors.	Nature neuroscience	2014	49
24586208	3064	Hoss AG	MicroRNAs located in the Hox gene clusters are implicated in huntington's disease pathogenesis.	PLoS genetics	2014	22
25017010	3064	Pecho-Vrieseling E	Transneuronal propagation of mutant huntingtin contributes to non-cell autonomous pathology in neurons.	Nature neuroscience	2014	26
25437566	3064	Brehme M	A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease.	Cell reports	2014	50
27479945	3064	Horvath S	Huntington's disease accelerates epigenetic aging of human brain and disrupts DNA methylation levels.	Aging	2016	16
11342433	3082	Majka M	Numerous growth factors, cytokines, and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner.	Blood	2001	95
12865405	3082	Kollet O	HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver.	The Journal of clinical investigation	2003	127
15059978	3082	De Wever O	Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac.	FASEB journal 	2004	86
15126362	3082	Ohuchida K	Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions.	Cancer research	2004	80
17283128	3082	Verras M	The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression.	Cancer research	2007	67
17483355	3082	Zou HY	An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.	Cancer research	2007	158
18519697	3082	Jin H	MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival.	Cancer research	2008	84
19074827	3082	Zhao D	Neural stem cell tropism to glioma: critical role of tumor hypoxia.	Molecular cancer research 	2008	59
19074879	3082	Migliore C	MicroRNAs impair MET-mediated invasive growth.	Cancer research	2008	61
20534479	3082	Grugan KD	Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion.	Proceedings of the National Academy of Sciences of the United States of America	2010	42
20568106	3082	Bendinelli P	Molecular basis of anti-inflammatory action of platelet-rich plasma on human chondrocytes: mechanisms of NF-κB inhibition via HGF.	Journal of cellular physiology	2010	44
21131364	3082	Ramani VC	Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity.	The Journal of biological chemistry	2011	38
21249190	3082	Tyan SW	Breast cancer cells induce cancer-associated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis.	PloS one	2011	41
21464397	3082	De Bacco F	Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.	Journal of the National Cancer Institute	2011	65
22763439	3082	Straussman R	Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.	Nature	2012	413
22763448	3082	Wilson TR	Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.	Nature	2012	336
24259426	3082	Yang X	MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway.	Hepatology	2014	42
24327602	3082	Eterno V	Adipose-derived Mesenchymal Stem Cells (ASCs) may favour breast cancer recurrence via HGF/c-Met signaling.	Oncotarget	2014	24
24607406	3082	Todaro M	CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis.	Cell stem cell	2014	92
24965569	3082	Iveson T	Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.	The Lancet. Oncology	2014	72
25887320	3082	Ho-Yen CM	The clinical and functional significance of c-Met in breast cancer: a review.	Breast cancer research 	2015	18
26432786	3082	Sameni M	Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.	Clinical cancer research 	2016	11
8756616	3091	Forsythe JA	Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1.	Molecular and cellular biology	1996	763
10640274	3091	Ravi R	Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.	Genes and development	2000	212
10699162	3091	Lee SH	Early expression of angiogenesis factors in acute myocardial ischemia and infarction.	The New England journal of medicine	2000	107
10987269	3091	Birner P	Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer.	Cancer research	2000	125
11786564	3091	Bos R	Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography.	Journal of clinical oncology 	2002	86
12124175	3091	Mandriota SJ	HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron.	Cancer cell	2002	125
12840067	3091	Danet GH	Expansion of human SCID-repopulating cells under hypoxic conditions.	The Journal of clinical investigation	2003	77
15677538	3091	Vleugel MM	Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer.	Journal of clinical pathology	2005	68
15780936	3091	Koshiji M	HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression.	Molecular cell	2005	105
16417408	3091	Chi JT	Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers.	PLoS medicine	2006	190
16510593	3091	Krishnamachary B	Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B.	Cancer research	2006	118
17015745	3091	Argaw AT	IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program.	Journal of immunology	2006	62
17075581	3091	Zagzag D	Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion.	Laboratory investigation; a journal of technical methods and pathology	2006	83
17101781	3091	Pan Y	Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro.	Molecular and cellular biology	2007	96
17118889	3091	Tatum JL	Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy.	International journal of radiation biology	2006	165
17245699	3091	Trastour C	HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome.	International journal of cancer	2007	61
17440684	3091	Vaupel P	Hypoxia in cancer: significance and impact on clinical outcome.	Cancer metastasis reviews	2007	374
17483326	3091	Hiraga T	Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.	Cancer research	2007	61
17533374	3091	Maxwell PJ	HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells.	Oncogene	2007	65
17624581	3091	Gillies RJ	Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis?	Journal of bioenergetics and biomembranes	2007	63
17785433	3091	Kim JW	Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1.	Molecular and cellular biology	2007	148
17964232	3091	Jiang BH	PI3K/PTEN signaling in tumorigenesis and angiogenesis.	Biochimica et biophysica acta	2008	69
18259201	3091	Weidemann A	Biology of HIF-1alpha.	Cell death and differentiation	2008	158
18297062	3091	Yang MH	Direct regulation of TWIST by HIF-1alpha promotes metastasis.	Nature cell biology	2008	316
18343725	3091	Vergis R	Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.	The Lancet. Oncology	2008	65
18635960	3091	Yang MH	TWIST activation by hypoxia inducible factor-1 (HIF-1): implications in metastasis and development.	Cell cycle	2008	73
19118021	3091	Chiche J	Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH.	Cancer research	2009	110
19291283	3091	Hu Z	A compact VEGF signature associated with distant metastases and poor outcomes.	BMC medicine	2009	61
19352387	3091	Maréchal R	High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma.	British journal of cancer	2009	54
19479945	3091	Ruan K	Role of hypoxia in the hallmarks of human cancer.	Journal of cellular biochemistry	2009	92
19718046	3091	Soeda A	Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha.	Oncogene	2009	157
19727403	3091	Dunn LK	Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment.	PloS one	2009	65
19778933	3091	Hung JJ	Prognostic significance of hypoxia-inducible factor-1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer.	Thorax	2009	46
19782034	3091	Huang X	Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation.	Molecular cell	2009	181
19801454	3091	Zhou G	Hypoxia-induced alveolar epithelial-mesenchymal transition requires mitochondrial ROS and hypoxia-inducible factor 1.	American journal of physiology. Lung cellular and molecular physiology	2009	54
20110409	3091	Fijalkowska I	Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells.	The American journal of pathology	2010	72
20463368	3091	Michelakis ED	Metabolic modulation of glioblastoma with dichloroacetate.	Science translational medicine	2010	188
20515450	3091	Méndez O	Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres.	Molecular cancer	2010	46
20665378	3091	Rosmorduc O	Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease.	Seminars in liver disease	2010	46
20864819	3091	Chiavarina B	HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis.	Cell cycle	2010	75
21278237	3091	Kim TH	NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α.	Cancer research	2011	59
21283755	3091	Wei J	Hypoxia potentiates glioma-mediated immunosuppression.	PloS one	2011	41
21321221	3091	Keunen O	Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma.	Proceedings of the National Academy of Sciences of the United States of America	2011	167
21576632	3091	Xu CF	Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.	Journal of clinical oncology 	2011	39
21637285	3091	Martin SK	The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.	Leukemia	2011	37
21654190	3091	Lisanti MP	Accelerated aging in the tumor microenvironment: connecting aging, inflammation and cancer metabolism with personalized medicine.	Cell cycle	2011	35
21712410	3091	Mathieu J	HIF induces human embryonic stem cell markers in cancer cells.	Cancer research	2011	139
21782234	3091	Szot CS	3D in vitro bioengineered tumors based on collagen I hydrogels.	Biomaterials	2011	39
21911388	3091	Wong CC	Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation.	Proceedings of the National Academy of Sciences of the United States of America	2011	92
21917858	3091	Xu Q	MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis.	Nucleic acids research	2012	66
21984483	3091	Jing Y	Cadmium increases HIF-1 and VEGF expression through ROS, ERK, and AKT signaling pathways and induces malignant transformation of human bronchial epithelial cells.	Toxicological sciences 	2012	39
22084398	3091	Zhou Y	Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells.	Cancer research	2012	46
22231744	3091	Wong CC	Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis.	Journal of molecular medicine	2012	61
22305612	3091	Xia Y	Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.	European journal of medicinal chemistry	2012	54
22645176	3091	Carter BZ	Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML.	Blood	2012	32
23082126	3091	De Saedeleer CJ	Lactate activates HIF-1 in oxidative but not in Warburg-phenotype human tumor cells.	PloS one	2012	33
23358852	3091	Zhang Q	Wnt/β-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1α signaling.	Carcinogenesis	2013	35
23378577	3091	Gilkes DM	Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis.	Molecular cancer research 	2013	45
23389731	3091	Yeh YM	MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1α.	International journal of cancer	2013	53
23533994	3091	Capece D	The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages.	BioMed research international	2013	58
23633488	3091	Spivak-Kroizman TR	Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer.	Cancer research	2013	29
23674815	3091	Clem BF	Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.	Molecular cancer therapeutics	2013	35
23842546	3091	Chae YC	Landscape of the mitochondrial Hsp90 metabolome in tumours.	Nature communications	2013	33
23935962	3091	Cheng HH	Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia.	PloS one	2013	39
23954640	3091	Sun K	Fibrosis and adipose tissue dysfunction.	Cell metabolism	2013	90
23999440	3091	Semenza GL	HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations.	The Journal of clinical investigation	2013	215
24366912	3091	Chesnelong C	Lactate dehydrogenase A silencing in IDH mutant gliomas.	Neuro-oncology	2014	23
24434214	3091	Li J	Cbx4 governs HIF-1α to potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3 ligase activity.	Cancer cell	2014	24
24486645	3091	Martinez-Outschoorn UE	Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth.	Seminars in cancer biology	2014	45
24599125	3091	Zhao X	Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actin-bundling protein fascin.	Cancer research	2014	25
24670641	3091	Chen X	XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway.	Nature	2014	108
24787293	3091	Martinez-Outschoorn U	Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function.	Seminars in oncology	2014	37
24843020	3091	Wheaton WW	Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis.	eLife	2014	104
24857547	3091	Ferrer CM	O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway.	Molecular cell	2014	38
25186948	3091	Ye J	Serine catabolism regulates mitochondrial redox control during hypoxia.	Cancer discovery	2014	47
25725128	3091	Yang G	Discovery and validation of extracellular/circulating microRNAs during idiopathic pulmonary fibrosis disease progression.	Gene	2015	18
25746953	3091	Shalova IN	Human monocytes undergo functional re-programming during sepsis mediated by hypoxia-inducible factor-1α.	Immunity	2015	26
25891797	3091	Zhou J	miR-33a functions as a tumor suppressor in melanoma by targeting HIF-1α.	Cancer biology and therapy	2015	17
25965573	3091	El-Naggar AM	Translational Activation of HIF1α by YB-1 Promotes Sarcoma Metastasis.	Cancer cell	2015	22
26365179	3091	Dupuy F	PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer.	Cell metabolism	2015	31
26773935	3091	Barron CC	Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment.	Metabolism	2016	13
26837767	3091	Ye LY	Hypoxia-Induced Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma Induces an Immunosuppressive Tumor Microenvironment to Promote Metastasis.	Cancer research	2016	17
26992424	3091	Li L	Exosomes Derived from Hypoxic Oral Squamous Cell Carcinoma Cells Deliver miR-21 to Normoxic Cells to Elicit a Prometastatic Phenotype.	Cancer research	2016	14
9453485	3383	D'Haens GR	Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum.	Gastroenterology	1998	110
15021878	3383	Schenkel AR	Locomotion of monocytes on endothelium is a critical step during extravasation.	Nature immunology	2004	103
15731292	3383	Benito MJ	Synovial tissue inflammation in early and late osteoarthritis.	Annals of the rheumatic diseases	2005	143
15811956	3383	Yang L	ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow.	Blood	2005	150
19536890	3383	Higano CS	Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.	Cancer	2009	193
19587009	3383	Podgrabinska S	Inflamed lymphatic endothelium suppresses dendritic cell maturation and function via Mac-1/ICAM-1-dependent mechanism.	Journal of immunology	2009	54
19908231	3383	Harikumar KB	Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer.	International journal of cancer	2010	47
20100959	3383	Kantoff PW	Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.	Journal of clinical oncology 	2010	287
20585554	3383	Paré G	On the use of variance per genotype as a tool to identify quantitative trait interaction effects: a report from the Women's Genome Health Study.	PLoS genetics	2010	54
20610626	3383	Huh SJ	Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development.	Cancer research	2010	63
21164106	3383	Rautou PE	Microparticles from human atherosclerotic plaques promote endothelial ICAM-1-dependent monocyte adhesion and transendothelial migration.	Circulation research	2011	40
21390226	3383	Ochola LB	Specific receptor usage in Plasmodium falciparum cytoadherence is associated with disease outcome.	PloS one	2011	55
21448265	3383	Meijer K	Human primary adipocytes exhibit immune cell function: adipocytes prime inflammation independent of macrophages.	PloS one	2011	52
21727908	3383	Chen T	Identification and expansion of cancer stem cells in tumor tissues and peripheral blood derived from gastric adenocarcinoma patients.	Cell research	2012	37
21852557	3383	Rautou PE	Microparticles, vascular function, and atherothrombosis.	Circulation research	2011	63
22015609	3383	Kim JY	Soluble intracellular adhesion molecule-1 secreted by human umbilical cord blood-derived mesenchymal stem cell reduces amyloid-β plaques.	Cell death and differentiation	2012	30
22535415	3383	Kan AA	Genome-wide microRNA profiling of human temporal lobe epilepsy identifies modulators of the immune response.	Cellular and molecular life sciences 	2012	42
22744718	3383	Chalmers JD	Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis.	American journal of respiratory and critical care medicine	2012	30
23376424	3383	Liu S	Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells.	Gastroenterology	2013	29
26152369	3383	O'Carroll SJ	Pro-inflammatory TNFα and IL-1β differentially regulate the inflammatory phenotype of brain microvascular endothelial cells.	Journal of neuroinflammation	2015	20
19228619	3417	Yan H	IDH1 and IDH2 mutations in gliomas.	The New England journal of medicine	2009	972
19378339	3417	Kang MR	Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers.	International journal of cancer	2009	86
19554337	3417	Hartmann C	Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.	Acta neuropathologica	2009	219
19636000	3417	Sanson M	Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.	Journal of clinical oncology 	2009	178
19755387	3417	Nobusawa S	IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.	Clinical cancer research 	2009	117
19805672	3417	Weller M	Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.	Journal of clinical oncology 	2009	135
19935646	3417	Dang L	Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.	Nature	2009	672
20160062	3417	van den Bent MJ	IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.	Clinical cancer research 	2010	88
20399149	3417	Noushmehr H	Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.	Cancer cell	2010	587
20410924	3417	Pardanani A	IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.	Leukemia	2010	41
20513808	3417	Reitman ZJ	Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.	Journal of the National Cancer Institute	2010	101
20805365	3417	Schnittger S	IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.	Blood	2010	41
21075857	3417	Kim YH	Molecular classification of low-grade diffuse gliomas.	The American journal of pathology	2010	43
21088844	3417	Hartmann C	Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.	Acta neuropathologica	2010	98
21129061	3417	von Deimling A	The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations.	Brain pathology	2011	41
21163902	3417	Christensen BC	DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.	Journal of the National Cancer Institute	2011	89
21289278	3417	Reitman ZJ	Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.	Proceedings of the National Academy of Sciences of the United States of America	2011	143
21326614	3417	Jin G	2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.	PloS one	2011	47
21598255	3417	Amary MF	IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.	The Journal of pathology	2011	161
22015945	3417	Pope WB	Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.	Journal of neuro-oncology	2012	57
22052461	3417	Jin SG	5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations.	Cancer research	2011	110
22101433	3417	Metallo CM	Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia.	Nature	2011	387
22180306	3417	Borger DR	Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.	The oncologist	2012	126
22238332	3417	Andronesi OC	Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.	Science translational medicine	2012	78
22238333	3417	Elkhaled A	Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas.	Science translational medicine	2012	50
22343889	3417	Turcan S	IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.	Nature	2012	385
22343901	3417	Lu C	IDH mutation impairs histone demethylation and results in a block to cell differentiation.	Nature	2012	379
22415316	3417	Gorovets D	IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.	Clinical cancer research 	2012	40
22829908	3417	Orr BA	Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma.	PloS one	2012	39
22899282	3417	Duncan CG	A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation.	Genome research	2012	48
23095825	3417	Weller M	Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.	Neuro-oncology	2012	31
23115158	3417	Li S	Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.	Neuro-oncology	2013	30
23209033	3417	Ohgaki H	The definition of primary and secondary glioblastoma.	Clinical cancer research 	2013	107
23558173	3417	Wang F	Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.	Science	2013	152
23793099	3417	Tönjes M	BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1.	Nature medicine	2013	63
23801749	3417	Hughes LA	The CpG island methylator phenotype: what's in a name?	Cancer research	2013	40
24077805	3417	Borodovsky A	5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.	Oncotarget	2013	31
24478380	3417	Borger DR	Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.	Clinical cancer research 	2014	23
24516018	3417	Cairncross JG	Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.	Journal of clinical oncology 	2014	50
24722048	3417	Killela PJ	Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.	Oncotarget	2014	45
24857658	3417	Mullen AR	Oxidation of alpha-ketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects.	Cell reports	2014	54
25143301	3417	Sahm F	Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.	Acta neuropathologica	2014	32
25369307	3417	Rizvi S	Cholangiocarcinoma: molecular pathways and therapeutic opportunities.	Seminars in liver disease	2014	27
25701198	3417	Olar A	IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.	Acta neuropathologica	2015	17
25783747	3417	Weller M	Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.	Acta neuropathologica	2015	26
26212717	3417	Intlekofer AM	Hypoxia Induces Production of L-2-Hydroxyglutarate.	Cell metabolism	2015	41
26534967	3417	Andronesi OC	Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.	Clinical cancer research 	2016	11
26669865	3417	Emir UE	Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations.	Cancer research	2016	14
26691210	3417	de la Fuente MI	Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.	Neuro-oncology	2016	18
26901439	3417	Reznik E	Mitochondrial DNA copy number variation across human cancers.	eLife	2016	20
27005468	3417	Dang L	IDH mutations in cancer and progress toward development of targeted therapeutics.	Annals of oncology 	2016	16
27157931	3417	Louis DN	The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.	Acta neuropathologica	2016	233
27270107	3417	Wang J	Clonal evolution of glioblastoma under therapy.	Nature genetics	2016	15
27806376	3417	Tirosh I	Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma.	Nature	2016	17
7758109	3439	Symons JA	Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity.	Cell	1995	132
10856105	3439	Kirkwood JM	High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.	Journal of clinical oncology 	2000	100
14500688	3439	Bharti AC	Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells.	Journal of immunology	2003	117
14991609	3439	Coccia EM	Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells.	European journal of immunology	2004	122
15383579	3439	He B	CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10.	Journal of immunology	2004	90
15634892	3439	Gerosa F	The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions.	Journal of immunology	2005	106
15998792	3439	Nestle FO	Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production.	The Journal of experimental medicine	2005	173
16632604	3439	Herbeuval JP	Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients.	Proceedings of the National Academy of Sciences of the United States of America	2006	86
16799963	3439	Ikeda M	Different anti-HCV profiles of statins and their potential for combination therapy with interferon.	Hepatology	2006	73
17327884	3439	Capuron L	Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy.	Neuropsychopharmacology 	2007	65
17353365	3439	Dunn C	Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage.	The Journal of experimental medicine	2007	102
17488182	3439	Critchley-Thorne RJ	Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma.	PLoS medicine	2007	56
18521089	3439	Raison CL	Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior.	Molecular psychiatry	2010	69
18801471	3439	Raison CL	Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression.	Biological psychiatry	2009	96
18936475	3439	Rini BI	Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.	Journal of clinical oncology 	2008	202
19171708	3439	Escudier B	Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.	Journal of clinical oncology 	2009	101
19229667	3439	Dutcher JP	Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies.	Medical oncology	2009	53
19424421	3439	Brown KN	Rapid influx and death of plasmacytoid dendritic cells in lymph nodes mediate depletion in acute simian immunodeficiency virus infection.	PLoS pathogens	2009	65
19487381	3439	Motzer RJ	Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.	Journal of clinical oncology 	2009	413
19620293	3439	Subrata LS	Interactions between innate antiviral and atopic immunoinflammatory pathways precipitate and sustain asthma exacerbations in children.	Journal of immunology	2009	52
19910029	3439	Ogbogu PU	Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.	The Journal of allergy and clinical immunology	2009	60
20145197	3439	Fitzgerald-Bocarsly P	Plasmacytoid dendritic cells in HIV infection: striking a delicate balance.	Journal of leukocyte biology	2010	59
20179267	3439	Mocellin S	Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.	Journal of the National Cancer Institute	2010	83
20368553	3439	Escudier B	Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.	Journal of clinical oncology 	2010	152
20368558	3439	Rini BI	Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.	Journal of clinical oncology 	2010	170
20519386	3439	Gardner J	Chikungunya virus arthritis in adult wild-type mice.	Journal of virology	2010	94
22617827	3439	Knight JS	Lupus neutrophils: 'NET' gain in understanding lupus pathogenesis.	Current opinion in rheumatology	2012	38
22981791	3439	Baraldo S	Deficient antiviral immune responses in childhood: distinct roles of atopy and asthma.	The Journal of allergy and clinical immunology	2012	33
23046671	3439	Micco L	Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B.	Journal of hepatology	2013	35
23947345	3439	Durbin RK	Interferon induction and function at the mucosal surface.	Immunological reviews	2013	42
24297945	3439	Rini BI	Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.	Journal of clinical oncology 	2014	29
24481242	3439	Haroon E	IFN-alpha-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy.	Neuropsychopharmacology 	2014	20
10352304	3458	Pizarro TT	IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells.	Journal of immunology	1999	99
10428293	3458	Frostegård J	Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines.	Atherosclerosis	1999	141
10479160	3458	Day NP	The prognostic and pathophysiologic role of pro- and antiinflammatory cytokines in severe malaria.	The Journal of infectious diseases	1999	99
10955814	3458	Ueno T	Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer.	Clinical cancer research 	2000	160
11170064	3458	To KF	Pathology of fatal human infection associated with avian influenza A H5N1 virus.	Journal of medical virology	2001	104
11406550	3458	Woo EY	Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.	Cancer research	2001	243
11828007	3458	Gerosa F	Reciprocal activating interaction between natural killer cells and dendritic cells.	The Journal of experimental medicine	2002	218
11900986	3458	Ikeda H	The roles of IFN gamma in protection against tumor development and cancer immunoediting.	Cytokine and growth factor reviews	2002	152
12898444	3458	Wang SM	Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema.	The Journal of infectious diseases	2003	75
14512316	3458	Nieda M	Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity.	Blood	2004	86
14555512	3458	Ichihara F	Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers.	Clinical cancer research 	2003	97
15939793	3458	Ruprecht CR	Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia.	The Journal of experimental medicine	2005	103
16547287	3458	Longhi MS	Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis.	Journal of immunology	2006	64
16678181	3458	Hunt NH	Immunopathogenesis of cerebral malaria.	International journal for parasitology	2006	80
16785573	3458	Xu D	Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B.	Journal of immunology	2006	101
16971810	3458	Palucka AK	Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.	Journal of immunotherapy	2006	71
17185041	3458	Pillai V	Transient regulatory T-cells: a state attained by all activated human T-cells.	Clinical immunology	2007	89
17507983	3458	Barton ES	Herpesvirus latency confers symbiotic protection from bacterial infection.	Nature	2007	194
17916356	3458	Dolganiuc A	Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection.	Gastroenterology	2007	65
18039949	3458	Zaba LC	Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses.	The Journal of experimental medicine	2007	134
18276911	3458	Doran AC	Role of smooth muscle cells in the initiation and early progression of atherosclerosis.	Arteriosclerosis, thrombosis, and vascular biology	2008	167
18359186	3458	Witek-Janusek L	Effect of mindfulness based stress reduction on immune function, quality of life and coping in women newly diagnosed with early stage breast cancer.	Brain, behavior, and immunity	2008	75
18391061	3458	Luger D	Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category.	The Journal of experimental medicine	2008	221
18430495	3458	Hirao LA	Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques.	Vaccine	2008	68
18497880	3458	Kamada N	Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis.	The Journal of clinical investigation	2008	139
18678243	3458	Reale M	Peripheral cytokines profile in Parkinson's disease.	Brain, behavior, and immunity	2009	75
18684158	3458	Nograles KE	Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways.	The British journal of dermatology	2008	139
18802076	3458	Kryczek I	Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis.	Journal of immunology	2008	104
19055947	3458	Terabe M	The role of NKT cells in tumor immunity.	Advances in cancer research	2008	91
19105661	3458	Martinez FO	Alternative activation of macrophages: an immunologic functional perspective.	Annual review of immunology	2009	630
19255340	3458	Eid RE	Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells.	Circulation	2009	111
19287090	3458	Levy Y	Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment.	The Journal of clinical investigation	2009	114
19330474	3458	Wolk K	IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not.	Journal of molecular medicine	2009	58
19470694	3458	Kryczek I	Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments.	Blood	2009	202
19497992	3458	Moodley Y	Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury.	The American journal of pathology	2009	77
19536809	3458	Xu Q	Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens.	Stem cells	2009	54
19538319	3458	Schulzke JD	Epithelial tight junctions in intestinal inflammation.	Annals of the New York Academy of Sciences	2009	70
19542050	3458	Gao B	Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases.	Journal of leukocyte biology	2009	93
19585513	3458	Lynch L	Invariant NKT cells and CD1d(+) cells amass in human omentum and are depleted in patients with cancer and obesity.	European journal of immunology	2009	55
19818653	3458	Feuerer M	How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets.	Immunity	2009	83
19875682	3458	Mauad T	Lung pathology in fatal novel human influenza A (H1N1) infection.	American journal of respiratory and critical care medicine	2010	99
19890056	3458	Jäger A	Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes.	Journal of immunology	2009	186
20003352	3458	Bermejo-Martin JF	Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza.	Critical care	2009	91
20050849	3458	Schafer PH	Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.	British journal of pharmacology	2010	44
20164424	3458	Denny MF	A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs.	Journal of immunology	2010	110
20222111	3458	Shamji MF	Proinflammatory cytokine expression profile in degenerated and herniated human intervertebral disc tissues.	Arthritis and rheumatism	2010	53
20404924	3458	Verma S	Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis.	PloS one	2010	41
20437580	3458	Bar-Or A	Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?	Annals of neurology	2010	85
20677939	3458	Boulware DR	Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome.	The Journal of infectious diseases	2010	59
21085185	3458	Chiricozzi A	Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis.	The Journal of investigative dermatology	2011	77
21106641	3458	Brandau S	Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties.	Journal of leukocyte biology	2011	65
21169542	3458	Jagannathan-Bogdan M	Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes.	Journal of immunology	2011	70
21187448	3458	Rajasagi NK	Controlling herpes simplex virus-induced ocular inflammatory lesions with the lipid-derived mediator resolvin E1.	Journal of immunology	2011	44
21368230	3458	McClymont SA	Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes.	Journal of immunology	2011	98
21414808	3458	Saini D	Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts.	The Journal of heart and lung transplantation 	2011	45
21624938	3458	Zoller EE	Hemophagocytosis causes a consumptive anemia of inflammation.	The Journal of experimental medicine	2011	37
21628665	3458	Wauquier N	The acute phase of Chikungunya virus infection in humans is associated with strong innate immunity and T CD8 cell activation.	The Journal of infectious diseases	2011	39
22297636	3458	Harris JE	A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8⁺ T-cell accumulation in the skin.	The Journal of investigative dermatology	2012	31
22349514	3458	Schmieder A	Differentiation and gene expression profile of tumor-associated macrophages.	Seminars in cancer biology	2012	41
22370101	3458	Darmochwal-Kolarz D	The predominance of Th17 lymphocytes and decreased number and function of Treg cells in preeclampsia.	Journal of reproductive immunology	2012	31
22416258	3458	Jurado JO	IL-17 and IFN-γ expression in lymphocytes from patients with active tuberculosis correlates with the severity of the disease.	Journal of leukocyte biology	2012	42
22485125	3458	Zhang L	Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis.	PloS one	2012	36
23017648	3458	Devos D	Colonic inflammation in Parkinson's disease.	Neurobiology of disease	2013	29
23223131	3458	Hijnen D	CD8(+) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-γ, IL-13, IL-17, and IL-22.	The Journal of investigative dermatology	2013	29
23271808	3458	Fu B	Natural killer cells promote immune tolerance by regulating inflammatory TH17 cells at the human maternal-fetal interface.	Proceedings of the National Academy of Sciences of the United States of America	2013	36
23323860	3458	Padgett LE	The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis.	Annals of the New York Academy of Sciences	2013	54
23915137	3458	Swindell WR	Dissecting the psoriasis transcriptome: inflammatory- and cytokine-driven gene expression in lesions from 163 patients.	BMC genomics	2013	34
24009159	3458	Cosmi L	T helper cells plasticity in inflammation.	Cytometry. Part A 	2014	28
24655295	3458	Lowes MA	Immunology of psoriasis.	Annual review of immunology	2014	88
24967632	3458	Jo J	Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver.	PLoS pathogens	2014	29
25211344	3458	Sedegah M	Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopes.	PloS one	2014	25
25244096	3458	Kirabo A	DC isoketal-modified proteins activate T cells and promote hypertension.	The Journal of clinical investigation	2014	60
25534940	3458	Cardoso TM	Protective and pathological functions of CD8+ T cells in Leishmania braziliensis infection.	Infection and immunity	2015	16
25611466	3458	Gideon HP	Variability in tuberculosis granuloma T cell responses exists, but a balance of pro- and anti-inflammatory cytokines is associated with sterilization.	PLoS pathogens	2015	42
25644696	3458	Jiang W	Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease.	Scientific reports	2015	23
26350966	3458	Selleck EM	A Noncanonical Autophagy Pathway Restricts Toxoplasma gondii Growth in a Strain-Specific Manner in IFN-γ-Activated Human Cells.	mBio	2015	17
8520783	3553	Bonfield TL	Inflammatory cytokines in cystic fibrosis lungs.	American journal of respiratory and critical care medicine	1995	150
9233643	3553	Ferrari D	Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages.	Journal of immunology	1997	148
9240577	3553	Yoon BH	Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha), neonatal brain white matter lesions, and cerebral palsy.	American journal of obstetrics and gynecology	1997	116
10430608	3553	Frantz S	Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium.	The Journal of clinical investigation	1999	106
11734443	3553	Park WY	Cytokine balance in the lungs of patients with acute respiratory distress syndrome.	American journal of respiratory and critical care medicine	2001	102
12441323	3553	Figueiredo C	Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma.	Journal of the National Cancer Institute	2002	144
12891537	3553	Machado JC	A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma.	Gastroenterology	2003	106
14581396	3553	Mazurek T	Human epicardial adipose tissue is a source of inflammatory mediators.	Circulation	2003	266
15192144	3553	Andrei C	Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: Implications for inflammatory processes.	Proceedings of the National Academy of Sciences of the United States of America	2004	102
15777250	3553	Nagatsu T	Inflammatory process in Parkinson's disease: role for cytokines.	Current pharmaceutical design	2005	70
15855327	3553	Brusko TM	Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes.	Diabetes	2005	83
16006665	3553	Fiala M	Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients.	Journal of Alzheimer's disease 	2005	70
16503465	3553	Marks DJ	Defective acute inflammation in Crohn's disease: a clinical investigation.	Lancet	2006	104
17853946	3553	Schenk M	TREM-1--expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases.	The Journal of clinical investigation	2007	73
17965775	3553	Araya J	Squamous metaplasia amplifies pathologic epithelial-mesenchymal interactions in COPD patients.	The Journal of clinical investigation	2007	62
18227479	3553	Donath MY	Islet inflammation in type 2 diabetes: from metabolic stress to therapy.	Diabetes care	2008	81
18262644	3553	Challier JC	Obesity in pregnancy stimulates macrophage accumulation and inflammation in the placenta.	Placenta	2008	129
18276918	3553	Ganter MT	Interleukin-1beta causes acute lung injury via alphavbeta5 and alphavbeta6 integrin-dependent mechanisms.	Circulation research	2008	60
18385818	3553	Prasad AS	Zinc in human health: effect of zinc on immune cells.	Molecular medicine	2008	64
18397957	3553	Hoyland JA	Investigation of the role of IL-1 and TNF in matrix degradation in the intervertebral disc.	Rheumatology	2008	62
18928408	3553	Chen G	NOD-like receptors: role in innate immunity and inflammatory disease.	Annual review of pathology	2009	144
19008124	3553	Jones SW	The identification of differentially expressed microRNA in osteoarthritic tissue that modulate the production of TNF-alpha and MMP13.	Osteoarthritis and cartilage	2009	76
19085934	3553	Slominski A	Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells.	International journal of cancer	2009	48
19248089	3553	Wehling N	Interleukin-1beta and tumor necrosis factor alpha inhibit chondrogenesis by human mesenchymal stem cells through NF-kappaB-dependent pathways.	Arthritis and rheumatism	2009	51
19255163	3553	Chotikavanich S	Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome.	Investigative ophthalmology and visual science	2009	69
19686799	3553	Long-Smith CM	The influence of microglia on the pathogenesis of Parkinson's disease.	Progress in neurobiology	2009	51
19714579	3553	Miyaki S	MicroRNA-140 is expressed in differentiated human articular chondrocytes and modulates interleukin-1 responses.	Arthritis and rheumatism	2009	83
19717510	3553	Muñoz-Planillo R	A critical role for hemolysins and bacterial lipoproteins in Staphylococcus aureus-induced activation of the Nlrp3 inflammasome.	Journal of immunology	2009	99
19842207	3553	Zhang JY	Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B.	Hepatology	2010	89
19895991	3553	Zaba LC	Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes.	The Journal of allergy and clinical immunology	2009	63
20064793	3553	Samberg ME	Evaluation of silver nanoparticle toxicity in skin in vivo and keratinocytes in vitro.	Environmental health perspectives	2010	52
20127816	3553	Chakraborty S	Inflammasome signaling at the heart of central nervous system pathology.	Journal of neuroscience research	2010	45
20398664	3553	Ng J	Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome.	Gastroenterology	2010	54
20545607	3553	Goldberg JE	Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics.	Current drug targets	2010	55
20588114	3553	Dinarello CA	Role of IL-1beta in type 2 diabetes.	Current opinion in endocrinology, diabetes, and obesity	2010	74
21232790	3553	Roberts KA	Placental structure and inflammation in pregnancies associated with obesity.	Placenta	2011	48
21459803	3553	Dirat B	Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion.	Cancer research	2011	131
21486440	3553	Soria G	Inflammatory mediators in breast cancer: coordinated expression of TNFα &amp;amp; IL-1β with CCL2 &amp;amp; CCL5 and effects on epithelial-to-mesenchymal transition.	BMC cancer	2011	64
21599903	3553	Brochu ME	Developmental regulation of the neuroinflammatory responses to LPS and/or hypoxia-ischemia between preterm and term neonates: An experimental study.	Journal of neuroinflammation	2011	36
21752263	3553	Chang BY	The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.	Arthritis research and therapy	2011	46
21762124	3553	Menu P	The NLRP3 inflammasome in health and disease: the good, the bad and the ugly.	Clinical and experimental immunology	2011	61
21864400	3553	Levesque S	Air pollution &amp;amp; the brain: Subchronic diesel exhaust exposure causes neuroinflammation and elevates early markers of neurodegenerative disease.	Journal of neuroinflammation	2011	45
21901289	3553	Dayan V	Mesenchymal stromal cells mediate a switch to alternatively activated monocytes/macrophages after acute myocardial infarction.	Basic research in cardiology	2011	47
21906753	3553	Pandey GN	Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims.	Journal of psychiatric research	2012	46
21945322	3553	Rieder F	Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis.	The American journal of pathology	2011	60
22071871	3553	Zunszain PA	Interleukin-1β: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis.	Neuropsychopharmacology 	2012	55
22138609	3553	Lukiw WJ	NF-кB-regulated micro RNAs (miRNAs) in primary human brain cells.	Experimental neurology	2012	35
22195044	3553	Mitroulis I	Neutrophil extracellular trap formation is associated with IL-1β and autophagy-related signaling in gout.	PloS one	2011	58
22415665	3553	Hoque R	Sterile inflammatory response in acute pancreatitis.	Pancreas	2012	32
22723639	3553	Deretic V	Autophagy: an emerging immunological paradigm.	Journal of immunology	2012	51
22764097	3553	Denes A	Caspase-1: is IL-1 just the tip of the ICEberg?	Cell death and disease	2012	53
22829270	3553	Librizzi L	Seizure-induced brain-borne inflammation sustains seizure recurrence and blood-brain barrier damage.	Annals of neurology	2012	37
22923429	3553	Khosla S	Pathogenesis of age-related bone loss in humans.	The journals of gerontology. Series A, Biological sciences and medical sciences	2013	27
22993202	3553	Duboc H	Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases.	Gut	2013	61
23143332	3553	Zhu W	Interleukin receptor activates a MYD88-ARNO-ARF6 cascade to disrupt vascular stability.	Nature	2012	36
23401508	3553	Scotti C	Engineering of a functional bone organ through endochondral ossification.	Proceedings of the National Academy of Sciences of the United States of America	2013	49
23935251	3553	More SV	Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease.	Mediators of inflammation	2013	38
24203055	3553	Uhlig HH	Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease.	Gut	2013	39
24277153	3553	Guiducci C	RNA recognition by human TLR8 can lead to autoimmune inflammation.	The Journal of experimental medicine	2013	25
24356306	3553	Doitsh G	Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection.	Nature	2014	194
24356959	3553	van der Burgh R	Defects in mitochondrial clearance predispose human monocytes to interleukin-1β hypersecretion.	The Journal of biological chemistry	2014	24
24497828	3553	Sereti I	Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration.	PLoS pathogens	2014	32
24520123	3553	Dalmas E	T cell-derived IL-22 amplifies IL-1β-driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes.	Diabetes	2014	30
24556663	3553	Wollin L	Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.	The Journal of pharmacology and experimental therapeutics	2014	38
24876674	3553	Wojdasiewicz P	The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis.	Mediators of inflammation	2014	58
24920309	3553	Jansson D	A role for human brain pericytes in neuroinflammation.	Journal of neuroinflammation	2014	20
24948485	3553	Najjar S	Neuroinflammation and white matter pathology in schizophrenia: systematic review.	Schizophrenia research	2015	33
24952505	3553	Franklin BS	The adaptor ASC has extracellular and 'prionoid' activities that propagate inflammation.	Nature immunology	2014	84
24978137	3553	Ye SB	Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma.	Oncotarget	2014	44
25043017	3553	Arranz L	Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms.	Nature	2014	52
25164131	3553	Dong L	Decreased expression of microRNA-21 correlates with the imbalance of Th17 and Treg cells in patients with rheumatoid arthritis.	Journal of cellular and molecular medicine	2014	21
25412102	3553	Escudero-Pérez B	Shed GP of Ebola virus triggers immune activation and increased vascular permeability.	PLoS pathogens	2014	26
25453823	3553	Chittezhath M	Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression.	Immunity	2014	26
25690731	3553	Kim EK	Compromised MAPK signaling in human diseases: an update.	Archives of toxicology	2015	31
25762540	3553	Dudek-Perić AM	Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin.	Cancer research	2015	16
26926996	3553	Shirai T	The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease.	The Journal of experimental medicine	2016	16
27030597	3553	Masters SL	Familial autoinflammation with neutrophilic dermatosis reveals a regulatory mechanism of pyrin activation.	Science translational medicine	2016	15
2444978	3569	Gauldie J	Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.	Proceedings of the National Academy of Sciences of the United States of America	1987	261
8562936	3569	Chauhan D	Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B.	Blood	1996	119
9041933	3569	Tak PP	Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity.	Arthritis and rheumatism	1997	115
9389420	3569	Pickup JC	NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X.	Diabetologia	1997	150
9506738	3569	Fried SK	Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid.	The Journal of clinical endocrinology and metabolism	1998	272
10023775	3569	Catlett-Falcone R	Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.	Immunity	1999	346
10815894	3569	Almand B	Clinical significance of defective dendritic cell differentiation in cancer.	Clinical cancer research 	2000	144
11001908	3569	Keller SA	Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells.	Blood	2000	110
11022058	3569	Vila N	Proinflammatory cytokines and early neurological worsening in ischemic stroke.	Stroke	2000	103
11049970	3569	Hideshima T	Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.	Blood	2000	128
11287357	3569	Kern PA	Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance.	American journal of physiology. Endocrinology and metabolism	2001	280
11303144	3569	Bruunsgaard H	Aging and proinflammatory cytokines.	Current opinion in hematology	2001	131
11388092	3569	Pinede L	Clinical presentation of left atrial cardiac myxoma. A series of 112 consecutive cases.	Medicine	2001	92
11500339	3569	Harbarth S	Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis.	American journal of respiratory and critical care medicine	2001	106
12220549	3569	Ishihara K	IL-6 in autoimmune disease and chronic inflammatory proliferative disease.	Cytokine and growth factor reviews	2002	126
12629515	3569	Wei LH	Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway.	Oncogene	2003	93
15124018	3569	Nemeth E	IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin.	The Journal of clinical investigation	2004	452
15150588	3569	Michalaki V	Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer.	British journal of cancer	2004	73
15313862	3569	St John MA	Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma.	Archives of otolaryngology--head and neck surgery	2004	80
15598976	3569	Chen JJ	Tumor-associated macrophages: the double-edged sword in cancer progression.	Journal of clinical oncology 	2005	72
15705894	3569	Yang J	Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation.	Cancer research	2005	132
15978720	3569	Sarkar D	Molecular mechanisms of aging-associated inflammation.	Cancer letters	2006	72
15998837	3569	Nishimoto N	Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease.	Blood	2005	122
16012934	3569	Hart AL	Characteristics of intestinal dendritic cells in inflammatory bowel diseases.	Gastroenterology	2005	95
16412224	3569	Baker AR	Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease.	Cardiovascular diabetology	2006	121
16799139	3569	Maggio M	Interleukin-6 in aging and chronic disease: a magnificent pathway.	The journals of gerontology. Series A, Biological sciences and medical sciences	2006	117
16949415	3569	Andrews WW	The Alabama Preterm Birth study: polymorphonuclear and mononuclear cell placental infiltrations, other markers of inflammation, and outcomes in 23- to 32-week preterm newborn infants.	American journal of obstetrics and gynecology	2006	64
17062156	3569	Kode A	Differential effects of cigarette smoke on oxidative stress and proinflammatory cytokine release in primary human airway epithelial cells and in a variety of transformed alveolar epithelial cells.	Respiratory research	2006	72
17090751	3569	Creely SJ	Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes.	American journal of physiology. Endocrinology and metabolism	2007	160
17220301	3569	Meng F	The MicroRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes.	The Journal of biological chemistry	2007	65
17241887	3569	Isomoto H	Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing.	Gastroenterology	2007	64
17439648	3569	Bisht S	Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy.	Journal of nanobiotechnology	2007	137
17569118	3569	Tedelind S	Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease.	World journal of gastroenterology	2007	62
18156155	3569	Lee ST	Anti-inflammatory mechanism of intravascular neural stem cell transplantation in haemorrhagic stroke.	Brain 	2008	108
18242584	3569	Brydon L	Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans.	Biological psychiatry	2008	81
18245542	3569	Steele NL	A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors.	Clinical cancer research 	2008	60
18536030	3569	Duffy SA	Interleukin-6 predicts recurrence and survival among head and neck cancer patients.	Cancer	2008	83
18577591	3569	Serada S	IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis.	Proceedings of the National Academy of Sciences of the United States of America	2008	88
18627003	3569	van der Poorten D	Visceral fat: a key mediator of steatohepatitis in metabolic liver disease.	Hepatology	2008	78
18728182	3569	Pichiorri F	MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2008	184
18776137	3569	Miao F	Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: an epigenetic study in diabetes.	Diabetes	2008	53
18926166	3569	Libby P	Role of inflammation in atherosclerosis associated with rheumatoid arthritis.	The American journal of medicine	2008	54
19118018	3569	Ara T	Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells.	Cancer research	2009	51
19122178	3569	Chatterjee TK	Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding.	Circulation research	2009	112
19137011	3569	Lin L	The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling.	Oncogene	2009	67
19139294	3569	Sonnen JA	Different patterns of cerebral injury in dementia with or without diabetes.	Archives of neurology	2009	60
19189867	3569	Fonseca JE	Interleukin-6 as a key player in systemic inflammation and joint destruction.	Autoimmunity reviews	2009	63
19289234	3569	Scanzello CR	Local cytokine profiles in knee osteoarthritis: elevated synovial fluid interleukin-15 differentiates early from end-stage disease.	Osteoarthritis and cartilage	2009	49
19289637	3569	Greenstein AS	Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients.	Circulation	2009	113
19318968	3569	Tarantino G	Could inflammatory markers help diagnose nonalcoholic steatohepatitis?	European journal of gastroenterology and hepatology	2009	46
19483720	3569	Walter M	Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells.	Oncogene	2009	60
19581928	3569	Sullivan NJ	Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells.	Oncogene	2009	166
19585655	3569	Marra F	Adipokines in liver diseases.	Hepatology	2009	93
19589728	3569	Kraus S	Inflammation and colorectal cancer.	Current opinion in pharmacology	2009	66
19648274	3569	Goodman WA	IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells.	Journal of immunology	2009	59
19738918	3569	Bilbo SD	Early-life programming of later-life brain and behavior: a critical role for the immune system.	Frontiers in behavioral neuroscience	2009	123
19898853	3569	Knüpfer H	Serum interleukin-6 levels in colorectal cancer patients--a summary of published results.	International journal of colorectal disease	2010	56
19997642	3569	Yoshimura T	Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases.	PloS one	2009	67
20061650	3569	McGeer EG	Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy.	Journal of Alzheimer's disease 	2010	80
20125064	3569	Park KS	Trophic molecules derived from human mesenchymal stem cells enhance survival, function, and angiogenesis of isolated islets after transplantation.	Transplantation	2010	52
20215499	3569	Germano G	Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.	Cancer research	2010	52
20230889	3569	Boksa P	Effects of prenatal infection on brain development and behavior: a review of findings from animal models.	Brain, behavior, and immunity	2010	114
20335016	3569	Ara T	Interleukin-6 in bone metastasis and cancer progression.	European journal of cancer	2010	80
20446847	3569	Kalayjian RC	Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy.	The Journal of infectious diseases	2010	56
20581244	3569	Wong VW	Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years.	Gut	2010	87
20583924	3569	Uldrick TS	An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease.	Clinical infectious diseases 	2010	59
20816981	3569	Stannus O	Circulating levels of IL-6 and TNF-α are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults.	Osteoarthritis and cartilage	2010	45
21220315	3569	Iliopoulos D	Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion.	Proceedings of the National Academy of Sciences of the United States of America	2011	170
21224357	3569	Liu S	Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks.	Cancer research	2011	151
21245574	3569	Hassman LM	KSHV infects a subset of human tonsillar B cells, driving proliferation and plasmablast differentiation.	The Journal of clinical investigation	2011	36
21288813	3569	Chow A	Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor.	The Journal of infectious diseases	2011	62
21321193	3569	Chihara N	Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica.	Proceedings of the National Academy of Sciences of the United States of America	2011	47
21408027	3569	Bao B	Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer.	PloS one	2011	71
21408055	3569	Toth KG	IL-6 induced STAT3 signalling is associated with the proliferation of human muscle satellite cells following acute muscle damage.	PloS one	2011	37
21576701	3569	Piconi S	Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders.	Blood	2011	50
21685479	3569	Korkaya H	Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots.	Clinical cancer research 	2011	73
21709158	3569	Heusinkveld M	M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells.	Journal of immunology	2011	80
21726511	3569	Sandler NG	Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection.	Gastroenterology	2011	90
21809006	3569	Niu Q	Disturbed Th17/Treg balance in patients with rheumatoid arthritis.	Rheumatology international	2012	33
21964948	3569	Zeng C	The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications.	Journal of molecular medicine	2012	36
22065722	3569	Kulbe H	A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment.	Cancer research	2012	54
22184247	3569	Gibbs JE	The nuclear receptor REV-ERBα mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines.	Proceedings of the National Academy of Sciences of the United States of America	2012	108
22334567	3569	Antoniades CG	Source and characterization of hepatic macrophages in acetaminophen-induced acute liver failure in humans.	Hepatology	2012	46
22411804	3569	Villenave R	In vitro modeling of respiratory syncytial virus infection of pediatric bronchial epithelium, the primary target of infection in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2012	46
22698992	3569	Kesler S	Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors.	Brain, behavior, and immunity	2013	54
22743617	3569	Tu B	STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma.	Cancer letters	2012	37
23071313	3569	Rossato M	IL-10-induced microRNA-187 negatively regulates TNF-α, IL-6, and IL-12p40 production in TLR4-stimulated monocytes.	Proceedings of the National Academy of Sciences of the United States of America	2012	39
23136553	3569	Waldner MJ	Interleukin-6--a key regulator of colorectal cancer development.	International journal of biological sciences	2012	52
23136556	3569	Rincon M	Role of IL-6 in asthma and other inflammatory pulmonary diseases.	International journal of biological sciences	2012	59
23219374	3569	Allott EH	Obesity and prostate cancer: weighing the evidence.	European urology	2013	73
23219526	3569	Tzeng HE	Interleukin-6 induces vascular endothelial growth factor expression and promotes angiogenesis through apoptosis signal-regulating kinase 1 in human osteosarcoma.	Biochemical pharmacology	2013	28
23225204	3569	Candido J	Cancer-related inflammation.	Journal of clinical immunology	2013	79
23332012	3569	Longenecker CT	Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals.	HIV medicine	2013	52
23340215	3569	Singh AK	Metabolic syndrome and chronic kidney disease.	Current opinion in nephrology and hypertension	2013	27
23363979	3569	Schneider A	In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling.	Science translational medicine	2013	28
23389848	3569	Yang X	MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway.	Hepatology	2013	66
23390498	3569	Panchapakesan U	Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?	PloS one	2013	29
23482247	3569	Basaranoglu M	Fructose as a key player in the development of fatty liver disease.	World journal of gastroenterology	2013	44
23486877	3569	Desplats P	Molecular and pathologic insights from latent HIV-1 infection in the human brain.	Neurology	2013	53
23492367	3569	Shiota M	Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer.	Cancer research	2013	33
23530106	3569	Bower JE	Cytokine genetic variations and fatigue among patients with breast cancer.	Journal of clinical oncology 	2013	37
23532539	3569	Dethlefsen C	The role of intratumoral and systemic IL-6 in breast cancer.	Breast cancer research and treatment	2013	56
23633491	3569	Hartman ZC	Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8.	Cancer research	2013	76
23784932	3569	Reinartz S	Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse.	International journal of cancer	2014	38
23814496	3569	Chang Q	The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis.	Neoplasia	2013	66
24029605	3569	Middleton K	Interleukin-6: an angiogenic target in solid tumours.	Critical reviews in oncology/hematology	2014	23
24053309	3569	Nguyen DP	Inflammation and prostate cancer: the role of interleukin 6 (IL-6).	BJU international	2014	32
24346288	3569	Nagasaki T	Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction.	British journal of cancer	2014	46
24378753	3569	Noel N	Elevated IP10 levels are associated with immune activation and low CD4⁺ T-cell counts in HIV controller patients.	AIDS	2014	28
24417618	3569	Romero R	A novel molecular microbiologic technique for the rapid diagnosis of microbial invasion of the amniotic cavity and intra-amniotic infection in preterm labor with intact membranes.	American journal of reproductive immunology	2014	31
24473196	3569	Xiang M	STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypes.	Science signaling	2014	33
24667956	3569	Maude SL	Managing cytokine release syndrome associated with novel T cell-engaging therapies.	Cancer journal	2014	62
24751614	3569	Pal M	From cytokine to myokine: the emerging role of interleukin-6 in metabolic regulation.	Immunology and cell biology	2014	30
24819450	3569	Trayhurn P	Hypoxia and adipocyte physiology: implications for adipose tissue dysfunction in obesity.	Annual review of nutrition	2014	26
24841946	3569	Lleo A	Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells.	Hepatology	2014	23
24910242	3569	Umemura A	Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition.	Cell metabolism	2014	22
25174587	3569	Wang QS	Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia.	Molecular therapy 	2015	28
25190175	3569	Romero R	Sterile and microbial-associated intra-amniotic inflammation in preterm prelabor rupture of membranes.	The journal of maternal-fetal and neonatal medicine 	2015	30
25194572	3569	Tierney MT	STAT3 signaling controls satellite cell expansion and skeletal muscle repair.	Nature medicine	2014	65
25317870	3569	Maude SL	Chimeric antigen receptor T cells for sustained remissions in leukemia.	The New England journal of medicine	2014	447
25341798	3569	McLaughlin T	T-cell profile in adipose tissue is associated with insulin resistance and systemic inflammation in humans.	Arteriosclerosis, thrombosis, and vascular biology	2014	31
25368021	3569	Lee KW	Twist1 is a key regulator of cancer-associated fibroblasts.	Cancer research	2015	17
25387317	3569	Somsouk M	Gut epithelial barrier and systemic inflammation during chronic HIV infection.	AIDS	2015	26
25505246	3569	Park H	MicroRNA-146a and microRNA-146b regulate human dendritic cell apoptosis and cytokine production by targeting TRAF6 and IRAK1 proteins.	The Journal of biological chemistry	2015	26
25582579	3569	Loggia ML	Evidence for brain glial activation in chronic pain patients.	Brain 	2015	42
25720095	3569	Romero R	Clinical chorioamnionitis at term I: microbiology of the amniotic cavity using cultivation and molecular techniques.	Journal of perinatal medicine	2015	22
25731872	3569	Dubuquoy L	Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis.	Gut	2015	15
25787249	3569	Puthanveetil P	Long non-coding RNA MALAT1 regulates hyperglycaemia induced inflammatory process in the endothelial cells.	Journal of cellular and molecular medicine	2015	18
25802036	3569	de Vrij J	Glioblastoma-derived extracellular vesicles modify the phenotype of monocytic cells.	International journal of cancer	2015	18
25868978	3569	Deshmukh SK	Resistin and interleukin-6 exhibit racially-disparate expression in breast cancer patients, display molecular association and promote growth and aggressiveness of tumor cells through STAT3 activation.	Oncotarget	2015	17
25888319	3569	Ramis IB	Polymorphisms of the IL-6, IL-8 and IL-10 genes and the risk of gastric pathology in patients infected with Helicobacter pylori.	Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi	2017	5
26428501	3569	Kim CJ	Acute chorioamnionitis and funisitis: definition, pathologic features, and clinical significance.	American journal of obstetrics and gynecology	2015	26
27076371	3569	Teachey DT	Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.	Cancer discovery	2016	23
10487832	3791	Maniotis AJ	Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry.	The American journal of pathology	1999	309
11440984	3791	Vasa M	Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease.	Circulation research	2001	415
11719508	3791	Colavitti R	Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR.	The Journal of biological chemistry	2002	82
11781231	3791	Scharenberg CW	The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors.	Blood	2002	150
15082792	3791	Shao R	Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression.	Molecular and cellular biology	2004	85
15345590	3791	Massa M	Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction.	Blood	2005	90
15862416	3791	Heiss C	Impaired progenitor cell activity in age-related endothelial dysfunction.	Journal of the American College of Cardiology	2005	103
15896706	3791	Cao Y	Human adipose tissue-derived stem cells differentiate into endothelial cells in vitro and improve postnatal neovascularization in vivo.	Biochemical and biophysical research communications	2005	119
15899831	3791	Wedge SR	AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.	Cancer research	2005	160
16397235	3791	LaMontagne K	Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.	Cancer research	2006	74
18063830	3791	Yip HK	Level and value of circulating endothelial progenitor cells in patients after acute ischemic stroke.	Stroke	2008	51
18559524	3791	Hilberg F	BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.	Cancer research	2008	123
19717420	3791	Bearzi C	Identification of a coronary vascular progenitor cell in the human heart.	Proceedings of the National Academy of Sciences of the United States of America	2009	70
19935794	3791	Bengala C	Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.	British journal of cancer	2010	47
20010945	3791	Murukesh N	Biomarkers of angiogenesis and their role in the development of VEGF inhibitors.	British journal of cancer	2010	55
20368568	3791	Lam ET	Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.	Journal of clinical oncology 	2010	61
20371662	3791	Robinson BG	Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.	The Journal of clinical endocrinology and metabolism	2010	41
20472683	3791	Eder JP	A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.	Clinical cancer research 	2010	56
20488920	3791	Jutooru I	Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a.	Molecular pharmacology	2010	41
20872043	3791	Neyns B	Phase II study of sunitinib malate in patients with recurrent high-grade glioma.	Journal of neuro-oncology	2011	39
21882181	3791	Kim JJ	Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.	Cancer	2012	36
22393126	3791	Hamerlik P	Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth.	The Journal of experimental medicine	2012	92
23139354	3791	Hodgin JB	Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli.	Diabetes	2013	39
23169517	3791	Smith DC	Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.	Journal of clinical oncology 	2013	104
23213094	3791	Choueiri TK	Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.	Journal of clinical oncology 	2013	72
23454747	3791	Chatterjee S	Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.	The Journal of clinical investigation	2013	42
23516391	3791	Shah MA	Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.	PloS one	2013	47
23536763	3791	Yao X	Vascular endothelial growth factor receptor 2 (VEGFR-2) plays a key role in vasculogenic mimicry formation, neovascularization and tumor initiation by Glioma stem-like cells.	PloS one	2013	28
23553848	3791	Lee RJ	A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.	Clinical cancer research 	2013	30
23697367	3791	Vecchione A	A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2013	48
24297950	3791	Hutson TE	Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.	Journal of clinical oncology 	2014	63
24803676	3791	Karajannis MA	Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.	Neuro-oncology	2014	26
24827131	3791	Choueiri TK	A phase I study of cabozantinib (XL184) in patients with renal cell cancer.	Annals of oncology 	2014	22
24933332	3791	Garon EB	Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.	Lancet	2014	127
25225437	3791	Smith MR	Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.	Journal of clinical oncology 	2014	23
25240821	3791	Wilke H	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.	The Lancet. Oncology	2014	184
26001391	3791	Zhao Y	Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.	The oncologist	2015	35
26884585	3791	Li J	Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.	Journal of clinical oncology 	2016	44
9438854	3815	Hirota S	Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.	Science	1998	672
11213830	3815	Miettinen M	Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.	Virchows Archiv 	2001	241
11526490	3815	Tuveson DA	STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.	Oncogene	2001	100
12094370	3815	Fletcher CD	Diagnosis of gastrointestinal stromal tumors: A consensus approach.	Human pathology	2002	490
12181401	3815	Demetri GD	Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.	The New England journal of medicine	2002	651
12424067	3815	Joensuu H	Management of malignant gastrointestinal stromal tumours.	The Lancet. Oncology	2002	83
12522257	3815	Heinrich MC	PDGFRA activating mutations in gastrointestinal stromal tumors.	Science	2003	371
15010069	3815	Debiec-Rychter M	Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.	European journal of cancer	2004	80
15365079	3815	Corless CL	Biology of gastrointestinal stromal tumors.	Journal of clinical oncology 	2004	170
16981009	3815	Paniagua RT	Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis.	The Journal of clinical investigation	2006	60
17090188	3815	Miettinen M	Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.	Archives of pathology and laboratory medicine	2006	262
17193820	3815	Miettinen M	Gastrointestinal stromal tumors: pathology and prognosis at different sites.	Seminars in diagnostic pathology	2006	236
17325667	3815	Mahadevan D	A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.	Oncogene	2007	72
18076015	3815	Dematteo RP	Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).	Cancer	2008	96
18223323	3815	Espinosa I	A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors.	The American journal of surgical pathology	2008	84
18452550	3815	Virant-Klun I	Putative stem cells with an embryonic character isolated from the ovarian surface epithelium of women with no naturally present follicles and oocytes.	Differentiation; research in biological diversity	2008	65
18519691	3815	Zhang S	Identification and characterization of ovarian cancer-initiating cells from primary human tumors.	Cancer research	2008	366
18596272	3815	Sherman SI	Motesanib diphosphate in progressive differentiated thyroid cancer.	The New England journal of medicine	2008	113
18605894	3815	Virant-Klun I	Parthenogenetic embryo-like structures in the human ovarian surface epithelium cell culture in postmenopausal women with no naturally present follicles and oocytes.	Stem cells and development	2009	50
18623623	3815	Liegl B	Heterogeneity of kinase inhibitor resistance mechanisms in GIST.	The Journal of pathology	2008	77
18671239	3815	Kawai O	Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.	Cancer	2008	78
19303137	3815	Dematteo RP	Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.	Lancet	2009	245
19768731	3815	Haller F	Localization- and mutation-dependent microRNA (miRNA) expression signatures in gastrointestinal stromal tumours (GISTs), with a cluster of co-expressed miRNAs located at 14q32.31.	The Journal of pathology	2010	43
19865100	3815	Bodemer C	Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.	The Journal of investigative dermatology	2010	45
20100962	3815	Sternberg CN	Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.	Journal of clinical oncology 	2010	472
20224986	3815	Liu T	Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1.	Molecular and cellular biochemistry	2010	42
20226456	3815	Mekky MA	Diagnostic utility of EUS-guided FNA in patients with gastric submucosal tumors.	Gastrointestinal endoscopy	2010	49
20460510	3815	Adhikari AS	CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance.	Cancer research	2010	73
20802153	3815	Male V	Immature NK cells, capable of producing IL-22, are present in human uterine mucosa.	Journal of immunology	2010	44
21471108	3815	Montani D	C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension.	American journal of respiratory and critical care medicine	2011	39
21642685	3815	Carvajal RD	KIT as a therapeutic target in metastatic melanoma.	JAMA	2011	114
21690468	3815	Guo J	Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.	Journal of clinical oncology 	2011	91
22174191	3815	Nicolescu MI	Telocytes in parotid glands.	Anatomical record	2012	42
22381431	3815	Li TS	Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells.	Journal of the American College of Cardiology	2012	127
22500885	3815	Ceafalan L	Telocytes in human skin--are they involved in skin regeneration?	Journal of cellular and molecular medicine	2012	60
22797058	3815	Chau WK	c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.	Oncogene	2013	44
23371930	3815	Xiong Q	Functional consequences of human induced pluripotent stem cell therapy: myocardial ATP turnover rate in the in vivo swine heart with postinfarction remodeling.	Circulation	2013	30
23621814	3815	Díaz-Flores L	Telocytes in neuromuscular spindles.	Journal of cellular and molecular medicine	2013	27
23775962	3815	Hodi FS	Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.	Journal of clinical oncology 	2013	46
24009080	3815	Siemens H	Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness.	Oncotarget	2013	47
24170267	3815	Sanada F	c-Kit-positive cardiac stem cells nested in hypoxic niches are activated by stem cell factor reversing the aging myopathy.	Circulation research	2014	29
24379393	3815	Atay S	Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion.	Proceedings of the National Academy of Sciences of the United States of America	2014	33
24638003	3815	Corless CL	Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.	Journal of clinical oncology 	2014	30
25605837	3815	Joensuu H	KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence.	Journal of clinical oncology 	2015	17
26091043	3815	Cancer Genome Atlas Network.	Genomic Classification of Cutaneous Melanoma.	Cell	2015	197
27011036	3815	Boikos SA	Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.	JAMA oncology	2016	15
2438556	3845	Forrester K	Detection of high incidence of K-ras oncogenes during human colon tumorigenesis.	Nature	1987	165
2453289	3845	Almoguera C	Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.	Cell	1988	407
3587348	3845	Bos JL	Prevalence of ras gene mutations in human colorectal cancers.	Nature	1987	293
9586664	3845	Andreyev HJ	Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.	Journal of the National Cancer Institute	1998	155
9727023	3845	Yan J	Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase.	The Journal of biological chemistry	1998	102
11097226	3845	Samowitz WS	Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study.	Cancer epidemiology, biomarkers and prevention 	2000	99
12644542	3845	Singer G	Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.	Journal of the National Cancer Institute	2003	164
14966562	3845	Chan IT	Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.	The Journal of clinical investigation	2004	104
15494427	3845	Yu JL	Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis.	Blood	2005	108
15611288	3845	Timm J	CD8 epitope escape and reversion in acute HCV infection.	The Journal of experimental medicine	2004	100
15720814	3845	Löhr M	Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis.	Neoplasia	2005	69
15998951	3845	Ince WL	Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.	Journal of the National Cancer Institute	2005	69
16880785	3845	Eisen T	Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.	British journal of cancer	2006	142
16931950	3845	Brune K	Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer.	The American journal of surgical pathology	2006	69
17101316	3845	Spring KJ	High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy.	Gastroenterology	2006	82
17184525	3845	Krypuy M	High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer.	BMC cancer	2006	78
17332339	3845	Campbell PM	K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling.	Cancer research	2007	77
17512720	3845	Duffy MJ	Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.	European journal of cancer	2007	83
18669866	3845	Perrone F	PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.	Annals of oncology 	2009	112
19001320	3845	Di Nicolantonio F	Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.	Journal of clinical oncology 	2008	416
19033568	3845	Ogino S	A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer.	Journal of the National Cancer Institute	2008	134
19056857	3845	Santini D	High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.	The oncologist	2008	57
19196673	3845	Tol J	Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.	The New England journal of medicine	2009	287
19237633	3845	Ogino S	PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.	Journal of clinical oncology 	2009	111
19273710	3845	Iacobuzio-Donahue CA	DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.	Journal of clinical oncology 	2009	221
19323605	3845	Torrisani J	let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression.	Human gene therapy	2009	54
19380522	3845	Christensen BC	A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers.	Carcinogenesis	2009	70
19603018	3845	Loupakis F	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.	British journal of cancer	2009	136
19603024	3845	Souglakos J	Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.	British journal of cancer	2009	76
19686742	3845	Nosho K	A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers.	Gastroenterology	2009	53
19738126	3845	Jacobs B	Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.	Journal of clinical oncology 	2009	84
19884549	3845	Richman SD	KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.	Journal of clinical oncology 	2009	146
19908233	3845	Zlobec I	Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.	International journal of cancer	2010	58
20008640	3845	Roth AD	Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.	Journal of clinical oncology 	2010	282
20022659	3845	Mao C	KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.	Lung cancer	2010	74
20495549	3845	Singh M	Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.	Nature biotechnology	2010	91
20501503	3845	Fariña-Sarasqueta A	The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.	Annals of oncology 	2010	72
20570890	3845	Janakiraman M	Genomic and biological characterization of exon 4 KRAS mutations in human cancer.	Cancer research	2010	92
20607356	3845	Lee ST	Let-7 microRNA inhibits the proliferation of human glioblastoma cells.	Journal of neuro-oncology	2011	41
20610624	3845	Yu S	miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer.	Cancer research	2010	96
20699365	3845	Halilovic E	PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.	Cancer research	2010	49
20736745	3845	Irahara N	NRAS mutations are rare in colorectal cancer.	Diagnostic molecular pathology 	2010	43
20814421	3845	Morris JP 4th	KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma.	Nature reviews. Cancer	2010	171
20978259	3845	De Roock W	Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.	JAMA	2010	186
21167132	3845	Shin KH	miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras.	Biochemical and biophysical research communications	2011	48
21228335	3845	Bokemeyer C	Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.	Annals of oncology 	2011	163
21239505	3845	Tie J	KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.	Clinical cancer research 	2011	47
21300795	3845	Kim MJ	Involvement of autophagy in oncogenic K-Ras-induced malignant cell transformation.	The Journal of biological chemistry	2011	71
21305640	3845	Vaughn CP	Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.	Genes, chromosomes and cancer	2011	59
21364579	3845	Knijn N	KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.	British journal of cancer	2011	63
21383284	3845	Hutchins G	Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.	Journal of clinical oncology 	2011	125
21519026	3845	Bekaii-Saab T	Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.	Journal of clinical oncology 	2011	60
21543894	3845	Chan E	MicroRNA signatures differentiate melanoma subtypes.	Cell cycle	2011	35
21632860	3845	Molinari F	Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.	Clinical cancer research 	2011	56
21742770	3845	Babij C	STK33 kinase activity is nonessential in KRAS-dependent cancer cells.	Cancer research	2011	39
21985784	3845	Ebi H	Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.	The Journal of clinical investigation	2011	63
22266220	3845	O'Dell MR	Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.	Cancer research	2012	33
22314188	3845	Pai RK	BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.	The American journal of surgical pathology	2012	35
22473163	3845	Dewdney A	Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).	Journal of clinical oncology 	2012	49
22481281	3845	Chang DT	Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features.	Modern pathology 	2012	33
22613949	3845	Steckel M	Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.	Cell research	2012	45
22734028	3845	Tejpar S	Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.	Journal of clinical oncology 	2012	98
22753589	3845	Imamura Y	Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.	Clinical cancer research 	2012	62
22798500	3845	Tian S	A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.	Gut	2013	26
23017669	3845	Foxtrot Collaborative Group	Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial.	The Lancet. Oncology	2012	40
23200175	3845	Jänne PA	Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.	The Lancet. Oncology	2013	153
23293113	3845	Tougeron D	Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer.	Annals of oncology 	2013	29
23295441	3845	Sia D	Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.	Gastroenterology	2013	61
23348904	3845	Rosty C	Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features.	Modern pathology 	2013	47
23419522	3845	Fabbri F	Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs.	Cancer letters	2013	47
23426905	3845	Shiraha H	Human hepatocyte carcinogenesis (review).	International journal of oncology	2013	30
23453624	3845	Eser S	Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer.	Cancer cell	2013	78
23471846	3845	Heitzer E	Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing.	Cancer research	2013	122
23510984	3845	Cohn AL	A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.	Annals of oncology 	2013	27
23535601	3845	Son J	Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway.	Nature	2013	285
23569301	3845	Ye LC	Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.	Journal of clinical oncology 	2013	47
23630215	3845	Shepherd FA	Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.	Journal of clinical oncology 	2013	45
23660947	3845	Eklöf V	The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer.	British journal of cancer	2013	38
23690424	3845	Siu LL	Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.	Journal of clinical oncology 	2013	34
23700391	3845	Marisa L	Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.	PLoS medicine	2013	140
23725851	3845	Seymour MT	Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.	The Lancet. Oncology	2013	65
23792451	3845	Ogino S	Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.	Oncogene	2014	38
23912084	3845	Murphy SJ	Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor.	Gastroenterology	2013	33
23943799	3845	Licciulli S	Notch1 is required for Kras-induced lung adenocarcinoma and controls tumor cell survival via p53.	Cancer research	2013	27
24018645	3845	Vauthey JN	RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.	Annals of surgery	2013	29
24019539	3845	Sinicrope FA	Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.	Journal of clinical oncology 	2013	30
24024839	3845	Douillard JY	Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.	The New England journal of medicine	2013	383
24042191	3845	Mouradov D	Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations.	The American journal of gastroenterology	2013	27
24043732	3845	Piessevaux H	Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab.	Journal of clinical oncology 	2013	28
24256730	3845	Ostrem JM	K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.	Nature	2013	188
24293274	3845	Liao WT	MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2.	The Journal of pathology	2014	28
24297898	3845	Zorde Khvalevsky E	Mutant KRAS is a druggable target for pancreatic cancer.	Proceedings of the National Academy of Sciences of the United States of America	2013	37
24385213	3845	Tahara T	Fusobacterium in colonic flora and molecular features of colorectal carcinoma.	Cancer research	2014	46
24398677	3845	Kahlert C	Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer.	The Journal of biological chemistry	2014	94
24718886	3845	Douillard JY	Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.	Annals of oncology 	2014	69
24928083	3845	Taieb J	Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2014	24
24944469	3845	Binefa G	Colorectal cancer: from prevention to personalized medicine.	World journal of gastroenterology	2014	31
25051912	3845	Zoratto F	Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis.	Tumour biology 	2014	35
25088940	3845	Heinemann V	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.	The Lancet. Oncology	2014	184
25280443	3845	Phipps AI	Association between molecular subtypes of colorectal cancer and patient survival.	Gastroenterology	2015	75
25341011	3845	Ciombor KK	Recent therapeutic advances in the treatment of colorectal cancer.	Annual review of medicine	2015	19
25342560	3845	Sun Q	Competition between human cells by entosis.	Cell research	2014	25
25361982	3845	Klingbiel D	Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.	Annals of oncology 	2015	20
25632066	3845	Chen JS	A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.	Annals of oncology 	2015	17
25722381	3845	Blumenschein GR Jr	A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.	Annals of oncology 	2015	18
25823825	3845	Kinugasa H	Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer.	Cancer	2015	26
25877855	3845	Tabernero J	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.	The Lancet. Oncology	2015	69
25918287	3845	Dienstmann R	Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients.	Journal of clinical oncology 	2015	29
25937522	3845	Bokemeyer C	FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer.	European journal of cancer	2015	24
25961927	3845	Garcia PL	The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models.	Oncogene	2016	23
26085511	3845	Frenel JS	Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.	Clinical cancer research 	2015	31
26091037	3845	Dow LE	Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer.	Cell	2015	62
26178787	3845	Chiou SH	Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing.	Genes and development	2015	28
26491167	3845	Shi M	Divergent Viruses Discovered in Arthropods and Vertebrates Revise the Evolutionary History of the Flaviviridae and Related Viruses.	Journal of virology	2015	21
26608120	3845	Johnson DB	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.	European journal of cancer	2015	18
26625312	3845	Pécuchet N	Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer.	Oncotarget	2017	5
10606205	4072	Balzar M	The biology of the 17-1A antigen (Ep-CAM).	Journal of molecular medicine	1999	111
14745734	4072	Went PT	Frequent EpCam protein expression in human carcinomas.	Human pathology	2004	157
15195135	4072	Münz M	The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation.	Oncogene	2004	81
16404366	4072	Went P	Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.	British journal of cancer	2006	85
18097410	4072	Nagrath S	Isolation of rare circulating tumour cells in cancer patients by microchip technology.	Nature	2007	681
18781171	4072	Horst D	CD133 expression is an independent prognostic marker for low survival in colorectal cancer.	British journal of cancer	2008	74
20147742	4072	Coumans FA	All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer.	Annals of oncology 	2010	60
20190561	4072	Linke R	Catumaxomab: clinical development and future directions.	mAbs	2010	46
20930119	4072	Stott SL	Isolation of circulating tumor cells using a microvortex-generating herringbone-chip.	Proceedings of the National Academy of Sciences of the United States of America	2010	334
21261508	4072	Königsberg R	Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.	Acta oncologica	2011	58
21319194	4072	Yoon SM	Epithelial cell adhesion molecule (EpCAM) marks hepatocytes newly derived from stem/progenitor cells in humans.	Hepatology	2011	41
21576002	4072	Patriarca C	Epithelial cell adhesion molecule expression (CD326) in cancer: a short review.	Cancer treatment reviews	2012	60
22180853	4072	Pecot CV	A novel platform for detection of CK+ and CK- CTCs.	Cancer discovery	2011	48
22825490	4072	Saucedo-Zeni N	A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire.	International journal of oncology	2012	54
23230278	4072	Tauro BJ	Two distinct populations of exosomes are released from LIM1863 colon carcinoma cell-derived organoids.	Molecular and cellular proteomics 	2013	62
23480100	4072	Song Y	Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture.	Analytical chemistry	2013	30
23609047	4072	Baccelli I	Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay.	Nature biotechnology	2013	185
23616258	4072	Schulze K	Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma.	International journal of cancer	2013	31
24061411	4072	Sollier E	Size-selective collection of circulating tumor cells using Vortex technology.	Lab on a chip	2014	47
24141784	4072	Driemel C	Context-dependent adaption of EpCAM expression in early systemic esophageal cancer.	Oncogene	2014	21
25336717	4072	Satelli A	Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response.	Clinical chemistry	2015	28
26184843	4072	de Wit S	The detection of EpCAM(+) and EpCAM(-) circulating tumor cells.	Scientific reports	2015	24
1530909	4137	Goedert M	Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms.	Neuron	1992	152
3088567	4137	Grundke-Iqbal I	Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.	Proceedings of the National Academy of Sciences of the United States of America	1986	528
3131773	4137	Goedert M	Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau.	Proceedings of the National Academy of Sciences of the United States of America	1988	165
9836646	4137	Hong M	Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17.	Science	1998	200
10214737	4137	Delacourte A	The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease.	Neurology	1999	117
10595524	4137	Ishihara T	Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform.	Neuron	1999	137
12417659	4137	Allen B	Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein.	The Journal of neuroscience 	2002	124
15249677	4137	Liu F	O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease.	Proceedings of the National Academy of Sciences of the United States of America	2004	118
15615642	4137	Goedert M	Mutations causing neurodegenerative tauopathies.	Biochimica et biophysica acta	2005	107
15831501	4137	David DC	Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice.	The Journal of biological chemistry	2005	79
15914550	4137	Rouzier R	Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2005	70
17159101	4137	Arvanitakis Z	Diabetes is related to cerebral infarction but not to AD pathology in older persons.	Neurology	2006	88
17409229	4137	Berger Z	Accumulation of pathological tau species and memory loss in a conditional model of tauopathy.	The Journal of neuroscience 	2007	131
18199773	4137	Mocanu MM	The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy.	The Journal of neuroscience 	2008	70
21304998	4137	Whittington RA	Propofol directly increases tau phosphorylation.	PloS one	2011	42
21427723	4137	Cohen TJ	The acetylation of tau inhibits its function and promotes pathological tau aggregation.	Nature communications	2011	96
22608668	4137	Grossman M	The non-fluent/agrammatic variant of primary progressive aphasia.	The Lancet. Neurology	2012	31
22668776	4137	Chai X	Constitutive secretion of tau protein by an unconventional mechanism.	Neurobiology of disease	2012	36
23109154	4137	Bennett DA	Relation of neuropathology to cognition in persons without cognitive impairment.	Annals of neurology	2012	54
23411393	4137	Xia CF	(18)FT807, a novel tau positron emission tomography imaging agent for Alzheimer's disease.	Alzheimer's and dementia 	2013	89
23684085	4137	Spillantini MG	Tau pathology and neurodegeneration.	The Lancet. Neurology	2013	121
25393609	4137	Sokolow S	Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer's disease.	Journal of neurochemistry	2015	19
25921538	4137	Moore S	APP metabolism regulates tau proteostasis in human cerebral cortex neurons.	Cell reports	2015	23
27357347	4137	Smith R	18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers.	Brain 	2016	15
11877256	4170	Zhang B	Myeloid cell factor-1 is a critical survival factor for multiple myeloma.	Blood	2002	85
12070027	4170	Derenne S	Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.	Blood	2002	94
15637055	4170	Weng C	Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells.	The Journal of biological chemistry	2005	66
15940637	4170	Kobayashi S	Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells.	Gastroenterology	2005	71
16289418	4170	Sieghart W	Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy.	Journal of hepatology	2006	60
17043651	4170	Iwamaru A	A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo.	Oncogene	2007	97
17173063	4170	Lin X	'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.	Oncogene	2007	102
17178882	4170	Liu L	Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.	Cancer research	2006	270
17227835	4170	Pérez-Galán P	The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.	Blood	2007	69
17526595	4170	Masri FA	Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension.	American journal of physiology. Lung cellular and molecular physiology	2007	103
17545623	4170	Gomez-Bougie P	Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.	Cancer research	2007	76
18451170	4170	Tse C	ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.	Cancer research	2008	426
18574029	4170	Trachootham D	Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.	Blood	2008	56
18676833	4170	Ding Q	Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer.	Cancer research	2008	51
18806758	4170	Vogler M	Bcl-2 inhibitors: small molecules with a big impact on cancer therapy.	Cell death and differentiation	2009	106
18836097	4170	Balakrishnan K	AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance.	Blood	2009	58
19372583	4170	Boisvert-Adamo K	Mcl-1 is required for melanoma cell resistance to anoikis.	Molecular cancer research 	2009	51
19503096	4170	Saito Y	Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells.	Oncogene	2009	51
19654003	4170	Crawford M	MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer.	Biochemical and biophysical research communications	2009	56
20023629	4170	Schwickart M	Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival.	Nature	2010	194
20164920	4170	Beroukhim R	The landscape of somatic copy-number alteration across human cancers.	Nature	2010	936
20335218	4170	Buchner M	Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.	Blood	2010	60
20587533	4170	Voss V	The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma.	Molecular cancer research 	2010	47
21345578	4170	Jendrossek V	Targeting apoptosis pathways by Celecoxib in cancer.	Cancer letters	2013	37
21368833	4170	Inuzuka H	SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction.	Nature	2011	177
21636858	4170	Visone R	miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia.	Blood	2011	41
22064351	4170	Konopleva M	MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.	Leukemia	2012	39
22128299	4170	Tromp JM	Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.	Clinical cancer research 	2012	35
22999885	4170	Cohen NA	A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival.	Chemistry and biology	2012	39
23756231	4170	Ji F	MicroRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1.	Bone	2013	30
24019208	4170	Abulwerdi F	A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo.	Molecular cancer therapeutics	2014	44
25590800	4170	Leverson JD	Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).	Cell death and disease	2015	70
25679114	4170	Bruncko M	Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.	Journal of medicinal chemistry	2015	27
25733019	4170	Huskey NE	CDK1 inhibition targets the p53-NOXA-MCL1 axis, selectively kills embryonic stem cells, and prevents teratoma formation.	Stem cell reports	2015	17
25829398	4170	Cervantes-Gomez F	Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.	Clinical cancer research 	2015	25
25936818	4170	Mohammad RM	Broad targeting of resistance to apoptosis in cancer.	Seminars in cancer biology	2015	26
27760111	4170	Kotschy A	The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.	Nature	2016	21
8958220	4313	Rajagopalan S	Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability.	The Journal of clinical investigation	1996	164
10357558	4313	Kleiner DE	Matrix metalloproteinases and metastasis.	Cancer chemotherapy and pharmacology	1999	106
11181465	4313	Crisby M	Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization.	Circulation	2001	88
11289157	4313	Wild-Bode C	Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma.	Cancer research	2001	97
11349215	4313	John A	The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis.	Pathology oncology research 	2001	93
11426650	4313	Zucker S	Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.	Oncogene	2000	97
11583974	4313	Yang J	Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis.	The American journal of pathology	2001	163
14500349	4313	Belotti D	Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation.	Cancer research	2003	80
15588763	4313	Mook OR	The role of gelatinases in colorectal cancer progression and metastasis.	Biochimica et biophysica acta	2004	93
15591520	4313	Xu L	Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis.	Gut	2005	218
16428474	4313	Sood AK	Stress hormone-mediated invasion of ovarian cancer cells.	Clinical cancer research 	2006	130
17079456	4313	Yang EV	Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells.	Cancer research	2006	88
18093986	4313	Adya R	Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis.	Cardiovascular research	2008	70
18258847	4313	Asosingh K	Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension.	The American journal of pathology	2008	55
19187537	4313	Ma XJ	Gene expression profiling of the tumor microenvironment during breast cancer progression.	Breast cancer research 	2009	178
22260435	4313	Gomes LR	TGF-β1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells.	BMC cancer	2012	38
22532131	4313	Groblewska M	The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer.	Folia histochemica et cytobiologica	2012	35
22674130	4313	Toth M	Assessment of gelatinases (MMP-2 and MMP-9) by gelatin zymography.	Methods in molecular biology	2012	36
23232575	4313	Gao J	Knockdown of MACC1 expression suppressed hepatocellular carcinoma cell migration and invasion and inhibited expression of MMP2 and MMP9.	Molecular and cellular biochemistry	2013	29
24281743	4313	Jickling GC	Hemorrhagic transformation after ischemic stroke in animals and humans.	Journal of cerebral blood flow and metabolism 	2014	38
3520340	4609	Bentley DL	A block to elongation is largely responsible for decreased transcription of c-myc in differentiated HL60 cells.	Nature	1986	257
10360173	4609	Pelengaris S	Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion.	Molecular cell	1999	129
10637317	4609	Kyo S	Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT).	Nucleic acids research	2000	110
11139609	4609	Schuhmacher M	The transcriptional program of a human B cell line in response to Myc.	Nucleic acids research	2001	108
15778709	4609	Basso K	Reverse engineering of regulatory networks in human B cells.	Nature genetics	2005	461
16094360	4609	Hemann MT	Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.	Nature	2005	152
16760443	4609	Dave SS	Molecular diagnosis of Burkitt's lymphoma.	The New England journal of medicine	2006	179
17072308	4609	Söderberg O	Direct observation of individual endogenous protein complexes in situ by proximity ligation.	Nature methods	2006	630
17114293	4609	Palomero T	NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth.	Proceedings of the National Academy of Sciences of the United States of America	2006	254
17558397	4609	Popov N	The ubiquitin-specific protease USP28 is required for MYC stability.	Nature cell biology	2007	97
17646408	4609	Thompson BJ	The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia.	The Journal of experimental medicine	2007	147
17906636	4609	Soucek L	Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors.	Nature medicine	2007	136
18035408	4609	Takahashi K	Induction of pluripotent stem cells from adult human fibroblasts by defined factors.	Cell	2007	4123
18397753	4609	Wong DJ	Module map of stem cell genes guides creation of epithelial cancer stem cells.	Cell stem cell	2008	251
18567993	4609	Gurel B	Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis.	Modern pathology 	2008	112
18679422	4609	Zhuang D	C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.	Oncogene	2008	52
19276364	4609	Kaposi-Novak P	Central role of c-Myc during malignant conversion in human hepatocarcinogenesis.	Cancer research	2009	53
19597184	4609	Johnson NA	Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.	Blood	2009	73
19620500	4609	Nelson TJ	Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells.	Circulation	2009	150
19690609	4609	Chandriani S	A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response.	PloS one	2009	49
19697349	4609	Zhou W	Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells.	Stem cells	2009	119
19962879	4609	Soucek L	The ups and downs of Myc biology.	Current opinion in genetics and development	2010	60
20041972	4609	Germanguz I	Molecular characterization and functional properties of cardiomyocytes derived from human inducible pluripotent stem cells.	Journal of cellular and molecular medicine	2011	44
20133671	4609	Wolfer A	MYC regulation of a "poor-prognosis" metastatic cancer cell state.	Proceedings of the National Academy of Sciences of the United States of America	2010	62
20208519	4609	Chen D	Transcription-independent ARF regulation in oncogenic stress-mediated p53 responses.	Nature	2010	48
20399964	4609	Albihn A	MYC in oncogenesis and as a target for cancer therapies.	Advances in cancer research	2010	72
20940416	4609	Herishanu Y	The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.	Blood	2011	189
21098324	4609	Cho YJ	Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.	Journal of clinical oncology 	2011	180
21478273	4609	Sodir NM	Endogenous Myc maintains the tumor microenvironment.	Genes and development	2011	50
21692241	4609	Pike LS	Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells.	Biochimica et biophysica acta	2011	73
22002575	4609	Li S	B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.	Modern pathology 	2012	34
22037351	4609	Thayanithy V	Perturbation of 14q32 miRNAs-cMYC gene network in osteosarcoma.	Bone	2012	34
22463982	4609	De Los Angeles A	Accessing naïve human pluripotency.	Current opinion in genetics and development	2012	32
22806891	4609	Holien T	Addiction to c-MYC in multiple myeloma.	Blood	2012	41
23001146	4609	Calado DP	The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers.	Nature immunology	2012	53
23021215	4609	Lin CY	Transcriptional amplification in tumor cells with elevated c-Myc.	Cell	2012	375
23176581	4609	Yamada Y	Tumor-suppressive microRNA-135a inhibits cancer cell proliferation by targeting the c-MYC oncogene in renal cell carcinoma.	Cancer science	2013	29
23386128	4609	Merling RK	Transgene-free iPSCs generated from small volume peripheral blood nonmobilized CD34+ cells.	Blood	2013	28
24002871	4609	Wang L	c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma.	Hepatology	2014	41
24394663	4609	Roderick JE	c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells.	Blood	2014	28
24793789	4609	Tsai LH	The MZF1/c-MYC axis mediates lung adenocarcinoma progression caused by wild-type lkb1 loss.	Oncogene	2015	17
24890832	4609	Gabay M	MYC activation is a hallmark of cancer initiation and maintenance.	Cold Spring Harbor perspectives in medicine	2014	69
24927563	4609	Janghorban M	Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2014	25
24933113	4609	Tu WB	Myc and its interactors take shape.	Biochimica et biophysica acta	2015	17
24951766	4609	Ryan JJ	The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure.	Circulation research	2014	27
25009295	4609	Trabucco SE	Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.	Clinical cancer research 	2015	22
25038584	4609	Wahlström T	Impact of MYC in regulation of tumor cell metabolism.	Biochimica et biophysica acta	2015	33
26099045	4609	Yates LR	Subclonal diversification of primary breast cancer revealed by multiregion sequencing.	Nature medicine	2015	74
4047115	4613	Seeger RC	Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.	The New England journal of medicine	1985	281
17283129	4613	Chen Y	Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis.	Cancer research	2007	119
18463370	4613	Maris JM	Chromosome 6p22 locus associated with clinically aggressive neuroblastoma.	The New England journal of medicine	2008	82
19047291	4613	Cohn SL	The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.	Journal of clinical oncology 	2009	226
19111882	4613	Otto T	Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma.	Cancer cell	2009	116
19171713	4613	Janoueix-Lerosey I	Overall genomic pattern is a predictor of outcome in neuroblastoma.	Journal of clinical oncology 	2009	64
19515614	4613	Vermeulen J	Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study.	The Lancet. Oncology	2009	49
19924232	4613	Bray I	Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival.	PloS one	2009	47
20173740	4613	Ma L	miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis.	Nature cell biology	2010	368
20227189	4613	Modak S	Neuroblastoma: Therapeutic strategies for a clinical enigma.	Cancer treatment reviews	2010	42
20961996	4613	Qing G	Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha.	Cancer research	2010	43
21768459	4613	London WB	Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project.	Journal of clinical oncology 	2011	38
22389870	4613	Beltran H	Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.	Cancer discovery	2011	110
23358695	4613	Mosquera JM	Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.	Neoplasia	2013	44
23430699	4613	Puissant A	Targeting MYCN in neuroblastoma by BET bromodomain inhibition.	Cancer discovery	2013	135
23498719	4613	Rushlow DE	Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.	The Lancet. Oncology	2013	43
23890779	4613	Kreissman SG	Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.	The Lancet. Oncology	2013	36
25533335	4613	Hill RM	Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease.	Cancer cell	2015	18
11894862	4763	Ferner RE	International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis.	Cancer research	2002	89
16330947	4763	Miettinen M	Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases.	The American journal of surgical pathology	2006	69
17283119	4763	Sharma MK	Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin.	Cancer research	2007	59
17387725	4763	Listernick R	Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.	Annals of neurology	2007	64
19111880	4763	Alcantara Llaguno S	Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model.	Cancer cell	2009	197
19474676	4763	Zou C	Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome.	Annals of surgery	2009	50
19576851	4763	van Nederveen FH	An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis.	The Lancet. Oncology	2009	69
20027112	4763	Jett K	Clinical and genetic aspects of neurofibromatosis 1.	Genetics in medicine 	2010	59
21861229	4763	Stucky CC	Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience.	Annals of surgical oncology	2012	37
23099009	4763	Robertson KA	Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.	The Lancet. Oncology	2012	33
26017449	4763	Patch AM	Whole-genome characterization of chemoresistant ovarian cancer.	Nature	2015	123
26214590	4763	Krauthammer M	Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.	Nature genetics	2015	40
26580448	4763	Zhang J	Germline Mutations in Predisposition Genes in Pediatric Cancer.	The New England journal of medicine	2015	43
27165744	4763	Zheng S	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma.	Cancer cell	2016	23
8598754	5621	Will RG	A new variant of Creutzfeldt-Jakob disease in the UK.	Lancet	1996	314
8651649	5621	Parchi P	Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease.	Annals of neurology	1996	136
10443888	5621	Parchi P	Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects.	Annals of neurology	1999	211
11476832	5621	Wadsworth JD	Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay.	Lancet	2001	158
11504948	5621	Korth C	Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease.	Proceedings of the National Academy of Sciences of the United States of America	2001	111
14522861	5621	Gambetti P	Sporadic and familial CJD: classification and characterisation.	British medical bulletin	2003	118
15302196	5621	Peden AH	Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient.	Lancet	2004	139
15741275	5621	Safar JG	Diagnosis of human prion disease.	Proceedings of the National Academy of Sciences of the United States of America	2005	81
16135751	5621	Kong Q	Chronic wasting disease of elk: transmissibility to humans examined by transgenic mouse models.	The Journal of neuroscience 	2005	78
16297838	5621	Polymenidou M	Coexistence of multiple PrPSc types in individuals with Creutzfeldt-Jakob disease.	The Lancet. Neurology	2005	69
16518470	5621	Nonno R	Efficient transmission and characterization of Creutzfeldt-Jakob disease strains in bank voles.	PLoS pathogens	2006	62
17161728	5621	Wroe SJ	Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report.	Lancet	2006	86
17585315	5621	Aguzzi A	Insights into prion strains and neurotoxicity.	Nature reviews. Molecular cell biology	2007	98
17923484	5621	Barron RM	High titers of transmissible spongiform encephalopathy infectivity associated with extremely low levels of PrPSc in vivo.	The Journal of biological chemistry	2007	69
18571782	5621	Gambetti P	A novel human disease with abnormal prion protein sensitive to protease.	Annals of neurology	2008	76
19231987	5621	Caughey B	Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions.	Annual review of biochemistry	2009	119
19436715	5621	Barria MA	De novo generation of infectious prions in vitro produces a new disease phenotype.	PLoS pathogens	2009	50
19789378	5621	Aguzzi A	Prions: protein aggregation and infectious diseases.	Physiological reviews	2009	118
20070383	5621	Peden A	Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia.	Haemophilia 	2010	41
20547859	5621	Bishop MT	Defining sporadic Creutzfeldt-Jakob disease strains and their transmission properties.	Proceedings of the National Academy of Sciences of the United States of America	2010	51
21350487	5621	Sandberg MK	Prion propagation and toxicity in vivo occur in two distinct mechanistic phases.	Nature	2011	94
24336048	5621	Joshi P	Microglia convert aggregated amyloid-β into neurotoxic forms through the shedding of microvesicles.	Cell death and differentiation	2014	31
25099576	5621	Orrú CD	A test for Creutzfeldt-Jakob disease using nasal brushings.	The New England journal of medicine	2014	39
25823511	5621	Cramm M	Stability and Reproducibility Underscore Utility of RT-QuIC for Diagnosis of Creutzfeldt-Jakob Disease.	Molecular neurobiology	2016	20
26086786	5621	Orrú CD	Bank Vole Prion Protein As an Apparently Universal Substrate for RT-QuIC-Based Detection and Discrimination of Prion Strains.	PLoS pathogens	2015	24
26324905	5621	Prusiner SB	Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism.	Proceedings of the National Academy of Sciences of the United States of America	2015	63
26791950	5621	Minikel EV	Quantifying prion disease penetrance using large population control cohorts.	Science translational medicine	2016	24
9072974	5728	Li J	PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.	Science	1997	1013
9307275	5728	Tashiro H	Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies.	Cancer research	1997	127
9443392	5728	Suzuki H	Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.	Cancer research	1998	100
15077152	5728	Gozuacik D	Autophagy as a cell death and tumor suppressor mechanism.	Oncogene	2004	305
15193142	5728	Leslie NR	PTEN function: how normal cells control it and tumour cells lose it.	The Biochemical journal	2004	104
16412571	5728	Chow LM	PTEN function in normal and neoplastic growth.	Cancer letters	2006	69
17218261	5728	Trotman LC	Ubiquitination regulates PTEN nuclear import and tumor suppression.	Cell	2007	205
17452630	5728	Saal LH	Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.	Proceedings of the National Academy of Sciences of the United States of America	2007	178
17940504	5728	Frattini M	PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients.	British journal of cancer	2007	135
18032782	5728	Tamguney T	New insights into PTEN.	Journal of cell science	2007	83
18500259	5728	Yoshimoto M	Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.	Modern pathology 	2008	79
18767981	5728	Chalhoub N	PTEN and the PI3-kinase pathway in cancer.	Annual review of pathology	2009	251
19055754	5728	Marty B	Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.	Breast cancer research 	2008	60
19402094	5728	Sircar K	PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer.	The Journal of pathology	2009	70
19729658	5728	Fine B	Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a.	Science	2009	79
19884659	5728	Song LB	The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells.	The Journal of clinical investigation	2009	122
19962668	5728	Garofalo M	miR-221&amp;amp;222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation.	Cancer cell	2009	222
20516122	5728	Mao X	Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis.	Cancer research	2010	56
20600018	5728	Heald B	Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers.	Gastroenterology	2010	42
21241890	5728	Song MS	Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner.	Cell	2011	128
21779461	5728	Koh CM	MYC and Prostate Cancer.	Genes and cancer	2010	46
21878536	5728	Lotan TL	PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.	Clinical cancer research 	2011	73
22465665	5728	Fu X	Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells.	FEBS letters	2012	45
22473468	5728	Song MS	The functions and regulation of the PTEN tumour suppressor.	Nature reviews. Molecular cell biology	2012	431
22664040	5728	Zhou J	PTEN signaling in autism spectrum disorders.	Current opinion in neurobiology	2012	45
23060044	5728	Wu Z	Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer.	The Prostate	2013	29
23335809	5728	Bubien V	High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome.	Journal of medical genetics	2013	30
23613428	5728	Mester J	When overgrowth bumps into cancer: the PTEN-opathies.	American journal of medical genetics. Part C, Seminars in medical genetics	2013	33
24135135	5728	Haffner MC	Tracking the clonal origin of lethal prostate cancer.	The Journal of clinical investigation	2013	95
24136893	5728	Pilarski R	Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria.	Journal of the National Cancer Institute	2013	41
24768297	5728	Liang H	PTENα, a PTEN isoform translated through alternative initiation, regulates mitochondrial function and energy metabolism.	Cell metabolism	2014	38
24993522	5728	Lotan TL	PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy.	Modern pathology 	2015	19
26123120	5728	Ross AE	Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.	Prostate cancer and prostatic diseases	2016	11
26546618	5728	Aparicio AM	Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.	Clinical cancer research 	2016	11
26615022	5728	Ahearn TU	A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.	Journal of the National Cancer Institute	2016	13
10999740	6387	Koshiba T	Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression.	Clinical cancer research 	2000	93
11912162	6387	Taichman RS	Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone.	Cancer research	2002	245
15695388	6387	Kryczek I	CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers.	Cancer research	2005	92
15756007	6387	Scala S	Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma.	Clinical cancer research 	2005	83
15837989	6387	Kim J	Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival.	Journal of clinical oncology 	2005	102
15882617	6387	Orimo A	Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion.	Cell	2005	902
16269611	6387	Burger JA	CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment.	Blood	2006	277
16489019	6387	Yasumoto K	Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer.	Cancer research	2006	61
16880743	6387	Orimo A	Stromal fibroblasts in cancer: a novel tumor-promoting cell type.	Cell cycle	2006	218
16943240	6387	Kryczek I	Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis.	American journal of physiology. Cell physiology	2007	85
17174272	6387	Mehrad B	Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease.	Biochemical and biophysical research communications	2007	95
17476353	6387	Brem H	Cellular and molecular basis of wound healing in diabetes.	The Journal of clinical investigation	2007	190
17724466	6387	Wendt MK	Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells.	Oncogene	2008	53
18167337	6387	Yang L	Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis.	Cancer cell	2008	298
18182063	6387	Croker AK	Cancer stem cells: implications for the progression and treatment of metastatic disease.	Journal of cellular and molecular medicine	2008	71
18276777	6387	McCandless EE	Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis.	The American journal of pathology	2008	55
18371365	6387	Hermann PC	Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer.	Cell stem cell	2007	712
18519693	6387	Mishra PJ	Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells.	Cancer research	2008	207
19181699	6387	Muehlberg FL	Tissue-resident stem cells promote breast cancer growth and metastasis.	Carcinogenesis	2009	72
20460522	6387	Nimmagadda S	Molecular imaging of CXCR4 receptor expression in human cancer xenografts with 64CuAMD3100 positron emission tomography.	Cancer research	2010	43
20965212	6387	Ghadge SK	SDF-1α as a therapeutic stem cell homing factor in myocardial infarction.	Pharmacology and therapeutics	2011	52
21041659	6387	Kojima Y	Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts.	Proceedings of the National Academy of Sciences of the United States of America	2010	155
21508321	6387	Godier-Furnémont AF	Composite scaffold provides a cell delivery platform for cardiovascular repair.	Proceedings of the National Academy of Sciences of the United States of America	2011	45
22025564	6387	Obermajer N	PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment.	Cancer research	2011	96
22415233	6387	Popple A	The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer.	British journal of cancer	2012	33
22683307	6387	Domanska UM	A review on CXCR4/CXCL12 axis in oncology: no place to hide.	European journal of cancer	2013	116
22927248	6387	Xu J	Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome.	Blood	2012	43
23429605	6387	Penn MS	An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure.	Circulation research	2013	31
23540695	6387	Cheng L	Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth.	Cell	2013	132
25825601	6387	Wester HJ	Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging.	Theranostics	2015	17
26058075	6387	Pitt LA	CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance.	Cancer cell	2015	29
26909116	6387	Lapa C	(68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma.	Theranostics	2016	10
9726379	6622	Spillantini MG	Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies.	Neuroscience letters	1998	148
10391881	6622	Wood SJ	alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease.	The Journal of biological chemistry	1999	122
10678833	6622	Masliah E	Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.	Science	2000	326
10885656	6622	Hamilton RL	Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry.	Brain pathology	2000	106
10991663	6622	Braak H	Pathoanatomy of Parkinson's disease.	Journal of neurology	2000	95
11923443	6622	Kirik D	Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.	The Journal of neuroscience 	2002	150
12042811	6622	Xu J	Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease.	Nature medicine	2002	141
12062037	6622	Giasson BI	Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein.	Neuron	2002	239
12084935	6622	Lee MK	Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --&amp;gt; Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.	Proceedings of the National Academy of Sciences of the United States of America	2002	148
12122208	6622	Lo Bianco C	alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.	Proceedings of the National Academy of Sciences of the United States of America	2002	112
12177198	6622	Sherer TB	An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.	The Journal of neuroscience 	2002	116
12601150	6622	Kirik D	Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease.	Proceedings of the National Academy of Sciences of the United States of America	2003	82
12714745	6622	Giasson BI	Initiation and synergistic fibrillization of tau and alpha-synuclein.	Science	2003	162
12807436	6622	Lakso M	Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein.	Journal of neurochemistry	2003	82
15576511	6622	Lo Bianco C	Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.	Proceedings of the National Academy of Sciences of the United States of America	2004	71
15753419	6622	Bennett DA	Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions.	Neurology	2005	171
15851731	6622	Braak H	Cognitive status correlates with neuropathologic stage in Parkinson disease.	Neurology	2005	79
16237129	6622	McKeith IG	Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.	Neurology	2005	841
16358335	6622	Nishioka K	Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease.	Annals of neurology	2006	65
16399671	6622	Martin LJ	Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death.	The Journal of neuroscience 	2006	165
16794039	6622	Cooper AA	Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models.	Science	2006	396
16847063	6622	Anderson JP	Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.	The Journal of biological chemistry	2006	228
17055279	6622	Chu Y	Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?	Neurobiology of disease	2007	95
17254549	6622	Hoozemans JJ	Activation of the unfolded protein response in Parkinson's disease.	Biochemical and biophysical research communications	2007	87
17353469	6622	Lippa CF	DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers.	Neurology	2007	110
17949715	6622	Chesselet MF	In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?	Experimental neurology	2008	55
18036154	6622	Reynolds AD	Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease.	Journal of neurochemistry	2008	59
18178617	6622	Gorbatyuk OS	The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.	Proceedings of the National Academy of Sciences of the United States of America	2008	73
18245082	6622	Devi L	Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain.	The Journal of biological chemistry	2008	180
18451726	6622	Waxman EA	Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein.	Journal of neuropathology and experimental neurology	2008	72
18625222	6622	Mollenhauer B	Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration.	Experimental neurology	2008	86
18626651	6622	Beach TG	Evaluation of alpha-synuclein immunohistochemical methods used by invited experts.	Acta neuropathologica	2008	55
18769444	6622	Brundin P	Research in motion: the enigma of Parkinson's disease pathology spread.	Nature reviews. Neuroscience	2008	77
19018246	6622	Theodore S	Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease.	Journal of neuropathology and experimental neurology	2008	64
19230552	6622	Braak H	Neuroanatomy and pathology of sporadic Parkinson's disease.	Advances in anatomy, embryology, and cell biology	2009	49
19273758	6622	Tapiola T	Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.	Archives of neurology	2009	134
19295143	6622	Chung CY	Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy.	The Journal of neuroscience 	2009	88
19385059	6622	Cannon JR	A highly reproducible rotenone model of Parkinson's disease.	Neurobiology of disease	2009	96
19651612	6622	Desplats P	Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein.	Proceedings of the National Academy of Sciences of the United States of America	2009	403
19686384	6622	Danzer KM	Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology.	Journal of neurochemistry	2009	71
19745811	6622	Karpinar DP	Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models.	The EMBO journal	2009	94
19855133	6622	Chen L	Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation.	The Journal of clinical investigation	2009	54
19892735	6622	Luk KC	Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells.	Proceedings of the National Academy of Sciences of the United States of America	2009	193
19903734	6622	Tong J	Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.	Brain 	2010	40
20038714	6622	Su LJ	Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models.	Disease models and mechanisms	2010	51
20071342	6622	Lee HJ	Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies.	The Journal of biological chemistry	2010	170
20198645	6622	Li JY	Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease.	Movement disorders 	2010	49
20203178	6622	Paleologou KE	Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions.	The Journal of neuroscience 	2010	68
20229352	6622	Del Tredici K	Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease.	Acta neuropathologica	2010	41
20534649	6622	Garcia-Reitböck P	SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease.	Brain 	2010	56
20554859	6622	Scott DA	A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration.	The Journal of neuroscience 	2010	81
20599975	6622	Wills J	Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia.	Experimental neurology	2010	45
20696318	6622	Oueslati A	Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies.	Progress in brain research	2010	67
20856865	6622	Lebouvier T	Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms.	PloS one	2010	65
21489994	6622	Nakamura K	Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein.	The Journal of biological chemistry	2011	129
21613474	6622	Waxman EA	Induction of intracellular tau aggregation is promoted by α-synuclein seeds and provides novel insights into the hyperphosphorylation of tau.	The Journal of neuroscience 	2011	40
21700325	6622	Mazzulli JR	Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.	Cell	2011	216
21766334	6622	Shannon KM	Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease.	Movement disorders 	2012	52
21994367	6622	Ebrahimi-Fakhari D	Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein.	The Journal of neuroscience 	2011	76
22094370	6622	Jain S	Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis.	Neurobiology of disease	2012	35
22110584	6622	Byers B	SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress.	PloS one	2011	49
22350713	6622	Chesselet MF	A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice.	Neurotherapeutics 	2012	36
22399753	6622	Colla E	Endoplasmic reticulum stress is important for the manifestations of α-synucleinopathy in vivo.	The Journal of neuroscience 	2012	66
22574141	6622	Maudoux A	Auditory resting-state network connectivity in tinnitus: a functional MRI study.	PloS one	2012	41
22744791	6622	Ebrahimi-Fakhari D	Protein degradation pathways in Parkinson's disease: curse or blessing.	Acta neuropathologica	2012	33
23392688	6622	Boassa D	Mapping the subcellular distribution of α-synuclein in neurons using genetically encoded probes for correlated light and electron microscopy: implications for Parkinson's disease pathogenesis.	The Journal of neuroscience 	2013	35
23526723	6622	Lesage S	G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome.	Annals of neurology	2013	96
23703938	6622	Ulusoy A	Caudo-rostral brain spreading of α-synuclein through vagal connections.	EMBO molecular medicine	2013	29
23739956	6622	Harms AS	MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration.	The Journal of neuroscience 	2013	45
23812319	6622	Toledo JB	CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease.	Acta neuropathologica	2013	29
23900411	6622	Irwin DJ	Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.	Nature reviews. Neuroscience	2013	90
23925565	6622	Rey NL	Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice.	Acta neuropathologica	2013	40
24158904	6622	Chung CY	Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons.	Science	2013	76
24243558	6622	Recasens A	Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys.	Annals of neurology	2014	73
24381286	6622	Guardia-Laguarta C	α-Synuclein is localized to mitochondria-associated ER membranes.	The Journal of neuroscience 	2014	48
24590631	6622	Asi YT	Alpha-synuclein mRNA expression in oligodendrocytes in MSA.	Glia	2014	24
24788821	6622	Doppler K	Cutaneous neuropathy in Parkinson's disease: a window into brain pathology.	Acta neuropathologica	2014	20
24995389	6622	Seidel K	The brainstem pathologies of Parkinson's disease and dementia with Lewy bodies.	Brain pathology	2015	23
25352339	6622	Moussaud S	Alpha-synuclein and tau: teammates in neurodegeneration?	Molecular neurodegeneration	2014	20
25411441	6622	Hall S	CSF biomarkers and clinical progression of Parkinson disease.	Neurology	2015	19
25676491	6622	Sengupta U	Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies.	Biological psychiatry	2015	20
25732184	6622	Roberts RF	Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain.	Brain 	2015	21
26446103	6622	Uchihara T	Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.	Acta neuropathologica	2016	17
26564470	6622	Deas E	Alpha-Synuclein Oligomers Interact with Metal Ions to Induce Oxidative Stress and Neuronal Death in Parkinson's Disease.	Antioxidants and redox signaling	2016	16
27015771	6622	Stokholm MG	Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients.	Annals of neurology	2016	11
27018801	6622	Tuttle MD	Solid-state NMR structure of a pathogenic fibril of full-length human α-synuclein.	Nature structural and molecular biology	2016	34
9887342	7015	Cong YS	The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter.	Human molecular genetics	1999	96
17570133	7015	Berletch JB	Epigenetic and genetic mechanisms contribute to telomerase inhibition by EGCG.	Journal of cellular biochemistry	2008	61
17909019	7015	Bernardo ME	Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms.	Cancer research	2007	162
18201269	7015	Mitomo S	Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines.	Cancer science	2008	70
18222063	7015	Choi J	Reduced telomerase activity in human T lymphocytes exposed to cortisol.	Brain, behavior, and immunity	2008	68
19255426	7015	Fujii H	Telomerase insufficiency in rheumatoid arthritis.	Proceedings of the National Academy of Sciences of the United States of America	2009	52
20550519	7015	Liang S	Resistance to experimental tumorigenesis in cells of a long-lived mammal, the naked mole-rat (Heterocephalus glaber).	Aging cell	2010	44
21071633	7015	Indran IR	hTERT overexpression alleviates intracellular ROS production, improves mitochondrial function, and inhibits ROS-mediated apoptosis in cancer cells.	Cancer research	2011	45
21436073	7015	Parry EM	Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase.	Blood	2011	37
21768775	7015	Martinez-Outschoorn UE	Understanding the metabolic basis of drug resistance: therapeutic induction of the Warburg effect kills cancer cells.	Cell cycle	2011	41
22854964	7015	Zhang Y	Human telomerase reverse transcriptase (hTERT) is a novel target of the Wnt/β-catenin pathway in human cancer.	The Journal of biological chemistry	2012	45
23348503	7015	Horn S	TERT promoter mutations in familial and sporadic melanoma.	Science	2013	316
23535731	7015	Bojesen SE	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.	Nature genetics	2013	181
23555636	7015	Lan Q	Longer telomere length in peripheral white blood cells is associated with risk of lung cancer and the rs2736100 (CLPTM1L-TERT) polymorphism in a prospective cohort study among women in China.	PloS one	2013	34
23598174	7015	Castelo-Branco P	Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.	The Lancet. Oncology	2013	46
23610451	7015	Listerman I	The major reverse transcriptase-incompetent splice variant of the human telomerase protein inhibits telomerase activity but protects from apoptosis.	Cancer research	2013	29
23629941	7015	Pellatt AJ	Telomere length, telomere-related genes, and breast cancer risk: the breast cancer health disparities study.	Genes, chromosomes and cancer	2013	28
23887589	7015	Vinagre J	Frequency of TERT promoter mutations in human cancers.	Nature communications	2013	120
23955565	7015	Nonoguchi N	TERT promoter mutations in primary and secondary glioblastomas.	Acta neuropathologica	2013	40
24018021	7015	Allory Y	Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.	European urology	2014	37
24101484	7015	Rachakonda PS	TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.	Proceedings of the National Academy of Sciences of the United States of America	2013	55
24121487	7015	Kinde I	TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.	Cancer research	2013	41
24141777	7015	Liu T	The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.	Oncogene	2014	43
24154961	7015	Koelsche C	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.	Acta neuropathologica	2013	36
24174164	7015	Remke M	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma.	Acta neuropathologica	2013	28
24476079	7015	Melo M	TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.	The Journal of clinical endocrinology and metabolism	2014	49
24569790	7015	Heidenreich B	Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.	Nature communications	2014	24
25217772	7015	Griewank KG	TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.	Journal of the National Cancer Institute	2014	30
25314060	7015	Labussière M	TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.	British journal of cancer	2014	28
25722414	7015	Borah S	Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.	Science	2015	59
25843513	7015	Huang DS	Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.	European journal of cancer	2015	20
25977370	7015	Bell RJ	Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer.	Science	2015	67
26549025	7015	Lü MH	Long noncoding RNA BC032469, a novel competing endogenous RNA, upregulates hTERT expression by sponging miR-1207-5p and promotes proliferation in gastric cancer.	Oncogene	2016	20
26846696	7015	Akincilar SC	Reactivation of telomerase in cancer.	Cellular and molecular life sciences 	2016	13
19773371	7038	Hoftijzer H	Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.	European journal of endocrinology	2009	47
19860577	7038	American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer.	Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.	Thyroid 	2009	970
24434360	7038	Caturegli P	Hashimoto thyroiditis: clinical and diagnostic criteria.	Autoimmunity reviews	2014	35
26462967	7038	Haugen BR	2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.	Thyroid 	2016	328
7761852	7040	Markowitz S	Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability.	Science	1995	398
9822576	7040	Oft M	TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis.	Current biology 	1998	156
10028970	7040	Hojo M	Cyclosporine induces cancer progression by a cell-autonomous mechanism.	Nature	1999	115
10462204	7040	Sramkoski RM	A new human prostate carcinoma cell line, 22Rv1.	In vitro cellular and developmental biology. Animal	1999	141
10793168	7040	Blobe GC	Role of transforming growth factor beta in human disease.	The New England journal of medicine	2000	491
10802350	7040	Martin M	TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target?	International journal of radiation oncology, biology, physics	2000	122
11781349	7040	Huynh ML	Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation.	The Journal of clinical investigation	2002	281
12475801	7040	Phan SH	The myofibroblast in pulmonary fibrosis.	Chest	2002	145
14523048	7040	Tang B	TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression.	The Journal of clinical investigation	2003	118
14576166	7040	Horowitz JC	Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-beta1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor.	The Journal of biological chemistry	2004	71
15231748	7040	Colland F	Functional proteomics mapping of a human signaling pathway.	Genome research	2004	79
15857893	7040	Waghray M	Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts.	FASEB journal 	2005	78
16289860	7040	Bierie B	TGF-beta and cancer.	Cytokine and growth factor reviews	2006	127
16408108	7040	Liu Y	Renal fibrosis: new insights into the pathogenesis and therapeutics.	Kidney international	2006	235
16549783	7040	Henderson NC	Galectin-3 regulates myofibroblast activation and hepatic fibrosis.	Proceedings of the National Academy of Sciences of the United States of America	2006	91
16563223	7040	Gressner AM	Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets.	Journal of cellular and molecular medicine	2006	176
16904831	7040	Pardali K	Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer.	Biochimica et biophysica acta	2007	170
16951986	7040	Jakowlew SB	Transforming growth factor-beta in cancer and metastasis.	Cancer metastasis reviews	2006	129
17160136	7040	Dong M	The type III TGF-beta receptor suppresses breast cancer progression.	The Journal of clinical investigation	2007	73
17195236	7040	Denton CP	Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.	Arthritis and rheumatism	2007	95
17596875	7040	Matsuzaki K	Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma.	Hepatology	2007	76
17631612	7040	Willis BC	TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease.	American journal of physiology. Lung cellular and molecular physiology	2007	264
17895899	7040	ten Dijke P	Extracellular control of TGFbeta signalling in vascular development and disease.	Nature reviews. Molecular cell biology	2007	194
17916809	7040	Horan GS	Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation.	American journal of respiratory and critical care medicine	2008	89
17979495	7040	Moreira RK	Hepatic stellate cells and liver fibrosis.	Archives of pathology and laboratory medicine	2007	81
18413796	7040	Melisi D	LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.	Molecular cancer therapeutics	2008	90
18455123	7040	Hu M	Regulation of in situ to invasive breast carcinoma transition.	Cancer cell	2008	173
19111019	7040	Mishra L	Liver stem cells and hepatocellular carcinoma.	Hepatology	2009	95
19148281	7040	Walters KA	Genomic analysis reveals a potential role for cell cycle perturbation in HCV-mediated apoptosis of cultured hepatocytes.	PLoS pathogens	2009	59
19345330	7040	Peñuelas S	TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma.	Cancer cell	2009	108
19800967	7040	Liu RM	Oxidative stress and glutathione in TGF-beta-mediated fibrogenesis.	Free radical biology and medicine	2010	67
19812599	7040	Sargent JL	A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity.	The Journal of investigative dermatology	2010	49
19852727	7040	Wendt MK	Mechanisms of the epithelial-mesenchymal transition by TGF-beta.	Future oncology	2009	67
20382885	7040	Patel SA	Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta.	Journal of immunology	2010	78
20467795	7040	Taylor MA	The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells.	Journal of mammary gland biology and neoplasia	2010	89
20504320	7040	Ganapathy V	Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis.	Molecular cancer	2010	52
20525803	7040	Halwani R	Role of transforming growth factor-β in airway remodeling in asthma.	American journal of respiratory cell and molecular biology	2011	65
20538542	7040	Yang L	TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression.	Trends in immunology	2010	128
20578239	7040	Mimeault M	Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer.	Journal of cellular physiology	2010	55
20642439	7040	Tandon A	Role of transforming growth factor Beta in corneal function, biology and pathology.	Current molecular medicine	2010	45
20660732	7040	Sidhu SS	Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma.	Proceedings of the National Academy of Sciences of the United States of America	2010	81
20699127	7040	Juárez P	TGF-β in cancer and bone: implications for treatment of bone metastases.	Bone	2011	40
20888056	7040	Yarnold J	Pathogenetic mechanisms in radiation fibrosis.	Radiotherapy and oncology 	2010	76
20940046	7040	Tian M	Transforming growth factor-β and the hallmarks of cancer.	Cellular signalling	2011	66
20957627	7040	Meulmeester E	The dynamic roles of TGF-β in cancer.	The Journal of pathology	2011	97
20971881	7040	Cushing L	miR-29 is a major regulator of genes associated with pulmonary fibrosis.	American journal of respiratory cell and molecular biology	2011	139
21044893	7040	Murray LA	TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P.	The international journal of biochemistry and cell biology	2011	71
21047675	7040	Aceves SS	Mast cells infiltrate the esophageal smooth muscle in patients with eosinophilic esophagitis, express TGF-β1, and increase esophageal smooth muscle contraction.	The Journal of allergy and clinical immunology	2010	67
21303979	7040	Franco OE	Altered TGF-β signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis.	Cancer research	2011	64
21368745	7040	Trachtman H	A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis.	Kidney international	2011	59
21448580	7040	Parvani JG	Noncanonical TGF-β signaling during mammary tumorigenesis.	Journal of mammary gland biology and neoplasia	2011	46
21474781	7040	Navab R	Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer.	Proceedings of the National Academy of Sciences of the United States of America	2011	77
21497747	7040	Kisseleva T	Anti-fibrogenic strategies and the regression of fibrosis.	Best practice and research. Clinical gastroenterology	2011	53
21684291	7040	Liu W	Cross talk between activation of microglia and astrocytes in pathological conditions in the central nervous system.	Life sciences	2011	49
21691718	7040	Wendt MK	Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression.	Cell and tissue research	2012	54
21839702	7040	Achyut BR	Transforming growth factor-β in the gastrointestinal and hepatic tumor microenvironment.	Gastroenterology	2011	38
21866313	7040	van Meeteren LA	Regulation of endothelial cell plasticity by TGF-β.	Cell and tissue research	2012	54
21963846	7040	Cao L	Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer.	Oncogene	2012	57
22006249	7040	Dooley S	TGF-β in progression of liver disease.	Cell and tissue research	2012	107
22037216	7040	Horiguchi K	TGF-β drives epithelial-mesenchymal transition through δEF1-mediated downregulation of ESRP.	Oncogene	2012	50
22056140	7040	Lonardo E	Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy.	Cell stem cell	2011	91
22335797	7040	Vallon V	Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney.	Annual review of physiology	2012	46
22378298	7040	Heinemann U	Blood-brain barrier dysfunction, TGFβ signaling, and astrocyte dysfunction in epilepsy.	Glia	2012	33
22415826	7040	Akhmetshina A	Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis.	Nature communications	2012	133
22548724	7040	Moustakas A	Induction of epithelial-mesenchymal transition by transforming growth factor β.	Seminars in cancer biology	2012	34
22552294	7040	Mima K	CD44s regulates the TGF-β-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma.	Cancer research	2012	41
22815997	7040	Patel AS	Autophagy in idiopathic pulmonary fibrosis.	PloS one	2012	65
22937864	7040	Campbell JD	A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK.	Genome medicine	2012	32
22996328	7040	Liu J	TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma.	Proceedings of the National Academy of Sciences of the United States of America	2012	58
23437118	7040	Presser LD	Activation of TGF-β1 promoter by hepatitis C virus-induced AP-1 and Sp1: role of TGF-β1 in hepatic stellate cell activation and invasion.	PloS one	2013	26
23474494	7040	Morrison CD	The relevance of the TGF-β Paradox to EMT-MET programs.	Cancer letters	2013	35
23565148	7040	Peng R	Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease.	PloS one	2013	30
24393789	7040	Neuzillet C	Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas.	Oncotarget	2014	27
24486052	7040	Rieder F	T-helper 2 cytokines, transforming growth factor β1, and eosinophil products induce fibrogenesis and alter muscle motility in patients with eosinophilic esophagitis.	Gastroenterology	2014	26
24618589	7040	Morris JC	Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.	PloS one	2014	41
24638984	7040	Giannelli G	Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma.	Cancer research	2014	45
25134788	7040	Beilfuss A	Vitamin D counteracts fibrogenic TGF-β signalling in human hepatic stellate cells both receptor-dependently and independently.	Gut	2015	18
25548183	7040	Zhao Q	MSCs derived from iPSCs with a modified protocol are tumor-tropic but have much less potential to promote tumors than bone marrow MSCs.	Proceedings of the National Academy of Sciences of the United States of America	2015	17
25706628	7040	Calon A	Stromal gene expression defines poor-prognosis subtypes in colorectal cancer.	Nature genetics	2015	96
25839664	7040	Ajani JA	Cancer stem cells: the promise and the potential.	Seminars in oncology	2015	36
25871474	7040	Shi SJ	LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer.	Oncotarget	2015	35
25959210	7040	Della Latta V	Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions.	Pharmacological research	2015	20
25995225	7040	Reed NI	The αvβ1 integrin plays a critical in vivo role in tissue fibrosis.	Science translational medicine	2015	29
26335400	7040	Richter K	Redox-fibrosis: Impact of TGFβ1 on ROS generators, mediators and functional consequences.	Redox biology	2015	18
26716418	7040	Hanley CJ	A subset of myofibroblastic cancer-associated fibroblasts regulate collagen fiber elongation, which is prognostic in multiple cancers.	Oncotarget	2016	16
26807763	7040	Fabregat I	TGF-β signalling and liver disease.	The FEBS journal	2016	15
1589764	7157	Kern SE	Oncogenic forms of p53 inhibit p53-regulated gene expression.	Science	1992	234
1849234	7157	Hsu IC	Mutational hotspot in the p53 gene in human hepatocellular carcinomas.	Nature	1991	202
2047879	7157	Kern SE	Identification of p53 as a sequence-specific DNA-binding protein.	Science	1991	230
2233717	7157	Diller L	p53 functions as a cell cycle control protein in osteosarcomas.	Molecular and cellular biology	1990	175
2259385	7157	Srivastava S	Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome.	Nature	1990	174
8023160	7157	Speir E	Potential role of human cytomegalovirus and p53 interaction in coronary restenosis.	Science	1994	167
8030745	7157	Kim H	Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences.	The American journal of pathology	1994	124
8423624	7157	Allred DC	Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.	Journal of the National Cancer Institute	1993	132
9176490	7157	Heise C	ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents.	Nature medicine	1997	127
10446993	7157	Chang BD	A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents.	Cancer research	1999	107
10623654	7157	Vona G	Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells.	The American journal of pathology	2000	212
10728684	7157	Barcellos-Hoff MH	Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells.	Cancer research	2000	151
11343904	7157	Ryan KM	Regulation and function of the p53 tumor suppressor protein.	Current opinion in cell biology	2001	127
11830638	7157	Lingle WL	Centrosome amplification drives chromosomal instability in breast tumor development.	Proceedings of the National Academy of Sciences of the United States of America	2002	150
11859195	7157	Yu JL	Effect of p53 status on tumor response to antiangiogenic therapy.	Science	2002	86
11875500	7157	Bykov VJ	Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.	Nature medicine	2002	198
12058060	7157	Chen X	Gene expression patterns in human liver cancers.	Molecular biology of the cell	2002	189
12235210	7157	Zaika AI	DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors.	The Journal of experimental medicine	2002	92
12241875	7157	Klein CA	Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer.	Lancet	2002	96
12574499	7157	Yu J	PUMA mediates the apoptotic response to p53 in colorectal cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	2003	171
12649205	7157	Pihan GA	Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas.	Cancer research	2003	102
12941807	7157	Riley RR	Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis.	Cancer research	2003	97
14612504	7157	Massion PP	Significance of p63 amplification and overexpression in lung cancer development and prognosis.	Cancer research	2003	77
14639602	7157	Pim D	p53 polymorphic variants at codon 72 exert different effects on cell cycle progression.	International journal of cancer	2004	71
15187189	7157	Longworth MS	Pathogenesis of human papillomaviruses in differentiating epithelia.	Microbiology and molecular biology reviews 	2004	153
16172461	7157	Russo A	The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.	Journal of clinical oncology 	2005	72
16489069	7157	Olivier M	The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.	Clinical cancer research 	2006	119
16824017	7157	Stewart SA	Telomeres: cancer to human aging.	Annual review of cell and developmental biology	2006	91
16945824	7157	Houtgraaf JH	A concise review of DNA damage checkpoints and repair in mammalian cells.	Cardiovascular revascularization medicine 	2006	65
16951157	7157	Rodriguez J	Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers.	Cancer research	2006	82
17030796	7157	Feng Z	Acrolein is a major cigarette-related lung cancer agent: Preferential binding at p53 mutational hotspots and inhibition of DNA repair.	Proceedings of the National Academy of Sciences of the United States of America	2006	96
17255760	7157	Kindelberger DW	Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.	The American journal of surgical pathology	2007	194
17311302	7157	Petitjean A	Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.	Human mutation	2007	457
17401424	7157	Petitjean A	TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.	Oncogene	2007	190
17401431	7157	Li Y	Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?	Oncogene	2007	57
17468756	7157	Theodorou V	MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer.	Nature genetics	2007	69
17804712	7157	Nakahara T	YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.	Cancer research	2007	113
18094375	7157	Patocs A	Breast-cancer stromal cells with TP53 mutations and nodal metastases.	The New England journal of medicine	2007	93
18094376	7157	Poeta ML	TP53 mutations and survival in squamous-cell carcinoma of the head and neck.	The New England journal of medicine	2007	160
18193093	7157	Courtois-Cox S	Many roads lead to oncogene-induced senescence.	Oncogene	2008	106
18323444	7157	Halazonetis TD	An oncogene-induced DNA damage model for cancer development.	Science	2008	527
18394899	7157	Birkenfeld J	Cellular functions of GEF-H1, a microtubule-regulated Rho-GEF: is altered GEF-H1 activity a crucial determinant of disease pathogenesis?	Trends in cell biology	2008	66
18757330	7157	Carlson JW	Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention.	Journal of clinical oncology 	2008	70
18829542	7157	Lehmann BD	Senescence-associated exosome release from human prostate cancer cells.	Cancer research	2008	56
18840072	7157	Mitra AP	Molecular pathogenesis and diagnostics of bladder cancer.	Annual review of pathology	2009	52
19225112	7157	Sur S	A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53.	Proceedings of the National Academy of Sciences of the United States of America	2009	108
19237188	7157	Boren T	MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy.	Gynecologic oncology	2009	49
19349354	7157	Seligson DB	Global levels of histone modifications predict prognosis in different cancers.	The American journal of pathology	2009	109
19562738	7157	Zuckerman V	Tumour suppression by p53: the importance of apoptosis and cellular senescence.	The Journal of pathology	2009	49
19626115	7157	Suzuki HI	Modulation of microRNA processing by p53.	Nature	2009	393
19854137	7157	Li X	Two mammalian MOF complexes regulate transcription activation by distinct mechanisms.	Molecular cell	2009	58
19881536	7157	Liu DP	A common gain of function of p53 cancer mutants in inducing genetic instability.	Oncogene	2010	50
19887545	7157	Hirai H	Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.	Molecular cancer therapeutics	2009	90
20038740	7157	De Angelis A	Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function.	Circulation	2010	62
20107315	7157	Hirai H	MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil.	Cancer biology and therapy	2010	55
20229506	7157	Ahmed AA	Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.	The Journal of pathology	2010	149
20336134	7157	Sahin E	Linking functional decline of telomeres, mitochondria and stem cells during ageing.	Nature	2010	191
20538793	7157	Lin TT	Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis.	Blood	2010	42
20871609	7157	Swarbrick A	miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma.	Nature medicine	2010	52
20937856	7157	Scherz-Shouval R	p53-dependent regulation of autophagy protein LC3 supports cancer cell survival under prolonged starvation.	Proceedings of the National Academy of Sciences of the United States of America	2010	71
21205967	7157	Fabbri M	Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.	JAMA	2011	72
21263025	7157	Muller PA	p53 and its mutants in tumor cell migration and invasion.	The Journal of cell biology	2011	118
21317459	7157	Rao B	Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.	Oncotarget	2010	50
21364938	7157	Enerly E	miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors.	PloS one	2011	115
21389100	7157	Rajeshkumar NV	MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.	Clinical cancer research 	2011	63
21530747	7157	Ullman TA	Intestinal inflammation and cancer.	Gastroenterology	2011	197
21601526	7157	Villani A	Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.	The Lancet. Oncology	2011	46
21799033	7157	Bridges KA	MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.	Clinical cancer research 	2011	50
22084170	7157	Kreahling JM	MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells.	Molecular cancer therapeutics	2012	39
22265415	7157	Freed-Pastor WA	Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.	Cell	2012	163
22282659	7157	Donati G	Ribosome biogenesis and control of cell proliferation: p53 is not alone.	Cancer research	2012	36
22351930	7157	Scarlett UK	Ovarian cancer progression is controlled by phenotypic changes in dendritic cells.	The Journal of experimental medicine	2012	78
22789538	7157	Bywater MJ	Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.	Cancer cell	2012	107
22822097	7157	Walerych D	The rebel angel: mutant p53 as the driving oncogene in breast cancer.	Carcinogenesis	2012	61
22911014	7157	Mirzayans R	New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy.	Journal of biomedicine and biotechnology	2012	55
22965953	7157	Lehmann S	Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.	Journal of clinical oncology 	2012	58
22986101	7157	Zhang K	Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma.	Experimental hematology	2013	45
23114601	7157	Rodig SJ	Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus.	The Journal of clinical investigation	2012	41
23151455	7157	Rodriguez OC	Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy.	Cell cycle	2012	33
23199966	7157	Doorbar J	The biology and life-cycle of human papillomaviruses.	Vaccine	2012	128
23200980	7157	Kanda M	Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia.	Clinical gastroenterology and hepatology 	2013	35
23242140	7157	Maddocks OD	Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells.	Nature	2013	145
23256952	7157	Kastelein F	Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus.	Gut	2013	31
23297687	7157	Kulasekararaj AG	TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.	British journal of haematology	2013	44
23512991	7157	Batey MA	Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer.	Molecular cancer therapeutics	2013	25
23630207	7157	Vignot S	Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer.	Journal of clinical oncology 	2013	38
23775793	7157	Menendez D	Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells.	Nucleic acids research	2013	52
23835706	7157	Zhukova N	Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.	Journal of clinical oncology 	2013	43
23918355	7157	Lee MO	Inhibition of pluripotent stem cell-derived teratoma formation by small molecules.	Proceedings of the National Academy of Sciences of the United States of America	2013	42
24138928	7157	Horvath S	DNA methylation age of human tissues and cell types.	Genome biology	2013	377
24327604	7157	Abdi J	Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.	Oncotarget	2013	28
24469795	7157	Morrison CD	Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer.	Proceedings of the National Academy of Sciences of the United States of America	2014	24
24487586	7157	Arjonen A	Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis.	The Journal of clinical investigation	2014	36
24501221	7157	Rossi D	Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.	Blood	2014	50
24603336	7157	Xu J	Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity.	Cell death and disease	2014	21
24665023	7157	Leroy B	TP53 mutations in human cancer: database reassessment and prospects for the next decade.	Human mutation	2014	28
24682512	7157	Saft L	p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).	Haematologica	2014	22
24747423	7157	Golomb L	p53 and ribosome biogenesis stress: the essentials.	FEBS letters	2014	36
24819167	7157	Leotta M	A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells.	Journal of cellular physiology	2014	26
24859455	7157	Miao R	Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis.	Journal of hepatology	2014	30
24921086	7157	Schmeiser HH	Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy.	International journal of cancer	2014	20
25086664	7157	Gross AM	Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss.	Nature genetics	2014	32
25287991	7157	Malcikova J	Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.	Leukemia	2015	18
25362853	7157	Gao J	miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer.	Oncogene	2015	24
25555420	7157	Farooqui MZ	Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.	The Lancet. Oncology	2015	51
25634208	7157	Neskey DM	Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer.	Cancer research	2015	19
25689248	7157	Boulter L	WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited.	The Journal of clinical investigation	2015	23
25704383	7157	Span PN	Biology of hypoxia.	Seminars in nuclear medicine	2015	16
25792665	7157	Ahmad T	Impaired mitophagy leads to cigarette smoke stress-induced cellular senescence: implications for chronic obstructive pulmonary disease.	FASEB journal 	2015	19
25824729	7157	Goldar S	Molecular mechanisms of apoptosis and roles in cancer development and treatment.	Asian Pacific journal of cancer prevention 	2015	19
25827447	7157	Hong MK	Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer.	Nature communications	2015	39
25860607	7157	Lee DF	Modeling familial cancer with induced pluripotent stem cells.	Cell	2015	28
25883152	7157	Younger ST	Integrative genomic analysis reveals widespread enhancer regulation by p53 in response to DNA damage.	Nucleic acids research	2015	23
25894828	7157	Cristescu R	Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.	Nature medicine	2015	84
26024390	7157	Soussi T	TP53: an oncogene in disguise.	Cell death and differentiation	2015	26
26032560	7157	Amelio I	The p53 family and the hypoxia-inducible factors (HIFs): determinants of cancer progression.	Trends in biochemical sciences	2015	15
26398160	7157	Danilova N	Ribosomopathies: how a common root can cause a tree of pathologies.	Disease models and mechanisms	2015	20
26462838	7157	Gong Z	An integrative transcriptomic analysis reveals p53 regulated miRNA, mRNA, and lncRNA networks in nasopharyngeal carcinoma.	Tumour biology 	2016	16
26605532	7157	Jin W	Genome-wide detection of DNase I hypersensitive sites in single cells and FFPE tissue samples.	Nature	2015	31
26748848	7157	Soragni A	A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas.	Cancer cell	2016	19
26751173	7157	Korkmaz G	Functional genetic screens for enhancer elements in the human genome using CRISPR-Cas9.	Nature biotechnology	2016	36
26789255	7157	Martinez-Zapien D	Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53.	Nature	2016	10
27580721	7157	Zhang F	Molecular signatures associated with ZIKV exposure in human cortical neural progenitors.	Nucleic acids research	2016	20
7683111	7422	Kim KJ	Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.	Nature	1993	547
9707121	7422	Flore O	Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus.	Nature	1998	109
9916127	7422	Benjamin LE	Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal.	The Journal of clinical investigation	1999	225
10662790	7422	Yang TY	Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma.	The Journal of experimental medicine	2000	94
11005565	7422	Rubenstein JL	Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption.	Neoplasia	2000	137
11549582	7422	Skobe M	Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma.	The American journal of pathology	2001	99
12600822	7422	Tuder RM	Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade.	American journal of respiratory cell and molecular biology	2003	106
12890841	7422	Yang JC	A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.	The New England journal of medicine	2003	446
14517187	7422	Morgan B	Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.	Journal of clinical oncology 	2003	102
14745444	7422	Willett CG	Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.	Nature medicine	2004	378
15161630	7422	Galiano RD	Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells.	The American journal of pathology	2004	136
15175435	7422	Hurwitz H	Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.	The New England journal of medicine	2004	1840
15351965	7422	Storkebaum E	VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection.	BioEssays 	2004	93
15908660	7422	Hurwitz HI	Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.	Journal of clinical oncology 	2005	115
16172288	7422	Khurana R	Role of angiogenesis in cardiovascular disease: a critical appraisal.	Circulation	2005	79
16193288	7422	Perrin RM	Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor.	Diabetologia	2005	70
16258101	7422	Kindler HL	Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.	Journal of clinical oncology 	2005	105
16322226	7422	Mironchik Y	Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer.	Cancer research	2005	84
16376330	7422	Folkman J	Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action.	Experimental cell research	2006	116
16490250	7422	Leach JK	Coating of VEGF-releasing scaffolds with bioactive glass for angiogenesis and bone regeneration.	Biomaterials	2006	67
16571143	7422	Demedts IK	Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema.	Respiratory research	2006	101
16622265	7422	Zhu AX	Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.	Journal of clinical oncology 	2006	73
16828580	7422	Borzychowski AM	Inflammation and pre-eclampsia.	Seminars in fetal and neonatal medicine	2006	89
16880208	7422	Coppé JP	Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence.	The Journal of biological chemistry	2006	104
16912155	7422	Bao S	Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor.	Cancer research	2006	351
17046701	7422	Nguyen QD	Vascular endothelial growth factor is a critical stimulus for diabetic macular edema.	American journal of ophthalmology	2006	69
17236958	7422	Gonzalez J	Effect of bevacizumab on radiation necrosis of the brain.	International journal of radiation oncology, biology, physics	2007	64
17475821	7422	Lindenmeyer MT	Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy.	Journal of the American Society of Nephrology 	2007	69
17533168	7422	Rigau V	Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy.	Brain 	2007	69
17559806	7422	Liang Z	CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway.	Biochemical and biophysical research communications	2007	69
17591953	7422	Nishijima K	Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.	The American journal of pathology	2007	170
17634482	7422	Drevs J	Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.	Journal of clinical oncology 	2007	79
17908997	7422	Rich JN	Cancer stem cells in radiation resistance.	Cancer research	2007	113
17909199	7422	Herbst RS	Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.	Journal of clinical oncology 	2007	90
17947719	7422	Vredenburgh JJ	Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.	Journal of clinical oncology 	2007	325
18000042	7422	Rudge JS	VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade.	Proceedings of the National Academy of Sciences of the United States of America	2007	66
18006827	7422	Xia C	Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor.	Cancer research	2007	118
18160686	7422	Miller K	Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.	The New England journal of medicine	2007	637
18202416	7422	Glade Bender JL	Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study.	Journal of clinical oncology 	2008	58
18235126	7422	Socinski MA	Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.	Journal of clinical oncology 	2008	81
18263769	7422	Ramalingam S	Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.	The oncologist	2008	73
18316689	7422	Norden AD	Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.	Neurology	2008	230
18349829	7422	Varey AH	VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.	British journal of cancer	2008	74
18349830	7422	Maeda S	CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer.	British journal of cancer	2008	54
18362932	7422	Campochiaro PA	Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator.	Molecular therapy 	2008	61
18467655	7422	Pollard JW	Macrophages define the invasive microenvironment in breast cancer.	Journal of leukocyte biology	2008	128
18565886	7422	Siegel AB	Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.	Journal of clinical oncology 	2008	98
18824714	7422	Schneider BP	Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.	Journal of clinical oncology 	2008	165
18842611	7422	Scartozzi M	Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.	Annals of oncology 	2009	75
18854571	7422	Grothey A	Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).	Journal of clinical oncology 	2008	150
19074844	7422	Ma J	Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.	Molecular cancer therapeutics	2008	79
19249675	7422	Loges S	Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.	Cancer cell	2009	112
19305413	7422	Reynolds AR	Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors.	Nature medicine	2009	111
19332770	7422	Quant EC	Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.	Neuro-oncology	2009	48
19549711	7422	Linderholm BK	Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.	Annals of oncology 	2009	48
19549889	7422	Sorensen AG	A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.	Cancer research	2009	108
19666581	7422	Thangarajah H	The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues.	Proceedings of the National Academy of Sciences of the United States of America	2009	73
19671869	7422	Ebos JM	Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.	Clinical cancer research 	2009	69
19805054	7422	Yang F	Genetic engineering of human stem cells for enhanced angiogenesis using biodegradable polymeric nanoparticles.	Proceedings of the National Academy of Sciences of the United States of America	2010	68
19854291	7422	Laude A	Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease?	Progress in retinal and eye research	2010	46
19901561	7422	Bayet-Robert M	Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer.	Cancer biology and therapy	2010	46
20150572	7422	Reck M	Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).	Annals of oncology 	2010	129
20406897	7422	Gerstner ER	Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib.	Neuro-oncology	2010	44
20501804	7422	Hammers HJ	Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.	Molecular cancer therapeutics	2010	49
20811159	7422	Bird AC	Therapeutic targets in age-related macular disease.	The Journal of clinical investigation	2010	58
21167939	7422	Fidler IJ	The role of the organ microenvironment in brain metastasis.	Seminars in cancer biology	2011	63
21323540	7422	Mintz-Hittner HA	Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.	The New England journal of medicine	2011	124
21364524	7422	Ebos JM	Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.	Nature reviews. Clinical oncology	2011	164
21527770	7422	Rini BI	Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.	Journal of the National Cancer Institute	2011	115
21529957	7422	Sultan MB	A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema.	Ophthalmology	2011	38
21546089	7422	Do DV	The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema.	Ophthalmology	2011	55
21565214	7422	Tugues S	Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.	Molecular aspects of medicine	2011	49
21593862	7422	Carmeliet P	Molecular mechanisms and clinical applications of angiogenesis.	Nature	2011	810
21680800	7422	Battinelli EM	Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis.	Blood	2011	57
21708378	7422	Manjunath V	Analysis of choroidal thickness in age-related macular degeneration using spectral-domain optical coherence tomography.	American journal of ophthalmology	2011	36
21711246	7422	Koch S	Signal transduction by vascular endothelial growth factor receptors.	The Biochemical journal	2011	189
21752957	7422	Woroniecka KI	Transcriptome analysis of human diabetic kidney disease.	Diabetes	2011	93
22084445	7422	Hirschhaeuser F	Lactate: a metabolic key player in cancer.	Cancer research	2011	125
22222630	7422	Pastuskovas CV	Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model.	Molecular cancer therapeutics	2012	33
22495829	7422	Oki K	Human-induced pluripotent stem cells form functional neurons and improve recovery after grafting in stroke-damaged brain.	Stem cells	2012	56
22588059	7422	Rapisarda A	Role of the VEGF/VEGFR axis in cancer biology and therapy.	Advances in cancer research	2012	37
22767667	7422	Rosen LS	A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.	Clinical cancer research 	2012	57
22963562	7422	Moccia F	Store-dependent Ca(2+) entry in endothelial progenitor cells as a perspective tool to enhance cell-based therapy and adverse tumour vascularization.	Current medicinal chemistry	2012	30
22965961	7422	Schmoll HJ	Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).	Journal of clinical oncology 	2012	46
22965962	7422	Ramlau R	Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.	Journal of clinical oncology 	2012	33
22965965	7422	Hoff PM	Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).	Journal of clinical oncology 	2012	35
23121052	7422	Paessler S	Pathogenesis of the viral hemorrhagic fevers.	Annual review of pathology	2013	52
23143192	7422	Plate KH	Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited.	Acta neuropathologica	2012	35
23177514	7422	Grothey A	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.	Lancet	2013	340
23283490	7422	Shin L	Human mesenchymal stem cell grafts enhance normal and impaired wound healing by recruiting existing endogenous tissue stem/progenitor cells.	Stem cells translational medicine	2013	26
23312463	7422	Heng DY	External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.	The Lancet. Oncology	2013	71
23512266	7422	Soda Y	Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme.	Journal of molecular medicine	2013	35
23549101	7422	Kumar N	Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.	Retina	2013	35
23642377	7422	Jaffe GJ	Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.	Ophthalmology	2013	26
23664153	7422	Ho VY	Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.	American journal of ophthalmology	2013	35
23908119	7422	Welti J	Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer.	The Journal of clinical investigation	2013	102
23980090	7422	Llovet JM	Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.	Journal of clinical oncology 	2013	93
24013197	7422	Zangi L	Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction.	Nature biotechnology	2013	70
24030704	7422	Smith NR	Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy.	Clinical cancer research 	2013	27
24347168	7422	Pereira ER	Endoplasmic reticulum (ER) stress and hypoxia response pathways interact to potentiate hypoxia-inducible factor 1 (HIF-1) transcriptional activity on targets like vascular endothelial growth factor (VEGF).	The Journal of biological chemistry	2014	30
24532337	7422	Dispenzieri A	POEMS syndrome: 2014 update on diagnosis, risk-stratification, and management.	American journal of hematology	2014	26
24673341	7422	Abcouwer SF	Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment.	Annals of the New York Academy of Sciences	2014	24
24841777	7422	Albiges L	A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.	European urology	2015	22
25117977	7422	Baker GJ	Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy.	Neoplasia	2014	26
25204977	7422	Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group.	Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC.	Diabetes	2015	28
25337750	7422	Loupakis F	Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.	The New England journal of medicine	2014	83
25452452	7422	Motzer RJ	Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.	Journal of clinical oncology 	2015	120
25542520	7422	Grunwald JE	Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials.	Ophthalmology	2015	31
25700172	7422	McIntyre A	Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality.	EMBO molecular medicine	2015	25
25896459	7422	Ishibazawa A	Optical Coherence Tomography Angiography in Diabetic Retinopathy: A Prospective Pilot Study.	American journal of ophthalmology	2015	50
26095784	7422	Zhu AX	Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.	The Lancet. Oncology	2015	42
26137590	7422	Premer C	Allogeneic Mesenchymal Stem Cells Restore Endothelial Function in Heart Failure by Stimulating Endothelial Progenitor Cells.	EBioMedicine	2015	20
26164826	7422	Kuehlewein L	Optical Coherence Tomography Angiography of Type 1 Neovascularization in Age-Related Macular Degeneration.	American journal of ophthalmology	2015	26
26179201	7422	Valle JW	Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.	The Lancet. Oncology	2015	20
26431823	7422	Rakoczy EP	Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial.	Lancet	2015	19
27156698	7422	Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group.	Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials.	Ophthalmology	2016	16
14522905	8842	Singh SK	Identification of a cancer stem cell in human brain tumors.	Cancer research	2003	1201
15254585	8842	Torrente Y	Human circulating AC133(+) stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle.	The Journal of clinical investigation	2004	87
15378086	8842	Singh SK	Cancer stem cells in nervous system tumors.	Oncogene	2004	166
15558321	8842	Florek M	Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer.	Cell and tissue research	2005	73
16857948	8842	Fadini GP	Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy.	Arteriosclerosis, thrombosis, and vascular biology	2006	102
17122772	8842	O'Brien CA	A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.	Nature	2007	1048
17205516	8842	Yin S	CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity.	International journal of cancer	2007	149
17570225	8842	Ma S	Identification and characterization of tumorigenic liver cancer stem/progenitor cells.	Gastroenterology	2007	294
18037961	8842	Günther HS	Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria.	Oncogene	2008	113
18172261	8842	Zeppernick F	Stem cell marker CD133 affects clinical outcome in glioma patients.	Clinical cancer research 	2008	157
18560366	8842	Joo KM	Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas.	Laboratory investigation; a journal of technical methods and pathology	2008	108
18836486	8842	Baba T	Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.	Oncogene	2009	117
18941626	8842	Tirino V	Detection and characterization of CD133+ cancer stem cells in human solid tumours.	PloS one	2008	72
19047148	8842	Vander Griend DJ	The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells.	Cancer research	2008	78
19092120	8842	Ronconi E	Regeneration of glomerular podocytes by human renal progenitors.	Journal of the American Society of Nephrology 	2009	147
19621338	8842	Horst D	The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer.	The Journal of pathology	2009	47
19676044	8842	Salnikov AV	CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.	International journal of cancer	2010	53
19748175	8842	Zhang Q	A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy.	Cancer letters	2010	50
19805294	8842	Bertolini G	Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.	Proceedings of the National Academy of Sciences of the United States of America	2009	234
19816957	8842	Curley MD	CD133 expression defines a tumor initiating cell population in primary human ovarian cancer.	Stem cells	2009	123
19904829	8842	Fan X	NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts.	Stem cells	2010	191
20080668	8842	Pine SR	Microenvironmental modulation of asymmetric cell division in human lung cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	2010	53
20375132	8842	El Hallani S	A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry.	Brain 	2010	85
21220328	8842	Yan X	A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations.	Proceedings of the National Academy of Sciences of the United States of America	2011	40
21451132	8842	Stewart JM	Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells.	Proceedings of the National Academy of Sciences of the United States of America	2011	65
21695188	8842	Kim MP	ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma.	PloS one	2011	95
22079466	8842	Piao LS	CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma.	Cancer letters	2012	49
22080056	8842	Zhang J	CD133 expression associated with poor prognosis in ovarian cancer.	Modern pathology 	2012	33
22243781	8842	Wakamatsu Y	Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer.	Pathology international	2012	42
22431923	8842	Jamal M	The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells.	Neoplasia	2012	33
22899341	8842	Grosse-Gehling P	CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges.	The Journal of pathology	2013	75
23175471	8842	Sun YF	Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection.	Hepatology	2013	68
23409180	8842	Chen S	CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis.	PloS one	2013	30
23524583	8842	Zhang S	Generation of cancer stem-like cells through the formation of polyploid giant cancer cells.	Oncogene	2014	50
23586700	8842	Alamgeer M	Cancer stem cells in lung cancer: Evidence and controversies.	Respirology	2013	37
24436149	8842	Sarvi S	CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist.	Cancer research	2014	30
25262208	8842	Miranda-Lorenzo I	Intracellular autofluorescence: a biomarker for epithelial cancer stem cells.	Nature methods	2014	30
25938772	8842	Hu Y	Fibroblast-Derived Exosomes Contribute to Chemoresistance through Priming Cancer Stem Cells in Colorectal Cancer.	PloS one	2015	24
9145716	10178	Partin AW	Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.	JAMA	1997	150
9187198	10178	Mountain CF	Revisions in the International System for Staging Lung Cancer.	Chest	1997	408
12441925	10178	Frank I	An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score.	The Journal of urology	2002	122
15830281	10178	Llovet JM	Updated treatment approach to hepatocellular carcinoma.	Journal of gastroenterology	2005	121
15837991	10178	Patard JJ	Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience.	Journal of clinical oncology 	2005	86
17607115	10178	Rusch VW	The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer.	Journal of thoracic oncology 	2007	58
18230780	10178	Schetter AJ	MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.	JAMA	2008	505
19025987	10178	Fassnacht M	Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification.	Cancer	2009	61
19063642	10178	Chan EC	Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS).	Journal of proteome research	2009	83
20564099	10178	Rice TW	Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals.	Cancer	2010	109
21245428	10178	Mlecnik B	Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.	Journal of clinical oncology 	2011	176
21523730	10178	Farges O	AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: By the AFC-IHCC-2009 study group.	Cancer	2011	41
21627863	10178	Wei J	Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer.	Chinese journal of cancer	2011	48
22525418	10178	Rindi G	TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study.	Journal of the National Cancer Institute	2012	43
22790014	10178	Mitrovic B	Tumor budding in colorectal carcinoma: time to take notice.	Modern pathology 	2012	39
23018875	10178	Karamitopoulou E	Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer.	Modern pathology 	2013	32
23104212	10178	Roth AD	Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.	Journal of the National Cancer Institute	2012	45
23399908	10178	Walters S	Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007.	Thorax	2013	42
23649448	10178	Jett JR	Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.	Chest	2013	36
24183870	10178	Grégoire V	Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines.	Radiotherapy and oncology 	2014	34
25231913	10178	Zhang H	Infiltration of diametrically polarized macrophages predicts overall survival of patients with gastric cancer after surgical resection.	Gastric cancer 	2015	18
25575264	10178	Park JH	Colorectal Cancer, Systemic Inflammation, and Outcome: Staging the Tumor and Staging the Host.	Annals of surgery	2016	18
25897338	10178	Zhang J	Circulating MiR-16-5p and MiR-19b-3p as Two Novel Potential Biomarkers to Indicate Progression of Gastric Cancer.	Theranostics	2015	18
25903045	10178	Zheng Q	Aberrant expression of UCA1 in gastric cancer and its clinical significance.	Clinical and translational oncology 	2015	26
25919911	10178	Zhang X	Elevated expression of CCAT2 is associated with poor prognosis in esophageal squamous cell carcinoma.	Journal of surgical oncology	2015	18
26897166	10178	Sano T	Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project.	Gastric cancer 	2017	10
16814713	10413	Zender L	Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach.	Cell	2006	374
17889654	10413	Dong J	Elucidation of a universal size-control mechanism in Drosophila and mammals.	Cell	2007	582
18703216	10413	Steinhardt AA	Expression of Yes-associated protein in common solid tumors.	Human pathology	2008	172
19878874	10413	Zhou D	Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene.	Cancer cell	2009	261
19952108	10413	Fernandez-L A	YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation.	Genes and development	2009	110
20219076	10413	Wang Y	Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer.	Cancer science	2010	72
20226166	10413	Liu AM	MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties.	Biochemical and biophysical research communications	2010	64
20947521	10413	Hall CA	Hippo pathway effector Yap is an ovarian cancer oncogene.	Cancer research	2010	63
21102585	10413	Avruch J	Mst1/2 signalling to Yap: gatekeeper for liver size and tumour development.	British journal of cancer	2011	41
21112960	10413	Muramatsu T	YAP is a candidate oncogene for esophageal squamous cell carcinoma.	Carcinogenesis	2011	57
21267586	10413	Ellison DW	Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.	Acta neuropathologica	2011	94
21317925	10413	Zhang X	The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene.	Oncogene	2011	75
21346147	10413	Kang W	Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis.	Clinical cancer research 	2011	47
21610251	10413	Silvis MR	α-catenin is a tumor suppressor that controls cell accumulation by regulating the localization and activity of the transcriptional coactivator Yap1.	Science signaling	2011	92
22042863	10413	Zhou D	Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance.	Proceedings of the National Academy of Sciences of the United States of America	2011	99
22286761	10413	Mizuno T	YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes.	Oncogene	2012	46
22337891	10413	Konsavage WM Jr	Wnt/β-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells.	The Journal of biological chemistry	2012	62
22389730	10413	Haddow AD	Genetic characterization of Zika virus strains: geographic expansion of the Asian lineage.	PLoS neglected tropical diseases	2012	146
22609549	10413	Straßburger K	Insulin/IGF signaling drives cell proliferation in part via Yorkie/YAP.	Developmental biology	2012	32
22677547	10413	Liu-Chittenden Y	Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP.	Genes and development	2012	210
22886419	10413	Bai H	Yes-associated protein regulates the hepatic response after bile duct ligation.	Hepatology	2012	32
23178811	10413	Barry ER	Restriction of intestinal stem cell expansion and the regenerative response by YAP.	Nature	2013	106
23419361	10413	Tschaharganeh DF	Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma.	Gastroenterology	2013	57
23542177	10413	Mao B	SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma.	Oncogene	2014	24
23737213	10413	Antonescu CR	Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma.	Genes, chromosomes and cancer	2013	31
23762387	10413	Wang L	Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells.	PloS one	2013	55
24023255	10413	Sun G	Ajuba family proteins link JNK to Hippo signaling.	Science signaling	2013	38
24268772	10413	Anakk S	Bile acids activate YAP to promote liver carcinogenesis.	Cell reports	2013	25
24323901	10413	Touil Y	Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis.	Clinical cancer research 	2014	32
24362629	10413	Mohseni M	A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway.	Nature cell biology	2014	59
24468535	10413	Wang J	Mutual inhibition between YAP and SRSF1 maintains long non-coding RNA, Malat1-induced tumourigenesis in liver cancer.	Cellular signalling	2014	21
24622501	10413	Xia Y	YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients.	PloS one	2014	30
24803537	10413	Zhang W	Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.	Science signaling	2014	58
24882516	10413	Yu FX	Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.	Cancer cell	2014	66
24884509	10413	Tu K	Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma.	Molecular cancer	2014	25
24954536	10413	Shao DD	KRAS and YAP1 converge to regulate EMT and tumor survival.	Cell	2014	119
25010260	10413	Perra A	YAP activation is an early event and a potential therapeutic target in liver cancer development.	Journal of hepatology	2014	40
25087979	10413	Tremblay AM	The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation.	Cancer cell	2014	28
25180228	10413	Hong X	Opposing activities of the Ras and Hippo pathways converge on regulation of YAP protein turnover.	The EMBO journal	2014	22
25195862	10413	Liu G	Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo pathway.	Oncogene	2015	18
25480985	10413	Lange AW	Hippo/Yap signaling controls epithelial progenitor cell proliferation and differentiation in the embryonic and adult lung.	Journal of molecular cell biology	2015	25
25731159	10413	Taniguchi K	A gp130-Src-YAP module links inflammation to epithelial regeneration.	Nature	2015	61
25739674	10413	Song S	The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer.	Clinical cancer research 	2015	23
25772357	10413	Fitamant J	YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression.	Cell reports	2015	26
25846731	10413	Deng J	MicroRNA-506 inhibits gastric cancer proliferation and invasion by directly targeting Yap1.	Tumour biology 	2015	19
25908270	10413	Mannaerts I	The Hippo pathway effector YAP controls mouse hepatic stellate cell activation.	Journal of hepatology	2015	22
25965575	10413	Pajtler KW	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups.	Cancer cell	2015	42
26058078	10413	Nguyen LT	ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors.	Cancer cell	2015	18
26109051	10413	Chen Q	Homeostatic control of Hippo signaling activity revealed by an endogenous activating mutation in YAP.	Genes and development	2015	23
26119935	10413	Ciamporcero E	YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage.	Oncogene	2016	12
26121086	10413	Schramm A	Mutational dynamics between primary and relapse neuroblastomas.	Nature genetics	2015	37
26193883	10413	Cai J	β-Catenin destruction complex-independent regulation of Hippo-YAP signaling by APC in intestinal tumorigenesis.	Genes and development	2015	20
26701088	10413	Wang G	Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression.	Cancer discovery	2016	17
26950094	10413	Bonilla X	Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma.	Nature genetics	2016	19
27270433	10413	Selth LA	A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer.	Oncogene	2017	9
27300434	10413	Zanconato F	YAP/TAZ at the Roots of Cancer.	Cancer cell	2016	32
11441118	10563	Takemura S	Lymphoid neogenesis in rheumatoid synovitis.	Journal of immunology	2001	138
15193029	10563	Serafini B	Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis.	Brain pathology	2004	176
16473279	10563	Richardson AL	X chromosomal abnormalities in basal-like human breast cancer.	Cancer cell	2006	295
19491390	10563	Quiroga MP	B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.	Blood	2009	77
19996075	10563	Sellebjerg F	Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS.	Neurology	2009	48
20558389	10563	Piccio L	Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.	Archives of neurology	2010	42
21084753	10563	Moreth K	The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis.	The Journal of clinical investigation	2010	49
22279054	10563	de Rooij MF	The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.	Blood	2012	123
22362000	10563	Hoellenriegel J	Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.	Leukemia	2012	44
22591862	10563	Kowarik MC	CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation.	Journal of neuroinflammation	2012	39
22692510	10563	Pallikkuth S	Impaired peripheral blood T-follicular helper cell function in HIV-infected nonresponders to the 2009 H1N1/09 vaccine.	Blood	2012	66
23778140	10563	Gu-Trantien C	CD4⁺ follicular helper T cell infiltration predicts breast cancer survival.	The Journal of clinical investigation	2013	90
24138885	10563	Bindea G	Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.	Immunity	2013	157
25217476	10563	DePianto DJ	Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis.	Thorax	2015	27
25924065	10563	Shalapour S	Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy.	Nature	2015	39
10869059	10687	Gultekin SH	Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients.	Brain 	2000	121
11753617	10687	Gupta D	Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.	Leukemia	2001	89
11861292	10687	Zhan F	Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.	Blood	2002	161
17885048	10687	Taouli B	Diffusion-weighted MRI for quantification of liver fibrosis: preliminary experience.	AJR. American journal of roentgenology	2007	57
22451162	10687	Quek AM	Autoimmune epilepsy: clinical characteristics and response to immunotherapy.	Archives of neurology	2012	41
22539258	10687	Bien CG	Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis.	Brain 	2012	63
12832613	10891	Patti ME	Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1.	Proceedings of the National Academy of Sciences of the United States of America	2003	497
16380484	10891	Kukidome D	Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells.	Diabetes	2006	132
17991697	10891	Burgomaster KA	Similar metabolic adaptations during exercise after low volume sprint interval and traditional endurance training in humans.	The Journal of physiology	2008	131
19273754	10891	Qin W	PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia.	Archives of neurology	2009	71
19723495	10891	Barrès R	Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density.	Cell metabolism	2009	139
20032281	10891	Hernández-Alvarez MI	Subjects with early-onset type 2 diabetes show defective activation of the skeletal muscle PGC-1{alpha}/Mitofusin-2 regulatory pathway in response to physical activity.	Diabetes care	2010	45
20100740	10891	Little JP	A practical model of low-volume high-intensity interval training induces mitochondrial biogenesis in human skeletal muscle: potential mechanisms.	The Journal of physiology	2010	83
20339121	10891	Karamanlidis G	Defective DNA replication impairs mitochondrial biogenesis in human failing hearts.	Circulation research	2010	50
20538956	10891	Carré JE	Survival in critical illness is associated with early activation of mitochondrial biogenesis.	American journal of respiratory and critical care medicine	2010	70
20926834	10891	Zheng B	PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.	Science translational medicine	2010	167
21376232	10891	Shin JH	PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease.	Cell	2011	228
21451146	10891	Little JP	An acute bout of high-intensity interval training increases the nuclear abundance of PGC-1α and activates mitochondrial biogenesis in human skeletal muscle.	American journal of physiology. Regulatory, integrative and comparative physiology	2011	49
22077634	10891	Sheng B	Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease.	Journal of neurochemistry	2012	59
22301554	10891	Crane JD	Massage therapy attenuates inflammatory signaling after exercise-induced muscle damage.	Science translational medicine	2012	37
22318941	10891	Wang B	Stat3-mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha.	Hepatology	2012	54
22323564	10891	Xu XJ	Insulin sensitive and resistant obesity in humans: AMPK activity, oxidative stress, and depot-specific changes in gene expression in adipose tissue.	Journal of lipid research	2012	40
22446165	10891	Chowdhury SK	The role of aberrant mitochondrial bioenergetics in diabetic neuropathy.	Neurobiology of disease	2013	36
22681576	10891	Joseph AM	The impact of aging on mitochondrial function and biogenesis pathways in skeletal muscle of sedentary high- and low-functioning elderly individuals.	Aging cell	2012	57
23172368	10891	Sotgia F	Mitochondria "fuel" breast cancer metabolism: fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cells.	Cell cycle	2012	45
23449689	10891	Ryan JJ	PGC1α-mediated mitofusin-2 deficiency in female rats and humans with pulmonary arterial hypertension.	American journal of respiratory and critical care medicine	2013	30
24186207	10891	Tennakoon JB	Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch.	Oncogene	2014	35
24290359	10891	Ryan SD	Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1α transcription.	Cell	2013	74
24411942	10891	Roberts LD	β-Aminoisobutyric acid induces browning of white fat and hepatic β-oxidation and is inversely correlated with cardiometabolic risk factors.	Cell metabolism	2014	64
24506866	10891	Sawada N	Endothelial PGC-1α mediates vascular dysfunction in diabetes.	Cell metabolism	2014	27
25241037	10891	LeBleu VS	PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis.	Nature cell biology	2014	121
25297634	10891	Gopal YN	Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma.	Cancer research	2014	25
11672522	23411	Luo J	Negative control of p53 by Sir2alpha promotes cell survival under stress.	Cell	2001	634
12006491	23411	Langley E	Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence.	The EMBO journal	2002	233
12297502	23411	Bitterman KJ	Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1.	The Journal of biological chemistry	2002	262
15205477	23411	Cohen HY	Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase.	Science	2004	531
16170353	23411	Ota H	Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells.	Oncogene	2006	116
16751189	23411	Qin W	Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction.	The Journal of biological chemistry	2006	154
17447894	23411	Michan S	Sirtuins in mammals: insights into their biological function.	The Biochemical journal	2007	370
17581637	23411	Kim D	SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis.	The EMBO journal	2007	272
17806102	23411	Stünkel W	Function of the SIRT1 protein deacetylase in cancer.	Biotechnology journal	2007	67
17934453	23411	Yang Y	SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress.	Nature cell biology	2007	107
18235502	23411	Zhao W	Negative regulation of the deacetylase SIRT1 by DBC1.	Nature	2008	186
18414679	23411	Firestein R	The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth.	PloS one	2008	193
18641460	23411	Potente M	Emerging roles of SIRT1 in vascular endothelial homeostasis.	Cell cycle	2008	53
18755897	23411	Yamakuchi M	miR-34a repression of SIRT1 regulates apoptosis.	Proceedings of the National Academy of Sciences of the United States of America	2008	348
18835033	23411	Wang RH	Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice.	Cancer cell	2008	247
19060927	23411	Lara E	Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect.	Oncogene	2009	67
19104446	23411	Julien C	Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease.	Journal of neuropathology and experimental neurology	2009	56
19376817	23411	Nakamaru Y	A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9.	FASEB journal 	2009	52
19509139	23411	Cha EJ	Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma.	Clinical cancer research 	2009	61
20089851	23411	Tanno M	Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure.	The Journal of biological chemistry	2010	79
20644332	23411	Kao CL	Resveratrol protects human endothelium from H(2)O(2)-induced oxidative stress and senescence via SirT1 activation.	Journal of atherosclerosis and thrombosis	2010	52
21048160	23411	Bellet MM	Mammalian circadian clock and metabolism - the epigenetic link.	Journal of cell science	2010	60
21056897	23411	Lee H	Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma.	Human pathology	2011	55
21149730	23411	Ming M	Regulation of global genome nucleotide excision repair by SIRT1 through xeroderma pigmentosum C.	Proceedings of the National Academy of Sciences of the United States of America	2010	49
21527554	23411	Chen J	Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth.	Cancer research	2011	41
21596753	23411	Eades G	miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells.	The Journal of biological chemistry	2011	82
21778425	23411	Zhou S	Repression of P66Shc expression by SIRT1 contributes to the prevention of hyperglycemia-induced endothelial dysfunction.	Circulation research	2011	44
22146883	23411	Chen HC	SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis.	Annals of surgical oncology	2012	37
22190494	23411	Menssen A	The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop.	Proceedings of the National Academy of Sciences of the United States of America	2012	75
22207735	23411	Yuan H	Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis.	Blood	2012	49
22249256	23411	Byles V	SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis.	Oncogene	2012	68
22331558	23411	Zhang Q	A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53.	EMBO molecular medicine	2012	33
22340598	23411	Li L	Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib.	Cancer cell	2012	108
22728651	23411	Lee CW	AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells.	Cancer research	2012	50
22902550	23411	Castro RE	miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease.	Journal of hepatology	2013	54
23696823	23411	Endo H	Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis.	PloS one	2013	33
23728341	23411	Bae HJ	MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma.	Oncogene	2014	36
23932046	23411	Palomer X	An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy.	International journal of cardiology	2013	30
24184811	23411	Li Y	Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21.	Gastroenterology	2014	33
24439680	23411	Hubbard BP	Small molecule SIRT1 activators for the treatment of aging and age-related diseases.	Trends in pharmacological sciences	2014	77
24567379	23411	Cai W	Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans.	Proceedings of the National Academy of Sciences of the United States of America	2014	24
26768768	23411	Pan H	SIRT6 safeguards human mesenchymal stem cells from oxidative stress by coactivating NRF2.	Cell research	2016	19
17219193	23435	Davidson Y	Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43.	Acta neuropathologica	2007	85
17279000	23435	Neumann M	TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations.	Journal of neuropathology and experimental neurology	2007	92
17481916	23435	Strong MJ	TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein.	Molecular and cellular neurosciences	2007	96
17963732	23435	Higashi S	Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies.	Brain research	2007	82
18166704	23435	Josephs KA	Progressive aphasia secondary to Alzheimer disease vs FTLD pathology.	Neurology	2008	64
18396105	23435	Van Deerlin VM	TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis.	The Lancet. Neurology	2008	203
18474740	23435	Geser F	Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis.	Archives of neurology	2008	73
18520774	23435	Uryu K	Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies.	Journal of neuropathology and experimental neurology	2008	100
18546284	23435	Hasegawa M	Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.	Annals of neurology	2008	128
18779421	23435	Kühnlein P	Two German kindreds with familial amyotrophic lateral sclerosis due to TARDBP mutations.	Archives of neurology	2008	58
18845250	23435	Kimonis VE	VCP disease associated with myopathy, Paget disease of bone and frontotemporal dementia: review of a unique disorder.	Biochimica et biophysica acta	2008	57
19021630	23435	Nelson PT	Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons.	Brain pathology	2010	78
19139911	23435	Arai T	Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies.	Acta neuropathologica	2009	70
19192301	23435	Wijesekera LC	Amyotrophic lateral sclerosis.	Orphanet journal of rare diseases	2009	133
19204154	23435	Geser F	Clinical and pathological continuum of multisystem TDP-43 proteinopathies.	Archives of neurology	2009	80
19271105	23435	Geser F	Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases.	Journal of neurology	2009	56
19380227	23435	Weihl CC	Valosin-containing protein disease: inclusion body myopathy with Paget's disease of the bone and fronto-temporal dementia.	Neuromuscular disorders 	2009	52
19383787	23435	Zhang YJ	Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity.	Proceedings of the National Academy of Sciences of the United States of America	2009	158
19465477	23435	Johnson BS	TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity.	The Journal of biological chemistry	2009	182
19765185	23435	Colombrita C	TDP-43 is recruited to stress granules in conditions of oxidative insult.	Journal of neurochemistry	2009	125
19781077	23435	Lu Y	Frontotemporal dementia and amyotrophic lateral sclerosis-associated disease protein TDP-43 promotes dendritic branching.	Molecular brain	2009	57
19808791	23435	Pesiridis GS	Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis.	Human molecular genetics	2009	86
19830439	23435	Munoz DG	FUS pathology in basophilic inclusion body disease.	Acta neuropathologica	2009	66
19833869	23435	Wegorzewska I	TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration.	Proceedings of the National Academy of Sciences of the United States of America	2009	190
20133711	23435	Wils H	TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration.	Proceedings of the National Academy of Sciences of the United States of America	2010	154
20139998	23435	Grossman M	Primary progressive aphasia: clinicopathological correlations.	Nature reviews. Neurology	2010	77
20369906	23435	Rabinovici GD	Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management.	CNS drugs	2010	49
20530643	23435	Ash PE	Neurotoxic effects of TDP-43 overexpression in C. elegans.	Human molecular genetics	2010	71
20621187	23435	Stallings NR	Progressive motor weakness in transgenic mice expressing human TDP-43.	Neurobiology of disease	2010	58
20702714	23435	Xu YF	Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice.	The Journal of neuroscience 	2010	129
20740007	23435	Elden AC	Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS.	Nature	2010	238
20864052	23435	Mackenzie IR	TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia.	The Lancet. Neurology	2010	176
20971753	23435	Seelaar H	Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review.	Journal of neurology, neurosurgery, and psychiatry	2011	88
21131904	23435	Ayala YM	TDP-43 regulates its mRNA levels through a negative feedback loop.	The EMBO journal	2011	139
21172843	23435	Rohrer JD	TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia.	Neurology	2010	41
21346515	23435	Pao WC	Hippocampal sclerosis in the elderly: genetic and pathologic findings, some mimicking Alzheimer disease clinically.	Alzheimer disease and associated disorders	2011	37
21355045	23435	Zhang T	TDP-43 neurotoxicity and protein aggregation modulated by heat shock factor and insulin/IGF-1 signaling.	Human molecular genetics	2011	36
21454607	23435	Pesiridis GS	A "two-hit" hypothesis for inclusion formation by carboxyl-terminal fragments of TDP-43 protein linked to RNA depletion and impaired microtubule-dependent transport.	The Journal of biological chemistry	2011	41
21541367	23435	Sun Z	Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS.	PLoS biology	2011	119
21847013	23435	Gitler AD	RNA-binding proteins with prion-like domains in ALS and FTLD-U.	Prion	2011	43
21892620	23435	Nalbandian A	The multiple faces of valosin-containing protein-associated diseases: inclusion body myopathy with Paget's disease of bone, frontotemporal dementia, and amyotrophic lateral sclerosis.	Journal of molecular neuroscience 	2011	43
21908392	23435	Leyton CE	Subtypes of progressive aphasia: application of the International Consensus Criteria and validation using β-amyloid imaging.	Brain 	2011	47
22028219	23435	Jucker M	Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders.	Annals of neurology	2011	141
22029574	23435	Xu YF	Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice.	Molecular neurodegeneration	2011	44
22120149	23435	Robinson JL	Neocortical and hippocampal amyloid-β and tau measures associate with dementia in the oldest-old.	Brain 	2011	36
22127299	23435	Lee EB	Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration.	Nature reviews. Neuroscience	2011	149
22156203	23435	Huang C	Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats.	The Journal of clinical investigation	2012	30
22445064	23435	King OD	The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease.	Brain research	2012	159
22451909	23435	Bilican B	Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability.	Proceedings of the National Academy of Sciences of the United States of America	2012	96
22493728	23435	Pokrishevsky E	Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis.	PloS one	2012	43
22563080	23435	Bentmann E	Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43).	The Journal of biological chemistry	2012	63
22855461	23435	Egawa N	Drug screening for ALS using patient-specific induced pluripotent stem cells.	Science translational medicine	2012	119
23012333	23435	Hornberger M	In vivo and post-mortem memory circuit integrity in frontotemporal dementia and Alzheimer's disease.	Brain 	2012	32
23022481	23435	Yamazaki T	FUS-SMN protein interactions link the motor neuron diseases ALS and SMA.	Cell reports	2012	65
23380910	23435	Irwin DJ	Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone.	JAMA neurology	2013	43
23401527	23435	Serio A	Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy.	Proceedings of the National Academy of Sciences of the United States of America	2013	67
23475817	23435	McMillan CT	White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration.	Journal of neurology, neurosurgery, and psychiatry	2013	29
23587065	23435	Bentmann E	Stress granules in neurodegeneration--lessons learnt from TAR DNA binding protein of 43 kDa and fused in sarcoma.	The FEBS journal	2013	44
23629963	23435	Li YR	Stress granules as crucibles of ALS pathogenesis.	The Journal of cell biology	2013	159
23842566	23435	Toledo JB	Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre.	Brain 	2013	84
23864344	23435	Nelson PT	Hippocampal sclerosis of aging, a prevalent and high-morbidity brain disease.	Acta neuropathologica	2013	43
23891805	23435	Burkhardt MF	A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells.	Molecular and cellular neurosciences	2013	50
23900071	23435	Janssens J	Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders.	Human molecular genetics	2013	33
23900711	23435	Kovacs GG	Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series.	Acta neuropathologica	2013	39
24080705	23435	Wilson RS	TDP-43 pathology, cognitive decline, and dementia in old age.	JAMA neurology	2013	41
24240737	23435	Josephs KA	Staging TDP-43 pathology in Alzheimer's disease.	Acta neuropathologica	2014	35
24252435	23435	Toledo JB	Clinical and multimodal biomarker correlates of ADNI neuropathological findings.	Acta neuropathologica communications	2013	26
24439375	23435	Jackrel ME	Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events.	Cell	2014	42
24574501	23435	Mesulam MM	Asymmetry and heterogeneity of Alzheimer's and frontotemporal pathology in primary progressive aphasia.	Brain 	2014	40
24746362	23435	Pasanen P	Novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology.	Neurobiology of aging	2014	54
27015757	23435	Ratti A	Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins.	Journal of neurochemistry	2016	20
27495267	23435	McAleese KE	TDP-43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing.	Brain pathology	2017	5
12883497	26503	Wai CT	A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.	Hepatology	2003	518
14499785	26503	Harrison SA	The natural history of nonalcoholic fatty liver disease: a clinical histopathological study.	The American journal of gastroenterology	2003	85
15842581	26503	Huang MA	One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study.	The American journal of gastroenterology	2005	81
17393509	26503	Angulo P	The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.	Hepatology	2007	235
18390575	26503	Harrison SA	Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.	Gut	2008	92
19013463	26503	Patton HM	Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis.	Gastroenterology	2008	50
19148800	26503	Hashimoto E	Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.	Journal of gastroenterology	2009	50
20801772	26503	McPherson S	Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.	Gut	2010	78
21748296	26503	El-Khoueiry AB	SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.	Investigational new drugs	2012	36
22271046	26503	Corpechot C	Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis.	Hepatology	2012	32
23387384	26503	Musso G	Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis.	Obesity reviews 	2013	33
23396737	26503	Wong VW	Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study.	Annals of hepatology	2013	39
23485521	26503	Bernstein DL	Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease.	Journal of hepatology	2013	35
23575478	26503	Jimeno A	Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors.	Clinical cancer research 	2013	35
23928932	26503	Venkatesh SK	Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B.	European radiology	2014	30
23980084	26503	Johnson PJ	Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.	Journal of clinical oncology 	2013	96
24436062	26503	Konerman MA	Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs.	Hepatology	2014	21
12091876	29126	Dong H	Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.	Nature medicine	2002	813
15569934	29126	Thompson RH	Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.	Proceedings of the National Academy of Sciences of the United States of America	2004	181
15837746	29126	Ohigashi Y	Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer.	Clinical cancer research 	2005	169
16530813	29126	Wu C	Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance.	Acta histochemica	2006	109
16585157	29126	Thompson RH	Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.	Cancer research	2006	198
16699366	29126	Gajewski TF	Immune suppression in the tumor microenvironment.	Journal of immunotherapy	2006	62
17159987	29126	Parsa AT	Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.	Nature medicine	2007	281
17186290	29126	Nakanishi J	Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers.	Cancer immunology, immunotherapy 	2007	65
17340590	29126	Inman BA	PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.	Cancer	2007	63
17360651	29126	Hamanishi J	Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.	Proceedings of the National Academy of Sciences of the United States of America	2007	289
17363736	29126	Liu J	Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.	Blood	2007	100
17875753	29126	Gajewski TF	Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.	Clinical cancer research 	2007	82
18223165	29126	Azuma T	B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells.	Blood	2008	91
18268286	29126	Rawstron AC	Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.	Haematologica	2008	72
19155478	29126	Gong AY	MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes.	Journal of immunology	2009	50
19188168	29126	Gao Q	Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma.	Clinical cancer research 	2009	141
19229109	29126	Franceschini D	PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV.	The Journal of clinical investigation	2009	87
19451266	29126	Kuang DM	Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1.	The Journal of experimental medicine	2009	128
19825956	29126	Karim R	Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma.	Clinical cancer research 	2009	62
19826049	29126	Wu K	Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions.	Cancer research	2009	54
20068105	29126	Wei J	Glioma-associated cancer-initiating cells induce immunosuppression.	Clinical cancer research 	2010	68
20143437	29126	Hino R	Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma.	Cancer	2010	128
20308313	29126	Rodrigues JC	Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties.	Neuro-oncology	2010	57
20373055	29126	Mu CY	High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation.	Medical oncology	2011	105
20473887	29126	Shi F	PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.	International journal of cancer	2011	71
21523733	29126	Gadiot J	Overall survival and PD-L1 expression in metastasized malignant melanoma.	Cancer	2011	40
22461641	29126	Taube JM	Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.	Science translational medicine	2012	408
22828443	29126	Tamura H	Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.	Leukemia	2013	28
23340297	29126	Abiko K	PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction.	Clinical cancer research 	2013	28
23389362	29126	Chen YB	Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study.	Tumori	2012	51
23613317	29126	Bloch O	Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages.	Clinical cancer research 	2013	71
23674495	29126	Chen BJ	PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.	Clinical cancer research 	2013	95
23785454	29126	Song M	PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer.	PloS one	2013	35
23792703	29126	Gianchecchi E	Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity.	Autoimmunity reviews	2013	39
24217091	29126	Velcheti V	Programmed death ligand-1 expression in non-small cell lung cancer.	Laboratory investigation; a journal of technical methods and pathology	2014	145
24297569	29126	Maine CJ	Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer.	Cancer immunology, immunotherapy 	2014	22
24315741	29126	Sideras K	Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies.	Cancer treatment reviews	2014	25
24349382	29126	Kim JR	Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas.	PloS one	2013	48
24416729	29126	Lipson EJ	PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival.	Cancer immunology research	2013	53
24626392	29126	Bowers NL	Immune suppression by neutrophils in HIV-1 infection: role of PD-L1/PD-1 pathway.	PLoS pathogens	2014	37
24657498	29126	Hou J	Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer.	Experimental and molecular pathology	2014	27
24691993	29126	Lines JL	VISTA is an immune checkpoint molecule for human T cells.	Cancer research	2014	26
24714771	29126	Taube JM	Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.	Clinical cancer research 	2014	326
24804867	29126	Geng Y	Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance.	International journal of clinical oncology	2015	21
24866169	29126	Shen JK	Programmed cell death ligand 1 expression in osteosarcoma.	Cancer immunology research	2014	28
25193987	29126	Choueiri TK	PD-L1 expression in nonclear-cell renal cell carcinoma.	Annals of oncology 	2014	42
25314639	29126	Berghoff AS	Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.	Histopathology	2015	21
25337246	29126	Chen L	B7-H1 expression associates with tumor invasion and predicts patient's survival in human esophageal cancer.	International journal of clinical and experimental pathology	2014	24
25348003	29126	Chen L	Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression.	Nature communications	2014	75
25384063	29126	Ishii H	Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer.	Journal of thoracic oncology 	2015	24
25424850	29126	McDermott DF	The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.	Clinical cancer research 	2015	19
25428505	29126	Tumeh PC	PD-1 blockade induces responses by inhibiting adaptive immune resistance.	Nature	2014	512
25440090	29126	Ohaegbulam KC	Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.	Trends in molecular medicine	2015	47
25477049	29126	Madore J	PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.	Pigment cell and melanoma research	2015	25
25527356	29126	Wimberly H	PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.	Cancer immunology research	2015	41
25538263	29126	Choueiri TK	Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.	Clinical cancer research 	2015	27
25540867	29126	D'Angelo SP	Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment.	Human pathology	2015	23
25582496	29126	Schultheis AM	PD-L1 expression in small cell neuroendocrine carcinomas.	European journal of cancer	2015	24
25600565	29126	Bellmunt J	Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma.	Annals of oncology 	2015	29
25609202	29126	Mao Y	B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer.	Oncotarget	2015	18
25609381	29126	Khan AR	PD-L1hi B cells are critical regulators of humoral immunity.	Nature communications	2015	22
25622193	29126	Woo SR	Innate immune recognition of cancer.	Annual review of immunology	2015	43
25674748	29126	Zhang Y	Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis.	Medicine	2015	21
25682184	29126	Wang A	The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis.	European journal of surgical oncology 	2015	29
25695955	29126	Patel SP	PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.	Molecular cancer therapeutics	2015	104
25733810	29126	Qing Y	Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer.	Drug design, development and therapy	2015	25
25751499	29126	Lussier DM	Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.	Journal of immunotherapy	2015	22
25897014	29126	Ali HR	PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes.	Annals of oncology 	2015	29
25977331	29126	Heskamp S	Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies.	Cancer research	2015	19
26086854	29126	Carbognin L	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.	PloS one	2015	54
26134220	29126	Kerr KM	Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?	Journal of thoracic oncology 	2015	35
26181000	29126	Howitt BE	Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.	JAMA oncology	2015	35
26181250	29126	Larkin J	Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.	JAMA oncology	2015	25
26210691	29126	Eto S	Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection.	Gastric cancer 	2016	17
26239088	29126	Kiyasu J	Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.	Blood	2015	29
26279307	29126	He J	Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.	Scientific reports	2015	30
26313362	29126	Schmidt LH	PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.	PloS one	2015	28
26317305	29126	Phillips T	Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.	Applied immunohistochemistry and molecular morphology 	2015	22
26320063	29126	Lipson EJ	Antagonists of PD-1 and PD-L1 in Cancer Treatment.	Seminars in oncology	2015	31
26408403	29126	Vassilakopoulou M	Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.	Clinical cancer research 	2016	18
26527522	29126	Cimino-Mathews A	PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas.	Human pathology	2016	19
26541606	29126	Sivan A	Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.	Science	2015	114
26573597	29126	Gevensleben H	The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer.	Clinical cancer research 	2016	14
26712084	29126	Herbst RS	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.	Lancet	2016	207
26761210	29126	Chen MF	The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression.	Oncotarget	2016	13
26801886	29126	Thompson ED	Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma.	Gut	2017	21
26822383	29126	Johnson DB	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.	Nature communications	2016	26
26895815	29126	Gandini S	PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis.	Critical reviews in oncology/hematology	2016	27
26915032	29126	Ilie M	Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.	Virchows Archiv 	2016	17
26977880	29126	Tang H	Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade.	Cancer cell	2016	19
27030389	29126	Georgiou K	Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas.	Blood	2016	11
27069084	29126	Roemer MG	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.	Journal of clinical oncology 	2016	25
27093365	29126	Nghiem PT	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.	The New England journal of medicine	2016	56
27157491	29126	Muro K	Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.	The Lancet. Oncology	2016	36
27196573	29126	Masugi Y	Tumour CD274 (PD-L1) expression and T cells in colorectal cancer.	Gut	2017	8
27267608	29126	Goldberg SB	Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.	The Lancet. Oncology	2016	29
27269937	29126	Massard C	Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.	Journal of clinical oncology 	2016	31
27269947	29126	Lesokhin AM	Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.	Journal of clinical oncology 	2016	35
27281199	29126	Kataoka K	Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.	Nature	2016	31
27569912	29126	Daley D	γδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation.	Cell	2016	15
27592805	29126	Kaufman HL	Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.	The Lancet. Oncology	2016	20
27827313	29126	Champiat S	Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.	Clinical cancer research 	2017	11
27932067	29126	Hellmann MD	Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.	The Lancet. Oncology	2017	10
28081914	29126	Plimack ER	Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.	The Lancet. Oncology	2017	7
28131785	29126	Sharma P	Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.	The Lancet. Oncology	2017	16
28212060	29126	Bellmunt J	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.	The New England journal of medicine	2017	17
28278348	29126	Rimm DL	A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.	JAMA oncology	2017	8
11120765	50943	Chatila TA	JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome.	The Journal of clinical investigation	2000	185
12161590	50943	Wildin RS	Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome.	Journal of medical genetics	2002	131
15252446	50943	Oswald-Richter K	HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells.	PLoS biology	2004	113
15454488	50943	Balandina A	Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis.	Blood	2005	66
15466453	50943	Yagi H	Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells.	International immunology	2004	169
15791617	50943	Stoop JN	Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection.	Hepatology	2005	117
16278306	50943	Rieger K	Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD.	Blood	2006	66
16322292	50943	Wolf D	The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.	Clinical cancer research 	2005	103
16428488	50943	Badoual C	Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers.	Clinical cancer research 	2006	108
16825494	50943	Carreras J	High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma.	Blood	2006	84
16902147	50943	Nilsson J	HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS.	Blood	2006	130
16955142	50943	Vukmanovic-Stejic M	Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo.	The Journal of clinical investigation	2006	137
17099880	50943	Petersen RP	Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.	Cancer	2006	76
17289884	50943	Kobayashi N	FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis.	Clinical cancer research 	2007	89
17440451	50943	Zheng Y	Foxp3 in control of the regulatory T cell lineage.	Nature immunology	2007	225
18056169	50943	Kiniwa Y	CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.	Clinical cancer research 	2007	78
18698034	50943	Heimberger AB	Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas.	Clinical cancer research 	2008	79
18791714	50943	Leffers N	Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.	Cancer immunology, immunotherapy 	2009	91
19064967	50943	Salama P	Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer.	Journal of clinical oncology 	2009	207
19109157	50943	Lal G	Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation.	Journal of immunology	2009	139
19128359	50943	Willcox A	Analysis of islet inflammation in human type 1 diabetes.	Clinical and experimental immunology	2009	138
19255331	50943	Merlo A	FOXP3 expression and overall survival in breast cancer.	Journal of clinical oncology 	2009	71
19464196	50943	Miyara M	Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor.	Immunity	2009	401
19464988	50943	Riley JL	Human T regulatory cell therapy: take a billion or so and call me in the morning.	Immunity	2009	147
19577568	50943	Sinicrope FA	Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma.	Gastroenterology	2009	77
19641607	50943	Milne K	Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.	PloS one	2009	85
19856313	50943	Frey DM	High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients.	International journal of cancer	2010	80
19908042	50943	Suzuki H	Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer.	Cancer immunology, immunotherapy 	2010	44
20547850	50943	Welters MJ	Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses.	Proceedings of the National Academy of Sciences of the United States of America	2010	69
20559327	50943	Sakaguchi S	FOXP3+ regulatory T cells in the human immune system.	Nature reviews. Immunology	2010	463
20883548	50943	Gurkan S	Immune reconstitution following rabbit antithymocyte globulin.	American journal of transplantation 	2010	52
20920773	50943	Nadeau K	Ambient air pollution impairs regulatory T-cell function in asthma.	The Journal of allergy and clinical immunology	2010	77
21030558	50943	Rapoport AP	Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.	Blood	2011	41
21253593	50943	Golovina TN	Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells.	PloS one	2011	42
21719142	50943	Tao H	Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells.	Lung cancer	2012	41
21856944	50943	Long SA	CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game.	Journal of immunology	2011	66
21896932	50943	Ferraro A	Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes.	Diabetes	2011	45
22123319	50943	Hamid O	A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.	Journal of translational medicine	2011	100
22190180	50943	Fuchs S	Antiviral and regulatory T cell immunity in a patient with stromal interaction molecule 1 deficiency.	Journal of immunology	2012	39
22465232	50943	Whiteside TL	What are regulatory T cells (Treg) regulating in cancer and why?	Seminars in cancer biology	2012	50
22510350	50943	deLeeuw RJ	The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature.	Clinical cancer research 	2012	91
23010736	50943	Katz SC	Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases.	Annals of surgical oncology	2013	26
23097687	50943	Messina JL	12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?	Scientific reports	2012	61
23676463	50943	Kinnunen T	Specific peripheral B cell tolerance defects in patients with multiple sclerosis.	The Journal of clinical investigation	2013	29
24129245	50943	Balermpas P	Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer.	British journal of cancer	2014	38
24636474	50943	Syed A	Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3).	The Journal of allergy and clinical immunology	2014	51
25255802	50943	Fong L	Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer.	Journal of the National Cancer Institute	2014	22
25654811	50943	Li Z	By downregulating TIAM1 expression, microRNA-329 suppresses gastric cancer invasion and growth.	Oncotarget	2015	34
11067960	54474	Odendahl M	Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus.	Journal of immunology	2000	114
12011122	54474	Witzig TE	Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.	Journal of clinical oncology 	2002	133
12853585	54474	Sarwal M	Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling.	The New England journal of medicine	2003	138
16230395	54474	Fang D	A tumorigenic subpopulation with stem cell properties in melanomas.	Cancer research	2005	346
17709552	54474	Ahuja A	Depletion of B cells in murine lupus: efficacy and resistance.	Journal of immunology	2007	79
18003886	54474	Coiffier B	Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.	Blood	2008	78
18272891	54474	Hauser SL	B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.	The New England journal of medicine	2008	360
18662969	54474	Marcus R	Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.	Journal of clinical oncology 	2008	83
18698040	54474	Al-Shibli KI	Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer.	Clinical cancer research 	2008	89
18854568	54474	Morschhauser F	Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.	Journal of clinical oncology 	2008	69
19847908	54474	Hawker K	Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.	Annals of neurology	2009	101
20660832	54474	Gisselbrecht C	Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.	Journal of clinical oncology 	2010	140
20980506	54474	Ma SD	A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas.	Journal of virology	2011	60
21378274	54474	Alduaij W	Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.	Blood	2011	66
21555606	54474	Clifford DB	Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis.	Archives of neurology	2011	45
22047971	54474	Kappos L	Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.	Lancet	2011	105
23319647	54474	Marzi A	Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.	Proceedings of the National Academy of Sciences of the United States of America	2013	45
23720127	54474	Hallek M	Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.	American journal of hematology	2013	37
24475900	54474	Woo JR	Tumor infiltrating B-cells are increased in prostate cancer tissue.	Journal of translational medicine	2014	24
24817416	54474	Wallace ZS	Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations.	Annals of the rheumatic diseases	2015	31
25135992	54474	Nowakowski GS	Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.	Journal of clinical oncology 	2015	32
25344523	54474	Da Roit F	Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.	Haematologica	2015	25
25636338	54474	Castillo JJ	The biology and treatment of plasmablastic lymphoma.	Blood	2015	22
25653369	54474	Doyle KP	B-lymphocyte-mediated delayed cognitive impairment following stroke.	The Journal of neuroscience 	2015	21
25908509	54474	Hallek M	Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.	American journal of hematology	2015	38
26581594	54474	Campbell-Thompson M	Insulitis and β-Cell Mass in the Natural History of Type 1 Diabetes.	Diabetes	2016	25
26910282	58492	Brożyna AA	Melanin content in melanoma metastases affects the outcome of radiotherapy.	Oncotarget	2016	16
12483741	114548	Aksentijevich I	De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases.	Arthritis and rheumatism	2002	134
12766759	114548	Inohara N	NODs: intracellular proteins involved in inflammation and apoptosis.	Nature reviews. Immunology	2003	200
14872505	114548	Hawkins PN	Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra.	Arthritis and rheumatism	2004	89
17164409	114548	Kummer JA	Inflammasome components NALP 1 and 3 show distinct but separate expression profiles in human tissues suggesting a site-specific role in the inflammatory response.	The journal of histochemistry and cytochemistry 	2007	105
17393462	114548	Aksentijevich I	The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model.	Arthritis and rheumatism	2007	81
17442855	114548	Lamkanfi M	Caspase-1 inflammasomes in infection and inflammation.	Journal of leukocyte biology	2007	60
19798428	114548	Cillóniz C	Lethal influenza virus infection in macaques is associated with early dysregulation of inflammatory related genes.	PLoS pathogens	2009	93
20038581	114548	Okamoto M	Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta.	The Journal of biological chemistry	2010	66
20039428	114548	Neven B	Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.	Arthritis and rheumatism	2010	52
20383149	114548	Ichinohe T	Influenza virus activates inflammasomes via its intracellular M2 ion channel.	Nature immunology	2010	166
20688930	114548	Vilaysane A	The NLRP3 inflammasome promotes renal inflammation and contributes to CKD.	Journal of the American Society of Nephrology 	2010	81
20835230	114548	Masters SL	Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes.	Nature immunology	2010	281
21349431	114548	Guarda G	Type I interferon inhibits interleukin-1 production and inflammasome activation.	Immunity	2011	203
22258606	114548	Strowig T	Inflammasomes in health and disease.	Nature	2012	347
22541070	114548	Tarallo V	DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88.	Cell	2012	149
22948162	114548	Juliana C	Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation.	The Journal of biological chemistry	2012	98
23221073	114548	Tseng WA	NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: implications for age-related macular degeneration.	Investigative ophthalmology and visual science	2013	59
23264657	114548	Wang W	Inflammasome-independent NLRP3 augments TGF-β signaling in kidney epithelium.	Journal of immunology	2013	32
23737748	114548	McAuley JL	Activation of the NLRP3 inflammasome by IAV virulence protein PB1-F2 contributes to severe pathophysiology and disease.	PLoS pathogens	2013	45
23937860	114548	Hillegass JM	Asbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cells.	Particle and fibre toxicology	2013	27
24008734	114548	Fann DY	Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke.	Cell death and disease	2013	38
24163269	114548	Mulay SR	Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease.	Nephrology, dialysis, transplantation 	2014	23
24243015	114548	Kim HS	Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer.	Cell	2013	54
24453977	114548	Ataide MA	Malaria-induced NLRP12/NLRP3-dependent caspase-1 activation mediates inflammation and hypersensitivity to bacterial superinfection.	PLoS pathogens	2014	30
24861026	114548	Wree A	NLRP3 inflammasome activation is required for fibrosis development in NAFLD.	Journal of molecular medicine	2014	30
24915862	114548	Hussain S	Inflammasome activation in airway epithelial cells after multi-walled carbon nanotube exposure mediates a profibrotic response in lung fibroblasts.	Particle and fibre toxicology	2014	34
25730877	114548	Carta S	Cell stress increases ATP release in NLRP3 inflammasome-mediated autoinflammatory diseases, resulting in cytokine imbalance.	Proceedings of the National Academy of Sciences of the United States of America	2015	16
25744023	114548	Kaushal V	Neuronal NLRP1 inflammasome activation of Caspase-1 coordinately regulates inflammatory interleukin-1-beta production and axonal degeneration-associated Caspase-6 activation.	Cell death and differentiation	2015	17
26341399	114548	Bronner DN	Endoplasmic Reticulum Stress Activates the Inflammasome via NLRP3- and Caspase-2-Driven Mitochondrial Damage.	Immunity	2015	27
26549800	114548	Jo EK	Molecular mechanisms regulating NLRP3 inflammasome activation.	Cellular and molecular immunology	2016	26
26814970	114548	He Y	NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux.	Nature	2016	24
27313051	114548	Arbore G	T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4⁺ T cells.	Science	2016	26
27650785	114548	Montesinos J	Impact of the Innate Immune Response in the Actions of Ethanol on the Central Nervous System.	Alcoholism, clinical and experimental research	2016	12
27669650	114548	He Y	Mechanism and Regulation of NLRP3 Inflammasome Activation.	Trends in biochemical sciences	2016	22
15680457	120892	Gilks WP	A common LRRK2 mutation in idiopathic Parkinson's disease.	Lancet	2005	151
16272164	120892	Khan NL	Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data.	Brain 	2005	73
16352719	120892	Smith WW	Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration.	Proceedings of the National Academy of Sciences of the United States of America	2005	114
16437559	120892	Ross OA	Lrrk2 and Lewy body disease.	Annals of neurology	2006	64
16437584	120892	Giasson BI	Biochemical and pathological characterization of Lrrk2.	Annals of neurology	2006	67
16750377	120892	Greggio E	Kinase activity is required for the toxic effects of mutant LRRK2/dardarin.	Neurobiology of disease	2006	227
17706965	120892	Guo L	The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity.	Experimental cell research	2007	78
18093566	120892	Schapira AH	Mitochondria in the aetiology and pathogenesis of Parkinson's disease.	The Lancet. Neurology	2008	186
18978800	120892	Henchcliffe C	Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis.	Nature clinical practice. Neurology	2008	175
19545277	120892	Gillardon F	Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration?	Journal of neurochemistry	2009	76
21159966	120892	Lee S	LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction.	The Journal of neuroscience 	2010	48
21168496	120892	Winner B	Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice.	Neurobiology of disease	2011	50
21248115	120892	Dusonchet J	A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2.	The Journal of neuroscience 	2011	44
21362567	120892	Nguyen HN	LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress.	Cell stem cell	2011	178
21494637	120892	Ramonet D	Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2.	PloS one	2011	96
21552986	120892	Hakimi M	Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures.	Journal of neural transmission	2011	47
22363216	120892	Stafa K	GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.	PLoS genetics	2012	40
22407749	120892	Sánchez-Danés A	Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease.	EMBO molecular medicine	2012	98
22764206	120892	Cooper O	Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease.	Science translational medicine	2012	100
23075850	120892	Liu GH	Progressive degeneration of human neural stem cells caused by pathogenic LRRK2.	Nature	2012	72
23125283	120892	Cho HJ	MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein.	Human molecular genetics	2013	30
23472874	120892	Reinhardt P	Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression.	Cell stem cell	2013	82
24403142	120892	Skibinski G	Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies.	The Journal of neuroscience 	2014	32
24682598	120892	Schapansky J	Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy.	Human molecular genetics	2014	23
25080504	120892	Gómez-Suaga P	LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity.	Human molecular genetics	2014	21
25416817	120892	Hockey LN	Dysregulation of lysosomal morphology by pathogenic LRRK2 is corrected by TPC2 inhibition.	Journal of cell science	2015	28
25653221	120892	Fuji RN	Effect of selective LRRK2 kinase inhibition on nonhuman primate lung.	Science translational medicine	2015	19
21986680	203228	Rohrer JD	Phenotypic signatures of genetic frontotemporal dementia.	Current opinion in neurology	2011	44
22083254	203228	Murray ME	Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72.	Acta neuropathologica	2011	97
22101323	203228	Al-Sarraj S	p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS.	Acta neuropathologica	2011	132
22105541	203228	Ince PG	Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology.	Acta neuropathologica	2011	45
22181065	203228	Troakes C	An MND/ALS phenotype associated with C9orf72 repeat expansion: abundant p62-positive, TDP-43-negative inclusions in cerebral cortex, hippocampus and cerebellum but without associated cognitive decline.	Neuropathology 	2012	40
22228244	203228	Stewart H	Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p.	Acta neuropathologica	2012	46
22300873	203228	Snowden JS	Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations.	Brain 	2012	112
22300876	203228	Simón-Sánchez J	The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions.	Brain 	2012	73
22305801	203228	Byrne S	Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study.	The Lancet. Neurology	2012	89
22366792	203228	Cooper-Knock J	Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72.	Brain 	2012	71
22366793	203228	Boeve BF	Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72.	Brain 	2012	82
22366794	203228	Chiò A	Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72.	Brain 	2012	47
22366795	203228	Whitwell JL	Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics.	Brain 	2012	95
22875087	203228	Sha SJ	Frontotemporal dementia due to C9ORF72 mutations: clinical and imaging features.	Neurology	2012	36
23117491	203228	Irwin DJ	Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis.	Journal of neurology, neurosurgery, and psychiatry	2013	29
23381195	203228	Mori K	hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-negative inclusions in the hippocampus of patients with C9orf72 mutations.	Acta neuropathologica	2013	91
23393093	203228	Mori K	The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS.	Science	2013	233
23720273	203228	Ciura S	Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis.	Annals of neurology	2013	71
23818065	203228	Fratta P	Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia.	Acta neuropathologica	2013	34
24011653	203228	van Blitterswijk M	Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study.	The Lancet. Neurology	2013	51
24170860	203228	Lagier-Tourenne C	Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration.	Proceedings of the National Academy of Sciences of the United States of America	2013	110
24248382	203228	Zu T	RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia.	Proceedings of the National Academy of Sciences of the United States of America	2013	116
24252525	203228	Mann DM	Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72.	Acta neuropathologica communications	2013	40
24379375	203228	Meyer K	Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS.	Proceedings of the National Academy of Sciences of the United States of America	2014	64
24394885	203228	Gendron TF	Mechanisms of toxicity in C9FTLD/ALS.	Acta neuropathologica	2014	32
24493408	203228	Cooper-Knock J	The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype.	Acta neuropathologica	2014	27
24559645	203228	Waite AJ	Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion.	Neurobiology of aging	2014	38
24598541	203228	Haeusler AR	C9orf72 nucleotide repeat structures initiate molecular cascades of disease.	Nature	2014	155
24703839	203228	Wainger BJ	Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons.	Cell reports	2014	94
24704492	203228	Kiskinis E	Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1.	Cell stem cell	2014	83
24806409	203228	Liu EY	C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD.	Acta neuropathologica	2014	39
25081482	203228	Kwon I	Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells.	Science	2014	95
25120191	203228	May S	C9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration.	Acta neuropathologica	2014	51
25132468	203228	Su Z	Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS.	Neuron	2014	53
25173361	203228	Zhang YJ	Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress.	Acta neuropathologica	2014	54
25398948	203228	Yamakawa M	Characterization of the dipeptide repeat protein in the molecular pathogenesis of c9FTD/ALS.	Human molecular genetics	2015	25
25521377	203228	Wen X	Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death.	Neuron	2014	61
25557955	203228	Ng AS	Frontotemporal dementia: a bridge between dementia and neuromuscular disease.	Annals of the New York Academy of Sciences	2015	18
25580746	203228	Devlin AC	Human iPSC-derived motoneurons harbouring TARDBP or C9ORF72 ALS mutations are dysfunctional despite maintaining viability.	Nature communications	2015	34
25662776	203228	Rohrer JD	Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis.	The Lancet. Neurology	2015	30
26085200	203228	Schludi MH	Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing.	Acta neuropathologica	2015	29
26308891	203228	Zhang K	The C9orf72 repeat expansion disrupts nucleocytoplasmic transport.	Nature	2015	105
26308899	203228	Freibaum BD	GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport.	Nature	2015	94
26481318	203228	Gijselinck I	The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter.	Molecular psychiatry	2016	16
26637797	203228	Peters OM	Human C9ORF72 Hexanucleotide Expansion Reproduces RNA Foci and Dipeptide Repeat Proteins but Not Neurodegeneration in BAC Transgenic Mice.	Neuron	2015	27
27334615	203228	Webster CP	The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy.	The EMBO journal	2016	23
12629218	100133941	Al-Hajj M	Prospective identification of tumorigenic breast cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	2003	2582
15709183	100133941	Abraham BK	Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis.	Clinical cancer research 	2005	128
16778178	100133941	Liu S	Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells.	Cancer research	2006	360
17020963	100133941	Balic M	Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype.	Clinical cancer research 	2006	161
17229949	100133941	Liu R	The prognostic role of a gene signature from tumorigenic breast-cancer cells.	The New England journal of medicine	2007	282
17283135	100133941	Li C	Identification of pancreatic cancer stem cells.	Cancer research	2007	864
17900673	100133941	Runz S	Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM.	Gynecologic oncology	2007	64
17975224	100133941	Cho RW	Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors.	Stem cells	2008	108
17978305	100133941	Lazzeri E	Regenerative potential of embryonic renal multipotent progenitors in acute renal failure.	Journal of the American Society of Nephrology 	2007	55
18268494	100133941	Hurt EM	CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis.	British journal of cancer	2008	118
18366788	100133941	Fillmore CM	Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy.	Breast cancer research 	2008	344
18445819	100133941	Li X	Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.	Journal of the National Cancer Institute	2008	499
18539958	100133941	Lee CJ	Pancreatic cancer stem cells.	Journal of clinical oncology 	2008	112
18559090	100133941	Honeth G	The CD44+/CD24- phenotype is enriched in basal-like breast tumors.	Breast cancer research 	2008	176
18681906	100133941	Croker AK	High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability.	Journal of cellular and molecular medicine	2009	125
19188015	100133941	Keller S	Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes.	Cancer letters	2009	64
19264983	100133941	Chen GY	CD24 and Siglec-10 selectively repress tissue damage-induced immune responses.	Science	2009	186
19437567	100133941	Choi D	Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma.	World journal of gastroenterology	2009	51
19509181	100133941	Tanei T	Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.	Clinical cancer research 	2009	135
19582426	100133941	Li C	Identification of human pancreatic cancer stem cells.	Methods in molecular biology	2009	57
19619935	100133941	Theodoropoulos PA	Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer.	Cancer letters	2010	71
19666588	100133941	Creighton CJ	Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.	Proceedings of the National Academy of Sciences of the United States of America	2009	405
20027313	100133941	Hwang-Verslues WW	Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers.	PloS one	2009	70
20103682	100133941	Park SY	Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer.	Clinical cancer research 	2010	113
20176987	100133941	Lian Q	Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice.	Circulation	2010	117
20190812	100133941	Gao MQ	CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells.	Oncogene	2010	83
20405247	100133941	Giatromanolaki A	The CD44+/CD24- phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients.	Medical oncology	2011	41
20691079	100133941	Bhat-Nakshatri P	SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype.	BMC cancer	2010	61
20937839	100133941	Wu K	Cell fate determination factor Dachshund reprograms breast cancer stem cell function.	The Journal of biological chemistry	2011	35
20964822	100133941	Keller PJ	Mapping the cellular and molecular heterogeneity of normal and malignant breast tissues and cultured cell lines.	Breast cancer research 	2010	65
21067584	100133941	Louie E	Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation.	Breast cancer research 	2010	47
21169070	100133941	Kamalakaran S	DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables.	Molecular oncology	2011	44
21281815	100133941	Lindgren D	Isolation and characterization of progenitor-like cells from human renal proximal tubules.	The American journal of pathology	2011	53
21392411	100133941	May CD	Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression.	Breast cancer research 	2011	87
21394208	100133941	Song Z	Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer.	PloS one	2011	42
21407814	100133941	Yuan SH	Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells.	PloS one	2011	108
21480217	100133941	Kryczek I	Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells.	International journal of cancer	2012	70
21559013	100133941	Lee HE	An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer.	British journal of cancer	2011	45
21633165	100133941	Marotta LL	The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.	The Journal of clinical investigation	2011	209
21726833	100133941	Lee TK	CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation.	Cell stem cell	2011	139
21835433	100133941	Idowu MO	CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.	Human pathology	2012	46
21996751	100133941	Buijs JT	The BMP2/7 heterodimer inhibits the human breast cancer stem cell subpopulation and bone metastases formation.	Oncogene	2012	37
22308459	100133941	Meirelles K	Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance.	Proceedings of the National Academy of Sciences of the United States of America	2012	33
22496457	100133941	Palafox M	RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.	Cancer research	2012	40
22565037	100133941	Cufi S	Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.	Oncotarget	2012	61
22610780	100133941	Meng E	CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival.	Clinical and experimental metastasis	2012	37
22692575	100133941	Leth-Larsen R	Functional heterogeneity within the CD44 high human breast cancer stem cell-like compartment reveals a gene signature predictive of distant metastasis.	Molecular medicine	2012	34
23124355	100133941	Smeets B	Proximal tubular cells contain a phenotypically distinct, scattered cell population involved in tubular regeneration.	The Journal of pathology	2013	36
23318426	100133941	Nishi M	Induction of cells with cancer stem cell properties from nontumorigenic human mammary epithelial cells by defined reprogramming factors.	Oncogene	2014	25
23340294	100133941	Schott AF	Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors.	Clinical cancer research 	2013	41
24127583	100133941	Kusaba T	Differentiated kidney epithelial cells repair injured proximal tubule.	Proceedings of the National Academy of Sciences of the United States of America	2014	62
24129232	100133941	Seo AN	Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer.	British journal of cancer	2013	38
24497554	100133941	Lau AN	Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis.	The EMBO journal	2014	38
24955581	100133941	Yang CH	Identification of CD24 as a cancer stem cell marker in human nasopharyngeal carcinoma.	PloS one	2014	21
25086633	100133941	Gwak JM	MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.	Breast cancer research and treatment	2014	26
25605369	100133941	de Masson A	CD24(hi)CD27⁺ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease.	Blood	2015	24
25823923	100133941	Qin L	WNT5A promotes stemness characteristics in nasopharyngeal carcinoma cells leading to metastasis and tumorigenesis.	Oncotarget	2015	19
26421710	100133941	Farnie G	High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant.	Oncotarget	2015	22
